{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal WJ-MSC",
            "NStudiesAvail": 430108,
            "NStudiesFound": 409,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 409,
            "FieldList": [
                  "ResultsFirstSubmitDate",
                  "ResultsFirstSubmitQCDate",
                  "RetractionPMID",
                  "RetractionSource",
                  "SamplingMethod",
                  "SecondaryId",
                  "SecondaryIdDomain",
                  "SecondaryIdLink",
                  "SecondaryIdType",
                  "SecondaryOutcomeDescription",
                  "SecondaryOutcomeMeasure",
                  "SecondaryOutcomeTimeFrame",
                  "SeeAlsoLinkLabel",
                  "SeeAlsoLinkURL",
                  "SeriousEventAssessmentType",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "CTN 2012/0174"
                        ],
                        "SecondaryIdDomain": [
                              "Therapeutics Goods Administration, Government of Australia"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Other Identifier"
                        ],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Response at 14 days after commencement of treatment for acute graft versus host disease",
                              "Response at 28 days after commencement of treatment of acute graft versus host disease",
                              "Incidence of severe infection",
                              "Disease free survival at one year",
                              "Time to treatment failure, requiring salvage therapy"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "14 days",
                              "28 days",
                              "One year",
                              "One year",
                              "28 days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01589549"
                        ]
                  },
                  {
                        "Rank": 2,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "graft versus host disease will be assessed at day +7, +9, +12, +14, +16, +19, +21, +28, + 35, +42 e +49 and after 6 months and 1 year from the last UC-MSC infusion. Efficacy on acute graft versus host disease is defined as complete or partial resolution of acute GvHD evaluated according to conventional staging and grading score systems.The efficacy will be evaluated at day +30 after the third UC-MSC infusion or, if less, at day +30 after the last UC-MSC infusion."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "assessed of acute graft versus host disease (GvHD)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "one year"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Agenzia Italiana del Farmaco (AIFA)"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://www.agenziafarmaco.gov.it"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02032446"
                        ]
                  },
                  {
                        "Rank": 3,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Changes of Kellgren-Lawrence Score"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Kellgren-Lawrence score"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1, 3, 6, 12 months after injection"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05160831"
                        ]
                  },
                  {
                        "Rank": 4,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The size, depth of cartilage defect, and regenerated cartilage were measured using MRI.",
                              "Change in WOMAC pain score,composite score and function and stiffness index scores."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Magnetic resonance imaging (MRI) of the knee",
                              "Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Before and 1,3,6,12 month after treatment",
                              "Before and 1,3,6,12 month after treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02291926"
                        ]
                  },
                  {
                        "Rank": 5,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2013-005407-14"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Comparison of fibrosis by quantitative Sirius Red scoring",
                              "Serious adverse events",
                              "Renal function measured by cGFR (MDRD formula) and iohexol clearance",
                              "CMV, BK infection (viremia, disease and syndrome; and subtypes of BK viremia) and other opportunistic infections",
                              "Development of de novo donor specific antibodies (DSA) and immunological responses"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Before MSC infusion (week 24 after transplantation) and 6 months after MSC infusion (week 52 after transplantation)",
                              "12 months after transplantation",
                              "week 24 after transplantation (before MSC infusion) and 52 after transplantation",
                              "from baseline up to 26 weeks after MSC treatment",
                              "at baseline, week 24 after transplantation (before MSC treatment) up to week 26 after MSC treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02387151"
                        ]
                  },
                  {
                        "Rank": 6,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Changes from baseline in St. George's respiratory questionnaire SGRQ, dyspnea score, cough score and 6-minute walk test (grade and distance)in the treatment of idiopathic pulmonary fibrosis (IPF), and to recommend the appropriate dose of cell therapy for subsequent clinical studies",
                              "Changes in lung function (FVC, DLCO sb) compared with baseline"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Preliminary efficacy evaluation",
                              "Preliminary efficacy evaluation"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "The 4th, 12th, 24th and 48th week after administration",
                              "The 4th, 12th, 24th and 48th week after administration"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05468502"
                        ]
                  },
                  {
                        "Rank": 7,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Changes from baseline in Visual Analogue Scale of Lower back pain and leg pain",
                              "Changes from baseline in Oswestry Disability Index",
                              "Changes from baseline in The Short Form (36) Health survey (SF36)",
                              "Changes from baseline in Disc Height Index",
                              "Changes from baseline in size of nucleus pulposus from magnetic resonance imaging",
                              "Assessing for worsening of patients' baseline symptoms or functions (will be considered an AE); (also general AE events), particular AE events related to the procedures/treatment. All AEs will be assessed by common terminology criteria for adverse events."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Visual Analogue Scale (VAS) (0-10 scores, the higher scores mean a worse outcome)",
                              "Oswestry Disability Index(ODI) (0-50 scores, the higher scores mean a worse outcome)",
                              "The Short Form (36) Health survey (SF36) (0-100 scores, the higher scores mean a better outcome)",
                              "Disc Height Index (DHI) from X ray",
                              "Size of herniated nucleus pulposus from magnetic resonance imaging",
                              "Number of participants with treatment-related adverse events by CTCAE v4.0"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, post-op 3months, post-op 6months, post-op 12months",
                              "Baseline, post-op 3months, post-op 6months, post-op 12months",
                              "Baseline, post-op 3months, post-op 6months, post-op 12months",
                              "Baseline, post-op 3months, post-op 6months, post-op 12months",
                              "Baseline, post-op 3months, post-op 6months, post-op 12months",
                              "From baseline until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04414592"
                        ]
                  },
                  {
                        "Rank": 8,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Include AST, ALT, T-Bil and A/G.",
                              "The level of Hyaluronidase,Laminin,Procollagen \u2162 and Collagen Type IV in serum."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Hepatic function",
                              "Liver fibrosis index"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1, 3 ,6 and 12 months",
                              "1, 3 ,6 and 12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02652351"
                        ]
                  },
                  {
                        "Rank": 9,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Expression levels of various cytokines including interferon-\u03b3\u3001IL-2\u3001IL-1\u03b2\u3001IL-4 and transforming growth factor-\u03b21 in serum(U/ml)."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Immunological Indicator in serum",
                              "The level of ceruloplasmin in serum",
                              "The level of type \u2162 procollagen peptide in serum",
                              "Lung function as assessed by spirometry",
                              "Chest high kilovolt X-ray examination"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1, 3 ,6 and 12 months",
                              "1, 3 ,6 and 12 months",
                              "1, 3 ,6 and 12 months",
                              "1, 3 ,6 and 12 months",
                              "12 month"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02790762"
                        ]
                  },
                  {
                        "Rank": 10,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Main evaluation index of curative effect:percentage changes in estimated glomerular filtration rate (eGFR), urinary albumin creatinine ratio, and 24-hour urinary protein quantification from baseline to 60 weeks of treatment. Other efficacy indicators included fasting blood glucose, blood glucose 2 hours after breakfast, HbA1c, blood and urine routine, liver and renal function, blood lipid, blood electrolyte, and daily insulin dosage."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Changes in eGFR before and after treatment; Changes in 24h urine protein quantification before and after treatment"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "60Weeks,but the major evaluated time is 12 weeks after the last treatment, compared with baseline (0W)"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04125329"
                        ]
                  },
                  {
                        "Rank": 11,
                        "ResultsFirstSubmitDate": [
                              "May 21, 2020"
                        ],
                        "ResultsFirstSubmitQCDate": [
                              "June 13, 2020"
                        ],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "American Spinal Injury Association (ASIA) form is used to assess ASIA total score (Range: 0-324 scores). The higher scores mean a better outcome.",
                              "SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) form is used to assess IANR-SCIFRS total score (Range: 0-51 scores). The higher scores mean a better outcome.",
                              "International Standards to document remaining Autonomic Function after Spinal Cord Injury (ISAFSCI) form is used to assess ISAFSCI score (autonomic nervous function) (Range: 5-32 scores). The higher scores mean a better outcome.",
                              "Penn scale form is used to assess muscle spasm (Range: 0-4 scores). The higher scores mean a worse outcome.",
                              "Modified Ashworth scale form is used to assess muscle spasticity (Range: 0-16 scores). The higher scores mean a worse outcome.",
                              "Geffner scale form is used to assess bladder function (Range: 0-7 scores). The higher scores mean a better outcome.",
                              "Neurogenic Bowel Dysfunction (NBD) scale form is used to assess bowel function (Range: 0-47 scores). The higher scores mean a worse outcome.",
                              "Ultrasonic examination is used to assess residual urine volume"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "American Spinal Injury Association (ASIA) Total Score",
                              "SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) Total Score",
                              "International Standards to Document Remaining Autonomic Function After Spinal Cord Injury (ISAFSCI) Score",
                              "Penn Scale",
                              "Modified Ashworth Scale",
                              "Geffner Scale",
                              "Neurogenic Bowel Dysfunction (NBD) Scale",
                              "Residual Urine Volume"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "at first, second, third, and fourth transplantation and 1, 3, 6 months following the final administration of hUC-MSCs",
                              "at first, second, third, and fourth transplantation and 1, 3, 6 months following the final administration of hUC-MSCs",
                              "at first transplantation and 12 months following the final administration of hUC-MSCs",
                              "at first transplantation and 12 months following the final administration of hUC-MSCs",
                              "at first transplantation and 1, 3, 12 months following the final administration of hUC-MSCs",
                              "at first transplantation and 12 months following the final administration of hUC-MSCs",
                              "at first transplantation and 12 months following the final administration of hUC-MSCs",
                              "at first transplantation and 12 months following the final administration of hUC-MSCs"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02481440"
                        ]
                  },
                  {
                        "Rank": 12,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2013-000819-25"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Renal function and proteinuria",
                              "Number of participants with CMV and BK infection an other opportunistic infections between groups",
                              "Number of participants with adverse events",
                              "composite end point efficacy failure (biopsy proven acute rejection, graft loss or death)",
                              "Presence of donor specific antibodies and immunologic monitoring",
                              "Progression of subclinical cardiovascular disease in the different treatment groups bij assessing echocardiographic parameters"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months",
                              "6 months",
                              "6 months",
                              "6 months",
                              "6 months",
                              "6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02057965"
                        ]
                  },
                  {
                        "Rank": 13,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "time to complete wound closure"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "healing"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "24 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03509870"
                        ]
                  },
                  {
                        "Rank": 14,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "A measure of skin thickness; difference between Month 12 and Month 0 on the mRss [Khanna et al., 2017]"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in modified Rodnan skin score (mRss) between Month 0 and Month 12"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Month 0 and Month 12"
                        ],
                        "SeeAlsoLinkLabel": [
                              "US Department of Health and Human Services. National Cancer Institute Common Terminology Criteria For Adverse Events (CTCAE), Version 5.0. 2017"
                        ],
                        "SeeAlsoLinkURL": [
                              "https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04356287"
                        ]
                  },
                  {
                        "Rank": 15,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "CTN2010/0098"
                        ],
                        "SecondaryIdDomain": [
                              "Therapeutics Good Administration, Government of Australia"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Other Identifier"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Subjects will receive mesenchymal stromal cell therapy, 2X10E6/kg weekly by IV infusion for 4 weeks and will be assessed for 4 hours post infusion",
                              "Crohn's disease activity index assessed as below 150",
                              "Increase in IBDQ and SF-36 scores measured at six weeks",
                              "Crohn's disease endoscopic improvement score will be measured at repeat endoscopy six weeks after start of treatment"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Incidence of infusional toxicity",
                              "Induction of remission",
                              "Improved quality of life",
                              "Endoscopic improvement."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Six weeks",
                              "Six weeks",
                              "Six weeks",
                              "Six weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01090817"
                        ]
                  },
                  {
                        "Rank": 16,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Improvement of infarct size measured by brain MRI",
                              "Modified Barthel index",
                              "National Institutes of Health stroke scale(NIHSS) score"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "before the transplant and 1, 6, 12 months after transplantation",
                              "before and 1, 3, 6 and 12 months after transplantation",
                              "before the transplant and after the transplant 1, 2 and 3 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02283879"
                        ]
                  },
                  {
                        "Rank": 17,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The change in THE WORLD HEALTH ORGANIZATION QUALITY OF LIFE (WHOQOL) -BREF after the operation"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "THE WORLD HEALTH ORGANIZATION QUALITY OF LIFE (WHOQOL) -BREF"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Day 0, Day 30, Day 90, Day 180, Day 360, Day 720"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04939077"
                        ]
                  },
                  {
                        "Rank": 18,
                        "ResultsFirstSubmitDate": [
                              "January 15, 2019"
                        ],
                        "ResultsFirstSubmitQCDate": [
                              "March 18, 2019"
                        ],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "1U01HL108713-01"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [
                              "https://reporter.nih.gov/quickSearch/1U01HL108713-01"
                        ],
                        "SecondaryIdType": [
                              "U.S. NIH Grant/Contract"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Efficacy endpoint: PaO2:FiO2 change from baseline to day 3",
                              "Murray score for acute lung injury. The range is 0 to 4. The higher score, the worst outcome.",
                              "Oxygenation index with the following validated measure of respiratory function: FiO2 (%) x mean airway pressure / PaO2",
                              "Sequential organ failure assessment score (SOFA). The SOFA score ranges from 0 to 24. The higher, the worse.",
                              "Efficacy endpoint: all-cause mortality at day 28",
                              "Efficacy endpoint: all-cause mortality at day 60",
                              "Efficacy endpoint: Number of ventilator-free days to day 28.",
                              "Efficacy endpoint: Non-pulmonary organ-failure-free days to day 28",
                              "Biological markers of endothelial injury: angiopoietin 2",
                              "Biological markers of endothelial injury: angiopoietin 2",
                              "Biological markers of inflammation: interleukin 6",
                              "Biological markers of inflammation: interleukin 6",
                              "Biological markers of inflammation: interleukin 8",
                              "Biological markers of inflammation: interleukin 8",
                              "Biological markers of alveolar epithelial injury: receptor for advanced glycation end products (RAGE)",
                              "Biological markers of alveolar epithelial injury: receptor for advanced glycation end products (RAGE)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "PaO2:FiO2 Change From Baseline to Day 3",
                              "Lung Injury Score From Baseline to Day 3",
                              "Oxygenation Index Change From Baseline to Day 2",
                              "SOFA Score Change From Baseline to Day 3",
                              "Number of Patients Death to Day 28",
                              "Mortality to Day 60",
                              "Number of Ventilator-free Days to Day 28",
                              "Non-pulmonary Organ-failure-free Days to Day 28",
                              "Angiopoietin 2 Change From Baseline to 6 h",
                              "Angiopoietin 2 Change From Baseline to 24 h",
                              "Interleukin 6 Change From Baseline to 6 h",
                              "Interleukin 6 Change From Baseline to 24 h",
                              "Interleukin 8 Change From Baseline to 6 h",
                              "Interleukin 8 Change From Baseline to 24 h",
                              "RAGE Change From Baseline to 6 h",
                              "RAGE Change From Baseline to 24 h"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "baseline and day 3",
                              "baseline and day 3",
                              "baseline and day 2",
                              "baseline and day 3",
                              "28 days",
                              "60 days",
                              "28 days",
                              "28 days",
                              "baseline and 6 hours",
                              "baseline and 24 hours",
                              "baseline and 6 hours",
                              "baseline and 24 hours",
                              "baseline and 6 hours",
                              "baseline and 24 hours",
                              "baseline and 6 hours",
                              "baseline and 24 hours"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment"
                        ],
                        "NCTId": [
                              "NCT02097641"
                        ]
                  },
                  {
                        "Rank": 19,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Mainly on re-epithelialization of external opening"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Clinical healing"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "24 and/or 48 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05039411"
                        ]
                  },
                  {
                        "Rank": 20,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Amputation sited proximal from the ankle joint",
                              "Amputation sited distal from the ankle joint",
                              "Composite outcome measure considering mortality, limb status, clinical classification and changes in pain score. To be a \"success\" a subject must: A, be alive; B, be without a major amputation on the index limb; C, have not worsened in Rutherford classification or visual analog pain scale; and D, have improved in either Rutherford classification or visual analog pain scale. Subjects not meeting all of the criteria are classified as failures.",
                              "Mortality",
                              "Changes in the number and extent of leg ulcers,",
                              "Resolution of rest pain and alteration in visual analogue pain (VAS) score",
                              "Changes in pain free walking distance (treadmill at 3 km/h without incline)",
                              "Alterations in ankle-brachial index (ABI)",
                              "Alterations in toe-brachial index (TBI)",
                              "Alterations in quality of life assessed using EuroQoL 5D quality of life questionnaire",
                              "Alterations in quality of life assessed using Short Form 36 quality of life questionnaire",
                              "Alterations clinical status according to Fontaine classification",
                              "Alterations clinical status according to Rutherford classification"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Major amputation",
                              "Minor amputation",
                              "Therapy Success",
                              "Mortality",
                              "Ulcer healing",
                              "Changes in pain",
                              "Pain-free walking distance",
                              "Ankle-brachial index (ABI)",
                              "Toe-brachial index (TBI)",
                              "Quality of life based on EuroQol 5D (EQ5D) questionnaire scores",
                              "Quality of life based on Short Form 36 (SF36) questionnaire scores",
                              "Clinical status according to Fontaine classification",
                              "Clinical status according to Rutherford classification"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "2, 6, 12, 24, and 60 months",
                              "2, 6, 12, 24, and 60 months",
                              "2, 6, 12, 24, and 60 months",
                              "2, 6, 12, 24, and 60 months",
                              "2 and 6 months",
                              "2, 6, 12, 24, and 60 months",
                              "2 and 6 months",
                              "2 and 6 months",
                              "2 and 6 months",
                              "2, 6, 12, 24, and 60 months",
                              "2, 6, 12, 24, and 60 months",
                              "2, 6, 12, 24, and 60 months",
                              "2, 6, 12, 24, and 60 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03042572"
                        ]
                  },
                  {
                        "Rank": 21,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Proportion of subjects that achieve a clinical response by 45 days after last infusion, as defined by a decrease in PCDAI from baseline by greater than or equal to 12.5 points (for CD) or a decrease in PUCAI of greater than or equal to 20 points (for UC).",
                              "Improvement in laboratory parameters (i.e. C-reactive protein, fecal calprotectin, anti-HLA antibodies, and viral specific T-cell activity)",
                              "Proportion of subjects with endoscopic improvement, as assessed by change in baseline endoscopic scores (Simple Endoscopic Score Crohn's Disease [SES-CD] for CD or Endoscopic SubScore within the Mayo Score for UC)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Proportion of patients with clinical response",
                              "Number of subjects demonstrating an improvement of laboratory tests reflecting systemic inflammation.",
                              "Number of subjects with endoscopic healing after treatment."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "45 days after last infusion",
                              "45 days after last infusion",
                              "45 days after last infusion"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02150551"
                        ]
                  },
                  {
                        "Rank": 22,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The improvement in PASI score from baseline after treatment. PASI scores the average redness, thickness, and scaliness of the lesions (0-4 scale), weighted by the area of involvement. PASI scores range from 0 to 72.",
                              "Relapse can be defined only for patients who achieve PASI50\uff0cand occurs when the improvement in the PASI score falls below 50% from the baseline PASI score.",
                              "The proportion of patients who achieve at least 50% improvement in PASI score from baseline. PASI scores the average redness, thickness, and scaliness of the lesions (0-4 scale), weighted by the area of involvement. PASI scores range from 0 to 72.",
                              "The proportion of patients who achieve at least 75% improvement in PASI score from baseline. PASI scores the average redness, thickness, and scaliness of the lesions (0-4 scale), weighted by the area of involvement. PASI scores range from 0 to 72.",
                              "Pruritus Scores on the Visual Analogue Scale",
                              "the Body Surface Area",
                              "the score of Dermatology Life Quality Index. Dermatology Life Quality Index (DLQI) is a self-administered 10-item questionnaire. It covers Symptoms and feelings, Daily activities, Leisure, Work and school, Personal relationships, and Treatment."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Psoriasis Area and Severity Index(PASI)",
                              "Relapse rate in treatment period / follow-up period",
                              "PASI-50",
                              "PASI-75",
                              "Pruritus Scores on the Visual Analogue Scale",
                              "the Body Surface Area (BSA%)",
                              "the Dermatology Life Quality Index\uff08DLQI\uff09"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 weeks (plus or minus 3 days) after treatment",
                              "During the treatment period of 12 weeks / follow-up period of 12 weeks after treatment period",
                              "12 weeks (plus or minus 3 days) after treatment",
                              "12 weeks (plus or minus 3 days) after treatment",
                              "12 weeks (plus or minus 3 days) after treatment",
                              "12 weeks (plus or minus 3 days) after treatment",
                              "12 weeks (plus or minus 3 days) after treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03745417"
                        ]
                  },
                  {
                        "Rank": 23,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Frequency of complications, infections and relapse",
                              "Proportion of patients free from corticosteroids at 1 year after finishing MSC treatment."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in disease activity as measured by histological examination",
                              "Change in self-assessed disease activity and quality of life",
                              "Safety (Adverse events, infections and relapse)",
                              "Freedom from steroids at 1 year after MSC treatment"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline to 9 months",
                              "Baseline to 9 months",
                              "21 months",
                              "1 year after finishing treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01522716"
                        ]
                  },
                  {
                        "Rank": 24,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The efficacy of the intra-articular injection of WJMSC will be assessed by Magnetic Resonance Imaging (MRI)."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Assessment of the efficacy of intra-articular injection of WJMSC"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02963727"
                        ]
                  },
                  {
                        "Rank": 25,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Safety will be determined by the assessment of major adverse coronary events (MACE) defined as cardiac death, peri-procedural myocardial infarction, or any repeat coronary intervention at 4 months-1year. Furthermore, safety is also determined by the occurrence of stent thrombosis, arrhythmias events. immune system disorders. The trial will be monitored by a Data and Safety Monitoring Board (DSMB) and the trial will be discontinued in case of safety concerns."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Secondary endpoints: safety will be determined by the assessment of major adverse coronary events (MACE)."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "4 months-1year"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01291329"
                        ]
                  },
                  {
                        "Rank": 26,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Rheumatoid Factor, C-reactive protein"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "RA Serology",
                              "Disease Activity Score (DAS 28) Index"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1, 3 ,6 and 12 months",
                              "1, 3, 6 and 12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02643823"
                        ]
                  },
                  {
                        "Rank": 27,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2013-003221-29"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02012153"
                        ]
                  },
                  {
                        "Rank": 28,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "LIS over 7 days, or on the last day of positive pressure ventilation prior to day 7. The LIS is a composite 4-point scoring system including the PaO2/FiO2, PEEP, lung compliance, and the extent of infiltrates on the chest X-ray. Each of the four components is categorized from 0 to 4, where a higher number is worse. The total Lung Injury Score is obtained by dividing the aggregate sum by the number of components used.",
                              "Pulmonary Dead Space at day 1, 2, 3 and 7. The dead-space fraction is calculated as: (PaCO2 - PeCO2) \u00f7 PaCO2",
                              "RALE score at day 1, 2, 3 and 7. To calculate RALE, each radiographic quadrant is scored for extent of consolidation (0-4) and density of opacification (1-3). The product of the consolidation and density scores for each of the four quadrants is summed. The RALE score ranges from 0 (best) to 48 (worst).",
                              "Ventilator free-days over 7, 14 and 28 days",
                              "Duration of assisted ventilation over 28 days in the survivors",
                              "Percentage of patients achieving pressure support ventilation equal to 5 cm H2O with positive end-expiratory pressure (PEEP) equal to 5 cm H2O for 2 hours",
                              "Superficial incisional/wound infections, deep incisional wound infections, and organ/space infections, and ventilator associated pneumonia (all during the 14 days after enrollment)",
                              "SOFA score at 3 and 7 days. The score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems which are added up. Each score ranges from 0 to 4. SOFA score ranges from 0 (best) to 24 (worst).",
                              "All-cause hospital mortality at 14, 28 and 60 days",
                              "Glasgow Outcome Score at hospital discharge. The GCS is a scale to evaluate level of consciousness in patients with acute brain injury. The scale assesses 3 functions: Eye Opening, Verbal Response, and Motor Response. GCS scores range from 15 (best) to 3 (worst)",
                              "Thromboembolic events are measured by ultrasound of the deep venous system or CT-angiography of the chest ordered for clinical purposes/by treating clinicians",
                              "Change in levels of plasma angiopoietin-2 from baseline compared to 6, 24, 48 and 72 hours",
                              "Change in levels of plasma RAGE from baseline compared to 6, 24, 48 and 72 hours",
                              "Change in levels of plasma interleukin-6 from baseline compared to 6, 24, 48 and 72 hours",
                              "Change in levels of plasma interleukin-8 from baseline compared to 6, 24, 48 and 72 hours",
                              "Change in levels of plasma sTNF-1 from baseline compared to 6, 24, 48 and 72 hours",
                              "Change in levels of plasma protein C from baseline compared to 6, 24, 48 and 72 hours",
                              "Change in levels of plasma lipoxin A4 from baseline compared to 6, 24, 48 and 72 hours",
                              "Change in levels of plasma Resolvin D1 from baseline compared to 6, 24, 48 and 72 hours",
                              "Change in levels of plasma angiopoietin-1 from baseline compared to 6, 24, 48 and 72 hours",
                              "Change in levels of plasma KGF from baseline compared to 6, 24, 48 and 72 hours",
                              "Change in levels of urine microalbumin from baseline compared to 24 and 48 hours",
                              "Change in total protein levels in from baseline to day 2",
                              "Tolerability of the hMSCs, defined as the incidence of pre-specified infusion-associated events and unexpected severe adverse events in ARDS patients treated with human MSCs"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Acute Lung Injury Score (LIS)",
                              "Pulmonary Dead Space Fraction",
                              "Chest radiograph assessment of pulmonary edema (RALE score)",
                              "Ventilator free-days",
                              "Duration of assisted ventilation over 28 days",
                              "Percentage of patients achieving pressure support ventilation for 2 hours",
                              "Occurrence of Infection",
                              "Sequential Organ Failure Assessment (SOFA) over 7 days",
                              "All-cause hospital mortality",
                              "Glasgow Outcome Score (GCS)",
                              "Percentage of patients occurred any thromboembolic events",
                              "Plasma angiopoietin-2",
                              "Plasma Receptor for Advanced Glycation Endproducts (RAGE)",
                              "Plasma interleukin-6",
                              "Plasma interleukin-8",
                              "Plasma Soluble tumor necrosis factor 1 (sTNF-1)",
                              "Plasma protein C",
                              "Plasma lipoxin A4",
                              "Plasma Resolvin D1",
                              "Plasma angiopoietin-1",
                              "Plasma keratinocyte growth factor (KGF)",
                              "Urine microalbumin",
                              "Total protein in min-bronchoalveolar lavage (mBAL)",
                              "Tolerability of the hMSCs - incidence of pre-specified infusion-associated events and unexpected severe adverse events"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "7 days",
                              "7 days",
                              "7 days",
                              "28 days",
                              "28 days",
                              "28 days",
                              "14 days",
                              "7 days",
                              "60 days",
                              "60 days",
                              "60 days",
                              "72 hours",
                              "72 hours",
                              "72 hours",
                              "72 hours",
                              "72 hours",
                              "72 hours",
                              "72 hours",
                              "72 hours",
                              "72 hours",
                              "72 hours",
                              "48 hours",
                              "2 days",
                              "24 hours"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03818854"
                        ]
                  },
                  {
                        "Rank": 29,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "to reveal objective data on quality of sleep, skin healing time, amount of dressings used, improvement in oral diet, improvement in energy levels, mood, quality of family life/relationships."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Presence of new type VII collagen at the dermal-epidermal junction post treatment.",
                              "Change in general markers of inflammation",
                              "Changes in specific markers of inflammation",
                              "Change in the clinical changes in the skin assessed with clinical photographs",
                              "Differences in quality of life data",
                              "Change in BEBSS and EBDASI scores",
                              "Change in Pain scores",
                              "Change in pruritus score using the Leuven Itch Scale (LIS)",
                              "Quantification of total blister numbers over the entire body surface area",
                              "10. Increase in the skin strength measured by time to blister formation after negative pressure skin suction test",
                              "Qualitative analyses based on a series of interview questions"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Day 14, Day 28, Day 60, Day 100 and Month 6.",
                              "Day 14, Day 28, Day 60, Day 100, Month 6 and Month 12 compared to baseline",
                              "Day 14, Day 28, Day 60 and Month 6 compared to baseline",
                              "Day 14, Day 28, Day 60, Day 100, Month 6 and Month 12.",
                              "Day 28, Day 60, Day 100, Month 6 and Month 12 compared to baseline",
                              "at Day 28, Day 60, Day 100, Month 6 and Month 12 compared to baseline",
                              "Day 28, Day 60, Day 100, Month 6 and Month 12 compared to baseline",
                              "Day 28, Day 60, Day 100, Month 6 and Month 12 compared to baseline.",
                              "Day 28, Day 60, Day 100, Month 6 and Month 12 compared to baseline",
                              "Day 28, Day 60, Day 100, Month 6 and Month 12 compared to baseline",
                              "between screening and Day 0, between Day 28 and Day 60, and between Month 6 and Month 12."
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02323789"
                        ]
                  },
                  {
                        "Rank": 30,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "UL1TR000135"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [
                              "https://reporter.nih.gov/quickSearch/UL1TR000135"
                        ],
                        "SecondaryIdType": [
                              "U.S. NIH Grant/Contract"
                        ],
                        "SecondaryOutcomeDescription": [
                              "The ALSFRS-R includes 12 questions. Each task is rated on a five-point scale from 0 = can't do, to 4 = normal ability. Individual item scores are summed to produce a reported score of between 0=worst and 48=best."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in slope of ALS Functional Rating Scale - Revised (ALSFRS-R)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "baseline, approximately 1 year"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Mayo Clinic Clinical Trials"
                        ],
                        "SeeAlsoLinkURL": [
                              "https://www.mayo.edu/research/clinical-trials"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03268603"
                        ]
                  },
                  {
                        "Rank": 31,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Physical function improvement measured by WOMAC OA index",
                              "Change in pain density measured by Visual analogue scale (VAS)",
                              "QoL improvement measured by SF-36",
                              "Changes in WORMS scale measured by knee MRI"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02580695"
                        ]
                  },
                  {
                        "Rank": 32,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03529136"
                        ]
                  },
                  {
                        "Rank": 33,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Clinical improvements"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 and 12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT00644410"
                        ]
                  },
                  {
                        "Rank": 34,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Overall survival",
                              "Progression-free survival",
                              "Time without systemic immunosuppression",
                              "Cumulative incidents of non-relapse mortality",
                              "Adverse events"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "2 year",
                              "2 year",
                              "2 year",
                              "2 year",
                              "2 year"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02291770"
                        ]
                  },
                  {
                        "Rank": 35,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Change in low back pain will be measured by a 10 cm visual analog scale (VAS) score, with one end of the scale 0 indicating no pain, and the other end 10 indicating the worst pain ever.",
                              "Change in low back pain and function will be measured by Global Health Scale (GHS) which includes health related questions with Likert Scales of 1 to 5, or 1 to 10. Based on the question, 1 may indicate a higher amount, or lower amount for the measured variable.",
                              "Change in low back pain and function will be measured by Oswestry Disability Index (ODI), which contains 10 questions about daily activities with scores ranging from 0 to 5, where 0 indicates no difficulty/disability, and 5 indicates the most severe difficulty/disability. The final score is multiplied by 2 to give a final score from 0 to 100, where 0 is no difficulty/disability and 100 is severe difficulty/disability.",
                              "Change in low back pain and function will be measured by Quality of Life (SF-36 questionnaire, which has questions regarding health and activity scored from 1 to 3, 1 to 5, or yes/no (1 to 2). Based on the question, 1 may indicate a lower amount/frequency or higher amount/frequency.",
                              "Change in low back pain and function will be measured by Narcotic Use Questionnaire, which includes questions regarding the current use of narcotics (yes/no) and how long participants have used narcotics for pain relief (days, months, years).",
                              "An x-ray will be performed using standard radiography technology and interpreted by a trained radiologist.",
                              "Images will be obtained by MRI and interpreted by a trained radiologist."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in low back pain and function following injection of AD-MSCs",
                              "Change in low back pain and function following injection of AD-MSCs",
                              "Change in low back pain and function following injection of AD-MSCs",
                              "Change in low back pain and function following injection of AD-MSCs",
                              "Change in low back pain and function following injection of AD-MSCs",
                              "Changes from Baseline in disc height index as measured by X-ray at 12 months and 24 months",
                              "Changes from Baseline in T2 weighted signal intensity of the Nucleus Pulposus (NP) as measured by MRI without contrast"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, treatment day, 2 weeks, 4 weeks, 3 months, 6 months, 12 months, 18 months, 24 months",
                              "Baseline, treatment day, 2 weeks, 4 weeks, 3 months, 6 months, 12 months, 18 months, 24 months",
                              "Baseline, treatment day, 2 weeks, 4 weeks, 3 months, 6 months, 12 months, 18 months, 24 months",
                              "Baseline, treatment day, 2 weeks, 4 weeks, 3 months, 6 months, 12 months, 18 months, 24 months",
                              "Baseline, treatment day, 2 weeks, 4 weeks, 3 months, 6 months, 12 months, 18 months, 24 months",
                              "Baseline, 12 Months, 24 Months",
                              "Baseline, 6 Months, 12 Months, 24 Months"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Mayo Clinic Clinical Trials"
                        ],
                        "SeeAlsoLinkURL": [
                              "https://www.mayo.edu/research/clinical-trials"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03461458"
                        ]
                  },
                  {
                        "Rank": 36,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Cumulative incidence of all serious adverse events",
                              "Need for transfer to an intensive care unit",
                              "Type and duration of respiratory support",
                              "Hospital mortality and length of stay",
                              "Days off of mechanical ventilation",
                              "28 day mortality"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Serious Adverse Events",
                              "ICU transfer",
                              "Respiratory support",
                              "Hospital mortality and length of stay",
                              "Ventilator free days",
                              "28 day mortality"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "90 days",
                              "90 days",
                              "90 days",
                              "90 days",
                              "90 Days",
                              "28 days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05286255"
                        ]
                  },
                  {
                        "Rank": 37,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2008-007869-23"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Complete resolution of GvHD: Control of all signs and symptoms attributed to acute GvHD\nPartial resolution of GvHD: Control of some signs and symptoms attributed to acute GvHD with an improvement of overall grade\nRefractory GvHD: No change in signs or symptoms of GvHD within 10 days of MSC infusion.\nWorsening GvHD: Any progress of GvHD signs and symptoms that increase overall grade. a and b will be defined as response. c and d will be defined as no response."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Number of patients with GvHD resolution",
                              "Determination of recurrence of GvHD",
                              "Relapse of haematological disease",
                              "Survival"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "One month",
                              "After 1 month from MSCs infusion",
                              "Every three months",
                              "Every three months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01764100"
                        ]
                  },
                  {
                        "Rank": 38,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The investigator will observe the concentration of hUC-MSCs in peripheral blood from female patients after the first hUC-MSCs infusion at 10 time points, including 30 minutes before hUC-MSCs infusion, 30 minutes, 60 minutes, 2 hours, 4 hours, 8 hours, 16 hours, 24 hours,48 hours and 96 hours after the first hUC-MSCs infusion.",
                              "The investigator will detect antibody production of hUC-MSCs in peripheral blood from the first 9 patients at 2 time points, including 30 minutes before the first hUC-MSCs infusion and 48 hours after the last hUC-MSCs infusion.",
                              "The investigator will observe the changes of immune function in refractory ITP patients after hUC-MSCs infusion at 7 time points, including one day before the first hUC-MSCs infusion, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 16weeks and 28 weeks after the first hUC-MSCs infusion. The changes of immune function will include the changes of the percentage of Th cell subsets\uff0c regulatory T cells (Treg)\uff0csupressor T cells\uff08Ts\uff09, activation and proliferation of B and T lymphocyte, apoptosis of platelets by cytotoxic T cells(CTLs) and function of dendritic cells in peripheral blood mononuclear cells\uff08PBMCs\uff09at the 7 time points, and to compare with the healthy controls. The investigator also will assess the changes of cytokines in the cell culture supernatants and plasma at the 7 time points, and to compare with the healthy controls."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Changes of concentration of hUC-MSCs in peripheral blood",
                              "Changes of antibody production of hUC-MSCs in peripheral blood",
                              "Changes of immune function in refractory ITP patients after hUC-MSCs infusion"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "96 hours",
                              "24 days",
                              "28 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04014166"
                        ]
                  },
                  {
                        "Rank": 39,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "To determine if MSCs elicit an immune response after repeated infusions.",
                              "To determine the change in clinical course (growth, bone mineral content, fracture rate, development/activities) of subjects after experimental MSC intervention therapy as compared with each subject's own pre-MSC intervention therapy."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Completion of study",
                              "Completion of Study"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01061099"
                        ]
                  },
                  {
                        "Rank": 40,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04345601"
                        ]
                  },
                  {
                        "Rank": 41,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Adverse Events (AE) and Serious Adverse Events (SAE) after MSC transplantation"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The number of Adverse Events (AE) and Serious Adverse Events (SAE)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "baseline, 3 months, 6 months, 9 months, 12 months (time frame: up to the 12-month period following treatment)"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04522869"
                        ]
                  },
                  {
                        "Rank": 42,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04348461"
                        ]
                  },
                  {
                        "Rank": 43,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [
                              "Non-Probability Sample"
                        ],
                        "SecondaryId": [
                              "2017-A02088-45"
                        ],
                        "SecondaryIdDomain": [
                              "ANSM"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Other Identifier"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Number of differential biomarkers expressed by MDS or AML-derived mesenchymal stromal cells"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Number of differential biomarkers in mesenchymal stromal cells"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Day 0"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03233074"
                        ]
                  },
                  {
                        "Rank": 44,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "I.e infection, fever, effect on end-organ function",
                              "kidney, liver, heart functions"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Pulmonary compliance",
                              "Pulmonary tidal volume",
                              "Adverse events",
                              "All-cause mortality",
                              "Recovery of organ functions"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "During ventilator treatment, an expected average of 1 month",
                              "During ventilator treatment, an expected average of 1 month",
                              "6 months",
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02215811"
                        ]
                  },
                  {
                        "Rank": 45,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "survival rate after 2 years since the first therapy",
                              "Child-Pugh grade is defined according to hepatic encephalopathy, ascites\uff0cserum albumin, total bilirubin, prothrombin time. Score 5-6 is grade A. Score 7-9 is grade B. Score 10-15 is grade C.\n\nWe compare the Child-Pugh grade in first day, 4th, 8th, 12th and 24th week, to describe its tendency.",
                              "We compare the weight in first day, 4th, 8th, 12th and 24th week, to describe its tendency.",
                              "We test the ascites via ultrasound, CT and MRI. We classify the ascite level into none, low and high.\n\nWe compare the Child-Pugh grade in first day, 4th, 8th, 12th and 24th week, to describe its tendency.",
                              "Including lower limb edema, hematemesis, jaundice, fatigue, poor appetite. We compare these symptoms in first day, 4th, 8th, 12th and 24th week, to describe their tendency.",
                              "We compare this index in first day, 4th, 8th, 12th and 24th week, to describe their tendency.",
                              "We compare this index in first day, 4th, 8th, 12th and 24th week, to describe their tendency.",
                              "We compare this index in first day, 4th, 8th, 12th and 24th week, to describe their tendency.",
                              "We compare this index in first day, 4th, 8th, 12th and 24th week, to describe their tendency.",
                              "We compare this index in first day, 4th, 8th, 12th and 24th week, to describe their tendency.",
                              "We compare this index in first day, 4th, 8th, 12th and 24th week, to describe their tendency.",
                              "We compare this index in first day, 4th, 8th, 12th and 24th week, to describe their tendency.",
                              "We compare this index in first day, 4th, 8th, 12th and 24th week, to describe their tendency.",
                              "We compare this index in first day, 4th, 8th, 12th and 24th week, to describe their tendency.",
                              "We compare this index in first day, 4th, 8th, 12th and 24th week, to describe their tendency.",
                              "Ultrasound in first day, 4th, 8th, 12th and 24th; enhanced CT scanning and/or MRI-Primovist scanning in first day, 12th week and 24th week.",
                              "SF-36 scale is a measurement for patients' living quality. The scores contain 8 parts, including physical functioning, role-physica, bodily pain, general health, vitality, social functioning, role-emotional and mental health. Conversion score=(actual score-minimum score in this part)/(maximum score in this part-minimum score in this part)*100. Score of each part range from 0 to 100. The higher score means more healthy. We proceed SF-36 test in 12th week and 24th week",
                              "MELD=3.78*Ln(total bilirubin mg/dL)+11.2*Ln(INR)+9.57*Ln(serum creatine mg/dL)+6.43 (for HBV patient) We compare MELD score in first day, 4th, 8th, 12th and 24th week, to describe its tendency."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "survival rate",
                              "Child-Pugh grade",
                              "Rate of weight change",
                              "Ascites",
                              "clinical symptoms",
                              "Th1 cells in percentage",
                              "Th2 cells in percentage",
                              "Natural killer T cells in percentage",
                              "Interleukin-1\u03b2 cells in pg/mL",
                              "Interleukin-4 cells in pg/mL",
                              "Interleukin-6 cells in pg/mL",
                              "Interleukin-8 cells in pg/mL",
                              "Interleukin-12 cells in pg/mL",
                              "Interleukin-15 cells in pg/mL",
                              "Interleukin-17A cells in pg/mL",
                              "Medical images",
                              "The Medical outcomes study 36-item Short Form Health Survay scale (SF-36 scale)",
                              "MELD score"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "2 years",
                              "24 weeks",
                              "24 weeks",
                              "24 weeks",
                              "24 weeks",
                              "24 weeks",
                              "24 weeks",
                              "24 weeks",
                              "24 weeks",
                              "24 weeks",
                              "24 weeks",
                              "24 weeks",
                              "24 weeks",
                              "24 weeks",
                              "24 weeks",
                              "24 weeks",
                              "24 weeks",
                              "24 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05442437"
                        ]
                  },
                  {
                        "Rank": 46,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2014-001462-99"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Frequency of drug consumption (analgesic, opiate)",
                              "Quality of life evaluated by SF36 questionnaire (short form survey)",
                              "Quality of life evaluated by questionnaire Hospital Anxiety and Depression Scale (HADS)",
                              "Mean pain intensity evaluated by Visual Analogue Scale (VAS) during the week prior to the visit.",
                              "diminution of the frequency of diarrhea"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The effect of treatment on analgesic drug consumption (analgesic, opiates).",
                              "The effect of treatment on quality of life with SF36 questionnaire",
                              "The effect of treatment on quality of life with HADS questionnaire",
                              "The effect of treatment on pain",
                              "Frequency of diarrhea"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "4 months after the first injection of MSCs",
                              "4 months after the first injection of MSCs",
                              "4 months after the first injection of MSCs",
                              "4 months after the first injection of MSCs",
                              "4 months after the first injection of MSCs"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02814864"
                        ]
                  },
                  {
                        "Rank": 47,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "W81XWH-18-1-0661"
                        ],
                        "SecondaryIdDomain": [
                              "United States Department of Defense"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Other Grant/Funding Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Best-corrected distance visual acuity will be measured using standard e-ETDRS protocols.",
                              "Time to completion of corneal epithelialization will be assessed at each visit throughout the trial. Corneal epithelialization will be assessed as previously described.",
                              "Durability of the corneal epithelization and healing will be assessed as an outcome measure at DAY #28 and DAY #90. Participants with corneal epithelialization prior to DAY #28 will be assessed at each subsequent follow-up visit (e.g., DAYS #7, #14, #28) to assess persistence of the healing response. Corneal epithelialization will be assessed as previously described.",
                              "Corneal stromal haze will be measured from Scheimpflug imaging and anterior segment OCT images (using Image J software). The treatment effect on corneal haze on DAY #28 will be compared relative to baseline.",
                              "Corneal epithelial thickness measured by anterior segment OCT imaging will assess the treatment effect on thickness on DAY #28 and compared relative to baseline."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Secondary Efficacy Outcomes: Visual Acuity",
                              "Secondary Efficacy Outcomes: Time to Completion of Corneal Epithelialization",
                              "Secondary Efficacy Outcomes: Durability of the Corneal Epithelialization and Healing",
                              "Secondary Efficacy Outcomes: Corneal stromal haze",
                              "Secondary Efficacy Outcomes: Corneal epithelial thickness"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Enrollment, Treatment, and Days #1, #7, #14, #28, #90",
                              "Enrollment, Treatment, and Days #1, #7, #14, #28, #90",
                              "Enrollment, Treatment, and Days #1, #7, #14, #28, #90",
                              "Enrollment and Days #7, #14, #28, #90",
                              "Enrollment and Days #7, #14, #28, #90"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products"
                        ],
                        "SeeAlsoLinkURL": [
                              "https://www.fda.gov/media/106369/download"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04626583"
                        ]
                  },
                  {
                        "Rank": 48,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2015-000168-32"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Any treatment-related serious adverse events (SAE) defined as events leading to hospitalization, death, or persistent or significant disability. To establish the presence or absence of a causal relationship, the World Health Organisation guidelines for pharmacovigilance will be followed.",
                              "Change in pain as assessed using the Numerical Rating Scale,",
                              "Change in pain as assessed using the digital ulcer visual analogue scale (part of the S-HAQ).",
                              "Change in pain as assessed using the pain VAS (S-HAQ), use of analgesics.",
                              "Change in pain as assessed by analyzing the use of analgesics.",
                              "SF-36 questionnaire.",
                              "EuroQol questionnaire",
                              "Assessed with the HAQ-DI questionnaire.",
                              "Cochin Hand Function Score",
                              "Healing of ulcers is defined as complete epithelialization, regardless of residual pain. This will be established using sequential pictures in addition to the clinical examination.",
                              "Using sequential pictures, ulcer area and circumference will be measured.",
                              "The need to alter the medication regime as determined by the patient's attending rheumatologist.",
                              "Raynaud Condition Score",
                              "as visualized with video-assisted nailfold capillaroscopy by a trained investigator. The images will be scored by a certified rheumatologist and a trained investigator.",
                              "A range of haematological and chemical parameters will be measured for safety assessment. Additionally, serum, plasma and peripheral blood mononuclear cells will be collected and stored for analysis at a later time point. Samples will be analysed and used to assess markers for endothelial activation and injury, proangiogenic factors, inflammation and oxidative stress. The presence of HLA-antibodies will be determined as well.",
                              "Circulating cell populations will be studied by immunofluorescence labelling and analysis using fluorescence assisted cell sorting (FACS Canto machine)."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Serious adverse events",
                              "Change in perceived pain based on the Numerical Rating Scale",
                              "Change in perceived pain based on the digital ulcer visual analogue scale (part of the S-HAQ)",
                              "Change in perceived pain based on the pain VAS ( part of the S-HAQ)",
                              "Change in perceived pain based on the use of analgesics.",
                              "Quality of life - SF-36",
                              "Quality of life - Euroqol",
                              "Disability",
                              "Hand function",
                              "Number (and change in number) of digital ulcers",
                              "Healing of digital ulcers",
                              "Ulcer size",
                              "Time to healing of digital ulcers",
                              "Need to alter medication regime",
                              "Modified Rodnan Skin Score",
                              "Severity of Raynaud's symptoms",
                              "Changes in capillary morphology and architecture",
                              "Changes in laboratory parameters",
                              "Changes in circulating cell populations"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration",
                              "48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration",
                              "48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration",
                              "48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration",
                              "48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration",
                              "12, 24 and 52 weeks after MSC administration",
                              "12, 24 and 52 weeks after MSC administration",
                              "12, 24 and 52 weeks after MSC administration",
                              "12, 24 and 52 weeks after MSC administration",
                              "48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration",
                              "48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration",
                              "48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration",
                              "48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration",
                              "48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration",
                              "12, 24 and 52 weeks after MSC administration",
                              "12 , 24 and 52 weeks after MSC administration",
                              "2, 12, 24 weeks and 52 weeks after MSC administration",
                              "48 hours, 2, 4, 8, 12 weeks after MSC administration",
                              "48 hours, 2, 4, 8, 12 weeks after MSC administration"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03211793"
                        ]
                  },
                  {
                        "Rank": 49,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Number of Participants with Adverse Events as a Measure of Safety and Tolerability",
                              "Number of Participants with Serious Adverse Events as a Measure of Safety and Tolerability"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1 year after treatment",
                              "1 year after treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01360164"
                        ]
                  },
                  {
                        "Rank": 50,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "MT2020-12"
                        ],
                        "SecondaryIdDomain": [
                              "University of Minnesota Masonic Cancer Center"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Other Identifier"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Acute Lung Injury Score is a composite 4 point scoring system validated by the NHLBI ARDS Network that considers PaO2/FiO2, the level of positive end-expiratory airway pressure, respiratory compliance, and the extent of pulmonary infiltrates on the chest radiograph"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Incidence of a reduction in one or more biomarkers of inflammation by day 7",
                              "Trend changes in PaO2:FiO2 ratio",
                              "Trend changes in Mean Airway Pressure",
                              "Trend changes in peak pressure",
                              "Trend changes in plateau pressure",
                              "Trend changes in Positive end-expiratory airway pressure (PEEP)",
                              "Incidence of mortality",
                              "Incidence of mortality",
                              "Number of ICU-free days",
                              "Number of days alive and ventilator free composite score 3",
                              "Change in acute lung injury (ALI) score 2",
                              "Incidence of serious adverse events",
                              "Number of days alive off supplemental oxygen"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Day 7 after first infusion",
                              "On the day of screening and on days 3, 7 and 14 after first infusion",
                              "On the day of screening and on days 3, 7 and 14 after first infusion",
                              "On the day of screening and on days 3, 7 and 14 after first infusion",
                              "On the day of screening (baseline) and on days 3, 7 and 14 after first infusion",
                              "On the day of screening and on days 3, 7 and 14 after first infusion",
                              "28 days after first infusion",
                              "100 days after first infusion",
                              "28 days after first infusion",
                              "28 days after first infusion",
                              "Baseline and Day 28 after first infusion",
                              "28 days after first infusion",
                              "100 days after first infusion"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04466098"
                        ]
                  },
                  {
                        "Rank": 51,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Recovery of the estimated functional status according to the New York Heart Association (NYHA) classification",
                              "Change in the median score for quality of life of the Minnesota Living with Heart Failure Questionnaire (MLHFQ)",
                              "Changes in the delayed enhancement of the left ventricle on MRI, defined as percentage of the wall thickness involved when adding each segment visually",
                              "Improvement in the 6-minute walk test, defined as the percentage of change of the distance traveled",
                              "Mortality at 3 and 12 months due to cardiovascular causes",
                              "Mortality at 3 and 12 months due to all causes"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Estimated functional status",
                              "Change in the median score of Quality of life",
                              "Delayed enhancement of the left ventricle",
                              "Improvement in the 6-minute walk test",
                              "Mortality at 3 and 12 months due to cardiovascular causes",
                              "Mortality at 3 and 12 months due to all causes"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04011059"
                        ]
                  },
                  {
                        "Rank": 52,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "To assess the clinical status (on a 7-point WHO ordinal scale)",
                              "To assess the duration of oxygen therapy and/or mechanical ventilation",
                              "To assess the length of stay at the intensive care unit and of hospitalization",
                              "To assess the number of organ failures",
                              "To assess the intensity of the inflammatory response",
                              "To assess the evolution of coagulation parameter",
                              "To assess the presence of Biomarker of lung lesion, repair and scarring",
                              "To assess the v iral load over the 28 days after inclusion and seroconversion to COVID-19 over the 90 days after inclusion",
                              "To assess the pulmonary function",
                              "To assess the number of adverse reactions (ARs), ARs grade > 3, serious adverse events (SAEs), serious ARs (SARs), suspected expected and unexpected SARs (SESARs and SUSARs)."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)",
                              "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)",
                              "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)",
                              "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)",
                              "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)",
                              "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)",
                              "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)",
                              "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)",
                              "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)",
                              "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Day 28",
                              "Day 28",
                              "Day 90",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 90",
                              "Day 90",
                              "Day 90"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04445454"
                        ]
                  },
                  {
                        "Rank": 53,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Results of Real-Time Polymerase Chain Reaction of Viral RNA, Turing negative"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "RT-PCR results"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "8 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04313322"
                        ]
                  },
                  {
                        "Rank": 54,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [
                              "Mayo Clinic Clinical Trials"
                        ],
                        "SeeAlsoLinkURL": [
                              "https://www.mayo.edu/research/clinical-trials"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02805855"
                        ]
                  },
                  {
                        "Rank": 55,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [
                              "Probability Sample"
                        ],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Flow cytometric analysis of cell surface antigens, Alkaline phosphatase activity, DNA content as measure for cellular proliferation"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "variable 2 days up to 21 days after msc cultivation"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01038596"
                        ]
                  },
                  {
                        "Rank": 56,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Evaluated by Ultrasound B. The endometrium thickness increased \u2265 2mm and \"B\" or \"A\" endometrium appeared in the endometrium proliferation stage."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Intrauterine adhesion patients efficacy evaluation"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05495711"
                        ]
                  },
                  {
                        "Rank": 57,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "According to 'Diagnostic and Curative Criteria of Hematological Diseases' 3rd edition edited by Zhang Zhinan and Shen Di, evaluate the hUC-MSCs efficacy. The result as follow:\n\ncomplete remission (CR);\npartial remission (PR);\nstable disease (SD);\nprogressive disease (PD)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Improvement in clinical function"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "16 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03184935"
                        ]
                  },
                  {
                        "Rank": 58,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Secondary measures were assessed at 3, 6, 12 and 24 weeks before and after treatment, including:\n\nSubjective indicators:\n\nODI(The Oswestry Disability Index) score:\n\n0%-20%: Minimal disability: This group can cope with most living activities. Don't need treatment.\n\n20%-40% Moderate disability: This group experiences more pain and problems with sitting, lifting, and standing. Personal care, sexual activity, and sleeping are not grossly affected, and the back condition can usually be managed by conservative means.\n\n40%-60%: Severe disability: Pain remains the main problem in this group of patients, but travel, personal care, social life, sexual activity, and sleep are also affected.\n\n60%-80%: Crippled: Back pain impinges on all aspects of these patients' lives-both at home and at work-and positive intervention is required.\n\n80%-100%: These patients are either bed-bound or exaggerating their symptoms. Need evaluated by careful observation of the patient during medical examination.",
                              "Observe for any adverse reactions, including fever, pain, or bleeding to evaluate the changes of safety indexes at the 3\u30016\u300112\u300124weeks after treatment.",
                              "Being the Activated partial thromboplastin time (APTT) test for the patients to examine the changes of safety indexes at the 3\u30016\u300112\u300124 weeks after treatment.\n\ntime of 25-37 seconds. Abnormalities over 10 seconds should be compared with normal controls.",
                              "Being the Prothrombin time (PT) test for the patients to examine the changes of safety indexes at the 3\u30016\u300112\u300124 weeks after treatment.\n\ntime of 11-14 seconds. Abnormalities over 3 seconds in comparison with normal controls are required. Activity: 80-120% INR: 0.8-1.2",
                              "Fibrinogen test for the patients to examine the changes of safety indexes at the 3\u30016\u300112\u300124 weeks after treatment.\n\nThe Fibrinogen should in 2-4g/L",
                              "Thrombin time (TT) test for the patients to examine the changes of safety indexes at the 3\u30016\u300112\u300124 weeks after treatment.\n\nthe time of 12-16 seconds, TT need to be abnormal for more than 3 seconds compared with normal controls"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Observe treatment",
                              "Safety evaluation by detecting adverse events and serious adverse events",
                              "Safety evaluation by detecting Activated partial thromboplastin time (APTT)",
                              "Safety evaluation by detecting Prothrombin time (PT)",
                              "Safety evaluation by detecting Fibrinogen",
                              "Safety evaluation by detecting Thrombin time (TT)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "24weeks",
                              "24 weeks",
                              "24 weeks",
                              "24 weeks",
                              "24 weeks",
                              "24 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04104412"
                        ]
                  },
                  {
                        "Rank": 59,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Evaluate the efficacy by calculating the 50% or more reduction, the equation is, Efficacy = (Area of lacuna and diverticulum after treatment - Area of lacuna and diverticulum after treatment before treatment)/Area of lacuna and diverticulum before treatment * 100%.\n\nClassified the efficacy in 4 grade as follow, A. Recovery, efficacy 86% - 100%; B. Obvious improve, efficacy 46% - 85%; C. Improve, efficacy 16% -45%; D. Invalid, efficacy < 16% Grade A, B, and C is proposed to be effective.",
                              "Ultrasound of uterus. Compare with the baseline images, evaluate the changes/improvement after cell treatment.",
                              "Do hysteroscopy examination, compare with the baseline images, evaluate the change/improvement after cell treatment.",
                              "Measure the pain score of patients by Visual Analog Score (VAS) for pain"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Incision lacuna and incision diverticulum patients efficacy evaluation",
                              "Ultrasound of uterus evaluation",
                              "Hysteroscopy evaluation",
                              "Pain score"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03386708"
                        ]
                  },
                  {
                        "Rank": 60,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The Outcome Measure will be the presence or absence of fistula drainage (Yes vs. No)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Number of Subjects with healing in response to the study drug treatment"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Time Frame: 2-24 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03014219"
                        ]
                  },
                  {
                        "Rank": 61,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2018-004158-11"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Number of patients insulin independent (ADA criteria) at day 372.",
                              "Number of patients with daily insulin needs <0.25U/kg at day 372.",
                              "HbA1c at day 372",
                              "Glucose variability (mean amplitude of glycaemic excursions and glycaemic lability index) duration derived from the continuous glucose monitoring system\u00ae at day 372",
                              "Delta change of levels of fasting C-peptide at day 372 when compared to test before start of treatment",
                              "Numbers of patients with peak C-peptide >0.20 nmol/l, in response to the MMTT, at day 372."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "372 days",
                              "372 days",
                              "372 days",
                              "372 days",
                              "372 days",
                              "372 days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03973827"
                        ]
                  },
                  {
                        "Rank": 62,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Rate of death until discharge or 40 weeks corrected gestational age, whichever comes first",
                              "Blood culture-proven sepsis\nPatent ductus arteriosus (treated medically or surgically)\nNecrotizing enterocolitis\nIsolated intestinal perforation\nRetinopathy of prematurity requiring treatment\nSevere intraventricular hemorrhage (\u2265 grade 3)\nCystic periventricular leukomalacia",
                              "Measures of gas exchange",
                              "Time to extubation\nDuration of mechanical ventilation\nDuration of non-invasive positive pressure respiratory support\nDuration of supplemental oxygen",
                              "This is a yes/no measure",
                              "Measured as mild, moderate, or severe",
                              "Measured according to the physiological definition of BPD (BPD at 36 weeks corrected age)",
                              "Targeted neonatal echocardiography to assess pulmonary hypertension using validated parameters",
                              "Markers of inflammation will be assessed in patient serum samples",
                              "Biomarkers of lung improvement will be assessed in patient tracheal aspirate samples",
                              "Successful recruitment and administration of cells to nine patients in 18 months",
                              "Proportion of potentially eligible patients that are successfully screened\nProportion of participants successfully screened who do not enroll (reason for failure to enroll will be recorded)",
                              "Median time from screening to enrollment\nMedian time from screening to cell administration",
                              "Proportion of patients that do not complete cell infusion\nProportion of patients enrolled that do not undergo scheduled follow-up",
                              "Assessment of cognitive, language, and motor development",
                              "Participant's overall health will be assessed through a questionnaire administered over the phone, once a year for 10 years",
                              "Characterize parental views of an animated MSC information video through brief semi-structured interviews"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Rate of Death",
                              "Occurrence of Other Severe Complications of Prematurity",
                              "FiO2 and Oxygen Index",
                              "Need for Ventilatory Support",
                              "Need for Postnatal Steroids",
                              "Incidence and Severity of BPD",
                              "Rate of Survival Without (moderate or severe) BPD",
                              "Changes in Pulmonary Hemodynamics",
                              "Biological Measure of Clinical Improvement",
                              "Biological Measure of Lung Improvement",
                              "Feasibility: Cell Administration",
                              "Feasibility: Recruitment Efficiency",
                              "Feasibility: Recruitment Timing",
                              "Feasibility: Participant Retainment",
                              "Bayley Scale of Infant and Toddler Development",
                              "Long-term Safety Follow-Up",
                              "Animated Information Video"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "From enrollment until discharge or 40 weeks corrected gestational age (whichever occurs first)",
                              "From enrollment until discharge or 40 weeks corrected gestational age (whichever occurs first)",
                              "From enrollment until discharge, 40 weeks corrected gestational age, or death (whichever occurs first)",
                              "From enrollment until discharge, 40 weeks corrected gestational age, or death (whichever occurs first)",
                              "From enrollment until discharge, 40 weeks corrected gestational age, or death (whichever occurs first)",
                              "From enrollment until discharge, 40 weeks corrected gestational age, or death (whichever occurs first)",
                              "From enrollment until 36 weeks corrected gestational age",
                              "At enrollment, 48 hours following uc-MSC injection, 28 days of life, and 36 weeks corrected gestational age",
                              "72-96 hours following uc-MSC injection",
                              "72-96 hours following uc-MSC injection",
                              "Day of life 7-21",
                              "Day of life 7-21",
                              "Day of life 7-21",
                              "From enrollment until follow-up at 18-24 months-of-age",
                              "18-24 months-of-age",
                              "Ten years following follow-up visit",
                              "Day of life 7-21"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04255147"
                        ]
                  },
                  {
                        "Rank": 63,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "To assess the efficacy of hUC-MSCs in the treatment of ACLF patients, patients will be followed-up, and the prognosis at each time point will be collected as our schedule."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Short-time efficacy of treatment"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "90 days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04822922"
                        ]
                  },
                  {
                        "Rank": 64,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "This is the thickness from the outer plexiform layer to the Bruch membrane in the 3x3 mm area of the fovea measured (and recorded automatically) by the multimodal imaging OCTA device."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Outer retinal thickness"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Change from baseline outer retinal thickness at 6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04224207"
                        ]
                  },
                  {
                        "Rank": 65,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Survival rate at 28 days after the first dose of MSCs",
                              "Description of duration of inotrope support after the first dose of MSCs",
                              "Description of number of days to hospital discharge to home",
                              "Description of Duration of ICU stay",
                              "Incidence of cardiac abnormalities at day 28, defined as persistent abnormalities in ECG, Echo, or biochemical markers (pro-BNP, troponin)."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Survival",
                              "Inotrope support",
                              "Hospital Discharge",
                              "Duration of ICU stay",
                              "cardiac abnormalities"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "from first dose of MSCs to 28 days after first dose",
                              "from first dose of MSCs to 90 days after first dose",
                              "from first dose of MSCs to 90 days after first dose",
                              "from first dose of MSCs to 90 days after first dose",
                              "from first dose of MSCs to 28 days after first dose"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04549285"
                        ]
                  },
                  {
                        "Rank": 66,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Changes in motor and sensory scores assessed by IANR-SCIRFS scale (total score range from 0 to 51, higher values represent a better outcome)",
                              "Changes in electromyogram test",
                              "Changes in residual urine measured by ultrasound test (volume of urine in mL, lower values represent a better outcome)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Changes in International Association of Neural Restoration Spinal Cord Injury Functional Rating Scale (IANR-SCIRFS)",
                              "Changes in electromyogram test",
                              "Changes in residual urine"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, 1 month, 3 months, 6 months and 12 months post-treatment",
                              "Baseline, 6 months and 12 months post-treatment",
                              "Baseline, 6 months and 12 months post-treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03505034"
                        ]
                  },
                  {
                        "Rank": 67,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The proportion of study participants independent of insulin at 6 months",
                              "The proportion of study participants independent of insulin at 12 months",
                              "The proportion of study participants with daily insulin needs <0.25 U/kg at 6 months",
                              "The proportion of study participants with daily insulin needs <0.25 U/kg at 12 months",
                              "Insulin requirement/kg body weigh at 6 months",
                              "Insulin requirement/kg body weigh at 12 months",
                              "HbA1c at 6 months",
                              "HbA1c at 12 months",
                              "Time in target (4-8 mmol/l) as measured by flash glucose monitoring for 14 days at 6 months",
                              "Time in target (4-8 mmol/l) as measured by flash glucose monitoring for 14 days at 12 months",
                              "Time in target (3.9-10 mmol/l) as measured by flash glucose monitoring for 14 days at 6 months",
                              "Time in target (3.9-10 mmol/l) as measured by flash glucose monitoring for 14 days at 12 months",
                              "Change in C-peptide Area under the curve (AUC) (0-120 min) for mixed meal tolerance test (MMTT) at 6 months following Protrans/Placebo infusion when compared to test performed before the start of treatment (baseline).",
                              "Change in peak C-peptide concentration during the first 6 months",
                              "Change in peak C-peptide concentration during the first 12 months"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Insulin independency",
                              "Insulin independency",
                              "Low insulin needs",
                              "Low insulin needs",
                              "Insulin needs",
                              "Insulin needs",
                              "HbA1c",
                              "HbA1c",
                              "Time in target",
                              "Time in target",
                              "Time in range",
                              "Time in range",
                              "C-peptide",
                              "Change in peak C-peptide",
                              "Change in peak C-peptide"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "One year",
                              "One year",
                              "6 months",
                              "12 months",
                              "6 months",
                              "12 months",
                              "6 months",
                              "12 months",
                              "6 months",
                              "12 months",
                              "6 months",
                              "12 months",
                              "6 months",
                              "6 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05061030"
                        ]
                  },
                  {
                        "Rank": 68,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "NCI-2018-01441",
                              "2018-0126"
                        ],
                        "SecondaryIdDomain": [
                              "CTRP (Clinical Trial Reporting Program)",
                              "M D Anderson Cancer Center"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Registry Identifier",
                              "Other Identifier"
                        ],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [
                              "MD Anderson Cancer Center Website"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://www.mdanderson.org"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03608631"
                        ]
                  },
                  {
                        "Rank": 69,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "To evaluate the efficacy of hUC-MSCs to prevent preterm infants at high risk of BPD from developing BPD",
                              "To evaluate the safety and efficacy of human umbilical cord -derived mesenchymal stem cells for BPDmesenchymal stem cells for BPD.",
                              "To evaluate the safety of human umbilical cord -derived mesenchymal stem cells for BPD.mesenchymal stem cells for BPD.",
                              "To evaluate the safety of human umbilical cord -derived mesenchymal stem cells for BPD. Blood pressure is measured by electronic sphygmomanometer.",
                              "To evaluate the safety of human umbilical cord -derived mesenchymal stem cells for BPD.",
                              "To evaluate the safety of human umbilical cord -derived mesenchymal stem cells for BPD."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The incidence and severity of BPD defined by the National Institutes of Child Health and Human Development (NICHD) workshop.",
                              "Changes of high-resolution chest CT in participants",
                              "Changes of temperature in participants",
                              "Changes of blood pressure in participants",
                              "Changes of respiratory rate in participants",
                              "Changes of oxygen saturation in participants"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "at the corrected gestational age of 36 weeks",
                              "within 2 years after administration",
                              "3 days after administration",
                              "3 days after administration",
                              "3 days after administration",
                              "3 days after administration"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03774537"
                        ]
                  },
                  {
                        "Rank": 70,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The days without invasive ventilator support(at least 2 consecutive calendar days) in 28 days.\n\nIf the ventilator weaned multiple times, VFDs is the sum of the days without ventilator support.\n\nIf any of following occurring in 28 days, VFDs equals 0:\n\nThe patient dies in 28 days;\nVentilator never be weaned;\nCensored case with ventilator never being weaned.",
                              "The oxygenation index(OI)=partial pressure of oxygen in arterial blood(PaO2) divide inspiration fraction of oxygen(FiO2). OI is measured at day0, day1,day3,day7.",
                              "Murray lung injury scores (LIS) consist of the following 4 parts:\n\nA.Hypoxemia (PaO2/FiO2\u2265300, 225-299,175-224,100-174,<100, assigned 0,1,2,3,4 scores respectively); B.PEEP (cmH2O) (\u22645,6-8,9-11,11-14,\u226515, assigned 0,1,2,3,4 scores respectively) ; C.Compliance (ml/cmH2O)(\u226580,60-79,40-59,20-39,\u226419, assigned 0,1,2,3,4 scores respectively); D.Quadrants infiltrated in Chest X-Ray(CXR) (0,1,2,3,4, assigned 0,1,2,3,4 scores respectively).\n\nThe total LIS score is obtained by dividing the total sum of points by the number of criteria present. For example, if only 3 criteria are answered to, the total sum is divided by 3 to reveal the final score.\n\nThe LIS score ranges between 0 and 4, with scores closer to 4 indicating severe acute lung injury.",
                              "Monitored by ventilator and recorded per hour, obtain the average value of the day. unit-cmH20",
                              "Monitored by ventilator in one inspiration pause, measured 4 times a day. Record the average value of the day. unit-cmH20",
                              "Calculate the driving pressure by Pplat minus PEEP, measured 4 times a day. Record the average value of the day. unit-cmH20",
                              "Calculate the static compliance by the following formula:\n\nstatic compliance=tidal volume/(Pplat-PEEP), unit-ml/cmH2O"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Ventilation free days(VFDs)",
                              "Oxygenation index(OI) changes",
                              "Lung injury score(LIS)",
                              "Positive end expiratory pressure(PEEP)",
                              "Plateau pressure(Pplat)",
                              "Driving pressure",
                              "Static compliance"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "From the day of UCMSCs use(day 0) to day 28",
                              "From day 0 to day 7, each day",
                              "From day 0 to day 7, day0,1,3,7",
                              "From day 0 to day 7, each day",
                              "From day 0 to day 7, each day",
                              "From day 0 to day 7, each day",
                              "From day 0 to day 7, each day"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03608592"
                        ]
                  },
                  {
                        "Rank": 71,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Markers including osteocalcin, BAP, CTX, PICP, Calcium/Creatinine Ratio (urine), and NTX/Creatinine Ratio (urine) will be assessed for both bone health as well as bone formation/resorption.",
                              "This is a validated survey that will serve as a patient-reported outcome measure evaluating health status for these patients and the burden of their caregivers. The scores can range from 0-100 with a higher score correlating with a better outcome.",
                              "This validated survey contains 10 point ordinal scales that outline rapid descriptions for gross and fine motor performance. The higher you score on the BAMF survey, the more developed your gross and fine motor skills are.",
                              "The PODCI questionnaire will used to quantify function abilities in our studied population. The scores can range from 0-100, with higher scores indicating higher levels of disability, and lower scores indicating better functioning."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Number of participants with changes in bone metabolism markers",
                              "Change in Limb Deformity Modified EOS Questionnaire (LD-EOSQ-22) from baseline",
                              "Change in BAMF (Brief Assessment of Motor Function) from baseline",
                              "Change in Pediatric Orthopedic Data Collection Instrument (PODCI) from baseline"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, every 12 months post-intervention, and at the conclusion of the study (up to 36 months post-intervention)",
                              "Baseline, annually until 1 year after last infusion",
                              "Baseline, annually until 1 year after last infusion",
                              "Baseline, annually until 1 year after last intervention"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05559801"
                        ]
                  },
                  {
                        "Rank": 72,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Evaluate criteria:\n\nRecovery: symptoms disappear\nExcellent: symptoms improved obviously\nEfficient: symptoms improved\nInefficient: symptoms no change or worse"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Single therapy effectiveness evaluation"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03180450"
                        ]
                  },
                  {
                        "Rank": 73,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Secondary objective will be measured by using the Pediatric Cardiac Critical Care Consortium (PC4) registry system."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Actual magnitude of differences in neuroimaging and neurodevelopmental variables will be measured after MSC delivery."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "18 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04236479"
                        ]
                  },
                  {
                        "Rank": 74,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "PASI score will be assessed at month 6, 9 and 12 from the first UC-MSC infusion as followed-up.",
                              "DLQI score will be assessed at month 6, 9 and 12 from the first UC-MSC infusion as followed-up."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "body temperature will be monitored for any possible infusion-related toxicities.",
                              "blood pressure will be monitored for any possible infusion-related toxicities.",
                              "Psoriasis Area and Severity Index (PASI) score",
                              "Dermatology Life Quality Index (DLQI) score"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "up to 3 months",
                              "up to 3 months",
                              "month 6, 9, and 12",
                              "month 6, 9, and 12"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02491658"
                        ]
                  },
                  {
                        "Rank": 75,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "To assess the anti-inflammatory effect of the proposed treatment with assessment of the levels of C-reactive protein (mg/dL)",
                              "days of the patients in hospital",
                              "Evaluation of functional respiratory changes: PaO2 / FiO2 ratio",
                              "Improvement in Liao's score (2020)",
                              "Computed tomography Chest assesment will be done to assess improvement in radiological findings of COVID-19",
                              "PCR testing to check PCR negativity"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Changes on inflammatory C-reactive protein",
                              "Hospital stay",
                              "Oxygenation index (PaO2/FiO2)",
                              "Improvement in Liao's score (2020)",
                              "Radiological improvement",
                              "Time of COVID19 PCR negativity"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "60 days",
                              "60 days",
                              "60 days",
                              "60 days",
                              "60 days",
                              "28 days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04467047"
                        ]
                  },
                  {
                        "Rank": 76,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04315025"
                        ]
                  },
                  {
                        "Rank": 77,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Imaging procedure",
                              "Medical assessment",
                              "Quantification of disability",
                              "Imaging procedure"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Cumulative number of MRI Gd-enhancing lesions",
                              "Multiple Sclerosis Outbreaks",
                              "Expanded Disability Status Scale (EDDS) score",
                              "Cumulative number of lesions visualized on T2 sequence"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Blood and Tissue Bank of Catalonia",
                              "Multiple Sclerosis center of Catalonia",
                              "Vall d'Hebron Research Institute"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://www.bancsang.net",
                              "http://www.cem-cat.org/",
                              "http://www.vhir.org"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02495766"
                        ]
                  },
                  {
                        "Rank": 78,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Change in the ODI at 1, 3, 6, 9, and 12 months after the transplantation of WJ-MSCs, compared to before the transplantation.\n\non a scale of 0 to 3, with 0 meaning no disability and 10 meaning severe disability",
                              "Change in the T score (lumbar spine and femoral neck) of dual-energy x-ray absorptiometry at 6 and 12 months after the transplantation compared to before the transplantation",
                              "identification of spine fracture based on x ray",
                              "Change in the bone mineral density (computed tomography) at 6 and 12 months after the transplantation compared to before the transplantation"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "improvement in Oswestry Disability Index",
                              "Change in the T score (lumbar spine and femoral neck) of dual-energy x-ray absorptiometry",
                              "Presence of new vertebral fracture",
                              "Change in the bone mineral density (computed tomography) of fractured vertebrae"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05018637"
                        ]
                  },
                  {
                        "Rank": 79,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Liver function improvement",
                              "The size of liver and the width of portal venous",
                              "Incidence of hepatocellular carcinoma within 1 year",
                              "Child-Pugh score, MELD score,SF36-quality of life (SF36-QOL)",
                              "The clinical symptom improvement(including appetite, debilitation, abdominal distension, edema of lower limbs, et al )"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1 year after treatment",
                              "1 year after treatment",
                              "1 year after treatment",
                              "1 year after treatment",
                              "1 year after treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01342250"
                        ]
                  },
                  {
                        "Rank": 80,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The Inflammatory Bowel Disease Questionnaire (IBDQ) is a widely used questionnaire for Health-related quality of life assessment in patients with inflammatory bowel diseases (IBDs).",
                              "Albumin is an important component of the blood, and patients with severe Crohn's disease can present with clinical signs of hypoproteinemia.",
                              "Hemoglobin is an important component of the blood, and patients with severe Crohn's disease can present with clinical signs of anemia.",
                              "Fecal calprotectin (FC) is a non-invasive marker of gastrointestinal inflammation with advocated diagnostic precision in distinguishing inflammatory bowel disease (IBD) from non-IBD diagnoses.",
                              "Weight and height will be combined to report BMI in kg/m^2"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Inflammatory Bowel Disease Questionnaire",
                              "Albumin",
                              "Hemoglobin",
                              "Fecal calprotectin",
                              "body mass index (BMI)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Changes from baseline to week 4, week 8, week 12 and week 24 after stem cell treatment.",
                              "Changes from baseline to week 4, week 8, week 12 and week 24 after stem cell treatment.",
                              "Changes from baseline to week 4, week 8, week 12 and week 24 after stem cell treatment.",
                              "Changes from baseline to week 4, week 8, week 12 and week 24 after stem cell treatment.",
                              "Changes from baseline to week 4, week 8, week 12 and week 24 after stem cell treatment."
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05262829"
                        ]
                  },
                  {
                        "Rank": 81,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Incidences of Adverse Event and Serious Adverse Event",
                              "Change from baseline in CK",
                              "Change from baseline in LDH",
                              "Change from baseline in ALT",
                              "Change from baseline in AST",
                              "Change from baseline to manual muscle test(MMT)",
                              "Change from baseline in electromyography(EMG)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1 year after treatment",
                              "1 year after treatment",
                              "1 year after treatment",
                              "1 year after treatment",
                              "1 year after treatment",
                              "1 year after treatment",
                              "1 year after treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01610440"
                        ]
                  },
                  {
                        "Rank": 82,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02421484"
                        ]
                  },
                  {
                        "Rank": 83,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Mild: <14; moderate: 14-26; serious: >26",
                              "Test the level change of Follicle-Stimulating Hormone (FSH), estrogen (E2), and Anti Mullerian Hormone (AMH)",
                              "Observe the size of ovarian follicles in each cycle."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Kupperman score",
                              "hormone level",
                              "Follicular development"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "270 days",
                              "270 days",
                              "270 days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03816852"
                        ]
                  },
                  {
                        "Rank": 84,
                        "ResultsFirstSubmitDate": [
                              "May 30, 2018"
                        ],
                        "ResultsFirstSubmitQCDate": [
                              "July 9, 2018"
                        ],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Overall survival is reported at the count of participants alive 6 months following HCT.",
                              "Overall survival is reported at the count of participants alive 1 year following HCT.",
                              "Disease-free survival is defined as alive without underlying disease.",
                              "Disease-free survival is defined as alive without underlying disease."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Overall Survival 6 Months Following HCT",
                              "Overall Survival 1 Year Following HCT",
                              "Count of Participants With Disease-free Survival 6 Months Following HCT",
                              "Count of Participants With Disease-free Survival 1 Year Following HCT"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months",
                              "1 year",
                              "6 months",
                              "1 year"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment"
                        ],
                        "NCTId": [
                              "NCT00957931"
                        ]
                  },
                  {
                        "Rank": 85,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Incidence of acute and chronic treatment-related adverse events in patients with novel coronavirus severe pneumonia receiving UC-MSCs infusion as assessed.",
                              "Marker for efficacy of treatment",
                              "Markers of organ function\uff08Score each criterion on a scale of 0 to 4, and the higher the score, the worse the prognosis.\uff09",
                              "Markers of Infection",
                              "Markers of Infection",
                              "Marker of Immunological function",
                              "Marker of Immunological function",
                              "Marker of Immunological function"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Side effects in the UC-MSCs treatment group",
                              "28-days survival",
                              "Sequential organ failure assessment",
                              "C-reactive protein",
                              "Procalcitonin",
                              "Lymphocyte count",
                              "CD3+, CD4+ and CD8+ T celll count",
                              "CD4+/CD8+ratio"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "From Baseline (0W) to 96 week after treatment",
                              "Day 28",
                              "Day 28",
                              "From Baseline (0W) to 12 week after treatment",
                              "From Baseline (0W) to 12 week after treatment",
                              "From Baseline (0W) to 12 week after treatment",
                              "From Baseline (0W) to 12 week after treatment",
                              "From Baseline (0W) to 12 week after treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04273646"
                        ]
                  },
                  {
                        "Rank": 86,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2015-002186-27"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02565459"
                        ]
                  },
                  {
                        "Rank": 87,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Adverse events were categorized using National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.0 scale (NCI-CTCAE v4.0)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Severity of adverse events"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02776943"
                        ]
                  },
                  {
                        "Rank": 88,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "To document changes in lung function and 6 minute walk distance (6MWD) following infusion of MSC",
                              "To document survival post MSC infusion"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01175655"
                        ]
                  },
                  {
                        "Rank": 89,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2020-002193-27"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Secondary endpoint",
                              "Secondary endpoint",
                              "Secondary endpoint.\n\nCategories:\n\nNot hospitalized, no limitations on activities.\nNot hospitalized, limitation on activities.\nHospitalized, not requiring supplemental oxygen.\nHospitalized, requiring supplemental oxygen.\nHospitalized, on non-invasive ventilation or high flow oxygen devices.\nHospitalized, on invasive mechanical ventilation or ECMO .\nDeath.",
                              "Secondary endpoint",
                              "Secondary endpoint Sequential Organ Failure Assessment score (0-24)",
                              "Secondary endpoint",
                              "Secondary endpoint",
                              "Secondary endpoint",
                              "Secondary endpoint Proportion of patients with non-invasive ventilation",
                              "Secondary endpoint Proportion of patients with invasive mechanical ventilation",
                              "Secondary endpoint (number of days)",
                              "Secondary endpoint (number of days)",
                              "Secondary endpoint",
                              "Secondary endpoint",
                              "Secondary endpoint"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "All-cause mortality",
                              "Time to PaO2/FiO2 ratio greater than 200 mmHg",
                              "Clinical status on the World Health Organization ordinal scale",
                              "PaO2/FiO2 ratio",
                              "SOFA score",
                              "Oxygen therapy-free days",
                              "Duration of hospitalization",
                              "Duration of ICU admission",
                              "Incidence of non-invasive ventilation",
                              "Incidence of invasive mechanical ventilation",
                              "Duration of non-invasive ventilation",
                              "Duration of invasive mechanical ventilation",
                              "Mechanical ventilation-free days",
                              "Survival rate",
                              "Cumulative incidence SAEs, Grade 3 and 4 AEs, ADR and AEs of special interest."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Days 7, 14, and 28 after treatment",
                              "12 months",
                              "Baseline, daily until day 14, and on day 28 after treatment",
                              "Baseline and days 2, 4, 14 and 28 after treatment",
                              "Baseline and days 2, 4, 7, 14 and 28 after treatment",
                              "Day 28",
                              "12 months",
                              "12 months",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "3 and 12 months.",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04615429"
                        ]
                  },
                  {
                        "Rank": 90,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Quantify pulmonary respiratory function measured by chest computerized tomography",
                              "The efficacy of UC-MSC treatment was measured by arterial blood gas analysis",
                              "The efficacy of UC-MSC treatment was measured by biological markers,including markers of inflammation\uff0cIL-6",
                              "The efficacy of UC-MSC treatment was measured by biological markers,including markers of inflammation\uff0cIL-8"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Participants will be followed for the duration of hospital,2 day post-infusion, and days 7,14.",
                              "Participants will be followed for the duration of hospital,2 day post-infusion, and days 7,14.",
                              "6 hours post-infusion, and days 1, 2, and 3",
                              "6 hours post-infusion, and days 1, 2, and 3"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02444455"
                        ]
                  },
                  {
                        "Rank": 91,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Changes in motor and sensory scores assessed by IANR-SCIRFS scale (total score range from 0 to 51, higher values represent a better outcome)",
                              "Changes in electromyogram test",
                              "Changes in residual urine measured by ultrasound test (volume of urine in mL, lower values represent a better outcome)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Changes in International Association of Neural Restoration Spinal Cord Injury Functional Rating Scale (IANR-SCIRFS)",
                              "Changes in electromyogram test",
                              "Changes in residual urine"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, 1 month, 3 months, 6 months and 12 months post-treatment",
                              "Baseline, 6 months and 12 months post-treatment",
                              "Baseline, 6 months and 12 months post-treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03521336"
                        ]
                  },
                  {
                        "Rank": 92,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Changes in motor and sensory scores assessed by IANR-SCIRFS scale (total score range from 0 to 51, higher values represent a better outcome)",
                              "Changes in electromyogram test",
                              "Changes in residual urine measured by ultrasound test (volume of urine in mL, lower values represent a better outcome)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Changes in International Association of Neural Restoration Spinal Cord Injury Functional Rating Scale (IANR-SCIRFS)",
                              "Changes in electromyogram test",
                              "Changes in residual urine"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, 1 month, 3 months, 6 months and 12 months post-treatment",
                              "Baseline, 6 months and 12 months post-treatment",
                              "Baseline, 6 months and 12 months post-treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03521323"
                        ]
                  },
                  {
                        "Rank": 93,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2020-001682-36"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Index based in the 4 most relevant symptoms and signs: fever, shortness of bread, %Hemoglobin Saturation and PaO2 / FiO2",
                              "Evaluation of pneumonia changes"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Proportion of patients who have achieved clinical response",
                              "Proportion of patients who have achieved radiological responses"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "0-7days",
                              "0-28 days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04361942"
                        ]
                  },
                  {
                        "Rank": 94,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "5R21DK099696"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [
                              "https://reporter.nih.gov/quickSearch/5R21DK099696"
                        ],
                        "SecondaryIdType": [
                              "U.S. NIH Grant/Contract"
                        ],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Liver function, kidney function",
                              "The absence of severe hypoglycemic episodes"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months after transplant",
                              "12 months after transplant"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02384018"
                        ]
                  },
                  {
                        "Rank": 95,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Comparison of National Institutes of Health stroke scale (NIHSS).",
                              "Comparison of modified Rankin scale (mRS).",
                              "Distinguish of EuroQol 5d (EQ-5D) between pre- and post-treatment 180 days.",
                              "Comparison of infarct size measured by brain MRI."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "180 days after the cell treatment.",
                              "180 days after the cell treatment.",
                              "180 days after the cell treatment.",
                              "180 days after the cell treatment."
                        ],
                        "SeeAlsoLinkLabel": [
                              "This review article provides an update role of hUC-MSCs implantation in the treatment of ischemic stroke.",
                              "Human umbilical cord blood-derived mesenchymal stem cell transplantation attenuates severe brain injury by permanent middle cerebral artery occlusion in newborn rats"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://journal.hep.com.cn/fmd/EN/Y2015/V9/I1/20",
                              "http://www.nature.com/pr/journal/v72/n3/full/pr201271a.html"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02580019"
                        ]
                  },
                  {
                        "Rank": 96,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Frequency of complications, infections and relapse"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in self-assessed disease activity and quality of life",
                              "Safety"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline to 6 months",
                              "Baseline to 21 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02055625"
                        ]
                  },
                  {
                        "Rank": 97,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The efficacy of UC-MSC treatment was measured clinical evaluation defined as wheezing, coughing and other symptoms improved than before.",
                              "The efficacy of UC-MSC treatment was quantified by the differences between the two groups and from baseline to 2 months, as measured by chest computerized tomography(CT).",
                              "The pulmonary function efficacy of UC-MSC treatment was measured by arterial blood gas analysis (oxygenation index).",
                              "The efficacy of UC-MSC treatment was measured by lab Indicators defined as blood cell analysis, markers of inflammation (C-reactive protein)."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The efficacy of UC-MSC treatment was measured clinical evaluation.",
                              "The efficacy of UC-MSC treatment was measured by chest computerized tomography.",
                              "The efficacy of UC-MSC treatment was monitored by pulmonary function.",
                              "The efficacy of UC-MSC treatment was measured by lab Indicators."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "2 months",
                              "2 months",
                              "2 months",
                              "2 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02444858"
                        ]
                  },
                  {
                        "Rank": 98,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "St. George Respiratory Questionnaire",
                              "Spirometry, flow-volume curve, post-bronchodilator test, determination of residual volume, airway resistance by plethysmography, diffusing capacity of the lung for carbon monoxide, and six-minute walk test",
                              "Collection of blood samples for determination of C-reactive protein (CRP), erythrocyte"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Quality of Life",
                              "Pulmonary function",
                              "Inflammation"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "120 days",
                              "120 days",
                              "120 days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01872624"
                        ]
                  },
                  {
                        "Rank": 99,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Proportion of Patients that achieve CR criteria including: 1) Urinary Protein:Creatinine (UPC) ratio < 0.5; 2) estimated Glomerular Filtration Rate (GFR) \u2265 120 ml/min/m2, or at least 80% of baseline; 3) urinalysis < 10 red blood cells (RBC) and no RBC casts per high power field; 4) Prednisone dose \u226410 mg/day.",
                              "Proportion of Patients that achieve PR criteria including: 1) reduction of UPC ratio to at least 50% of baseline; 2) estimated GFR \u2265120 ml/min/m2, or at least 80% of baseline; 3) Prednisone dose \u226410 mg/day.",
                              "Proportion of Patients that fulfill any of the following criteria for Treatment Failure including: 1) Daily Prednisone dose cannot be reduced \u2264 10 mg at week 24; 2) Daily Prednisone is increased above 10 mg after week 24; 3) Introduction of a new immunosuppressive regimen, not included in the trial; 4) Use of Rituximab prior to month 12.",
                              "Proportion of Patients that achieve SRI response, defined as a >4-point reduction in the SELENA-SLEDAI score, no new British Isles Lupus Assessment Group [BILAG] A organ domain score and no more than 1 new BILAG B score, with no worsening in physician's global assessment score versus baseline).\n\nThe Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) version of the SLE Disease Activity Index (SLEDAI) is employed for this calculation.(SELENA-SLEDAI score). The SELENA-SLEDAI score addresses 24 descriptors in 9 organ-systems. Disease worsening increases the score that ranges from 0-105.\n\nThe BILAG addresses 97 items in organ-system domains, in an ordinal (A-E) scale, converted to a numerical (0-96) scale for usual calculations.",
                              "Average change in Selena Sledai Score in patients and controls",
                              "Average hange in BILAG score in patients and controls",
                              "Proportion of patients that experience flares as defined in the Selena Flare Index (SFI). Mild/Moderate Flares are defined by change of 3 or more points in the SELENA-SLEDAI score. Severe Flares are defined as an increase in the SELENA-SLEDAI score to more than 12 points",
                              "Changes in the levels of disease relevant biomarkers in peripheral blood/plasma, including 1) anti-dsDNA antibodies by ELISA; 2) complement proteins C3/C4 by nephelometry (mg/dL); 3) Percentage of CD4+ T helper cell subpopulations (Th1, Th17, Treg) and 4) B cell subpopulations (Naive, Memory, Transitional) by Flow cytometry; and 5) Cytokine Panel by Luminex, including Tumor Necrosis Factor (TNF) alpha, Transforming Growth Factor (TGF) Beta1, Interleukin (lL) 6, IL-17A, IL-10, B-cell activating factor/B Lymphocyte Stimulator (BAFF/BLys), Monocyte chemoattractant protein-1 (MCP-1/CCL2), C-X-C motif chemokine 10 (CXCL10), Interferon (IFN) gamma."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Achievement of Complete Renal Response (CR) at Study Endpoint",
                              "Achievement of Partial Renal Response (PR) at Study Endpoint",
                              "Treatment Failure",
                              "Response of SLE Responder Index (SRI).",
                              "Selena Sledai",
                              "BILAG score",
                              "Disease Flares",
                              "Biomarker Response"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months",
                              "24 weeks and 12 months",
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months",
                              "24 weeks and 12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03917797"
                        ]
                  },
                  {
                        "Rank": 100,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Change from baseline of weight",
                              "Change of muscle diameter (circumferential measurements) from baseline",
                              "Change from baseline of Pulmonary Maximum Expiratory Pressure",
                              "Change from baseline of Pulmonary Forced Vital Capacity",
                              "Maximum Change from baseline of Predicted Inspiratory Pressure %",
                              "Change from baseline of Predicted Maximum Expiratory Pressure %",
                              "Change from baseline of Predicted Forced Vital Capacity %"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "3 months after final treatment",
                              "3 months after final treatment",
                              "3 months after final treatment",
                              "3 months after final treatment",
                              "3 months after final treatment",
                              "3 months after final treatment",
                              "3 months after final treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02235844"
                        ]
                  },
                  {
                        "Rank": 101,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The IL-1\u03b2, IL-6, PGE-2, TGF-\u03b2, TNF-\u03b1 and IGF-1 of articular cavity fluid"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The number of cartilage defects, thickness of cartilage evaluated by X-ray and MRI",
                              "The IL-1\u03b2, IL-6, PGE-2, TGF-\u03b2, TNF-\u03b1 and IGF-1 of articular cavity fluid"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, 1, 3, 6 and 12 weeks",
                              "Baseline, 1, 3, 6 and 12 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03166865"
                        ]
                  },
                  {
                        "Rank": 102,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2012/022238"
                        ],
                        "SecondaryIdDomain": [
                              "Aust Govt Dept of Health and Ageing"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Other Identifier"
                        ],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Quantitative bone density of the tissue engineered construct and adjacent bone from CT scan at 12 months.",
                              "Assessment of cosmesis by photography"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01742260"
                        ]
                  },
                  {
                        "Rank": 103,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2709"
                        ],
                        "SecondaryIdDomain": [
                              "The Marcus Foundation"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Other Grant/Funding Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Change in lung function test and asthma characterization will determine the clinical impact of MSC therapy",
                              "In vivo trafficking of MSCs after intravenous infusion",
                              "Upper airway inflammation will be determined by analysis of small molecule inflammatory constituents in exhaled breath condensate.",
                              "Circulating cell inflammation will be determined by flow cytometric analysis of peripheral blood cells and AbSeq analysis of peripheral blood cells.",
                              "Characteristics of the \u03b3MSCs will be determined by comprehensive analysis at the Marcus Center for Therapeutic Cell Characterization and Manufacturing (MC3M)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in lung function test",
                              "In- vivo trafficking of MSCs after intravenous infusion",
                              "Upper airway inflammation of MSC treatment",
                              "Circulating inflammatory cells of MSC treatment",
                              "Biophysical characteristics of the cell products and correlation with clinical outcome"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, 7 to 30 days post-infusion (study day 14 to 37)",
                              "7 to 30 days post-infusion (study day 14 to 37)",
                              "7 to 30 days post-infusion (study day 14 to 37)",
                              "7 to 30 days post-infusion (study day 14 to 37)",
                              "7 to 30 days post-infusion (study day 14 to 37)"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05035862"
                        ]
                  },
                  {
                        "Rank": 104,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "This endpoint will be defined as lack of neutrophil recovery (defined as ANC > 500/\u03bcL for three consecutive days) by 42 days post-transplant or neutrophil recovery with lack of myeloid donor chimerism. Relapse and death prior to neutrophil engraftment are considered competing risks for the endpoint of primary graft failure.",
                              "Secondary graft failure is defined as initial donor-derived neutrophil engraftment followed by subsequent decline in absolute neutrophil count (ANC) to < 500/\u03bcL for fourteen consecutive measurements on different days, and unresponsive to growth factor therapy, with loss of donor chimerism to < 50%.",
                              "Platelet engraftment is defined as the first day of a minimum of three consecutive measurements on different days such that the patient has achieved a platelet count > 20,000/\u03bcL and > 50,000/\u03bcL with no platelet transfusions in the preceding seven days. The first day of the three measurements will be designated as the day of platelet engraftment.",
                              "The event is death in continuous remission treating relapse as the competing risk. Patients alive and in remission at the time of last observation will be censored.",
                              "Incidences of grade II-IV and III-IV acute GvHD will be measured according to Revised Glucksberg criteria.",
                              "Incidence of chronic GvHD will be scored according to the recent NIH scoring.",
                              "Disease-free survival is defined as the minimum time interval from transplant to relapse/recurrence of disease, to death or to last follow-up.",
                              "Primary cause of death will be classified as:\n\nRelapse/Primary disease: If the patient relapsed/progressed after day 0 prior to death, the primary cause of death is relapse/progression, even if they subsequently developed GvHD, organ toxicities or infections that may have contributed to subsequent death. GvHD: Death from acute or chronic GvHD, in the absence of relapse or disease progression.\n\nInfection: Death from documented viral, bacterial or fungal infections in the absence of GvHD or relapse/disease progression.\n\nOrgan toxicity: Death from major organ toxicities not attributable to acute myeloid leukemia (AML)/MDS, infection or GvHD.\n\nOther: Any other causes of death.",
                              "Testing for recurrent malignancy in the blood, marrow or other sites will be used to assess relapse after transplantation. For the purpose of this study, relapse is defined by either morphological or cytogenetic evidence of AML, acute lymphoblastic leukemia (ALL) or MDS and including minimal residual disease (MRD) in ALL consistent with pre-transplant features. The event for this endpoint is the time interval from transplant to relapse/recurrence of disease or to last follow-up. Death in remission is considered a competing risk.",
                              "If a patient is enrolled on the study but does not start protocol treatment, a study exit form must be submitted documenting the reason for not starting protocol treatment. Such a subject will not be considered evaluable.",
                              "Viral activations of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) will be documented. For the purpose of the study viral activation is defined as any polymerase chain reaction (PCR) assay result considered positive by Laboratory Medicine which may or may not lead to the initiation of antiviral therapy as per institutional guidelines."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Primary graft failure",
                              "Secondary graft failure",
                              "Platelet engraftment",
                              "Non-relapse mortality (NRM)",
                              "Change in Acute graft-versus-host disease (aGvHD) Incidence",
                              "Change in Chronic graft-versus-host disease (cGvHD) Incidence",
                              "Disease-free survival (DFS)",
                              "Primary cause of death",
                              "Relapse",
                              "Early discontinuation",
                              "Viral activation"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Up to Year 2",
                              "Up to Year 2",
                              "Up to Year 2",
                              "Up to Year 2",
                              "Day 30, Day 100",
                              "Day 30, Day 100, Day 180, Day 365",
                              "Up to Year 2",
                              "Up to Year 2",
                              "Up to Year 2",
                              "Up to Year 2",
                              "Up to Day 100"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04328714"
                        ]
                  },
                  {
                        "Rank": 105,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Exercise time and level as assessed via six minute walk test.",
                              "The efficacy of UC-MSC treatment was quantified by the differences between the two groups and from baseline to 6 and 12 months in perfusion images, as measured by SPECT.",
                              "Change in left ventricular ejection fraction was assessed with echocardiography after cell implantation.",
                              "The NYHA scale ranges from 1 (best)\"Mild- no limitation of physical activity due to heart failure\" to 4 (worst) \"Severe-Unable to carry out any physical activity without discomfort due to heart failure\"."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Exercise Time and Level",
                              "Quantify myocardium perfusion measured by SPECT",
                              "Assessment of heart function by left ventricular ejection fraction",
                              "Clinical Improvement in NYHA Classification"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Post cell transplantation: 1, 3, 6, 12 months",
                              "Post cell transplantation: 6, 12 months",
                              "Post cell transplantation: 1, 3, 6\uff0c12 months",
                              "1 year"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02439541"
                        ]
                  },
                  {
                        "Rank": 106,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01306513"
                        ]
                  },
                  {
                        "Rank": 107,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Score 0. No clinical or virological evidence of infection. 1. No limitations of activities. 2. Ambulatory, limitation of activities. 3. Hospitalized, not requiring supplemental oxygen. 4. Hospitalized, requiring supplemental oxygen. 5. Hospitalized, on non-invasive ventilation or high flow oxygen devices. 6. Hospitalized, intubated and on mechanical ventilation. 7. Hospitalized, ventilation + additional organ support - pressors, RRT, ECMO, 8. Death",
                              "Rate of patients alive at Day 7, Day 15 and Day 30",
                              "Score 0. No clinical or virological evidence of infection. 1. No limitations of activities. 2. Ambulatory, limitation of activities. 3. Hospitalized, not requiring supplemental oxygen. 4. Hospitalized, requiring supplemental oxygen. 5. Hospitalized, on non-invasive ventilation or high flow oxygen devices. 6. Hospitalized, intubated and on mechanical ventilation. 7. Hospitalized, ventilation + additional organ support - pressors, RRT (Renal Replacement Therapy), ECMO, 8. Death",
                              "Length of hospitalization and ICU stay in days"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Clinical status evaluation assessed by the 9-point ordinal scale",
                              "Survival",
                              "Time to clinical improvement assessed by the 9-point ordinal scale",
                              "Duration of hospitalization and ICU stay"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "day 7, 15 and 30",
                              "day 7, 15 and 30",
                              "time from randomization to either an improvement of 1 point on the 9-point ordinal scale or discharge from hospital",
                              "From enrolment to discharge or ICU transfer or death"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04869397"
                        ]
                  },
                  {
                        "Rank": 108,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Rate of Survival",
                              "Incidence of Tumorigenicity",
                              "Growth measured by Z-score",
                              "Number of neurological developmental delay",
                              "Number of blindness and deafness"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "within two years",
                              "within two years",
                              "within two years",
                              "within two years",
                              "within two years"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03873506"
                        ]
                  },
                  {
                        "Rank": 109,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Evaluate curative effects by the change of Harris hip score."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Harris Hip Score"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03180463"
                        ]
                  },
                  {
                        "Rank": 110,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2013-005025-23"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Safety will be assessed by collecting adverse events throughout the experimental phase which includes a follow-up of 12 month.",
                              "Characteristics of the callus by tomography and Characteristics of the callus by standard x-ray in both treatment arms",
                              "Quality of life will be measured by EUROQOL-5D test"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Safety assessment of XCEL-MT-OSTEO-ALPHA in non-union fractures",
                              "Efficacy assessment of XCEL-MT-OSTEO-ALPHA in non-union fractures by imaging procedures",
                              "Efficacy assessment by quality of life test"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 month",
                              "6 month",
                              "12 month"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Banc de Sang i Teixits (Blood and Tissue Bank of Catalonia)",
                              "Hospital ASEPEYO Sant Cugat"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://www.bancsang.net/",
                              "http://www.asepeyo.es/hospital-sant-cugat"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02230514"
                        ]
                  },
                  {
                        "Rank": 111,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Incidence of infections and bleedings in burn wounds",
                              "Engraftment assessment: Vitality of the graft",
                              "McGill pain Questionnaire",
                              "Incidence of Adverse Events and Serious Adverse Events"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months after treatment]",
                              "6 months after treatment]",
                              "6 months after treatment",
                              "6 months after treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01443689"
                        ]
                  },
                  {
                        "Rank": 112,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "A psychometric instrument that evaluates memory, attention, reasoning, language, orientation, and praxis.",
                              "A frequently used screening instrument for Alzheimer's disease drug studies. It evaluates orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy two intersecting polygons.",
                              "ADCS-ADL assesses functional performance in subjects with Alzheimer's disease. In a structured interview format, informants are queried as to whether subjects attempted each item in the inventory during the prior 4 weeks and their level of performance. The ADCS-ADL scale discriminates well between normal controls and mild AD patients. It has good test-retest reliability. The ADCS-ADL includes some items from traditional basic ADL scales (e.g., grooming, dressing, walking, bathing, feeding, toileting) as well as items from instrumental activities of daily living scales (e.g., shopping, preparing meals, using household appliances, keeping appointments, reading).",
                              "The NPI is a well-validated, reliable, multi-item instrument to assess psychopathology and behavior in AD based on interview with the informant.",
                              "Plasma beta-amyloid proteins will be collected from blood samples obtained."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)Score",
                              "Change in Mini-Mental State Examination (MMSE) Score",
                              "Change in Clinician's Interview-Based Impression of Change (CIBIC-plus) Score",
                              "Change in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) Score",
                              "Change in Neuropsychiatric Inventory (NPI) Score",
                              "Changes in AD Biomarkers"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "10 weeks,18 weeks,24 weeks,48weeks from post-administration",
                              "10 weeks,18 weeks,36 weeks\uff0c24 weeks,48weeks from post-administration",
                              "10 weeks,18 weeks,24 weeks,36 weeks\uff0c48weeks from post-administration",
                              "10 weeks,18 weeks,24 weeks,36 weeks\uff0c48weeks from post-administration",
                              "10 weeks,18 weeks,24 weeks,36 weeks\uff0c48weeks from post-administration",
                              "36 weeks from post-administration"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02672306"
                        ]
                  },
                  {
                        "Rank": 113,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Change of humoral immunity after stem cell treatment",
                              "Change of humoral immunity after stem cell treatment",
                              "Change of humoral immunity after stem cell treatment",
                              "Change of humoral immunity after stem cell treatment",
                              "Change of humoral immunity after stem cell treatment",
                              "Changes in inflammatory and immunological serologic indicators after stem cell treatment",
                              "Changes in inflammatory and immunological serologic indicators after stem cell treatment",
                              "Changes in inflammatory and immunological serologic indicators after stem cell treatment",
                              "To observe the change of urine test after stem cell treatment",
                              "To observe the change of urine test after stem cell treatment",
                              "To observe the change of urine test after stem cell treatment",
                              "To observe the change of urine test after stem cell treatment",
                              "The change of electrolytes was detected after treatment",
                              "The change of hemoglobin was detected after treatment",
                              "The change of albumin was detected after treatment",
                              "To assess the incidence of complications in other organ systems, such as cardiovascular, skeletal, and hematopoietic systems",
                              "To assess the incidence of complications in other organ systems, such as cardiovascular, skeletal, and hematopoietic systems",
                              "To assess the incidence of complications in other organ systems, such as cardiovascular, skeletal, and hematopoietic systems",
                              "To assess the incidence of complications in other organ systems, such as cardiovascular, skeletal, and hematopoietic systems"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "IgA",
                              "IgG",
                              "IgM",
                              "C3",
                              "C4",
                              "CRP",
                              "IL-6",
                              "Peripheral hemolymocyte subsets",
                              "Urine protein",
                              "Urine RBC",
                              "24-hour urine protein",
                              "Urine albumin/creatinine",
                              "Electrolytes",
                              "Hemoglobin",
                              "Albumin",
                              "Heart ultrasound",
                              "Carotid ultrasound",
                              "NT-proBNP",
                              "iPTH+1,25-VitD3"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment",
                              "2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment",
                              "2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment",
                              "2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment",
                              "2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment",
                              "2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment",
                              "2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment",
                              "2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment",
                              "2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment",
                              "2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment",
                              "2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment",
                              "2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment",
                              "2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment",
                              "2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment",
                              "2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment",
                              "Baseline, 3 months, 6 months and 9 months, 12 months,18 months, 24 months after the second treatment",
                              "Baseline, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment",
                              "Baseline, 2nd treatment, 1 months, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment",
                              "Baseline, 2nd treatment, 1 months, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05512988"
                        ]
                  },
                  {
                        "Rank": 114,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Visual Evoked Potential (VEP)",
                              "Brainstem Auditory Evoked Potential (BAEP)",
                              "Somatosensory Evoked Potential(SEP)",
                              "Brain Magnetic Resonance Imaging \uff08MRI\uff09 Scan"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1 year after treatment",
                              "1 year after treatment",
                              "1 year after treatment",
                              "1 year after treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01364246"
                        ]
                  },
                  {
                        "Rank": 115,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Difference in rate of decline of Frailty assessed using Fried phenotype scale:\n\nSlowing of Mobility (assessed via a 4-meter gait speed test; Timed up and go (TUG) test and Short Physical Performance Battery (SPPB) assessment)\nWeight Loss (assessed via weighing scale)\nReduced Activity (assessed via Minnesota Leisure Time Activities (MLTA) questionnaire)\nDiminished handgrip strength (assessed via dynamometer)\nExhaustion (assessed by two items from the Center for Epidemiological Studies-Depression, CES-D):\" I felt that everything I did was an effort? and I could not get going.\"",
                              "Health-related quality of life will be assessed via Short-Form 36 Health Survey (SF-36), including physical functioning scale and mental health index; the health status including Health State Index (HSI) and respondent's self-rated health on a vertical scale will be accessed via EuroQol 5-Dimension (ED-5D).",
                              "Enzyme-linked immunosorbent assay will be used to identify the serum levels of pro-inflammatory cytokines (e.g.,Interleukin-6).",
                              "Flow cytometry will be used to identify the changes in numbers of lymphocyte subpopulations (e.g., B cells, T cells)."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Difference in rate of decline of Frailty",
                              "Difference in subject quality of life assessments",
                              "Changes in the pro-inflammatory cytokines of blood sample between the HUC-MSC and placebo cohorts",
                              "Changes in cellular components of the immune system between the HUC-MSC and placebo cohorts"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, month 1, 3 month and 6 months post infusion",
                              "Baseline, month 1, month 3 and month 6 post infusion",
                              "Baseline, month 1, month 3 and month 6 post infusion",
                              "Baseline, month 1, month 3 and month 6 post infusion"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04314011"
                        ]
                  },
                  {
                        "Rank": 116,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2014-001531-37"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02260375"
                        ]
                  },
                  {
                        "Rank": 117,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05016011"
                        ]
                  },
                  {
                        "Rank": 118,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Liver: levels of serum total bilirubin, transaminases, lactate dehydrogenase, plasma protrombin level\nPancreas: amylase level\nRenal: number of hemodialysis/ hemodiafiltration, blood urea and creatinine levels\nPulmonary: requirement for mechanical ventilation or non-invasive mechanical ventilation, pulmonary function-coefficient, partial oxygen pressure arterial blood level\nCardiac: requirement for vasopressors, main parameters obtained from Transpulmonary Thermodilution- Systemic Vascular Resistance Index ( SVRI ), Cardiac Output (CO)",
                              "plasma concentration of proinflammatory cytokine IL-6 and the antiinflammatory cytokine IL-10, concentration of procalcitonin, C-reactive protein Fibrinogen level, lactate level , the factor XII-dependent fibrinolytic activity blood routine examination",
                              "SOFA score"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Evaluation of MSC therapy effects on organ dysfunction",
                              "Evaluation of MSC therapy effects on systemic inflammatory parameters",
                              "Evaluation of MSC therapy effects on septic shock reversal"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "At Baseline and at day 2,3,7,14,21,28",
                              "At Baseline and at day 2,3,7,14,21,28",
                              "At Baseline and at day 2,3,7,14,21,28"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01849237"
                        ]
                  },
                  {
                        "Rank": 119,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "According to Chinese scale of clinical neurologic deficit to analysis, the result as follow:\n\nExcellent: after treatment, patient with consciousness, and clinical symptoms improved;\nEffective: vital signs and main symptoms in remission;\nInefficient: no obvious improvement or condition worsened.",
                              "Using fugl-meyer assessment evaluate motor function. Mild movement disorder: 96 - 99; Moderate movement disorder: 85 - 95; Obvious movement disorder: 50 - 84; Serious movement disorder: < 50",
                              "Obvious effective: Barthel Index score between 96 - 99, patient with self care ability.\n\nEffective:Barthel Index score between 70 - 89, patient with condition improved. Invalid: The effect do not meet above standards."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Neurological deficits analysis",
                              "Limb motor function analysis",
                              "Barthel Index analysis"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months",
                              "6 months",
                              "6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03176498"
                        ]
                  },
                  {
                        "Rank": 120,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Difference in estimated Glomerular Filtration Rate (eGFR)/1,73 m2. Normal > 60 ml/min",
                              "Differences in C-reactive protein. Normal value < 10mg/ml"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Kidney glomerular Filtration Rate",
                              "Inflammatory markers"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 weeks after treatment",
                              "through the 12 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04714801"
                        ]
                  },
                  {
                        "Rank": 121,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "U1111-1169-2289"
                        ],
                        "SecondaryIdDomain": [
                              "Universal Trial Number"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Other Identifier"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Rejection will be determined as biopsy-proven allograft rejection (BPAR). Graft loss will be counted when the patient loses kidney function to the point that they require chronic renal replacement therapy (e.g., dialysis for more than 8 weeks or a re-transplant)."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Number of participants without any acute rejection, graft loss, or death at 6 months post transplant."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months post transplant"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03478215"
                        ]
                  },
                  {
                        "Rank": 122,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Ovarian artery blood flow spectrum PI; RI; S/D (L; R)",
                              "Clinical pregnancy was defined as diagnosed by increasing serum concentration of beta-HCG 14 days after embryo transfer, and the subsequent demonstration of an intrauterine gestational sac by ultrasonography on 30 days after embryo transfer"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Changes in blood flow index in the ovary",
                              "Clinical pregnancy rate"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "9-12 months",
                              "9-12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05308342"
                        ]
                  },
                  {
                        "Rank": 123,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Improve biochemical indexes [alanine aminotransferase (ALT), albumin (ALB), total bilirubin (TBIL), prothrombin time (PT), INR and so on]",
                              "The clinical symptom improvement [including appetite, debilitation, abdominal distension, edema of lower limbs, et al]",
                              "Liver function evaluation using Child-Pugh score and MELD score",
                              "Immune function improvement [including Th1/Th2]",
                              "The occurrence of complications [including body temperature, tetter and allergy]",
                              "Incidence of hepatocellular carcinoma"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "24 weeks after treatment",
                              "24 weeks after treatment",
                              "24 weeks after treatment",
                              "24 weeks after treatment",
                              "Between 0 to 8 hours after UC-MSCs transfusion",
                              "48 weeks after treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01724398"
                        ]
                  },
                  {
                        "Rank": 124,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "CDAI is defined as Clinical Disease Activity Index.",
                              "UCEIS is defined as Ulcerative Colitis Endoscopic Index of Severity."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Clinical response (CDAI points)",
                              "Endoscopic improvement is assessed by UCEIS.",
                              "Level of C-reactive protein"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Post first cell transplantation: 3 weeks and months 1,3 and 6",
                              "Post first cell transplantation 6 months",
                              "Post first cell transplantation: 3 weeks and months 1,3 and 6"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02442037"
                        ]
                  },
                  {
                        "Rank": 125,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Patient and graft survival, and prevalence of adverse events"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "48 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01690247"
                        ]
                  },
                  {
                        "Rank": 126,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Number of patients with treatment-emergent adverse events, by treatment group",
                              "Number of patients who, after the start of treatment, required rescue medication, by treatment group",
                              "Number of days that the patient requires invasive mechanical ventilation from the start of treatment to day +28, by treatment group",
                              "Days after treatment in which the patient remains alive and free of invasive mechanical ventilation, per treatment group.",
                              "Variation of the oxygenation index (PaO2 / FiO2) with respect to the baseline value, by treatment group.",
                              "Variation of the score of the Sequential Organ Failure Assessment (SOFA) Index with respect to the baseline value, by treatment group.",
                              "Variation of Acute Physiology and Chronic Health disease Classification System II (APACHE II) score, by treatment group.",
                              "Days of stay in the ICU from the day of admission until discharge to day 28, or date of death if earlier, by treatment group.",
                              "Variation in the count and percentage of leukocytes and neutrophils, by treatment group.",
                              "Feasibility will be evaluated by the time elapsed from the request of the treatment by the hospital center until the delivery date",
                              "Feasibility will be evaluated by the number of patients treated within 2 days of the request for treatment.",
                              "Variation in the values of the biomarker, by treatment group.",
                              "Variation in the values of the biomarker, by treatment group.",
                              "Variation in the values of the biomarker, by treatment group.",
                              "Variation in the values of the biomarker, by treatment group."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Safety of WJ-MSC",
                              "Need for treatment with rescue medication",
                              "Need and duration of mechanical ventilation",
                              "Ventilator free days",
                              "Evolution of PaO2 / FiO2 ratio",
                              "Evolution of the SOFA index",
                              "Evolution of the APACHE II score",
                              "Duration of hospitalization",
                              "Evolution of markers of immune response (leucocyte count, neutrophils)",
                              "Feasibility of WJ-MSC administration",
                              "Feasibility of WJ-MSC administration",
                              "Evolution of disease biomarker: polymerase chain reaction (RT-PCR)",
                              "Evolution of disease biomarker: lactate dehydrogenase (LDH)",
                              "Evolution of disease biomarker: D-dimer",
                              "Evolution of disease biomarker: Ferritin"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Blood and Tissue Bank of Catalonia",
                              "Hospital Cl\u00ednic de Barcelona",
                              "Hospital Vall d'Hebron",
                              "Hospital del Mar",
                              "M\u00fatua de Terrassa",
                              "Hospital de Bellvitge"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://www.bancsang.net",
                              "http://www.clinicbarcelona.org",
                              "http://www.vallhebron.com",
                              "http://www.parcdesalutmar.cat",
                              "http://www.mutuaterrassa.com",
                              "http://bellvitgehospital.cat"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04390139"
                        ]
                  },
                  {
                        "Rank": 127,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Measurement of left ventricular function with echocardiography",
                              "Occurrence of mortality due to cardiovascular causes",
                              "Occurrence of mortality due to cardiovascular causes or heart failure"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in Left Ventricular Function from base line",
                              "Cardiovascular Death",
                              "Composite outcome of cardiovascular death and heart failure incidence"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "At baseline and after six months",
                              "Checked at three years",
                              "Checked at three years"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05043610"
                        ]
                  },
                  {
                        "Rank": 128,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Using Magnetic Resonance Imaging (MRI) examination to diagnose patients by Assessment of Preoperative Cartilage Defect Severity (AMADEUS).",
                              "Using Lysholm Knee Scoring Scale to grade the knee function of patients, and examine the changes or improvement compare to baseline.",
                              "The international knee documentation committee knee evaluation form is used to assess the knee function of patients, examine the changes or improvement compare to baseline.",
                              "Using Visual Analogue Scale/Score for pain to examine the change/improvement of knee joint function."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Assessment of Preoperative Cartilage Defect Severity (AMADEUS)",
                              "Lysholm scoring",
                              "The international knee documentation committee (IKDC) knee evaluation form",
                              "Visual Analogue Scale/Score\uff08VAS\uff09"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03383081"
                        ]
                  },
                  {
                        "Rank": 129,
                        "ResultsFirstSubmitDate": [
                              "September 24, 2014"
                        ],
                        "ResultsFirstSubmitQCDate": [
                              "November 4, 2014"
                        ],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2011-005321-51",
                              "EC11-309",
                              "MSV_allo"
                        ],
                        "SecondaryIdDomain": [
                              "Spanish Ministry of Health, Independent Clinical Investigatio",
                              "Protocol code"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number",
                              "Other Grant/Funding Number",
                              "Registry Identifier"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Clinical review, questionaires for pain, disability and quality of life at 0, 3, 6 and 12 months.\n\nWOMAC (Western Ontario and McMaster Universities Osteoarthritis Index): Questionnaire to quantify the pain, stiffness and physical function in patients with osteoarthritis of the knee or hip.\n\nSF-12 (Short Form 12, an abbreviated form of SF36) is a questionnaire for the detection of changes in quality of life.\n\nThe visual analogue scale (VAS) is a psychometric response scale which can be used for subjective measurements of knee pain.\n\nLEQUESNE algofunctional index: is a composite measure of pain and disability, with specific self-report questionnaires for knee (osteoarthritis).\n\nAll the scale ranges ranges (minimum and maximum scores) are between 0 and 100%.\n\nValues are given in differences from baseline (usually negative values). More negative values show more improvement on both scales.",
                              "Magnetic Resonance imaging measurements of T2 relaxation (Cartigram) performed at 0, 6 and 12 months to quantify articular cartilage degeneration. The values (in milliseconds) are T1/2 for decay of the T2 MRI signals. Normal values are below 50 ms; values above 50 ms correspond to inflamed cartilage.\n\nMean (SD) are expressed as the number of values (of a total of 88 measurements) that are between 50 and 90 ms. A value =<4.4 is considered normal (can be attained by chance). Values above 4.4 are considered pathological. The worst possible is 88."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Pain and Disability Evolution (WOMAC, Visual Analogue Scale, Lequesne Index and SF-12 Scores)",
                              "Evolution of Cartilage Degeneration by T2 Relaxation Measurements in MRI (Cartigram)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "up to one year",
                              "up to one year"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Cell Therapy Network",
                              "MSV providing",
                              "osteoarthritis, knee",
                              "mesenchymal stem cells"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://www.red-tercel.com",
                              "http://www.citospin.com",
                              "http://www.ncbi.nlm.nih.gov/mesh/68020370",
                              "http://www.ncbi.nlm.nih.gov/mesh?term=cell%2C%20mesenchymal%20stem"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01586312"
                        ]
                  },
                  {
                        "Rank": 130,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Rheumatoid Factor, C-reactive protein"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "RA Serology",
                              "Disease Activity Score (DAS 28) Index Mean Change From Baseline",
                              "Patient's assessment of pain."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1, 3 and 6 months",
                              "1, 3 and 6 months",
                              "1, 3 and 6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01547091"
                        ]
                  },
                  {
                        "Rank": 131,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2012-004444-30",
                              "Disc_allo_MSV"
                        ],
                        "SecondaryIdDomain": [
                              "Red TerCel"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number",
                              "Other Identifier"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Clinical review and questionaires (Visual Analogue Scales (VAS) and Oswestry questionnaires) at 0, 3, 6 and 12 months.",
                              "RMI density measurements in T2 weighted images performed at 0, 6 and 12 months used as an indication of disc fluid content",
                              "SF-12 scores at 0, 3, 3 and 12 months"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Pain and disability evolution",
                              "Evolution of affected disc(s) by quantitative Magnetic Resonance Imaging (RMI)",
                              "Llife quality evolution (Short Form (SF)-12 questionnaire)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "up to 1 year",
                              "up to one year",
                              "up to 1 year"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Treatment of Degenerative Disc Disease with Autologous Mesenchymal Stem Cells",
                              "Spanish Cell Therapy Network",
                              "Citospin S.L. (MSV Cell Production)",
                              "Intervertebral disk",
                              "mesenchymal stem cells"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://www.ncbi.nlm.nih.gov/pubmed/?term=orozco+and+garcia-sancho",
                              "http://www.red-tercel.com",
                              "http://www.citospin.com",
                              "http://www.ncbi.nlm.nih.gov/mesh/?term=intervertebral",
                              "http://www.ncbi.nlm.nih.gov/mesh?term=cell%2C%20mesenchymal%20stem"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01860417"
                        ]
                  },
                  {
                        "Rank": 132,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Improvement of quality of life inpatients after at least 3months of BM-MSC transplantation that is evaluated by Visual Analogue Score (VAS). The patients depends on their severity of the pain during daily activity choose a score between 1-10. The score will be saved in score sheets.",
                              "presence of any sign or symptoms of infection in site of surgery during 1 week.",
                              "presence of any cyst or mass formation at least 3 months after BM-MSC transplantation with surgery."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Quality of life evaluated by Visual Analogue Score (VAS)",
                              "Infection: Presence of any sign or symptoms of infection",
                              "Cyst formation: Presence of any cyst or mass formation"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "3 months",
                              "1week",
                              "3months"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Related Info"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://royaninstitute.org"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02646007"
                        ]
                  },
                  {
                        "Rank": 133,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Change of Liver function",
                              "Change of Liver function",
                              "Change of Liver function",
                              "Change of Liver function",
                              "Change of Liver function",
                              "Status of HBV infection",
                              "Status of the liver"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "ALB",
                              "ALT",
                              "AST",
                              "TBIL",
                              "DBIL",
                              "HBV-DNA",
                              "Change of ultrasound examination of liver"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Change from Baseline at week 24",
                              "Change from Baseline at week 24",
                              "Change from Baseline at week 24",
                              "Change from Baseline at week 24",
                              "Change from Baseline at week 24",
                              "Change from Baseline at week 24",
                              "Change from Baseline at week 24"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05507762"
                        ]
                  },
                  {
                        "Rank": 134,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Biliary blood supply indicated by contrast-enhanced ultrasound."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Changes in biliary enzymology",
                              "Biliary blood supply"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "18 months",
                              "18 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02223897"
                        ]
                  },
                  {
                        "Rank": 135,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Assess the changes in Insulin dose and drug dosage after transplantation"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Insulin dose and drug dosage"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "enrollment, 1 month, 3 months and 6 months after transplantation"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03943940"
                        ]
                  },
                  {
                        "Rank": 136,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "All-cause mortality at 60 days and then annually",
                              "Changes from baseline (Day 1; prior to administration of ATIMP) in the leucocyte Count (number/L)",
                              "Changes from baseline (Day 1; prior to administration of ATIMP) in the trombocyte Count (number/L)",
                              "Changes from baseline (Day 1; prior to administration of ATIMP) in the plasma concentration of CRP (mg/L)",
                              "Changes from baseline (Day 1; prior to administration of ATIMP) in the plasma concentration of PK (INR)",
                              "Changes from baseline (Day 1; prior to administration of ATIMP) in the plasma concentration of creatinine (\u03bcmol/L)",
                              "Changes from baseline (Day 1; prior to administration of ATIMP) in the plasma concentration of ASAT (\u03bckat/L)",
                              "Changes from baseline (Day 1; prior to administration of ATIMP) in the plasma concentration of ALAT (\u03bckat/L)",
                              "Changes from baseline (Day 1; prior to administration of ATIMP) in the plasma concentration of NT-proBNP (ng/L)",
                              "Changes from baseline (Day 1; prior to administration of ATIMP) in blood pressure (mmHg)",
                              "Changes from baseline (Day 1; prior to administration of ATIMP) in body temperature (\u00b0C)",
                              "Changes from baseline (Day 1; prior to administration of ATIMP) in pulmonary compliance (dynamic and static) until day 10 post-infusion",
                              "Changes from baseline (Day 1; prior to administration of ATIMP) in driving pressure (Plateau pressure- PEEP) until day 10 post-infusion",
                              "Changes from baseline (Day 1; prior to administration of ATIMP) in oxygenation (PaO2/FiO2) until day 10 post-infusion",
                              "Number of days with ventilator support",
                              "Changes in amount of pulmonary bilateral infiltrates assessed by pulmonary X-ray from baseline (Day 1; prior to administration of ATIMP) until day 60",
                              "Changes in Sequential Organ Failure Assessment (SOFA) score from baseline (Day 1; prior to administration of ATIMP) and during the ICU-period",
                              "Duration of ICU stay and hospital stay (number of days; whole hospital period + calculated from Day 1)",
                              "Recovery of lung function assessed by Spirometry (FEV1, Vital Capacity) at day 60 and then annually",
                              "To assess development of lung fibrosis using the HRCT Fibrosis Score using Computed tomography (CT) at baseline and on day 1, 3, 7, 10, end of ICU-residence, end of hospital stay, day 60, 6 month and 12 month and end of study (if possible during the infectious stage depending on hospital safety regimen during the pandemic).",
                              "Assessment of the patient's physical capacity by 6-Minute-Walk-Test (6MWT), starting at 6 months post Day 1 and then annually",
                              "Changes in Quality of Life by assessing the Short Form Health Survey (SF-36) score (starting at 6 months post Day 1 and then annually; patient reported outcome)",
                              "Change in blood biomarkers related to the proposed mechanisms of action of KI-MSC-PL-205 in ARDS",
                              "Sensitisation tests (test for donor-specific antibodies) against KI-MSC-PL-205 donor"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Safety; All-cause mortality",
                              "Changes in Leucocytes",
                              "Changes in Trombocytes",
                              "Changes in plasma concentration of C-reactive protein (CRP)",
                              "Changes in plasma concentration of Prothrombin complex (PK)",
                              "Changes in plasma concentration of Creatinine",
                              "Changes in plasma concentration of Aspartate amino transferase (ASAT)",
                              "Changes in plasma concentration of Alanine amino transferase (ALAT)",
                              "Changes in plasma concentration of N-terminal pro-brain natriuretic peptide (NT-proBNP)",
                              "Changes in Blood pressure",
                              "Changes in Body temperature",
                              "Efficacy; Changes in pulmonary compliance",
                              "Efficacy; Changes in driving pressure (Plateau pressure- PEEP)",
                              "Efficacy; Changes in oxygenation (PaO2/FiO2)",
                              "Efficacy; Duration of ventilator support",
                              "Efficacy; Pulmonary bilateral infiltrates",
                              "Efficacy; Sequential Organ Failure Assessment (SOFA) score",
                              "Efficacy; Hospital stay",
                              "Lung function",
                              "Lung fibrosis",
                              "Six minutes walk test",
                              "Changes in Quality of life",
                              "Blood biomarkers",
                              "Sensitisation test"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "60 days post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion",
                              "Baseline (pre-infusion),day 1, 2, 3, 4, 7, 10 and 60 post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, end of ICU",
                              "Day 60 post-infusion",
                              "Day 60 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 1, 3, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 60 post-infusion"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04447833"
                        ]
                  },
                  {
                        "Rank": 137,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "The differences in expression of Surfactant Protein-C expression by alveolar type II cells in lung tissue obtained from study patients treated with placebo or MSC.",
                              "The difference in immunostaining of various leukocytes in resected lung tissue, including T lymphocytes, B lymphocytes, macrophages and neutrophils obtained from study patients treated with placebo or MSC.",
                              "The difference in shear stress responses, expressed as % elongation of 100 cells, of isolated pMVECs ex vivo obtained from study patients treated with placebo or MSC.",
                              "The difference in endothelial microparticles concentration and concentration of immunological markers in blood samples from study patients treated with placebo or MSC.",
                              "The correlation between arterial pO2 or gas transfer value TLCO (measured as standard of care) and the outcome of the primary objective of the study for patients treated with MSC or placebo."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Within one year after the last study patient had its second lung surgical procedure",
                              "Within one year after the last study patient had its second lung surgical procedure",
                              "Within one year after the last study patient had its second lung surgical procedure",
                              "Within one year after the last study patient had its second lung surgical procedure",
                              "at 12 weeks, as well as after 6 and 12 months, after discharge of admission for LVRS2"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04918706"
                        ]
                  },
                  {
                        "Rank": 138,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Change in myocardial blood flow evaluated by Cardiac magnetic resonance imaging (MRI).",
                              "Change in LVEF as measured by ultrasonic cardiogram (UCG) and Cardiac magnetic resonance imaging (MRI).",
                              "Change in infarct size evaluated by Cardiac magnetic resonance imaging (MRI).",
                              "Change in clinical symptoms evaluated by NYHA.",
                              "Change in clinical symptoms evaluated by CCS."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Myocardial blood flow",
                              "Left ventricle ejection fraction (LVEF)",
                              "Infarct size",
                              "New York Heart Association (NYHA) Functional Classification",
                              "Canadian Cardiovascular Society (CCS) Angina Grading Scale"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1, 3, 6, 12 and 24 months",
                              "1, 3, 6, 12 and 24 months",
                              "1, 3, 6, 12 and 24 months",
                              "1, 3, 6, 12 and 24 months",
                              "1, 3, 6, 12 and 24 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02635464"
                        ]
                  },
                  {
                        "Rank": 139,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The Functioning Assessment Short Test (FAST) assesses functional impairment. FAST is a 24-item scale and assesses six functional domains: autonomy, occupational functioning, cognitive, financial issues, interpersonal relationships, and leisure time. Higher scores indicate higher degrees of functional impairment.",
                              "The Global Assessment of Functioning (GAF) is a numeric scale (1 through 100) used to rate subjectively the social, occupational, and psychological functioning of adults, e.g., how well or adaptively one is meeting various problems-in-living. The scale is presented and described in the DSM-IV-TR on page 34.",
                              "The Clinical Global Impression Scale for bipolar lllness (CGI-BP) is a modification of the CGI specifically for use in assessing global illness severity and change in patients with bipolar disorder (BD). The revised scale and manual provide a focused set of instructions to facilitate the reliability of these ratings of mania, depression, and overall bipolar illness during treatment of an acute episode or in longer-term illness prophylaxis. The clinician forms a global judgment both of the severity of the illness as compared to other cases with the same diagnosis and the global degree of change during treatment. There are 3 subscales (severity of mania, severity of depression, severity overall); and each subscale has a range of values from 1 (best) to 7 (worst).",
                              "The Clinical Global Impression Scale for bipolar lllness (CGI-BP) is a modification of the CGI specifically for use in assessing global illness severity and change in patients with bipolar disorder (BD). The revised scale and manual provide a focused set of instructions to facilitate the reliability of these ratings of mania, depression, and overall bipolar illness during treatment of an acute episode or in longer-term illness prophylaxis. The clinician forms a global judgment both of the severity of the illness as compared to other cases with the same diagnosis and the global degree of change during treatment. There are 3 subscales (severity of mania, severity of depression, severity overall); and each subscale has a range of values from 1 (best) to 7 (worst).",
                              "The Clinical Global Impression Scale for bipolar lllness (CGI-BP) is a modification of the CGI specifically for use in assessing global illness severity and change in patients with bipolar disorder (BD). The revised scale and manual provide a focused set of instructions to facilitate the reliability of these ratings of mania, depression, and overall bipolar illness during treatment of an acute episode or in longer-term illness prophylaxis. The clinician forms a global judgment both of the severity of the illness as compared to other cases with the same diagnosis and the global degree of change during treatment. There are 3 subscales (severity of mania, severity of depression, severity overall); and each subscale has a range of values from 1 (best) to 7 (worst).",
                              "California Verbal Learning Test (second edition (CVLT-II)). The adult version was chosen because it is one of the most widely used neuropsychological tests. This test consists of verbal list learning and memory test.",
                              "The Wisconsin Card Sorting Test (WCST) assesses problem-solving ability and is thought to be an index of functioning of the prefrontal cortex. The task requires subjects to match cards to one of four target cards according to a certain sorting rule (color, shape or number) without explicit instructions regarding the nature of the sorting rule. After 10 consecutive matches, the sorting rule changes without warning, and the subject needs to determine the new principle. Perseverative errors and number of categories achieved will be used as dependent measures.",
                              "The Bioplex 200 (Bio-Rad) will be used for multiplex biomarker analysis.",
                              "The Bioplex 200 (Bio-Rad) will be used for multiplex biomarker analysis.",
                              "The YMRS is an 11-item scale that is used to assess the severity of mania. Each item is given a severity rating--four items are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. These four items (irritability, speech, thought content, and disruptive/aggressive behavior) are given twice the weight of the others to compensate for poor cooperation from severely ill patients."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in Functional impairment as assessed by the Functioning Assessment Short Test (FAST)",
                              "Change in Overall functioning in living as assessed by the Global Assessment of Functioning (GAF)",
                              "Change in Clinical Global Impression Scale for Bipolar illness (CGI-BP), severity of mania subscale",
                              "Change in Clinical Global Impression Scale for Bipolar illness (CGI-BP), severity of depression subscale",
                              "Change in Clinical Global Impression Scale for Bipolar illness (CGI-BP), severity overall subscale",
                              "Change in neurocognition as assessed by the California Verbal Learning Test",
                              "Change in problem-solving ability as assessed by the Wisconsin Card Sorting Test (WCST)",
                              "Number of participants with inflammatory markers as assessed by multiplex biomarker analysis",
                              "Number of participants with inflammatory markers as assessed by multiplex biomarker analysis",
                              "Change in brain-derived neurotrophic factor (BDNF) level as assessed by enzyme-linked immunosorbent assay (ELISA)",
                              "Change in C-reactive protein (CRP) level as assessed by enzyme-linked immunosorbent assay (ELISA)",
                              "Number of participants with a change in brain activity between baseline and week 26 as assessed by Magnetic Resonance Imaging (MRI)",
                              "Number of participants who withdrawal due to Adverse Events (AEs)",
                              "Number of participants with suicidal ideation based on clinical assessment",
                              "Number of participants with treatment emergent mania or hypomania as assessed by the Young Mania Rating Scale (YMRS) and clinical assessment"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "baseline, week 26",
                              "baseline, week 26",
                              "baseline, week 26",
                              "baseline, week 26",
                              "baseline, week 26",
                              "baseline, week 26",
                              "baseline, week 26",
                              "baseline",
                              "week 26",
                              "baseline, week 26",
                              "baseline, week 26",
                              "baseline, week 26",
                              "week 26",
                              "week 26",
                              "week 26"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03522545"
                        ]
                  },
                  {
                        "Rank": 140,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "1K23HL133446"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [
                              "https://reporter.nih.gov/quickSearch/1K23HL133446"
                        ],
                        "SecondaryIdType": [
                              "U.S. NIH Grant/Contract"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Defined as the absence of donor cells assessed by peripheral blood chimerism assays on day 42.",
                              "Defined as the absence of donor hematopoietic cells in peripheral blood beyond day 42 in a patient who had initial evidence of hematopoietic recovery with > 20% donor cells.",
                              "Defined as the first of 3 measurements on different days when the patient has an absolute neutrophil count of 500/\u00b5L after conditioning.",
                              "Defined as the first day of a minimum of 3 measurements on different days that the patient has achieved a platelet count > 50,000/\u00b5L AND did not receive a platelet transfusion in the previous 7 days.",
                              "Genomic deoxyribonucleic acid (DNA) extracted from peripheral blood will be analyzed for variable number of tandem repeats (VNTR) to detect donor engraftment in myeloid and lymphoid fractions.",
                              "Immune reconstitution will be assessed post-transplant by standard clinical testing and research testing.",
                              "Incidence of grade II-IV and III-IV acute GVHD",
                              "Incidence and severity of chronic GVHD",
                              "Defined as any death occurring in continuous complete remission",
                              "Defined as survival with stable donor erythropoiesis and no new clinical evidence SCD. Primary or late graft rejection with disease recurrence or death will count as events for this endpoint.",
                              "Defined as survival with or without SCD after HCT"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Primary graft rejection",
                              "Late graft rejection",
                              "Time to neutrophil engraftment",
                              "Time to platelet engraftment",
                              "Lineage specific donor chimerism",
                              "Immune reconstitution",
                              "Acute GVHD",
                              "Chronic GVHD",
                              "Transplant-related mortality (TRM)",
                              "Event-free survival (EFS)",
                              "Overall survival (OS)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "42 days after HCT",
                              "One year after HCT",
                              "Up to one year after HCT",
                              "Up to one year after HCT",
                              "Up to one year after HCT",
                              "Up to one year after HCT",
                              "One year after HCT",
                              "One year after HCT",
                              "One year after HCT",
                              "One year after HCT",
                              "One year after HCT"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03298399"
                        ]
                  },
                  {
                        "Rank": 141,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "changes in the clinical condition evaluated by the Scale for Heart failure to Optimize Clinical Status (SHOCS). The SHOCS scale consists of 10 points. The maximum possible score is 20, and the minimum is 0. Higher scores indicate a worse or worsening clinical condition, while lower scores or decreasing scores indicate a better clinical condition.",
                              "changes in the markers of myocardial dysfunction of the serum level of amino-terminal pro-brain natriuretic peptide",
                              "changes in the 6-minute walk test, defined as the changes in the distance of traveled",
                              "change in the functional status according to the New York Heart Association classification",
                              "change in the quality of life evaluated by the questionnaire Short Form 12 Healthy Survey (SF-12). The SF 12 questionnaire consists of 12 items. The low level of the quality of life corresponds to estimates of 36-47 points, average of 24-35 points, high of 12-23 points.",
                              "changes in the quality of life evaluated by the Kansas City Cardiomyopathy Questionnaire (KCCQ). The KCCQ is composed of 23 items. The options for the answers are of 1 to 5, 6 or 7 points and the score of each of its dimensions has a theoretical range from 0 to 100, 100 being the best outcome.",
                              "changes in the quality of life evaluated by the Minnesota Living with Heart Failure (MLHF) Questionnaire. The MLHF questionnaire is composed of 21 items. The maximum possible scores being 105 and the minimum 0. Higher scores indicate a worse or worsening quality of life, while lower scores or decreasing scores indicate a better quality of life."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "change in the clinical condition evaluated by the Scale for Heart failure to Optimize Clinical Status",
                              "change in the markers of myocardial dysfunction",
                              "change in the in the 6-minute walk test",
                              "change in the functional status",
                              "change in the quality of life evaluated by the questionnaire Short Form 12 Healthy Survey",
                              "change in the quality of life evaluated by the Kansas City Cardiomyopathy Questionnaire",
                              "change in the quality of life evaluated by the Minnesota Living with Heart Failure Questionnaire"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1,3,6 months",
                              "1, 3 and 6 months",
                              "1, 3 and 6 months",
                              "1, 3 and 6 months",
                              "1, 3 and 6 months",
                              "1, 3 and 6 months",
                              "1, 3 and 6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04325594"
                        ]
                  },
                  {
                        "Rank": 142,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Number of participants with a change in joint function from baseline WOMAC assessment",
                              "Number of participants with a change in radiogrpahic evidence of knee OA from baseline Kellegren-Lawrence grading system"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "3 months and 12 months",
                              "3 months and 12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02237846"
                        ]
                  },
                  {
                        "Rank": 143,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Length of stay in the hospital of the study patients were compared with length of stay in the hospital previous observational study conducted in the same Intensive Care Units (ICUs) as control."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Length of stay in the hospital"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Through study completion, an average of 1 year"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05283317"
                        ]
                  },
                  {
                        "Rank": 144,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Change in VABS-3 (Vineland Adaptive Behavior Scales) Socialization Standard Score",
                              "Change in VABS-3 (Vineland Adaptive Behavior Scales) Communication Standard Score",
                              "Clinical Global Impression- Severity Scale",
                              "Clinical Global Impression- Impression",
                              "Pediatric Quality of Life Scale, raw scale range of 0-2300 with higher scores indicating a higher quality of life (better outcome)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in VABS-3 Socialization Standard Score",
                              "Change in VABS-3 Communication Standard Score",
                              "Change in CGI-Severity score",
                              "CGI-Intervention score",
                              "Change in the Pediatric Quality of Life Scale"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, 6 months",
                              "Baseline, 6 months",
                              "Baseline, 6 months",
                              "Baseline, 6 months",
                              "Baseline, 6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04089579"
                        ]
                  },
                  {
                        "Rank": 145,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Participants will have a clinical assessment of fistula drainage at each study visit.",
                              "Participants will have an assessment of healing radiographically by magnetic resonance imaging (MRI) at Week 2 visit, Week 8, and Week 24."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Number of participants with response to the treatment regarding cessation of drainage from the treated fistula.",
                              "Number of participants with radiographic response to the treatment regarding the treated fistula."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "2 months to approximately at 24 months",
                              "Week 2, Week 8, and Week 24"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Mayo Clinic Clinical Trials"
                        ],
                        "SeeAlsoLinkURL": [
                              "https://www.mayo.edu/research/clinical-trials"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03449069"
                        ]
                  },
                  {
                        "Rank": 146,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "1UG3EY031809-01"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [
                              "https://reporter.nih.gov/quickSearch/1UG3EY031809-01"
                        ],
                        "SecondaryIdType": [
                              "U.S. NIH Grant/Contract"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Best-corrected distance visual acuity will be measured using standard ETDRS protocols.",
                              "Corneal epithelial thickness measured by anterior segment OCT imaging (Cirrus 6000, Pachymetry, a-scans and b-scans) will assess the treatment effect on thickness on DAY #28 and compared relative to baseline.",
                              "Corneal scarring/haze will be assessed via anterior segment OCT imaging (Cirrus 6000; HD cornea, a-scans) to assess the treatment effect on DAY #28 relative to baseline(Images analysis done by Image-J/Metamorph)",
                              "Drop discomfort will be measured at DAYS #7, #14, and #28 using a visual analogue scale (VAS; range 0 -100), where 0 represents no discomfort and 100 the worst discomfort.",
                              "Durability of the improved corneal epithelial barrier function/integrity will be assessed an outcome measure at DAY #56 and DAY #90. Participants with improved corneal epithelial barrier function/integrity to DAY #28 will be assessed at each subsequent follow-up visits (e.g., DAYS #56, #90) to assess persistence of the healing response.",
                              "The time required for an improved epithelial barrier function will be assessed at each visit throughout the trial."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Visual Acuity",
                              "Corneal Epithelial thickness",
                              "Corneal Scarring / Haze",
                              "Tolerability of MSC secretome drops",
                              "Durability of Corneal Epithelial Status Improvement",
                              "Time to Improvement of Corneal Epithelial Barrier"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, Days 7, 14, 28, 56, 90",
                              "Baseline, Days 14, 28, 56, 90",
                              "Baseline, Days 14, 28, 56, 90",
                              "Baseline, Days 7, 14, 28, 56, 90",
                              "Baseline, Days 7, 14, 28, 56, 90",
                              "Baseline, Days 7, 14, 28, 56, 90"
                        ],
                        "SeeAlsoLinkLabel": [
                              "U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products."
                        ],
                        "SeeAlsoLinkURL": [
                              "https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM564952.pdf"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05204329"
                        ]
                  },
                  {
                        "Rank": 147,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Chest X-ray evaluation; mMRC(Modified Medical Research Council) Dyspnea scale;",
                              "Evaluation of all adverse event or serious adverse event that is observed or reported by"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Post-administration clinical and radiological improvement",
                              "Adverse Event and Serious Adverse Event Evaluation"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline/day-1 (-2 days), day-15 (+/- 2 days), day-22 (+/1 2 days) post randomization day",
                              "20 - 24 days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05132972"
                        ]
                  },
                  {
                        "Rank": 148,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Images will be used to assess the amount of granulation tissue present in the wound",
                              "Digital images will be used to evaluate color changes in the wound",
                              "Visual observation of the wound to determine the presence of exudate"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Granulation tissue percentage",
                              "Pigmentation change",
                              "Presence of Exudate"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "One year",
                              "One year",
                              "One year"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02943486"
                        ]
                  },
                  {
                        "Rank": 149,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The patients achieves 20%, 50%, or 70% remission according to American College of Rheumatology (ACR) criteria.",
                              "White blood cell count increases to the 3.5\u00d710^9/L and platelet count increases to 80\u00d710^ 9.",
                              "The HGB increases by 10 g compared to the baseline is considered improvement.",
                              "FVC increases by 0.5% and DLCO increases by 10% compared to baseline",
                              "The area change of image of lung."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The remission rates of American College of Rheumatology (ACR) 20, ACR 50 and ACR 70.",
                              "White blood cell count and platelet count improved compared to the baseline.",
                              "Improvement rate of blood routine hemoglobin (HGB) compared to baseline.",
                              "Improvement rate of forced vital capacity (FVC) and/or carbon monoxide",
                              "Image improvement of lung on high resolution CT.",
                              "Improvement of 6-minute walking distance compared to baseline."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 weeks and 24 weeks",
                              "12 weeks and 24 weeks",
                              "12 weeks",
                              "12 weeks",
                              "24 weeks",
                              "12 weeks and 24 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03798028"
                        ]
                  },
                  {
                        "Rank": 150,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Data collection will include: degree of drainage cessation from fistula. The Outcome Measure will be the number of Participants With Closure of their Fistula."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Incidence of Fistula Closure"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "2-18 months"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Mayo Clinic Clinical Trials"
                        ],
                        "SeeAlsoLinkURL": [
                              "https://www.mayo.edu/research/clinical-trials"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02807389"
                        ]
                  },
                  {
                        "Rank": 151,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "HbA1c",
                              "serum level of insulin/C peptide",
                              "insulin dosage",
                              "estimated glomerular filtration rate"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "HbA1c",
                              "insulin/C peptide",
                              "insulin dosage",
                              "eGFR"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "48weeks after treatment",
                              "48weeks after treatment",
                              "48weeks after treatment",
                              "48weeks after treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04216849"
                        ]
                  },
                  {
                        "Rank": 152,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Participants will have a clinical assessment of fistula drainage. Participants will be assessed during an office examination if their fistula is draining or not. The Outcome Measure will be the presence or absence of fistula drainage."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Number of participants with response to the treatment regarding potential cessation of drainage from their fistula."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "2-24 months"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Mayo Clinic Clinical Trials"
                        ],
                        "SeeAlsoLinkURL": [
                              "https://www.mayo.edu/research/clinical-trials"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02589119"
                        ]
                  },
                  {
                        "Rank": 153,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The comparison of the mortality between the two groups.",
                              "The change in NT-proBNP after the infusion.",
                              "The change in Left ventricular end diastolic diameter(LVEDD) after the infusion",
                              "The change in 6 minutes walking distance after the infusion.",
                              "The change in MLHFQ after the infusion.",
                              "The change in PET/CMR after the infusion"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Mortality",
                              "NT-proBNP",
                              "Left ventricular end diastolic diameter",
                              "6 minutes walking distance",
                              "Minnesota Living with Heart Failure Questionnaire\uff08MLHFQ\uff09",
                              "PET/CMR"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 month after treatment",
                              "Day 7, Day 43, Day 91, Day 180, Day 360",
                              "Day 7, Day 43, Day 91, Day 180, Day 360",
                              "Day 7, Day 43, Day 91, Day 180, Day 360",
                              "Day 43, Day 91, Day 180, Day 360",
                              "Day 43, Day 180"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04992832"
                        ]
                  },
                  {
                        "Rank": 154,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "the presence of a living intrauterine fetus on TVU at the 12th week of gestation",
                              "a live born baby \u226528 weeks of gestation",
                              "uterine blood flow evaluated by transvaginal sonography"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "ongoing pregnancy rate",
                              "live birth rate",
                              "endometrial blood flow"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "24 months",
                              "24 months",
                              "6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03592849"
                        ]
                  },
                  {
                        "Rank": 155,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Participants will have a clinical assessment of fistula drainage. Participants will be assessed during an office examination if their fistula is draining or not. The Outcome Measure will be the presence or absence of fistula drainage."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Number of participants with response to the treatment regarding potential cessation of drainage from their fistula."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "3-24 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03220243"
                        ]
                  },
                  {
                        "Rank": 156,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "To evaluate fine motor function.The scale is divided into 45 items covering visual tracing (7 items), upper extremity range of motion (8 items), grab ability (8 items), operational ability (10 items), and hand-eye coordination (12 items). The FMFM is a 4-point scale with the score range of 0-3. The original total score is 135. The summed score for evaluating fine motor function measure is 0-100.",
                              "To evaluate muscle tone. The MAS score is divided into six grades: 0, 1, 1+, 2, 3 and 4. Passive full ranges of motion exercises are performed by moving the knee and ankle until the patient feel a slight resistance from hamstrings and plantar flexor muscles (soleus muscle and gastrocnemius muscle). The average score is calculated across three repeated measurements.",
                              "To evaluate neurobehavioral development.",
                              "Liver and kidney dysfunction, fever, infection, vomiting."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Fine Motor Function Measure scale (FMFM) score",
                              "The Modified Ashworth scale (MAS) score",
                              "Gesell Development Schedule score",
                              "Incidence of adverse reactions"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1, 3, 6, 9 and 12 months after 2 courses of treatment with UC-MSCs.",
                              "1, 3, 6, 9 and 12 months after 2 courses of treatment with UC-MSCs.",
                              "1, 3, 6, 9 and 12 months after 2 courses of treatment with UC-MSCs.",
                              "1, 3, 6, 9 and 12 months after 2 courses of treatment with UC-MSCs."
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03414697"
                        ]
                  },
                  {
                        "Rank": 157,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "After the first time transplantation, follow-up visit for 26 weeks. Based on Modified Rankin Scale, counting the percentage of different symptom changes to evaluate MSC efficacy:\n\nthe percentage of participants run from 0-1, no symptom or no significant disability.\nthe percentage of participants run from 0-2, no symptom or slight disability.\nthe percentage of participants decline 2 scales compare to baseline.\nthe percentage of participants decline 1 scale compares to baseline.",
                              "Based on Activity of Daily Living Scale (ADL) to counting the percentage of patients in following condition:\n\nthe percentage of patients with score > 75\nthe decline of Barthel ADL Index range compares to baseline. Evaluate the efficacy of MSCs treatment",
                              "According to NIHSS changes after the treatment, evaluate MSCs efficacy by counting the percentage of patients in following condition:\n\nthe percentage of patients with score 0-1;\nthe percentage of patients with score declined 7 compare to baseline;\nthe percentage of patients with score declined 50% compare to baseline;\nthe declined ranges compare to baseline"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Modified Rankin Scale",
                              "Barthel activities of daily living (ADL) Index",
                              "NIH stroke scale (NIHSS)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "26 weeks",
                              "26 weeks",
                              "26 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03186456"
                        ]
                  },
                  {
                        "Rank": 158,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Number of Participants alive by Day 28",
                              "Number of Participants with ventilator-free Days by Day 28"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Number of Participants alive by Day 28",
                              "Number of Participants with ventilator-free Days by Day 28"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Day 28",
                              "Day 28"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04400032"
                        ]
                  },
                  {
                        "Rank": 159,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "LBingliang"
                        ],
                        "SecondaryIdDomain": [
                              "Bing-liang Lin"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Registry Identifier"
                        ],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "The influence on levels of ALT (U/L) and AST (U/L) after UC-MSC infusions",
                              "The influence on levels of ALB(g/L) after UC-MSC infusions",
                              "The influence on levels of TBil (umol/L) after UC-MSC infusions",
                              "The influence on levels of INR after UC-MSC infusions",
                              "The influence on levels of MELD score, SOFA score and CTP score after UC-MSC infusions",
                              "The incidence of fatal complications after UC-MSC infusions.",
                              "Comparison of levels of NKG2A among the groups after UC-MSC infusions",
                              "Comparison of levels of NKG2D among the groups after UC-MSC infusions",
                              "Comparison of levels of NKP46 among the groups after UC-MSC infusions",
                              "Comparison of levels of KIR2DL1 among the groups after UC-MSC infusions",
                              "Comparison of levels of KIR2DL3 among the groups after UC-MSC infusions",
                              "Comparison of levels of KIR3DL1 among the groups after UC-MSC infusions",
                              "Comparison of levels of perforin among the groups after UC-MSC infusions",
                              "Comparison of levels of FasL among the groups after UC-MSC infusions",
                              "Comparison of levels of gramzymeB among the groups after UC-MSC infusions"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1,2,3,4,8,12,24,36,52weeks",
                              "1,2,3,4,8,12,24,36,52weeks",
                              "1,2,3,4,8,12,24,36,52weeks",
                              "1,2,3,4,8,12,24,36,52weeks",
                              "1,2,3,4,8,12,24,36,52weeks",
                              "52 weeks",
                              "2,4,8,12,24,36,52 weeks",
                              "2,4,8,12,24,36,52 weeks",
                              "2,4,8,12,24,36,52 weeks",
                              "2,4,8,12,24,36,52 weeks",
                              "2,4,8,12,24,36,52 weeks",
                              "2,4,8,12,24,36,52 weeks",
                              "2,4,8,12,24,36,52 weeks",
                              "2,4,8,12,24,36,52 weeks",
                              "2,4,8,12,24,36,52 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02812121"
                        ]
                  },
                  {
                        "Rank": 160,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Percentage of subjects that had a complete response (CR) or partial response (PR). CR is resolution of acute GVHD in all involved organs and PR is improvement of at least 1 stage without worsening in other organ systems.",
                              "Percentage of subjects that had a reduction in the overall National Institute of Health (NIH) score at three months, without worsening any specific organ. NIH Criteria for Clinical Trials in Chronic Graft-versus-Host Disease scale: Organs and sites to be scored include skin, mouth, eyes, gastrointestinal tract, liver, lungs, joints and fascia, and the genital tract. Each organ or site is scored according to a 4-point scale (0 to 3), with 0 representing no involvement and 3 reflecting severe impairment. Total possible score: 63",
                              "Transplant-related mortality defined as any death occurring in continuous complete remission",
                              "Percentage of subjects who experience relapse of underlying malignancy",
                              "Disease-free survival will be defined as survival without relapse of underlying malignancy.",
                              "Overall-survival will be defined as survival with or without relapse of underlying malignancy."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Overall Response Rate for acute GVHD subjects",
                              "Overall Response Rate for chronic GVHD subjects",
                              "Transplant-related mortality",
                              "Incidence of Relapse",
                              "Disease-free survival",
                              "Overall-survival"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months",
                              "6 months",
                              "6 months",
                              "6 months",
                              "1 year post transplant",
                              "1 year post transplant"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02359929"
                        ]
                  },
                  {
                        "Rank": 161,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Change in serum inflammatory marker levels including Interleukin (IL) IL-6, IL-2, Tumor Necrosis Factor Alpha (TNF-a) and procalcitonin will be evaluated in ng/L.",
                              "Change in serum systemic inflammatory marker levels including D-dimer, high sensitivity C-reactive protein (hsCRP) and ferritin will be evaluated in mg/L.",
                              "Assessed using blood samples or nose/throat swabs.",
                              "Sequential Organ Failure Assessment (SOFA) will be used to assess organ failure including the cardiovascular system, coagulation system, liver, kidney and other extra-pulmonary organs. SOFA score ranges from 0-24 with the higher score indicating worse outcomes.",
                              "Sodium, Potassium, Chloride and Carbon Dioxide (CO2) will be evaluated in mmol/L. Changes from baseline to Day 30 will be compared between groups.",
                              "Serum Lactate Dehydrogenase (LDH) levels assessed in U/L. Changes in LDH from baseline to Day 30 will be compared between groups.",
                              "ICU monitoring status will be reported as the number of subjects discharged from the ICU within 7 days.",
                              "Percentage of participants requiring less use of vasoactive agents will be reported.",
                              "Percentage of participant deaths throughout the study period.",
                              "The percentage of participants with changes in serum immune marker levels including Cluster of Differentiation (CD) CD 4+ and CD 8+, as evaluated by treating physician will be reported.",
                              "Percentage of participants with changes in their chest imaging such as ground-glass opacity, local patch shadowing, bilateral patch shadowing and interstitial abnormalities will be reported. Imaging will be assessed by treating physician using chest radiography or chest Computed Tomography (CT).",
                              "Percentage of participants showing less pneumonia symptoms will be reported as evaluated by treating physician using chest radiography or chest CT."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in inflammatory marker levels",
                              "Change in systemic inflammatory marker levels",
                              "COVID-19 Viral Load",
                              "Change in SOFA score",
                              "Change in electrolytes levels",
                              "Change in LDH levels",
                              "Number of subjects discharged from the ICU",
                              "Percentage of participants with less requirement for vasoactive agents",
                              "Rate of Mortality",
                              "Percentage of participants with changes in immune marker expression",
                              "Percentage of participants with changes in radiologic findings",
                              "Percentage of participants with less pneumonia symptoms"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, Day 30",
                              "Baseline, Day 30",
                              "Up to 30 Days",
                              "Baseline, Up to 30 Days",
                              "Baseline, Up to 30 Days",
                              "Baseline, Up to 30 Days",
                              "Up to 7 Days",
                              "Up to 30 Days",
                              "Up to 30 Days",
                              "Up to 30 Days",
                              "Up to 30 Days",
                              "Up to 30 Days"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Interdisciplinary Stem Cell Institute at the University of Miami Miller School website"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://isci.med.miami.edu/"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04490486"
                        ]
                  },
                  {
                        "Rank": 162,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The NIH Stroke Scale (NIHSS) is a 15-item scale that is a well-validated and prognostically important measure of stroke-related neurologic deficits in research and clinical care",
                              "The Modified Rankin Scale (mRS) is used to measure the degree of disability in patients who have had a stroke"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The National Institute of Health Stroke Scale (NIHSS) Scoring",
                              "modified Rankin Scale (mRS)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Before treatment, one month after treatment, 3 months after treatment, and 6 month after treatment",
                              "Before treatment, one month after treatment, 3 months after treatment, and 6 month after treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05008588"
                        ]
                  },
                  {
                        "Rank": 163,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "The incidence and severity of adverse events related to the stem cell infusion procedure",
                              "The reduction in fasting blood glucose (FBG)",
                              "The increase in basal C-peptide",
                              "The reduction in exogenous insulin requirements",
                              "Decrease in HbA1c",
                              "insulin area under the curve during OGTT"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1 year",
                              "1 year",
                              "1 year",
                              "1 year",
                              "1 year",
                              "1 year"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01374854"
                        ]
                  },
                  {
                        "Rank": 164,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2020-001287-28"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Lung injury score",
                              "Oxygenation index",
                              "In-hospital mortality",
                              "Mortality",
                              "Ventilator-free days",
                              "Number of days between randomization and the first day the patient meets weaning criteria o Number of days between randomization and the first day the patient meets PaO2/FiO2 > 200 (out of a prone positioning session)",
                              "Cumulative use of sedatives",
                              "Cumulative duration of use of sedatives",
                              "Cumulative duration of use of neuromuscular blocking agents (other than used for intubation)",
                              "Cumulative use of neuromuscular blocking agents (other than used for intubation)",
                              "ICU-acquired weakness and delirium",
                              "Treatment-induced toxicity rate and adverse events up to day 28",
                              "Quality of life at one year (EQ5D-3L quality of life questionnaire)",
                              "Measurements of plasmatic cytokines (IL1, IL6, IL8, TNF-alpha, IL10, TGF-beta, sRAGE, Ang2) level",
                              "Anti-HLA antibodies plasmatic dosage"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "From baseline to day 28",
                              "From baseline to day 28",
                              "From baseline to day 28",
                              "At day 28",
                              "From baseline to day 28",
                              "From baseline to day 28",
                              "From baseline to day 28",
                              "From baseline to day 28",
                              "From baseline to day 28",
                              "From baseline to day 28",
                              "From baseline to day 28",
                              "From baseline to day 28",
                              "At 6 months and 12 months",
                              "At day 1, 3, 5, 7 and 14",
                              "From baseline to day 14, and at 6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04333368"
                        ]
                  },
                  {
                        "Rank": 165,
                        "ResultsFirstSubmitDate": [
                              "September 3, 2018"
                        ],
                        "ResultsFirstSubmitQCDate": [
                              "May 14, 2019"
                        ],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2011-005684-24"
                        ],
                        "SecondaryIdDomain": [
                              "2011-005684-24"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Registry Identifier"
                        ],
                        "SecondaryOutcomeDescription": [
                              "- The safety will be valued with number of adverse events related with administration of subarachnoid autologous Bone Marrow Expanded Mesenchymal Cells in Incomplete Spinal Cord Injury (SCI).",
                              "Changes in expression of neurotrophins in CSF (CerebroSpinal Fluid) samples obtained previously to first administration of cell therapy, and previously to the last administration, at month 10, in order to study the variability in the expression of neurotrophins along time. The mean+SD (standard deviation) at each time point was obtained. The tested neurotrophins were: BDNF."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Number of Adverse Events .",
                              "Efficacy- Expression of Neurotrophins in CSF (CerebroSpinal Fluid) Samples"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Up to 12 months",
                              "Basal and 10 months after the administration"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [
                              "Systematic Assessment"
                        ],
                        "NCTId": [
                              "NCT02165904"
                        ]
                  },
                  {
                        "Rank": 166,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Measurements were obtained with mixed meal tolerance test",
                              "Measurement of HOMA-IR, calculated using fasting C-peptide and fasting plasma glucose formula",
                              "Measurements of Interleukin-10 and TNF-alfa from serum and supernatant from PBMC stimulation",
                              "Thrombosis, hemorrhage, and infection",
                              "Stable HbA1c or decreasing HbA1c (from baseline)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Increasing of C-peptide level",
                              "Decreasing of insulin resistance level",
                              "Immunology/inflammatory markers",
                              "Adverse events",
                              "HbA1c"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Before intervention, 1st, 3rd, 6th, and 12th month after intervention",
                              "Before intervention, 1st, 3rd, 6th, and 12th month after intervention",
                              "Before intervention, 1st, 3rd, 6th, and 12th month after intervention",
                              "Up to 12 months after intervention",
                              "Before intervention, 1st, 3rd, 6th, and 12th month after intervention"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04501341"
                        ]
                  },
                  {
                        "Rank": 167,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Clinical evaluation"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01449032"
                        ]
                  },
                  {
                        "Rank": 168,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2018-001162-42"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "As described by the Common Terminology Criteria for Adverse Events",
                              "As measured by the ratio of urinary protein to urinary creatinine",
                              "Reduction of the ongoing immunosuppressive treatment",
                              "The minimal dose of immunosuppressive therapy necessary to maintain the patient in remission following the therapy",
                              "Changes in quality of life as reported by the patients and/or parents"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The percentage of adverse events",
                              "The time to recurrence of nephrotic syndrome",
                              "The percentage of participants achieving a reduction in the immunosuppressive therapy",
                              "The dose of immunosuppressive therapy to prevent further NS relapses",
                              "Reported Quality of Life"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months following completion of the intervention",
                              "Within 6 months from the completion of the intervention",
                              "6 months following completion of the intervention",
                              "6 months following completion of the intervention",
                              "6 months following completion of the intervention"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04034316"
                        ]
                  },
                  {
                        "Rank": 169,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Change in estimated glomerular filtration rate (eGFR) from baseline.",
                              "Change in 24-hour urinary protein quantification from baseline.",
                              "Change in urinary albumin/creatinine ratio from baseline",
                              "The proportion of subjects in both groups who progressed to end-stage renal disease (ESRD) or doubled their serum creatinine.",
                              "The MOS item short from health survey, SF-36 and changes per visit. As a concise health questionnaire, SF-36 comprehensively summarizes the quality of life of the surveyed from 8 aspects: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. Higher scores mean a better outcome.",
                              "Change in Glycosylated Hemoglobin (HbA1c) from baseline."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Kidney function",
                              "Kidney function",
                              "Kidney function",
                              "Kidney function",
                              "SF-36 (The MOS item short from health survey)",
                              "Change in HbA1c"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "From Baseline (0 W) to 48 weeks after treatment",
                              "From Baseline (0 W) to 48 weeks after treatment",
                              "From Baseline (0 W) to 48 weeks after treatment",
                              "From Baseline (0 W) to 48 weeks after treatment",
                              "From Baseline (0 W) to 48 weeks after treatment",
                              "From Baseline (0 W) to 48 weeks after treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04562025"
                        ]
                  },
                  {
                        "Rank": 170,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Articular cartilage volume evaluation by joint gap measurements",
                              "Articular cartilage quality evaluation in T-2 Mapping"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Changes in X-ray imaging of the knee joint in a standing position (AP view)",
                              "Changes in MRI with T-2 Mapping of the knee cartilage"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months and 1 year after procedure",
                              "6 months and 1 year after procedure"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04675359"
                        ]
                  },
                  {
                        "Rank": 171,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [
                              "Non-Probability Sample"
                        ],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05131412"
                        ]
                  },
                  {
                        "Rank": 172,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Complete remission rate (CR) and partial remission rate (PR)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The time for subjects of the two groups to achieve PR and CR",
                              "Levels of 24-hour urinary protein",
                              "Ratio of Urinary Protein / Creatinine",
                              "Levels of serum albumin",
                              "Levels of serum creatinine",
                              "The estimated glomerular filtration rate ( eGFR )",
                              "Levels of Complement component 3 (C3)",
                              "Levels of Complement component 4 (C4)",
                              "The antinuclear antibody (ANA) levels",
                              "The anti-double stranded DNA antibody (dsDNA) levels",
                              "Patient Health Assessment Questionnaire (HAQ) score",
                              "Physician Global Assessment (PhGA) score",
                              "The (Systemic lupus Erythematosis Disease Activity index) SLEDAI score",
                              "The (British Isles lupus assessment group ) BILAG score",
                              "The SLE reaction index",
                              "Total remission rate",
                              "Number of participants with treatment-related adverse events as assessed by CTCAE v4.0"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline to weeks 24",
                              "Baseline, weeks 4, 8, 12, 16, 20, 24",
                              "Baseline, weeks 4, 8, 12, 16, 20, 24",
                              "Baseline, weeks 4, 8, 12, 16, 20, 24",
                              "Baseline, weeks 4, 8, 12, 16, 20, 24",
                              "Baseline, weeks 4, 8, 12, 16, 20, 24",
                              "Baseline, weeks 4, 8, 12, 16, 20, 24",
                              "Baseline, weeks 4, 8, 12, 16, 20, 24",
                              "Baseline, weeks 4, 8, 12, 16, 20, 24",
                              "Baseline, weeks 4, 8, 12, 16, 20, 24",
                              "Baseline, weeks 4, 8, 12, 16, 20, 24",
                              "Baseline, weeks 4, 8, 12, 16, 20, 24",
                              "Baseline, weeks 4, 8, 12, 16, 20, 24",
                              "Baseline, weeks 4, 8, 12, 16, 20, 24",
                              "Baseline, weeks 4, 8, 12, 16, 20, 24",
                              "weeks 12",
                              "Baseline to weeks 24"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03580291"
                        ]
                  },
                  {
                        "Rank": 173,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "R01DK126454"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [
                              "https://reporter.nih.gov/quickSearch/R01DK126454"
                        ],
                        "SecondaryIdType": [
                              "U.S. NIH Grant/Contract"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Change in HbA1C levels from baseline to 12 months",
                              "Proportion of insulin-independent patients following IAT",
                              "Average daily insulin requirement",
                              "\u03b2-score is an assessment of beta cell function after islet transplantation incorporating fasting plasma glucose levels, HbA1c, daily insulin, and stimulated c-peptide. The range of the score is from 0 to 8. Higher number means better beta cell transplant function."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in HbA1C levels from baseline to 12 months.",
                              "Proportion of insulin-independent patients following IAT",
                              "Average daily insulin requirement",
                              "Beta cell function as assessed by beta-score"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1 year",
                              "1 year",
                              "1 year",
                              "1 year"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05095532"
                        ]
                  },
                  {
                        "Rank": 174,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Rate of observed and predicted death by the SCORTEN",
                              "Duration of hospitalisation according to our historical cohort related to BSA involved",
                              "Duration of hospitalisation according to our historical cohort related to onset of the disease",
                              "Duration of hospitalisation according to our historical cohort related to SCORTEN",
                              "Duration of each mucous membranes healing ie.(buccal, nasal, genital, eyes)",
                              "Rate of sepsis",
                              "Rate of intensive care transfer",
                              "Rate of sequelae",
                              "Th1/Th2 immune response in the peripheral blood of the patients",
                              "Evaluation of expression profile of Th1/Th2 associated chemokines and anti-inflammatory chemokines in the peripheral blood",
                              "Epidermal chimerism study on healed skin biopsy",
                              "Cutaneous re-epithelialization rate at D5, D10 and D15 post-infusion according to the percentage of cutaneous BSA re-epithelialized in comparison to maximal cutaneous detachable-detached BSA observed."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "at one month",
                              "Month 12",
                              "Month 12",
                              "Month 12",
                              "at Month 12",
                              "at Month 12",
                              "at Month 12",
                              "at Month 12",
                              "after injection at Day 0, Day 10, Month 1",
                              "after injection at Day 0, Day 10, Month 1.",
                              "at 1 month",
                              "at Day 5, Day 10 and Day15"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04711200"
                        ]
                  },
                  {
                        "Rank": 175,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Harvey-Bradshaw index",
                              "Corticosteroid dosage"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02445547"
                        ]
                  },
                  {
                        "Rank": 176,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Grid method was used to calculate the wound area, with 1 decimal place behind the length unit and 2 decimal places behind the area unit. The wound edges before, during and after treatment were depicted on the transparent mesh film respectively, and the original wound area and the unhealed wound area were calculated.\n\nWound shrinkage rate = (initial area of wound - area measured on the day)/original area of wound \u00d7 100%"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Wound shrinkage rate"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Epithelialization of the wound completely or 24 weeks after treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05319106"
                        ]
                  },
                  {
                        "Rank": 177,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The severity score of BPD ranging from 0 to 6 on the serial chest radiographs will be graded by a single radiologist, without knowledge of the infant's identity or clinical course, using the roentgenographic severity scoring system."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The severity score of BPD ranging from 0 to 6 on the serial chest radiographs"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months to 1 year"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01207869"
                        ]
                  },
                  {
                        "Rank": 178,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Overall survival (OS)",
                              "HBV-DNA",
                              "incidence of liver cancer",
                              "Number of Participants with abnormal immunoglobulin",
                              "portal vein flow rate",
                              "portal vein width",
                              "abdominal volume",
                              "Number of Participants with abnormal coagulation function"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Changes from baseline to 72 weeks",
                              "Changes from baseline to 72 weeks",
                              "Changes from baseline to 72 weeks",
                              "Changes from baseline to 72 weeks",
                              "Changes from baseline to 72 weeks",
                              "Changes from baseline to 72 weeks",
                              "Changes from baseline to 72 weeks",
                              "Changes from baseline to 72 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05106972"
                        ]
                  },
                  {
                        "Rank": 179,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Observe the changes during the study period",
                              "Observe the changes during the study period",
                              "Observe the changes during the study period",
                              "Observe the changes during the study period"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change of serum inflammatory factors",
                              "Change of growth factors (GF)",
                              "Change of fasting plasma glucose (FPG)",
                              "Change of glycosylated hemoglobin (HbA1c)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, week 4, week 12, week 24, week 36, week 48, week 96",
                              "Baseline, week 4, week 12, week 24, week 36, week 48, week 96",
                              "Baseline, week 12, week 24, week 36, week 48, week 96",
                              "Baseline, week 12, week 24, week 36, week 48, week 96"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05507697"
                        ]
                  },
                  {
                        "Rank": 180,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Before the infusion of UC MSCs and on the 1st, 3rd, 7th, 14th, 30th, 60th and 90th day after the infusion, the peripheral blood of the patients will be collected to detect the number of leukocyte (10^9/L) or lymphocyte (10^9/L).",
                              "Before the infusion of UC MSCs and on the 1st, 3rd, 7th, 14th, 30th, 60th and 90th day after the infusion, the peripheral blood of the patients will be collected to detect the percentage of lymphocytes(%).",
                              "Before the infusion of UC MSCs and on the 1st, 3rd, 7th, 14th, 30th, 60th and 90th day after the infusion, the peripheral blood serum of the patients will be collected to detect the level of CRP, SAA, ESR, PCT and IL-6 (\u03bcg/L).",
                              "Before the infusion of UC MSCs and on the 1st, 3rd, 7th, 14th, 30th, 60th and 90th day after the infusion, the arterial blood of the patients will be analyzed and the oxygenation index (mmHg) will be calculated according to the oxygen concentration of the patients. The change trend of the oxygenation index will be observed.",
                              "Before the infusion of UC MSCs and on the 1st, 3rd, 7th, 14th, 30th, 60th and 90th days after the infusion, the throat swabs and peripheral blood were collected respectively. The RNA copies of the virus will be detected by RT-PCR. The change trend of the viral load in the throat swabs/peripheral blood of the patients in each group will be observed after the treatment with different regimens, and the difference of the viral load between different groups will be compared",
                              "Two senior (associate chief physician and above) respiratory radiologists read the films independently. The chest CT images of the two groups will be evaluated before UC-MSCs infusion and on the 7th, 30th and 90th day after UC MSCs infusion. The changes of chest CT images at different time points before and after treatment will be observed and the differences between different treatment groups will be compared."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Changes of inflammatory index - the number of leukocyte or lymphocyte",
                              "Changes of inflammatory index - the percentage of lymphocytes",
                              "Changes of inflammatory index - cytokines",
                              "Changes of oxygenation index",
                              "Throat swab/blood viral load",
                              "Chest imaging outcome"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Day 0, Day 1\uff0cDay 3\uff0cDay 7\uff0cDay 14\uff0cDay 30\uff0cDay 60\uff0cDay 90",
                              "Day 0, Day 1\uff0cDay 3\uff0cDay 7\uff0cDay 14\uff0cDay 30\uff0cDay 60\uff0cDay 90",
                              "Day 0, Day 1\uff0cDay 3\uff0cDay 7\uff0cDay 14\uff0cDay 30\uff0cDay 60\uff0cDay 90",
                              "Day 0, Day 1\uff0cDay 3\uff0cDay 7\uff0cDay 14\uff0cDay 30\uff0cDay 60\uff0cDay 90",
                              "Day 0, Day 1\uff0cDay 3\uff0cDay 7\uff0cDay 14\uff0cDay 30\uff0cDay 60\uff0cDay 90",
                              "Day 0, Day 7, Day 30, Day 90"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04282928"
                        ]
                  },
                  {
                        "Rank": 181,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Defined as any untoward or undesirable medical occurrence in the form of signs, symptoms, abnormal findings, or diseases that emerge or worsen relative to baseline (i.e., if present upon study entry) during the study regardless of causal relationship.\n\nMethods i. Spontaneous subject reports ii. Subject interview by study personnel iii. Clinical examination during face-to-face clinic follow-ups. Defined as any untoward or undesirable medical occurrence in the form of signs, symptoms, abnormal findings, or diseases that emerge or worsen relative to baseline (i.e., if present upon study entry) during the study regardless of causal relationship.\n\nMethods i. Spontaneous subject reports ii. Subject interview by study personnel iii. Clinical examination during face-to-face clinic follow-ups",
                              "Change in radiographic/magnetic resonance joint morphology",
                              "Cartilage thickness on MRI",
                              "Cartilage volume on MRI",
                              "Cartilage morphology on MRI",
                              "Subchondral bone morphology (i.e. edema) on MRI",
                              "Baseline, and 12 months post-treatment cycle based on changes of concentrations of interleukin (IL)-1\u03b2 (pg/ml), IL-6 (pg/ml), IL-8 (pg/ml), IL-11 (pg/ml), CD40L (ng/ml), tumor necrosis factor (TNF)-alpha (pg/ml), high-sensivity C-reactive protein (hsCRP) (mg/dl) and miRNA expression (ug/dl) defined on microarray profilling."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "1. Nature, incidence and severity of adverse events (AEs)",
                              "2. Change in radiographic/magnetic resonance joint morphology",
                              "3. Change in cartilage thickness",
                              "4. Change in cartilage volume",
                              "5. Change in cartilage morphology",
                              "6. Change in subchondral bone morphology",
                              "8. Inflammation monitoring"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline (T0), 3 months (T1), 6 months (T2), 9 months (T3), 12 months (T4), 24 months (T5)",
                              "Baseline, and 12 months post-treatment cycle",
                              "Baseline, and 12 months post-treatment cycle",
                              "Baseline, and 12 months post-treatment cycle",
                              "Baseline, and 12 months post-treatment cycle",
                              "Baseline, and 12 months post-treatment cycle",
                              "Baseline, and 12 months post-treatment cycle]"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03866330"
                        ]
                  },
                  {
                        "Rank": 182,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Proportion of patients with a change in either gadolinium enhancing or new T2-weighted lesions on brain MRI",
                              "Proportion of patients with reduction in T2 lesion volume on brain MRI",
                              "Proportion of patients with reduction in brain volume on MRI",
                              "Proportion of patients with clinical improvement in EDSS score compared to baseline",
                              "Proportion of patients with clinical improvement in MSIS score compared to baseline",
                              "Proportion of patients with clinical improvement in MSFC score compared to baseline",
                              "Proportion of patients with a change in mobility and leg function as measured by the 25 foot walking test",
                              "Proportion of patients with a change in upper extremity function as measured by the Nine Hole Peg Test",
                              "Proportion of patients with a change in cognitive function as measured by the Paced Auditory Serial Addition Test (PASAT)",
                              "Proportion of patients with reduced number of relapses or freedom from progression of disease"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months",
                              "12 months",
                              "3 months and 6 months",
                              "3 months, 6 months and 12 months",
                              "3 months, 6 months and 12 months",
                              "12 months",
                              "12 months",
                              "12 months",
                              "3 months, 6 months and 12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02587715"
                        ]
                  },
                  {
                        "Rank": 183,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Proportion of patients with a change in either gadolinium enhancing or new T2-weighted lesions on brain MRI",
                              "Proportion of patients with reduction in T2 lesion volume on brain MRI",
                              "Proportion of patients with reduction in brain volume on MRI",
                              "Proportion of patients with clinical improvement in EDSS score compared to baseline",
                              "Proportion of patients with clinical improvement in MSIS score compared to baseline",
                              "Proportion of patients with clinical improvement in MSFC score compared to baseline",
                              "Proportion of patients with a change in mobility and leg function as measured by the 25 foot walking test",
                              "Proportion of patients with a change in upper extremity function as measured by the Nine Hole Peg Test",
                              "Proportion of patients with a change in cognitive function as measured by the Paced Auditory Serial Addition Test (PASAT)",
                              "Proportion of patients with reduced number of relapses or freedom from progression of disease"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months",
                              "12 months",
                              "3 months and 6 months",
                              "3 months, 6 months and 12 months",
                              "3 months, 6 months and 12 months",
                              "12 months",
                              "12 months",
                              "12 months",
                              "3 months, 6 months and 12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02418325"
                        ]
                  },
                  {
                        "Rank": 184,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Serum FSH level was evaluated once a month after surgery",
                              "Serum E2 level was evaluated once a month after surgery",
                              "Serum AMH level was evaluated once a month after surgery",
                              "The number of antral follicles developing was recorded by transvaginal ultrasound scan",
                              "The ovarian volume was recorded by transvaginal ultrasound scan",
                              "The incidence of pregnancy following transfer of embryos produced from oocytes recovered from follicles developing was assessed by Serum Human Chorionic Gonadotropin (HCG) detection."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Follicle-stimulating hormone (FSH) serum level",
                              "Estradiol (E2) serum level",
                              "Anti-Mullerian hormone (AMH) serum level",
                              "Number of antral follicle development",
                              "Ovarian volume",
                              "Pregnancy rate"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Up to 4 months",
                              "Up to 4 months",
                              "Up to 4 months",
                              "Up to 4 months",
                              "Up to 4 months",
                              "Up to 12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03033277"
                        ]
                  },
                  {
                        "Rank": 185,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Change in WOMAC score",
                              "Change in VAS score",
                              "Changes in structural joint assessment by MRI"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months",
                              "6 months",
                              "6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03810521"
                        ]
                  },
                  {
                        "Rank": 186,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "fever, coughing up blood, infection..."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "complication"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1 year"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02961725"
                        ]
                  },
                  {
                        "Rank": 187,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "as assessed by changes in mRS, NIHSS, Fugyl-Meyer and Barthel Index"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Improved functional outcome"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1 year"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01922908"
                        ]
                  },
                  {
                        "Rank": 188,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Exploratory evaluation of changes from baseline (percentage) in serum levels of CRP, LDH, Ferritin levels, a panel of cytokines, chemokines immune cell populations by flow cytometry"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Length of stay in the ICU and Hospital",
                              "Days without mechanical ventilation in 28 days",
                              "PaO2 / FiO2 ratio",
                              "Incidence of secondary infections",
                              "Incidence of adverse events",
                              "Quantification of inflammatory response markers"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "28 days",
                              "28 days",
                              "Day 1, Day 2 and Day 7 after cell infusion",
                              "28 days",
                              "28 days",
                              "Day 1, Day 3 and Day 7 after cell infusion"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04525378"
                        ]
                  },
                  {
                        "Rank": 189,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The NIHSS neurologic examination includes 15 individual elements that measure motor and sensory function, language and speech production, vision, level of consciousness and attention, and neglect. The scores of each element are summed (range from 0 to 42) to evaluate the severity of neurological deficits. The more higher score means the more severe neurological dysfunction.",
                              "The BI (range from 0 to 100) are used to assess the difference of activities of daily living between two groups. the score \u226440 means severe dependence\uff0c score 41~60 means moderate dependence, score 61~99 means mild dependence and score 100 means independence."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "the National Institutes of Health Stroke Scale (NIHSS) of 3 months",
                              "the Barthel index (BI) of 3 months"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "3 months post transplantation",
                              "3 months post transplantation"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04093336"
                        ]
                  },
                  {
                        "Rank": 190,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Assess disease activity in Crohn's disease over 7 days using the Crohn's disease activity index",
                              "min : 0 - max : 10 (worse)",
                              "which incorporates clinical, surgical, endoscopic, and imaging findings from all segments of the digestive tract into one composite score",
                              "Grade : from 0 to higher value 6"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Evolution of clinical disease activity index",
                              "Evolution of Short health scale (quality of life)",
                              "Evolution of the Lemann Index (measuring cumulated intestinal damage in Crohn's disease)",
                              "Evolution of the \" Group of Therapeutic Study of Inflammatory Disorders of the Digestive Tube\" obstructive score for Crohn Disease strictures"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "week 0, 12 and 48",
                              "week 0, 12 and 48",
                              "week 0, 12 and 48",
                              "weeks 0, 12 and 48"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03901235"
                        ]
                  },
                  {
                        "Rank": 191,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Complete, partial response rate at 28 and 180 days\nComplete response(CR)rate (%)=(number of CR/number of participants)*100%\nPartial response(PR)rate (%)=(number of PR/number of participants)*100%"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Efficacy of UC-MSC in patients with acute graft-versus-host disease"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "180 days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01754454"
                        ]
                  },
                  {
                        "Rank": 192,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Child-Turcotte-Pugh (CTP) score is a scoring system that evaluates the liver function."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in MELD score from baseline to 96 weeks",
                              "Incidence of each complication associated with decompensated cirrhosis",
                              "liver transplant-free survival",
                              "Incidence of liver failure",
                              "plasma albumin (ALB)",
                              "plasma prealbumin (PALB)",
                              "total bilirubin (TBIL)",
                              "serum cholinesterase (CHE)",
                              "prothrombin activity (PA)",
                              "Child-Turcotte-Pugh (CTP) score",
                              "EuroQol Group 5-Dimension Self-Report Questionnaire (EQ-5D)",
                              "ChronicLiver Disease Questionnaire (CLDQ)",
                              "Incidence of liver cancer",
                              "Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "up to 96 weeks",
                              "up to 96 weeks",
                              "up to 96 weeks",
                              "up to 96 weeks",
                              "up to 96 weeks",
                              "up to 96 weeks",
                              "up to 96 weeks",
                              "up to 96 weeks",
                              "up to 96 weeks",
                              "up to 96 weeks",
                              "up to 96 weeks",
                              "up to 96 weeks",
                              "up to 96 weeks",
                              "up to 96 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05224960"
                        ]
                  },
                  {
                        "Rank": 193,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Evaluation of Pneumonia Improvement",
                              "Evaluation of Pneumonia Improvement",
                              "Evaluation of Pneumonia Improvement",
                              "Evaluation of Pneumonia Improvement",
                              "Evaluation of Pneumonia Improvement",
                              "Evaluation of Pneumonia Improvement",
                              "Clinical improvement defined as a one-point deduction from baseline in a 6 ordinal scale:\n\nNot hospitalized;\nHospitalized, not requiring supplemental oxygen;\nHospitalized, requiring supplemental oxygen;\nHospitalized, on non-invasive ventilation or high flow oxygen devices;\nHospitalized, on invasive mechanical ventilation or ECMO;\nDeath.",
                              "Evaluation of Pneumonia Improvement",
                              "Evaluation of Pneumonia Improvement",
                              "Evaluation of Pneumonia Improvement",
                              "Evaluation of Pneumonia Improvement",
                              "Evaluation of Pneumonia Improvement",
                              "Evaluation of Pneumonia Improvement",
                              "Evaluation of Pneumonia Improvement\n\nNo limitation of activities, discharged from hospital =Score 1; Hospitalized, no oxygen therapy=Score 2; Oxygen by mask or nasal prongs-Score 3; Non-invasive ventilation or high-flow oxygen=Score 4; Mechanical ventilation or ECMO=Score 5; Death=Score 6.",
                              "Marker of Immunological function",
                              "Marker of Immunological function",
                              "Safety endpoints",
                              "Safety endpoints",
                              "Safety endpoints"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in lesion proportion (%) of full lung volume from baseline to day 10 and 90",
                              "Change in consolidation lesion proportion (%) of full lung volume from baseline to day 10, 28 and 90.",
                              "Change in ground-glass lesion proportion (%) of full lung volume from baseline to day 10, 28 and 90.",
                              "Pulmonary fibrosis - related morphological features in CT scan at day 90 a. cord-like shadow b. honeycomb-like shadows c. interlobular septal thickening d. intralobular interstitial thickening e. pleural thickening",
                              "Lung densitometry: Change in total voxel 'weight' in lesion area voxel 'weight'=voxel density (in HU) \u00d7 voxel volume (in voxel)",
                              "Lung densitometry: volumes histogram of lung density distribution (<-750, -750~-300, -300~50, >50) at day 10, 28 and 90.",
                              "Time to clinical improvement in 28 days.",
                              "Oxygenation index( PaO2/FiO2)",
                              "Duration of oxygen therapy(days)",
                              "Blood oxygen saturation",
                              "6-minute walk test",
                              "Maximum vital capacity (VCmax)",
                              "Diffusing Capacity (DLCO)",
                              "mMRC (Modified Medical Research Council) dyspnea scale",
                              "Changes of absolute lymphocyte counts and subsets from baseline to day 6, 10, 28 and 90.",
                              "Changes of cytokine/chemokine levels from baseline to day 6, 10, 28 and 90.",
                              "Adverse events",
                              "Serious adverse events",
                              "All-cause mortality"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Day 10, Day 90",
                              "Day 10, Day 28, Day 90",
                              "Day 10, Day 28, Day 90",
                              "Day 90",
                              "Day 10, Day 28, Day 90",
                              "Day 10, Day 28, Day 90",
                              "Day 28",
                              "Day 6, Day 10, Day 28",
                              "Day 28, Day 90",
                              "Day 6, Day 10, Day 28",
                              "Day 28, Day 90",
                              "Baseline, Day 10, Day 14, Day 21, Day 28, Day 90",
                              "Baseline, Day 10, Day 14, Day 21, Day 28, Day 90",
                              "Day 28, Day 90",
                              "Day 6, Day 10, Day 28, Day 90",
                              "Day 6, Day 10, Day 28, Day 90",
                              "Day 0 through Day 90",
                              "Day 0 through Day 90",
                              "Day 0 through Day 90"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04288102"
                        ]
                  },
                  {
                        "Rank": 194,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2020-002078-29"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Effect of ProTrans\u00ae -MSC on patient clinical status assessed on the 7-point ordinal scale; 1. Not hospitalized, no limitations on activities 2. Not hospitalized, limitation on activities 3. Hospitalized, not requiring supplemental oxygen 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, on non-invasive ventilation or high flow oxygen devices 6. Hospitalized, on invasive mechanical ventilation or Extracorporeal membrane oxygenation (ECMO) 7. Death.",
                              "Effect of ProTrans\u00ae -MSC on patient clinical status assessed on the 7-point ordinal scale; 1. Not hospitalized, no limitations on activities 2. Not hospitalized, limitation on activities 3. Hospitalized, not requiring supplemental oxygen 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, on non-invasive ventilation or high flow oxygen devices 6. Hospitalized, on invasive mechanical ventilation or ECMO 7. Death.",
                              "Effect of ProTrans\u00ae -MSC on patient clinical status assessed on the 7-point ordinal scale; 1. Not hospitalized, no limitations on activities 2. Not hospitalized, limitation on activities 3. Hospitalized, not requiring supplemental oxygen 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, on non-invasive ventilation or high flow oxygen devices 6. Hospitalized, on invasive mechanical ventilation or ECMO 7. Death.",
                              "Time to clinical improvement of one category from admission on the 7-point ordinal scale after ProTrans\u00ae - MSC infusion",
                              "Size of Chest lesion on lung damage using imaging techniques (Chest X ray/CT scan /or on doppler ultrasound) when assessed for clinical need up to hospital discharge X ray/CT scan /or on doppler ultrasound) when assessed for clinical need",
                              "Duration of hospitalization and ICU stay",
                              "Quantitative PCR for Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in throat swabs (time frame: before MSC infusion on Day 0 and after MSC infusion on day 30"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Effect of ProTrans\u00ae -MSC on patient clinical status, including mortality, at day 7",
                              "Effect of ProTrans\u00ae -MSC on patient clinical status, including mortality, at day 15",
                              "Effect of ProTrans\u00ae -MSC on patient clinical status, including mortality, at day 30",
                              "Time to clinical improvement after ProTrans\u00ae - MSC infusion",
                              "Effect of of ProTrans\u00ae -MSC on lung damage",
                              "Duration of hospitalization and Intensive Care Unit (ICU) stay",
                              "Kinetics of COVID-19 viral load after ProTrans\u00ae -MSC infusion"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "7 days",
                              "15 days",
                              "30 days",
                              "30 days",
                              "Up to 60 days",
                              "Up to 60 days",
                              "30 days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04896853"
                        ]
                  },
                  {
                        "Rank": 195,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Child-Turcotte-Pugh (CTP) score is a scoring system that evaluates the liver function."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in MELD score from baseline to 48 weeks",
                              "Incidence of each complication associated with decompensated cirrhosis",
                              "liver transplant-free survival",
                              "Incidence of liver failure",
                              "plasma albumin (ALB)",
                              "total bilirubin (TBIL)",
                              "serum cholinesterase (CHE)",
                              "prothrombin activity (PA)",
                              "Child-Turcotte-Pugh (CTP) score",
                              "EuroQol Group 5-Dimension Self-Report Questionnaire (EQ-5D)",
                              "ChronicLiver Disease Questionnaire (CLDQ)",
                              "Incidence of liver cancer",
                              "Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "up to 48 weeks",
                              "up to 48 weeks",
                              "up to 48 weeks",
                              "up to 48 weeks",
                              "up to 48 weeks",
                              "up to 48 weeks",
                              "up to 48 weeks",
                              "up to 48 weeks",
                              "up to 48 weeks",
                              "up to 48 weeks",
                              "up to 48 weeks",
                              "up to 48 weeks",
                              "up to 48weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05121870"
                        ]
                  },
                  {
                        "Rank": 196,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Changes of insulin requirement, HbA1c and proportion of patients reaching the HbA1c target (<7.0%)",
                              "Change of islet \u03b2 cell function and insulin resistance",
                              "Fever, pruritus, nausea and vomiting, anaphylactic shock, phlebitis\uff0ctumor formation, infection, impaired liver and kidney function."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Other efficacy parameter of umbilical-cord mesenchymal stem cells in Chinese adults with T2D",
                              "Other efficacy parameter of umbilical-cord mesenchymal stem cells in Chinese adults with T2D",
                              "safety parameter of umbilical-cord mesenchymal stem cells in Chinese adults with T2D"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "48 weeks from baseline",
                              "48 weeks from baseline",
                              "48 weeks from baseline"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Chinese PLA General Hospital Endocrinology medical characteristics"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://www.301hospital.com.cn"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02302599"
                        ]
                  },
                  {
                        "Rank": 197,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04288934"
                        ]
                  },
                  {
                        "Rank": 198,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "It's a standardized and widely used questionnaire to assess the condition of patients with osteoarthritis of the knee and includes assessment of pain, stiffness, and physical function of the joints. It can be administered to the patient.\n\nIt measures 5 items for pain (range 0-20), two for stiffness (range 0-8), and 17 for functional limitation (range 0-68) that mainly relate to activities of daily living (e.g., getting up from a sitting position, bending over, going up and down stairs etc.); The score is then normalized on a 0-100 scale. Higher values indicate a worse outcome",
                              "VAS is a visual analogue scale consisting of a range scale (10 cm length), the ends of which correspond to \"no pain\" and \"the strongest pain imaginable\".",
                              "This scale was developed for the evaluation of hip surgery outcomes and is intended to assess various hip disabilities and treatment methods in an adult population. The four sections that make up the questionnaire are: pain, function, absence of deformity, and range of motion. The HHS is a measure of dysfunction, so higher is the score, better is the outcome for the individual. The maximum possible score is 100."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)",
                              "Visual Analogue Scale (VAS)",
                              "Harris Hip Scale (HHS)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "baseline, 1 month, 3 months and 12 months follow-up",
                              "baseline, 1 month, 3 months, 6 months and 12 months follow-up",
                              "baseline, 1 month, 3 months, 6 and 12 months follow-up"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05465096"
                        ]
                  },
                  {
                        "Rank": 199,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2017-002766-50"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Insulin doses and measured plasma glucose values are written down in the subject's diary every day by the subject. Amount of insulin, recorded plasma glucose values, time and date will be included",
                              "Insulin doses and measured plasma glucose values are written down in the subject's diary every day by the subject. Amount of insulin, recorded plasma glucose values, time and date will be included",
                              "Insulin doses and measured plasma glucose values are written down in the subject's diary every day by the subject. Amount of insulin, recorded plasma glucose values, time and date will be included",
                              "Measurements of HbA1c will be performed to assess metabolic control during study.",
                              "Measurements of HbA1c will be performed to assess metabolic control during study.",
                              "Measured at day 372 compared to before start of treatment",
                              "Measured at day 372 compared to before start of treatment"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Number of patients insulin independent (ADA criteria) at days 187 and 372",
                              "Number of patients with daily insulin needs <0.25U/kg at days 187 and 372",
                              "Insulin requirement/kg BW at days 187 and 372",
                              "HbA1c at days 187 and 372.",
                              "Glucose variability at day 372",
                              "Delta change of levels of fasting C-peptide at day 372",
                              "Numbers of patients with peak C-peptide >0.20 nmol/l, in response to the MMTT, at day 372"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Days 187 and 372 following WJMSC/Placebo infusion",
                              "Days 187 and 372 following WJMSC/Placebo infusion",
                              "Days 187 and 372 following WJMSC/Placebo infusion",
                              "Days 187 and 372 following WJMSC/Placebo infusion",
                              "Day 372 following WJMSC/Placebo infusion",
                              "Day 372 following WJMSC/Placebo infusion",
                              "Day 372 following WJMSC/Placebo infusion"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03406585"
                        ]
                  },
                  {
                        "Rank": 200,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2011-006270-13"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Safety will be assessed by collecting adverse events, physical exam, laboratory tests, and vital signs.",
                              "Efficacy will be assessed by qualitative and quantitative changes of the meniscus and articular cartilage by imaging procedures (MRI) at 6 and 12 month follow-up.",
                              "Visual analogue scale (VAS) for pain at 1, 3 and 6 month follow-up.",
                              "IKDC, KOOS and Lysholm functionality test and SF-36 quality of life at 3, 6 and 12 month follow-up"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Safety",
                              "Efficacy by MRI",
                              "VAS for pain",
                              "Efficacy by clinical questionnaires"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 month",
                              "6 and 12 month",
                              "1, 3 and 6 month",
                              "3, 6 and 12 month"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Blood and tissue bank of Catalonia",
                              "Fundaci\u00f3n ICATME (Spanish only)"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://www.bancsang.net/en/index.html",
                              "http://www.icatme.com/"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02033525"
                        ]
                  },
                  {
                        "Rank": 201,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "softening in stiffness of bile duct"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Pathological score of liver inflammation",
                              "Changes of biliary lesions in magnetic resonance image",
                              "alanine aminotransferase"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1 year",
                              "1 year",
                              "1 year"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03516006"
                        ]
                  },
                  {
                        "Rank": 202,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Efficacy will be measured comparing hormonal changes (FSH, LH, AMH, estradiol) in patients' blood on monthly intervals",
                              "Patients ultrasounds of the ovaries will compare size and follicle numbers",
                              "Ultrasounds of uterus will be compared for endometrial thickness"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Number of patients with enhanced hormonal profile, ovarian changes and endometrial changes",
                              "Number of patients with positive ovarian changes",
                              "Number of patients with increased endometrial thickness"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04815213"
                        ]
                  },
                  {
                        "Rank": 203,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "UM1AI109565",
                              "NIAID CRMS ID#: 20676"
                        ],
                        "SecondaryIdDomain": [
                              "DAIT NIAID"
                        ],
                        "SecondaryIdLink": [
                              "https://reporter.nih.gov/quickSearch/UM1AI109565"
                        ],
                        "SecondaryIdType": [
                              "U.S. NIH Grant/Contract",
                              "Other Identifier"
                        ],
                        "SecondaryOutcomeDescription": [
                              "For the duration of their study participation, after completion of immunosuppression withdrawal (ISW).",
                              "Resumption of immunosuppressive therapy post completion of Immunosuppression Withdrawal (ISW), per standard of care.",
                              "Belatacept monotherapy, defined as remaining on belatacept as the sole maintenance regimen for 48 weeks with:\n\nNo evidence of biopsy-proven allograft rejection, while on belatacept monotherapy;\nAcceptable renal function, defined as an estimated GFR > 60 ml/min/1.73m^2 calculated using the CKD-EPI equation or a serum creatinine that has increased no more than 25% above baseline, as assessed at week 48 on belatacept monotherapy;\nNo evidence of sustained transplant renal derived pathologic proteinuria, defined as a persistent protein creatinine ratio of greater than 0.5, while on belatacept monotherapy; and\nNo Donor Specific Antibodies (DSA) at any time while on belatacept monotherapy.",
                              "This analysis will include all participants who provide informed consent for study participation and receive any form of study therapy including alemtuzumab, sirolimus, belatacept, or MSC infusions.",
                              "Kaplan-Meier Analysis of time-to-occurrence to the first episode of kidney allograft rejection.",
                              "Participants that Develop de novo Anti-Human Leukocyte Antigen (HLA) Antibody or Donor Specific Antibodies (DSA).",
                              "According to medical assessment/outcomes, investigator's brochure for MSCs, literature et al.",
                              "Select AEs include:\n\nInfection\nMalignancy\nWound complications, defined as wound dehiscence, hernia or lymphocele",
                              "New onset diabetes status post transplant (posttransplantation diabetes mellitus [PTDM])",
                              "Using the 2017 Banff Classification of Renal Allograft Pathology.",
                              "Using the 2017 Banff Classification of Renal Allograft Pathology.\n\nAs measured by the incidence of biopsy-proven chronic allograft nephropathy/IF/TA"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Proportion of Participants who Remain Off Immunosuppression",
                              "Proportion of Participants who Return to Immunosuppression",
                              "Proportion of Participants who Achieve Belatacept Monotherapy",
                              "Proportion of Participants who Die",
                              "Time from Transplant to the First Episode of Rejection",
                              "Incidence of Participants who Develop Donor Specific Antibody (DSA)",
                              "Incidence of Adverse Events Attributable to Mesenchymal Stromal Cells (MSC) Administration",
                              "Frequency of Select Adverse Events (AEs)",
                              "Incidence of Post-Transplant Diabetes",
                              "Frequency of Antibody-Mediated Acute Cellular Rejection",
                              "Frequency of Antibody-Mediated Chronic Rejection"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "From ISW completion to end of study participation (up to approximately 5 years)",
                              "From ISW completion to end of study participation (up to approximately 5 years)",
                              "48 weeks from the time of last sirolimus dose",
                              "From kidney transplant with alemtuzumab induction to to completion of study (up to approximately 6.5 years)",
                              "From kidney transplantation to completion of study (up to approximately 7 years)",
                              "From study enrollment to completion of study (up to approximately 7 years)",
                              "From initial MCS infusion (day 42 post kidney transplant) to end of study participation (up to 7 years)",
                              "From kidney transplantation to completion of study (up to approximately 7 years)",
                              "From post kidney transplantation to completion of study (up to approximately 7 years)",
                              "From kidney transplant to completion of study (up to approximately 7 years)",
                              "From kidney transplant to completion of study (up to approximately 7 years)"
                        ],
                        "SeeAlsoLinkLabel": [
                              "National Institute of Allergy and Infectious Diseases (NIAID) website",
                              "Division of Allergy, Immunology, and Transplantation (DAIT) website",
                              "Immune Tolerance Network (ITN) website",
                              "ITN's website for the study"
                        ],
                        "SeeAlsoLinkURL": [
                              "https://www.niaid.nih.gov/",
                              "https://www.niaid.nih.gov/about/dait",
                              "http://www.immunetolerance.org/",
                              "http://www.teachstudy.org/"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03504241"
                        ]
                  },
                  {
                        "Rank": 204,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Time to recovery, defined as discharge from the hospital (alive) or remaining in the hospital without the need for supplemental oxygen or other COVID-related medical care.",
                              "Increase in PaO2/FiO2 ratio by 50% by Day 4 (96 hours after first infusion). PaO2/FiO2 may be calculated from an arterial blood gas or imputed from the SpO2/FiO2 table",
                              "The number of days from hospitalization to discharge to home",
                              "The number of ventilator free days",
                              "Number of days requiring oxygen support",
                              "Percent of screened patients who are enrolled and randomized"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Time to recovery",
                              "Increase in PaO2/FiO2 ratio",
                              "Days to hospital discharge to home",
                              "The number of ventilator free days",
                              "Number of days requiring oxygen support",
                              "Percent of screened patients who are enrolled and randomized"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "28 days",
                              "4 days after MSCs",
                              "90 days",
                              "90 days",
                              "7 days",
                              "90 days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04399889"
                        ]
                  },
                  {
                        "Rank": 205,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "U1111-1267-1200",
                              "31935420.7.1001.0020"
                        ],
                        "SecondaryIdDomain": [
                              "UTN - WHO International Clinical Trials Registry Platform",
                              "CAAE - Certificado de Apresenta\u00e7\u00e3o para Aprecia\u00e7\u00e3o \u00c9tica"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Other Identifier",
                              "Other Identifier"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Evaluation of lung function.",
                              "Evaluation of pulmonary function using breathing chest radiography. Assessment of peripheral opacities, interstitial and airspace opacities, diffuse airspace opacities, interstitial opacities, lobar consolidation, atelectasis, cavities, pulmonary cysts, and emphysema.",
                              "Distance covered by the patient in a period of 6 minutes.",
                              "Analysis of ventilatory parameters and arterial blood gas analysis.",
                              "D-dimer, C-reactive protein, erythrocyte sedimentation rate, ferritin, creatine, urea, saline, potassium, bilirubin, total protein and fractions, albumin, globulin, oxalacetic transaminase, pyruvic transaminase, lactate dehydrogenase, creatine phosphokinase, troponin I, coagulogram.",
                              "Red blood cells, hemoglobin, hematocrit, total leukocytes, basophil, eosinophil, neutrophil, lymphocytes, monocytes, platelets.",
                              "Expression of the RpRd gene.",
                              "Granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL) -2, IL-6, IL-7, IL-8, tumor necrosis factor (TNF) \u03b1, monocyte chemoattractant protein-1 (MCP1/CCL2) and macrophage inflammatory protein 1-alpha (MIP1a/CCL3).",
                              "Evaluation of hospitalization days.",
                              "Chest computed tomography evaluation will analyze the following characteristics: ground glass opacities, linear opacities, consolidation, interlobular septal thickening, crazy-paving pattern, subpleural lines, bronchial wall thickening, lymph node enlargement and pleural effusion. Lesions will quantify by assigning a score to all abnormal areas involved. Each lobe will assigned a score of 0 (0% involvement), 1 (1-25% involvement), 2 (26-50% involvement), 3 (51-75% involvement) or 4 (76%-100% involvement). The total score will be the sum of all lobes, ranging from 0 to 25.",
                              "Clinical evaluation of patients.",
                              "Evaluation of the number of patients who died during the study."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Pulmonary function test to evaluate the improvement of respiratory function",
                              "Radiography to evaluate the improvement of respiratory function",
                              "6-minute walk to evaluate the improvement of respiratory function",
                              "Decrease on days of non-invasive mechanical ventilation",
                              "Biochemical tests to evaluate the improvement of laboratory parameters",
                              "Blood count to evaluate the improvement of laboratory parameters",
                              "Viral load to evaluate the improvement of laboratory parameters",
                              "Cytokine dosage to evaluate inflammatory parameters",
                              "Decrease in hospital stay",
                              "Computed tomography score to evaluate the improvement of pulmonary function",
                              "Reduction in the percentage of intubated patients",
                              "Decrease in mortality"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Pre-infusion, on days 5 and 28, 3 and 6 months.",
                              "Pre-infusion, on days 5 and 28, 3 and 6 months.",
                              "Pre-infusion, on days 5 and 28, 3 and 6 months.",
                              "Six hours after infusion, days 1, 5 and 28, 3 and 6 months.",
                              "Pre-infusion, on days 1, 5 and 28, 3 and 6 months.",
                              "Pre-infusion, on days 1, 5 and 28, 3 and 6 months.",
                              "Pre-infusion, on days 1, 5 and 28, 3 and 6 months.",
                              "Pre-infusion, on days 1, 5 and 28, 3 and 6 months.",
                              "From admission to discharge, or a maximum of 6 months.",
                              "Pre-infusion, on days 5 and 28, 3 and 6 months.",
                              "After first cell infusion until six months after the transplant.",
                              "After first cell infusion until the end of study. The clinical follow-up of patients will be six months after the transplant."
                        ],
                        "SeeAlsoLinkLabel": [
                              "UC-MSCs infusion is safe and can play an important role as an adjunctive therapy, both in the early stages, preventing severe complications and in the chronic phase with postacute sequelae reduction in critically ill COVID-19 patients.",
                              "The combination of tocilizumab and UC-MSC proved to be safe, with no adverse effects, and the results of this case report prove to be a promising alternative in the treatment of patients with severe acute respiratory syndrome due to SARS-CoV-2."
                        ],
                        "SeeAlsoLinkURL": [
                              "https://pubmed.ncbi.nlm.nih.gov/35313959/",
                              "https://pubmed.ncbi.nlm.nih.gov/34074163/"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05433298"
                        ]
                  },
                  {
                        "Rank": 206,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "The change of nasal mucosal physiology assessed by olfactory test",
                              "The change of nasal mucosal physiology assessed by nasal mucociliary clearance time (MCT)",
                              "The change of nasal airway resistance assessed by rhinomanometry",
                              "The change of nasal obstruction assessed by acoustic rhinometry",
                              "The change of nasal obstructive symptom assessed by visual analogue scale (VAS)",
                              "The change of nasal symptom severity assessed by total nasal symptom score (TNSS)",
                              "Change from baseline in computed tomography (CT)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "baseline, 12 weeks after surgery",
                              "baseline, 12 weeks after surgery",
                              "baseline, 12 weeks after surgery",
                              "baseline, 12 weeks after surgery",
                              "baseline, 12 weeks after surgery",
                              "baseline, 12 weeks after surgery",
                              "baseline, 12 weeks after surgery"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02947191"
                        ]
                  },
                  {
                        "Rank": 207,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Safety evaluation of WJ-MSC describing and comparing incidence, type and severity of adverse events in both groups.",
                              "Evaluation of the effect of WJ-MSC in the time of mechanical ventilation compared between the two groups, as prolonged mechanical ventilation days are associated with higher complication risks as pneumonia, tracheostomy and death.",
                              "Evaluation of the effect of WJ-MSC in the time of hospitalization between the two groups as a measure of efficacy.",
                              "Evaluation of the effect of WJ-MSC in the time of oxygen needs compared between the two groups as a measure of efficacy.",
                              "\"Sequential Organ Failure Assessment\" (SOFA) score is a tool used to determine the beginning and evolution of multiorgan failure, ranging from 0 to 24, being 24 the worst scenario. It has been proven useful as an outcome predictor of mortality and ICU stay. The result is the addition of the evaluation of each organ or system. Effect of WJ-MSC in the SOFA score will be compared between the two groups.",
                              "Murray score is a tool used to classify lung injury. 0 = no lung injury, 0.1-2.5, mild to moderate lund injury, >2.5 Acute respiratory distress syndrome.\n\nThe effect of WJ-MSC in the Murray score will be compared between the two groups.",
                              "APACHE II is a prognostic score based on 12 different items obtained in the first 24 hours of ICU admission. Its mainly used as a single measure, but some authors have used and described prediction usefulness with repeated measures. It ranges from 0 to 71 points. Higher scores are related to higher ICU mortality.\n\nThe effect of WJ-MSC in the APACHE II score will compared between the two groups.",
                              "Evaluation of the effect of WJ-MSC in lymphocyte count measured in absolute number/mm3.\n\nThese laboratory measures have been associated with COVID 19 severity.",
                              "Evaluation of the effect of WJ-MSC in C reactive protein concentration between the two groups, measured in mg/dl.\n\nHighest levels have been associated with COVID 19 severity and inflammation.",
                              "Evaluation of the effect of WJ-MSC in D dimer between the two groups, measured in micrograms Highest levels have been associated with COVID 19 severity and thromboembolic complications.",
                              "Evaluation of the effect of WJ-MSC in ferritin compared between the two groups, measured in nanograms/ml.\n\nThese laboratory measures have been associated with COVID 19 infection and severity.",
                              "Evaluation of the effect of WJ-MSC in LDH compared between the two groups, measured in units/liter.\n\nThese laboratory measures have been associated with COVID 19 infection and severity.",
                              "Cytokines are biomarkers of inflammation or inflammatory activity in the human body. Changes in this profile give information about underlying process of inflammation.The effect of WJ-MSC in IL-6 will be compared between the two groups. It will be measured in picograms/ml.",
                              "Cytokines are biomarkers of inflammation or inflammatory activity in the human body. Changes in this profile give information about underlying process of inflammation. The effect of WJ-MSC in IL 8 will be compared between the two groups. It will be measured in picograms/ml.",
                              "Cytokines are biomarkers of inflammation or inflammatory activity in the human body. Changes in this profile give information about underlying process of inflammation. The effect of WJ-MSC in IL 10 will be compared between the two groups. It will be measured in picograms/ml.",
                              "Cytokines are biomarkers of inflammation or inflammatory activity in the human body. Changes in this profile give information about underlying process of inflammation. The effect of WJ-MSC in TNF alpha will be compared between the two groups. It will be measured in nanograms/ml."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Number of patients with treatment related adverse events",
                              "Difference in days of mechanical ventilation between groups",
                              "Median reduction of days of hospitalization",
                              "Median reduction of days of oxygen needs",
                              "Difference between \"Sequential Organ Failure Assessment\" score between groups",
                              "Difference between median Murray score between groups",
                              "Difference in APACHE II score between groups",
                              "Difference in lymphocyte count between groups",
                              "Changes in C reactive protein concentration between groups",
                              "Changes in D dimer concentration",
                              "Changes in ferritin concentration",
                              "Changes in lactate dehydrogenase concentration",
                              "Impact on interleukin 6 concentrations between groups.",
                              "Impact on interleukin 8 concentrations between groups.",
                              "Impact on interleukin 10 concentrations between groups.",
                              "Impact on tumor necrosis factor alpha concentrations between groups."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months.",
                              "From ICU admission to 180 days.",
                              "From hospital admission to 180 days.",
                              "From hospital admission to 180 days.",
                              "Baseline to 7 days",
                              "Baseline and 7 days",
                              "Baseline and 7 days",
                              "baseline and 21 days or discharge",
                              "baseline and 21 days or discharge",
                              "baseline and 21 days or discharge",
                              "baseline and 21 days or discharge",
                              "baseline and 21 days or discharge",
                              "Baseline and 7 days",
                              "Baseline and 7 days",
                              "Baseline and 7 days",
                              "Baseline to 7 days."
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04390152"
                        ]
                  },
                  {
                        "Rank": 208,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04018729"
                        ]
                  },
                  {
                        "Rank": 209,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [
                              "Mayo Clinic Clinical Trials"
                        ],
                        "SeeAlsoLinkURL": [
                              "https://www.mayo.edu/research/clinical-trials"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05456243"
                        ]
                  },
                  {
                        "Rank": 210,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Clinical assessment of Knee injury and Osteoarthritis Outcome Score (KOOS)",
                              "Clinical assessment of visual analogue scale (VAS)",
                              "Clinical assessment of knee X-ray",
                              "Clinical assessment of knee MRI"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "48 weeks",
                              "48 weeks",
                              "48 weeks",
                              "48 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03007576"
                        ]
                  },
                  {
                        "Rank": 211,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04290182"
                        ]
                  },
                  {
                        "Rank": 212,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2011AA020114"
                        ],
                        "SecondaryIdDomain": [
                              "The \"863 Projects\" of MOST of PR China"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Other Grant/Funding Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Changes from the baseline in ADAS-cog, Clinician's Interview-Based Impression of Change(CIBIC), mini-mental state examination\uff08MMSE), CIBIC-plus, Activity of Daily Living Scales(ADL), Neuropsychiatric Inventory(NPI), serum transthyretin, amyloid beta and tau in cerebrospinal fluid, Thl/Th2 cytokines in the peripheral blood."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Changes from the baseline in Alzheimer' s Disease Assessment Scale-cognitive subscale(ADAS-Cog) at 10 weeks post-dose"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "10 weeks from post-administration"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01547689"
                        ]
                  },
                  {
                        "Rank": 213,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04366830"
                        ]
                  },
                  {
                        "Rank": 214,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Inhibition of the disease progression will be recorded by ALS functional rating scale (ALSFRS) at Visits I, III, and VI through X.\n\nMeasures (all 4-0):\n\nspeech\nsalivation\nswallowing\nhandwriting\ncutting food and handling utensils (with or without gastrostomy)\ndressing and hygiene\nturning in bed and adjusting bed clothes\nwalking\nclimbing stairs\nbreathing\n\nALSFRS = SUM (points for all 10 measures)\n\nInterpretation:\n\nminimum score: 0 maximum score: 40 The higher the score the more function is retained.",
                              "Inhibition of the disease progression will be recorded by Norris scale at Visits I, III, and VI through X.\n\nNorris scal has has 22 items examining bulbar, respiratory, trunk, arm, leg, and general domains involving reflexes, fasciculation, and muscle atrophy. The scale also measures emotional lability, fatigability and leg rigidity. The Norris scale has a linear decline during the course of ALS.",
                              "FVC (%) will be measured at Visits I, and VI through X."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Efficacy: Inhibition of the disease progression - ALS functional rating scale",
                              "Efficacy: Inhibition of the disease progression - Norris scale",
                              "Efficacy: Inhibition of the disease progression - Forced vital capacity (FVC)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "18 months",
                              "18 months",
                              "18 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03828123"
                        ]
                  },
                  {
                        "Rank": 215,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "NCI-2020-13889",
                              "2019-1122",
                              "P01CA148600"
                        ],
                        "SecondaryIdDomain": [
                              "CTRP (Clinical Trial Reporting Program)",
                              "M D Anderson Cancer Center"
                        ],
                        "SecondaryIdLink": [
                              "https://reporter.nih.gov/quickSearch/P01CA148600"
                        ],
                        "SecondaryIdType": [
                              "Registry Identifier",
                              "Other Identifier",
                              "U.S. NIH Grant/Contract"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Will assess complete response (CR), very good partial response (VGPR), partial response (PR), stable disease (SD), and progressive disease (PD).",
                              "Will assess proportion of patients with CR, PR, VGPR, and no-response (NR). The event NR is defined as stable disease, mixed response, disease progression, OR initiation of additional systemic (second-line) GVHD therapies.",
                              "Will be estimated by the method of Kaplan and Meier.",
                              "Will be estimated by the method of Kaplan and Meier.",
                              "Will be estimated by the method of Kaplan and Meier.",
                              "Patients alive, free of active acute or chronic GVHD, and without other systemic agents (or escalation of steroids to >= 2.5 mg/kg/day of prednisone [or methylprednisolone equivalent of 2 mg/kg/day]) added for treatment of GVHD will be considered successes for this endpoint",
                              "Chronic GVHD is defined per National Institutes of Health Consensus Criteria. Diagnosis of chronic GVHD of any severity (mild, moderate, or severe) is considered an event for this endpoint. Organ involvement and maximum severity will also be described at six months.",
                              "The incidence of grade 2 to 3 systemic infections occurring from study treatment until 28 days after last study drug will be described using standard Common Terminology Criteria for Adverse Events (CTCAE) criteria. Infections will be recorded by site of disease, date of onset, and severity.",
                              "The incidence of grade 3-5 treatment-emergent adverse events (per CTCAE version 5.0) that occur through 28 days after completing last MSC infusion study drug will be described."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Graft versus host disease status",
                              "Proportion of response",
                              "Time to complete response",
                              "Time to very good partial response",
                              "Time to partial response",
                              "Incidence of complete response for each organ",
                              "Incidence of very good partial response for each organ",
                              "Incidence of partial response for each organ",
                              "Durability of organ response",
                              "Cumulative incidence of non-relapse mortality (NRM)",
                              "Cumulative incidence of relapse/progression of the primary disease",
                              "Overall survival",
                              "Disease-free survival",
                              "Graft versus host disease-free survival",
                              "Incidence of chronic graft versus host disease",
                              "Incidence of systemic infections",
                              "Incidence of toxicities",
                              "Incidence of any grade cytokine release",
                              "Incidence of any infusional toxicity"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "At days 7, 14, 21 and 28 post treatment",
                              "At days 7, 14, 21 and 28 post treatment",
                              "Up to 6 months",
                              "Up to 6 months",
                              "Up to 6 months",
                              "Up to 6 months",
                              "Up to 6 months",
                              "Up to 6 months",
                              "Up to 6 months",
                              "At 6 months post treatment",
                              "At 6 months",
                              "From enrollment to death from any cause, assessed at 6 months",
                              "From enrollment to death from any cause or relapse/progression of the primary disease, assessed at 6 months",
                              "At 6 months",
                              "At 6 months after first mesenchymal stromal cells (MSC) infusion",
                              "28 days after last study drug",
                              "Up to 28 days after completing last MSC infusion study drug",
                              "Up to 28 days after completing last MSC infusion study drug",
                              "Within 24 hours of each cord blood-MSC infusion"
                        ],
                        "SeeAlsoLinkLabel": [
                              "M D Anderson Cancer Center"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://www.mdanderson.org"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04744116"
                        ]
                  },
                  {
                        "Rank": 216,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Defined as fall in FEV1 > 10% from the baseline (screening visit) FEV1",
                              "BOS grade 3 is defined as FEV1 <50% of the best-post-transplant FEV1",
                              "Defined as any death felt by the investigator to be at least partially related to CLAD.",
                              "Acute rejection defined as any biopsy proven episode of acute vascular (A1-A4) or airway (B1R or B2R) rejection.",
                              "An anti-HLA antibody (any mean fluorescent intensity level) with specificity for a donor HLA type at 3 months which was not present prior to IMP treatment",
                              "CLAD progression is defined as fall in FEV1 > 10% from the baseline (screening visit) FEV1 at 12 months.",
                              "Rate of FEV1 decline is defined as the slope of the regression line for FEV1 between the screening visit and week 54",
                              "Rate of FVC decline is defined as the slope of the regression line for FVC between the screening visit and week 54",
                              "Change in 6MWD is defined as the difference between the 6MWD at screening and the week 54 visit. Patients who have died by week 54 will receive a 6MWD of 0.",
                              "Change in SGRQ is defined as the difference between the total SGRQ at screening and the week 54 visit. Patients who have died by week 54 will receive a SGRQ of 0.",
                              "This is defined as the aggregate of inpatient bed-days between the screening visit and week 54."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Time to fall in FEV1 > 10%",
                              "Freedom from Bronchiolitis Obliterans Syndrome (BOS) grade 3",
                              "All cause mortality",
                              "CLAD-specific mortality",
                              "Freedom from acute rejection",
                              "Freedom from the development of new donor specific anti-HLA antibodies",
                              "Freedom from CLAD progression",
                              "Rate of FEV1 decline",
                              "Rate of FVC decline",
                              "Change in 6-minute walk distance (6MWD)",
                              "Change in St George's Respiratory Questionnaire (SGRQ) Score",
                              "Inpatient bed-days"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "From the baseline (screening) visit",
                              "Week 54",
                              "Week 54",
                              "Week 54",
                              "From baseline to week 54",
                              "From baseline to week 14",
                              "From baseline to week 54",
                              "From baseline to week 54",
                              "From baseline to week 54",
                              "From baseline to week 54",
                              "From baseline to week 54",
                              "From baseline to week 54"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02709343"
                        ]
                  },
                  {
                        "Rank": 217,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "A533300",
                              "SMPH/HUMAN ONCOLOGY/HUMAN ONCO",
                              "UW20025",
                              "NCI-2021-00070",
                              "1UG3DE030431-01",
                              "Protocol Version 10/7/2021",
                              "Head & Neck SPORE"
                        ],
                        "SecondaryIdDomain": [
                              "UW Madison",
                              "UW Madison",
                              "UWCCC",
                              "NCI CTRP",
                              "UW Madison",
                              "Dr. Jacques Galipeau, MD"
                        ],
                        "SecondaryIdLink": [
                              "https://reporter.nih.gov/quickSearch/1UG3DE030431-01"
                        ],
                        "SecondaryIdType": [
                              "Other Identifier",
                              "Other Identifier",
                              "Other Identifier",
                              "Registry Identifier",
                              "U.S. NIH Grant/Contract",
                              "Other Identifier",
                              "Other Identifier"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Whole saliva production rates will be measured under unstimulated and stimulated saliva collection conditions.",
                              "Salivary pH will be measured using a pH meter. The normal range of saliva pH is 6.2-7.6 .",
                              "ELISA will be used to quantify total protein concentration in saliva. The normal range of total protein in saliva is 2-5 mg/mL.",
                              "The enzyme-linked immunosorbent assay (ELISA) will be used to quantify amylase concentration in saliva. The normal range of amylase concentration in saliva is 10-150 U/mL.",
                              "ELISA will be used to quantify mucin concentration in saliva.The normal range of mucin concentration in saliva is 1,000-3,000 ug/mL.",
                              "The University of Michigan Xerostomia Related Quality of Life (XeQOL) scale is a validated patient-reported assessment 15 item scale with 4 domains: physical functioning, pain/discomfort, personal/psychologic functioning, and social functioning. Participants will answer the questions on a scale of 1-5 (not a all, a little, somewhat, quite a bit, very much) for every item. Higher scores represent greater degree of symptoms.",
                              "The MDADI is a 20-item questionnaire designed for evaluating the impact of dysphagia on the quality of life of patients with head and neck cancer. The MDADI score ranges from 20-100 with a lower scale representing worse dysphagia.",
                              "A Visual Analogue Scale questionnaire for subjective assessment of salivary dysfunction. The VAS xerostomia questionnaire is an 8-item questionnaire that provides a validated measure of the perception of dry mouth. Participants will be asked to mark their responses to each item by placing a vertical line on the 100-mm horizontal scale. The VAS ranges from 8-80 with a lower scale representing less dysphagia/symptoms",
                              "Salivary gland size measured by ultrasound imaging",
                              "Salivary gland stiffness (fibrosis) will be measured by acoustic radiation force impulse imaging. Evaluators will be blinded to the time point of evaluation (pre- or post- MSC injection)",
                              "Study feasibility will in part be measured by participant drop out rate."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in Saliva production rate",
                              "Saliva composition analysis: Change in salivary pH",
                              "Saliva composition analysis: Change in total protein concentration in saliva",
                              "Saliva composition analysis: Change in amylase concentration in saliva",
                              "Saliva composition analysis: Change in mucin concentration in saliva",
                              "Change in The University of Michigan Xerostomia Related Quality of Life (XeQOL) score",
                              "Change in The MD Anderson Dysphagia Index (MDADI) score",
                              "Change in Visual Analogue Scale (VAS) xerostomia score",
                              "Change in salivary gland size",
                              "Change in salivary gland stiffness measured by shear wave velocity",
                              "Participant Drop out Rate"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "baseline (up to 8 weeks before injection), 1, 3, 6, 12, and 24 months post-injection",
                              "baseline (up to 8 weeks before injection), 1, 3, 6, 12, and 24 months post-injection",
                              "baseline (up to 8 weeks before injection), 1, 3, 6, 12, and 24 months post-injection",
                              "baseline (up to 8 weeks before injection), 1, 3, 6, 12, and 24 months post-injection",
                              "baseline (up to 8 weeks before injection), 1, 3, 6, 12, and 24 months post-injection",
                              "baseline (up to 8 weeks before injection), 1, 3, 6, 12, and 24 months post-injection",
                              "baseline(up to 8 weeks before injection), 1, 3, 6, 12, and 24 months post-injection",
                              "baseline (up to 8 weeks before injection), 1, 3, 6, 12, and 24 months post-injection",
                              "baseline (up to 8 weeks before injection), 3, 6, and 12 months post-injection",
                              "baseline (up to 8 weeks before injection), 3, 6, and 12 months post-injection",
                              "up to 24 months post-injection (up to 26 months from consent)"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04489732"
                        ]
                  },
                  {
                        "Rank": 218,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Percentage of participants achieving ACR20",
                              "Percentage of participants achieving ACR50",
                              "Percentage of participants achieving ACR70",
                              "Change from baseline of the disease activity score based on DAS28-CRP",
                              "Change from baseline of the disease activity score based on DAS28-ESR",
                              "EULAR response",
                              "Change from baseline of the health assessment questionnaire(HAQ) score",
                              "Change from baseline of the simplified disease activity index (SDAI) score",
                              "Change from baseline of the clinical disease activity index (CDAI) score",
                              "Change from baseline of TNF-\u03b1 level",
                              "Change from baseline of IL-6 level"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Up to day 28\u00b13",
                              "Up to day 28\u00b13",
                              "Up to day 28\u00b13",
                              "Up to day 28\u00b13",
                              "Up to day 28\u00b13",
                              "Up to day 28\u00b13",
                              "Up to day 28\u00b13",
                              "Up to day 28\u00b13",
                              "Up to day 28\u00b13",
                              "Up to day 28\u00b13",
                              "Up to day 28\u00b13"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04971980"
                        ]
                  },
                  {
                        "Rank": 219,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Comparison of the rate of complications between the 2 groups",
                              "Incidence of increased temperature sensitivity by questionnaire",
                              "Incidence and severity of infections at grafting sites by questionnaire"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "6 months",
                              "6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02815423"
                        ]
                  },
                  {
                        "Rank": 220,
                        "ResultsFirstSubmitDate": [
                              "October 15, 2021"
                        ],
                        "ResultsFirstSubmitQCDate": [
                              "December 1, 2021"
                        ],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "20200370"
                        ],
                        "SecondaryIdDomain": [
                              "Secondary Protocol ID"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Other Identifier"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Number of participants that are alive at 31 days post first infusion follow up corresponding to 28 day post second infusion.",
                              "Number of participants alive at 60 days post first infusion follow up.",
                              "Time to discharge or, if the subject was hospitalized, no longer requiring supplemental oxygen and no longer requiring COVID-19-related medical care by 31 days. The numbers represent days at which 25%, 50%, 75% subjects within the treatment group had recovered.",
                              "Number of days participants were off ventilators during 28 days post second infusion.",
                              "Number of days participants were off ventilators within up to 90 days of hospitalization.",
                              "Respiratory Rate-Oxygenation (ROX) index is defined as the ratio of oxygen saturation as measured by pulse oximetry (SpO2)/ Fraction of inspired oxygen (FiO2) to respiratory rate. This index can be used in the assessment of disease progression and the risk of intubation in COVID-19 patients with pneumonia.",
                              "Measure of the fraction of inspired oxygen (FiO2) and its usage within the body during intensive care, measured using fNIRS (Functional Near Infrared Spectroscopy). The calculation for Oxygenation index is ((FIO2 * Mean airway pressure)/partial pressure of oxygen).",
                              "Measuring the respiratory mechanics; positive end-expiratory pressure (PEEP) and plateau pressure (Pplat) in ventilated patients visit 8 (day 6)",
                              "Sequential Organ Failure Assessment (SOFA) Scores is used to track a person's risk status during stay in the Intensive Care Unit (ICU). The score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal, and neurological systems. Each organ system is assigned a point value from a minimum of 0 (normal) to a maximum of 4 (high degree of dysfunction/failure). The total score corresponds to the sum of the six different scores of the organ systems. In total, the minimum SOFA score is 0 (normal) and the maximum SOFA score is 24 (highest degree dysfunction/failure).",
                              "SIT measures the participant's sense of smell. SIT has a total score ranging from 0 to 40 with the higher the score indicating a more normal sense of smell",
                              "As assessed via serum blood samples.",
                              "As assessed via serum blood samples.",
                              "Measures the total amount of the oxygen-carrying protein in the blood as assessed via serum blood samples.",
                              "The percentage by volume of red cells in your blood as assessed via serum blood samples.",
                              "the amount of immune cells (that is one of the first cell types to travel to the site of an infection) as assessed via serum blood samples",
                              "Lymphocyte count as assessed via serum blood samples",
                              "Glomerular filtration rate (GFR) as assessed via serum blood samples to check how well the kidneys are working. It estimates how much blood passes through the glomeruli each minute.",
                              "Total protein as assessed via serum blood samples as a part of the comprehensive metabolic panel (CMP). It is a measurement of the sum of albumin and globulins.",
                              "Sodium levels as assessed by serum blood samples.",
                              "Potassium levels as assessed via serum blood samples.",
                              "Creatinine levels as assessed via serum blood samples",
                              "Glucose levels as assessed via serum blood samples",
                              "Albumin levels as assessed via serum blood samples",
                              "Alkaline phosphatase levels as assessed via serum blood samples for the Comprehensive Metabolic Panel.",
                              "The alanine aminotransferase or serum glutamate-pyruvate transaminase (ALT or SGPT) test as assessed via serum blood samples",
                              "The aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST or SGOT) test as assessed via serum blood samples",
                              "Bilirubin levels as assessed via serum blood samples for the comprehensive metabolic panel.",
                              "Blood urea nitrogen (BUN) levels as assessed via serum blood samples for the comprehensive metabolic panel.",
                              "Calcium levels as assessed via serum blood samples for the comprehensive metabolic panel.",
                              "Chloride levels as assessed via serum blood samples for the comprehensive metabolic panel.",
                              "Carbon Dioxide (CO2) levels as assessed via serum blood samples for the comprehensive metabolic panel.",
                              "As assessed via serum blood samples.",
                              "As assessed via serum blood samples on day 6 (visit 8).",
                              "As assessed via serum blood samples.",
                              "As assessed via serum blood samples.",
                              "Analysis of TNF\u03b1 in peripheral blood plasma",
                              "Analysis of TNF\u03b2 in peripheral blood plasma",
                              "Analysis of soluble tumor necrosis factor receptor 2 (sTNFR2) in peripheral blood plasma",
                              "Viral load as assessed in blood plasma for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) via Reverse Transcriptase Polymerase Chain Reaction (RT-PCR).",
                              "Number of participants reporting panel reactive antibody (PRA) positivity at Day 3 post first infusion for class I and class II as assessed via serum blood samples. These antibodies can develop following a transplant. Recipients can become sensitized to certain molecules (Human Leukocyte Antigen Class I or Class II), which can affect immune responses to and rejection of potential future transplants.",
                              "Number of participants reporting panel reactive antibody (PRA) positivity at Day 6 post first infusion for class I and class II as assessed via serum blood samples. These antibodies can develop following a transplant. Recipients can become sensitized to certain molecules (Human Leukocyte Antigen Class I or Class II), which can affect immune responses to and rejection of potential future transplants.",
                              "Number of participants reporting panel reactive antibody (PRA) positivity at Day 14 post first infusion for class I and class II as assessed via serum blood samples. These antibodies can develop following a transplant. Recipients can become sensitized to certain molecules (Human Leukocyte Antigen Class I or Class II), which can affect immune responses to and rejection of potential future transplants.",
                              "Number of participants with positive, negative, or borderline SARS-CoV-2 Immunoglobulin M (IgM)/Immunoglobulin G (IgG) serology from serum blood samples."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Survival at 31 Days Post First Infusion",
                              "Survival at 60 Days Post First Infusion",
                              "Time to Recovery",
                              "Ventilator-Free Days Throughout 28 Days Post Second Infusion",
                              "Ventilator-Free Days Throughout 90 Days",
                              "Respiratory Rate and Oxygenation Index (ROX Index)",
                              "Oxygenation Index (OI)",
                              "Positive End-Expiratory Pressure (PEEP) and Plateau Pressure (Pplat)",
                              "Sequential Organ Failure Assessment (SOFA) Scores",
                              "Smell Identification Test (SIT) Scores",
                              "White Blood Cell Count (WBC)",
                              "Platelets Count",
                              "Hemogoblin",
                              "Hematocrit",
                              "Neutrophils",
                              "Lymphocytes",
                              "Glomerular Filtration Rate",
                              "Total Protein",
                              "Sodium",
                              "Potassium",
                              "Creatinine",
                              "Glucose",
                              "Albumin",
                              "Alkaline Phosphatase",
                              "Alanine Aminotransferase or Serum Glutamate-pyruvate Transaminase (ALT or SGPT)",
                              "Aspartate Aminotransferase or Serum Glutamic Oxaloacetic Transaminase (AST or SGOT)",
                              "Total Bilirubin",
                              "Blood Urea Nitrogen (BUN)",
                              "Calcium",
                              "Chloride",
                              "Carbon Dioxide (CO2)",
                              "C-Reactive Protein Levels",
                              "Arachidonic Acid/Eicosapentaenoic Acid (AA/EPA) Ratio",
                              "D-dimer Levels",
                              "25-Hydroxy Vitamin D Levels",
                              "Tumor Necrosis Factor-alpha (TNF\u03b1)",
                              "Tumor Necrosis Factor-beta (TNF\u03b2)",
                              "Soluble Tumor Necrosis Factor Receptor 2 (sTNFR2)",
                              "Viral Load by SARS-CoV-2 RT-PCR",
                              "Number of Participants Reporting Panel Reactive Antibody (PRA) Positivity at Day 3 Post First Infusion",
                              "Number of Participants Reporting Panel Reactive Antibody (PRA) Positivity at Day 6 Post First Infusion",
                              "Number of Participants Reporting Panel Reactive Antibody (PRA) Positivity at Day 14 Post First Infusion",
                              "Number of Participants With Positive, Negative, or Borderline Serology Testing for SARS-CoV-2 IgM/IgG"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "31 Days",
                              "60 days",
                              "31 days",
                              "28 days post second infusion",
                              "90 days or hospital discharge, whichever is earlier",
                              "day 6",
                              "day 6",
                              "day 6",
                              "Day 6",
                              "90 days",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "Day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 3 post first infusion",
                              "day 6",
                              "day 14",
                              "day 14 post first infusion"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment"
                        ],
                        "NCTId": [
                              "NCT04355728"
                        ]
                  },
                  {
                        "Rank": 221,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Impact as assessed in change from Baseline in Physiological and Quality of Life scores for each subject at 3, 6, 9, 12, 24 and up to 36 months post defect repair: QoL EQ-5D, 6-minute walking test, ambulatory O2 measurements.",
                              "Adverse events related to the BPF implant procedures reported after 3, 6, 9, 12, 24 and 36 months.",
                              "viability of the repair area and integration with vascular supply at 6, 9, 12, 24 and 36 months.",
                              "Interventions at the operative sites up to 6, 9, 12, 24 and 36 months"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change from Baseline in Physiological and Quality of Life scores at 3, 6, 9, 12 months, Evaluation Questionnaire 5D (EQ-5D), 6-minute walking test (6MWT), ambulatory oxygen (O2).",
                              "Safety and tolerability: - Adverse Events (AEs) including pre-defined postoperative AEs of special interest up to 30\u00b1 3 days post implantation- Related AEs reported after 3, 6, 9, 12, 24 and 36 months",
                              "Viability and the integrity of the repair area (closure) visually via bronchoscope. Integrity assessed by visual appearance of no visible leaks- Structural closure of the defect and visual health of the defect area and surrounding tissue",
                              "Absence of other surgical interventions at 6, 9, 12, 24 and 36 months"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "36 months",
                              "36 months",
                              "36 months",
                              "36 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04435249"
                        ]
                  },
                  {
                        "Rank": 222,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Outcome measures will be assessed at 3 months pre-treatment, baseline (prior injections), 3 months, 6 months, and 12 months.\n\nInformed consent will be obtained in writing from each subject prior to participation in the study. If the subject is unable to give consent or he/she scores less than 24 on the Mini Mental Status Examination (MMSE), they will be excluded from the study. The research personnel involved in the study will carefully explain the consent form to the subject. The subject will then be given ample opportunity to ask questions prior agreeing to participate. If the need arises the research personnel will be available to answer questions and address any concerns.",
                              "A number of motor function tests will be performed with every follow up visit for all 30 patients.",
                              "Clinical Tests ,all patients will be evaluated clinically using qualitative and quantitative tests.",
                              "Blood samples will be collected pre and post treatment for immediate or ulterior analysis. Results will be compared between individuals and then between the two groups that received one or two doses of UC-MSCs."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Safety and Efficacy Assessment Pre and Post Treatment",
                              "Motor Functions Assessments",
                              "Measuring Non-motor outcomes to assess treatment efficacy.",
                              "Biological Assessments"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "3-12 months",
                              "3-12 months",
                              "3-6 months",
                              "3-12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03326505"
                        ]
                  },
                  {
                        "Rank": 223,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Wound size change in percent at each post-baseline follow-up visit will be evaluated.",
                              "Time to complete wound closure will be evaluated.",
                              "Complete wound closures at each post-baseline follow-up visit will be evaluated.",
                              "Duration of wound closure will be evaluated.",
                              "Recurrence of the wound will be evaluated.",
                              "The Quality of wound healing will be assessed at each post-baseline follow-up visit on the basis of the amount and type of wound exudate.",
                              "The Quality of wound healing will be assessed at each post-baseline follow-up visit on the basis of the formation of granulation tissue together with epithelialization.",
                              "The Quality of wound healing will be assessed at each post-baseline follow-up visit on the basis of the questions regarding scar formation.",
                              "Quality of Life using the Wound-Quality of Life Questionnaire at V8, V11, V14 will be evaluated.",
                              "Pain assessment as per numerical rating scale on each post-baseline efficacy follow-up visit will be evaluated.",
                              "A physical body examination (e.g. general appearance, thyroid, head, lungs and thorax, ears, cardiovascular system, eyes, abdomen, nose-mouth-throat, musculoskeletal system, skin, extremities, lymph nodes, neurological system) will be performed and abnormal physical examination results will be evaluated and reported as AEs."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Wound size change in percent at each post-baseline follow-up visit",
                              "Time to complete wound closure",
                              "Complete wound closures at each post-baseline follow-up visit",
                              "Duration of wound closure",
                              "Recurrence of the wound",
                              "Quality of wound healing (wound exudate) at each post-baseline follow-up visit",
                              "Quality of wound healing (granulation tissue together with epithelialization) at each post-baseline follow-up visit",
                              "Quality of wound healing (scar formation) at each post-baseline follow-up visit",
                              "Assessment of Quality of Life using the Wound-Quality of Life Questionnaire at V8, V11, V14",
                              "Pain assessment as per numerical rating scale on each post-baseline efficacy follow-up visit",
                              "Physical examination and vital signs at V14"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10",
                              "Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10",
                              "Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10",
                              "Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10",
                              "Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10",
                              "Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10",
                              "Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10",
                              "Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10",
                              "Week 6, 12, 18",
                              "Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10",
                              "Week 18"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04971161"
                        ]
                  },
                  {
                        "Rank": 224,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The assessment of Rhinoconjunctivitis quality of life questionnaire (RQLQ) includes daily activities, sleep, non-rhino-conjunctivitis symptoms, rhinitis-related behaviors, nasal symptoms, eye symptoms, and emotional reactions.\n\nEach of the above aspect is composed of several measurements. A total of 28 measurements are individually scored from 0 to 6 points. A score of 0 indicates that the subject has not been affected by nose and eye symptoms in the past week, a score of 1 indicates that it is almost unaffected, a score of 2 indicates a minor influence, a score of 3 indicates a slight influence, a score of 4 indicates a moderate influence, and a score of 5 indicates a severe influence, a score of 6 indicates that it is extremely severely affected. In terms of daily activities, a score of 9 directly indicates that daily activity cannot be carried out due to nose and eye symptoms.",
                              "Visual analogue scale (VAS) is used to evaluate the severity of nasal symptoms by patients or their guardians. Visual line marks are made on the scale with a length of 10 cm. The VAS score is calculated as 0 is asymptomatic (0 cm), and 10 is the most serious symptom (10 cm).",
                              "Nasal expiratory nitric oxide (NO) test (NNO test), is a simple, noninvasive and convenient medical detection method, that can be used for the diagnosis, treatment and monitoring of nasal diseases such as rhinitis, sinusitis and nasal polyps.",
                              "The normal nasal mucosa is light red, with smooth, moist and shiny surface. The nasal cavity and nasopharyngeal mucosa have no congestion, edema, dryness, ulcers, hemorrhage, vasodilatation and new organisms; no purulent secretions.\n\nThe mucosa of allergic rhinitis is pale, edematous or lavender, and the discharge is watery.",
                              "The U-HCG test detects levels of hCG in the urine, positive result indicate pregnacy.",
                              "To test level of inflammatory factor Interferon \u03b3 (IFN-\u03b3) in the serum;",
                              "To test level of inflammatory factor Interferon \u03b1 (IFN-\u03b1) in the serum;",
                              "To test level of inflammatory factor Interleukin 1\u03b2 (IL-1\u03b2) in the serum;",
                              "To test level of inflammatory factor Interleukin 2 (IL-2) in the serum;",
                              "To test level of inflammatory factor Interleukin 4 (IL-4) in the serum;",
                              "To test level of inflammatory factor Interleukin 5 (IL-5) in the serum;",
                              "To test level of inflammatory factor Interleukin 6 (IL-6) in the serum;",
                              "To test level of inflammatory factor Interleukin 8 (IL-8) in the serum;",
                              "To test level of inflammatory factor Interleukin 10 (IL-10) in the serum;",
                              "To test level of inflammatory factor Interleukin 12P70 (IL-12P70) in the serum;",
                              "To test level of inflammatory factor Interleukin 17A (IL-17A) in the serum;",
                              "To test level of inflammatory factor Tumor necrosis factor-\u03b1\uff08TNF-\u03b1\uff09 in the serum;",
                              "To test level of inflammatory factor Interferon \u03b3 (IFN-\u03b3) in nasal secretions;",
                              "To test level of inflammatory factor Interferon \u03b1 (IFN-\u03b1) in nasal secretions;",
                              "To test level of inflammatory factor Interferon \u03b1 (IFN-\u03b1) in nasal secretions;",
                              "To test level of inflammatory factor Interleukin 2 (IL-2) in nasal secretions;",
                              "To test level of inflammatory factor Interleukin 4 (IL-4) in nasal secretions;",
                              "To test level of inflammatory factor Interleukin 5 (IL-5) in nasal secretions;",
                              "To test level of inflammatory factor Interleukin 6 (IL-6) in nasal secretions;",
                              "To test level of inflammatory factor Interleukin 8 (IL-8) in nasal secretions;",
                              "To test level of inflammatory factor Interleukin 10 (IL-10) in nasal secretions;",
                              "To test level of inflammatory factor Interleukin 12P70 (IL-12P70) in nasal secretions;",
                              "To test level of inflammatory factor Interleukin 17A (IL-17A) in nasal secretions;",
                              "To test level of inflammatory factor Tumor necrosis factor-\u03b1\uff08TNF-\u03b1\uff09 in nasal secretions;"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "RQLQ score",
                              "VAS score",
                              "Nasal function test",
                              "Nasal endoscopy",
                              "U-HCG",
                              "Detection of Serum Interferon \u03b3 (IFN-\u03b3)",
                              "Detection of Serum Interferon \u03b1 (IFN-\u03b1)",
                              "Detection of Serum Interleukin 1\u03b2 (IL-1\u03b2)",
                              "Detection of Serum Interleukin 2 (IL-2)",
                              "Detection of Serum Interleukin 4 (IL-4)",
                              "Detection of Serum Interleukin 5 (IL-5)",
                              "Detection of Serum Interleukin 6 (IL-6)",
                              "Detection of Serum Interleukin 8 (IL-8)",
                              "Detection of Serum Interleukin 10 (IL-10)",
                              "Detection of Serum Interleukin 12P70 (IL-12P70)",
                              "Detection of Serum Interleukin 17A (IL-17A)",
                              "Detection of Serum Tumor necrosis factor-\u03b1\uff08TNF-\u03b1\uff09",
                              "Detection of inflammatory factor Interferon \u03b3 (IFN-\u03b3) in nasal secretions",
                              "Detection of inflammatory factor Interferon \u03b1 (IFN-\u03b1) in nasal secretions",
                              "Detection of inflammatory factor Interleukin 1\u03b2 (IL-1\u03b2) in nasal secretions",
                              "Detection of inflammatory factor Interleukin 2 (IL-2) in nasal secretions",
                              "Detection of inflammatory factor Interleukin 4 (IL-4) in nasal secretions",
                              "Detection of inflammatory factor Interleukin 5 (IL-5) in nasal secretions",
                              "Detection of inflammatory factor Interleukin 6 (IL-6) in nasal secretions",
                              "Detection of inflammatory factor Interleukin 8 (IL-8) in nasal secretions",
                              "Detection of inflammatory factor Interleukin 10 (IL-10) in nasal secretions",
                              "Detection of inflammatory factor Interleukin 12P70 (IL-12P70) in nasal secretions",
                              "Detection of inflammatory factor Interleukin 17A (IL-17A) in nasal secretions",
                              "Detection of inflammatory factor Tumor necrosis factor-\u03b1\uff08TNF-\u03b1\uff09 in nasal secretions"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.",
                              "The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.",
                              "The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.",
                              "The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.",
                              "The day of enrollment screening, 3 months, 6 months, 12 months, and 24 months after the treatment.",
                              "The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.",
                              "The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.",
                              "The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.",
                              "The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.",
                              "The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.",
                              "The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.",
                              "The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.",
                              "The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.",
                              "The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.",
                              "The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.",
                              "The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.",
                              "The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.",
                              "The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.",
                              "The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.",
                              "The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.",
                              "The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.",
                              "The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.",
                              "The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.",
                              "The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.",
                              "The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.",
                              "The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.",
                              "The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.",
                              "The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.",
                              "The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment."
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05151133"
                        ]
                  },
                  {
                        "Rank": 225,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03237442"
                        ]
                  },
                  {
                        "Rank": 226,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The liver function tests included serum Albumin (Alb), Cholesterol, Cholinesterase (CHE), prothrombin activity.",
                              "Patients surviving more than 30 days after study registration."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Improvement of liver function measured by change in Child-Pugh score",
                              "Change in clinical laboratory parameters of liver function",
                              "30-Day Survival",
                              "Change in the size of liver and spleen and inner diameter of spleen portal venous"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1 week, 2 week, 1, 3, 6, 12, 24 month after intervention",
                              "1 day, 3 day, 1 week, 2 week, 1, 3, 6, 12, 24 month after intervention",
                              "30 days",
                              "1 week, 2 week, 1, 3, 6, 12, 24 month after intervention"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02786017"
                        ]
                  },
                  {
                        "Rank": 227,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Hysteroscopic inspection to verify degree of adhesion",
                              "Measure the endometrial thickness during late proliferating phase by ultrasound",
                              "The presence of at least one fetus with heart pulsation on ultrasound beyond 8 weeks"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Reduction of intrauterine adhesion",
                              "The change of endometrial thickness",
                              "ongoing pregnant rate"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "3 months post-surgery",
                              "up to 3 months",
                              "30 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02313415"
                        ]
                  },
                  {
                        "Rank": 228,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Participants will have a clinical assessment of fistula drainage. Participants will be assessed during an office examination if their fistula is draining or not. The Outcome Measure will be the presence or absence of fistula drainage."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Number of participants with response to the treatment regarding potential cessation of drainage from their fistula."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03209700"
                        ]
                  },
                  {
                        "Rank": 229,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "MELD score",
                              "Child Pugh Score",
                              "alpha fetoprotein",
                              "renal function"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1week, 4weeks,3months, 6months, 9months and 1year after treatment",
                              "1week, 4weeks,3months, 6months, 9months and 1year after treatment",
                              "1week, 4weeks,3months, 6months, 9months and 1year after treatment",
                              "1week, 4weeks,3months, 6months, 9months and 1year after treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01728727"
                        ]
                  },
                  {
                        "Rank": 230,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Insulin-like growth factor 1 (IGF-1); stromal derived factor-1\u03b1 (SDF-1\u03b1); brain derived neurotrophic factors (BDNF), Vascular endothelial growth factor (VEGF),glial cell line-derived neutrophic factor (GDNF), fibroblast growth factor (FGF), Doublecortin (DCX)",
                              "Insulin-like growth factor 1 (IGF-1); stromal derived factor-1\u03b1 (SDF-1\u03b1); brain derived neurotrophic factors (BDNF), Vascular endothelial growth factor (VEGF),glial cell line-derived neutrophic factor (GDNF), fibroblast growth factor (FGF), Doublecortin (DCX)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Chemical Marker",
                              "Chemical Marker"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "3 month after stem cells",
                              "6 month after stem cells"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04314687"
                        ]
                  },
                  {
                        "Rank": 231,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The final score ranges from 0 (better outcome) to 126 (worse outcome)",
                              "The final score ranges from 0 (better outcome) to 164 (worse outcome)",
                              "The final score ranges from 0 (better outcome) to 92 (worse outcome)",
                              "The final score ranges from 0 (better outcome) to 100 (worse outcome)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Overall survival (OS) rate at 3 months",
                              "Correlation between response to Cyto-MSC at Day 14 and Day 28 to survival at 90 days",
                              "Relapse-free survival at 3 months",
                              "Disease relapse at 3 months",
                              "Incidence of infection",
                              "Incidence of CMV reactivation",
                              "Measurement quality of life of cancer patients by using EORTC QLQ-C30 questionnaire",
                              "Measurement quality of life in bone marrow transplantation by using FACT-BMT questionnaire",
                              "Measurement of health-related quality of life in children and young people by using PEDsQL questionnaire (patients age less than 18 years old)",
                              "Measurement of generic health status among patients by using EQ-5D questionnaire"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "3 months",
                              "90 days",
                              "3 months",
                              "3 months",
                              "6 months",
                              "6 months",
                              "6 months",
                              "6 months",
                              "6 months",
                              "6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03847844"
                        ]
                  },
                  {
                        "Rank": 232,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Non-invasive clinical markers of fibrosis - Enhanced Liver Fibrosis (ELF) and transient elastography (Fibroscan\u00ae)",
                              "QoL as measured by Pruritus Visual Analogue Scale, nine-point fatigue severity scale and SF-36v2",
                              "Marker of immune activation - immunoglobulin G concentrations Non-invasive clinical markers of fibrosis - Enhanced Liver Fibrosis (ELF) and transient elastography (Fibroscan\u00ae)\n\n\u2022 QoL as measured by Pruritus Visual Analogue Scale, nine-point fatigue severity scale and SF-36v2",
                              "change in Individual markers of liver biochemistry and function including aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyltranspeptidase (GGT), bilirubin, albumin, international normalised ratio (INR) and composite risk score (Model for End Stage Liver Disease (MELD))",
                              "Individual markers of liver biochemistry and function including aspartate aminotransferase (AST), alanine transaminase (ALT), gamma-glutamyltranspeptidase (GGT), bilirubin, albumin, international normalised ratio (INR) and composite risk scores (Mayo PSC risk score and Model for End Stage Liver Disease (MELD))",
                              "QoL as measured by Pruritus Visual Analogue Scale, nine-point fatigue severity scale and SF-36v2",
                              "Severity of IBD as measured by the non-endoscopic aspects of the Mayo IBD score - stool frequency, rectal bleeding, and physician's global assessment"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Autoimmune Hepatitis secondary outcomes 1",
                              "Autoimmune Hepatitis secondary outcomes 2",
                              "AIH secondary outcomes 3",
                              "AIH secondary outcomes 4",
                              "PSC secondary outcomes 1",
                              "PSC secondary outcomes 2",
                              "PSC secondary outcomes 3"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "56 days",
                              "56 days",
                              "56 days",
                              "56 days",
                              "56 days",
                              "56 days",
                              "56 days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02997878"
                        ]
                  },
                  {
                        "Rank": 233,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The MELD score is negatively correlated with the liver function, in which higher scores indicative a poorer liver function. The MELD score decrease show clinical improvement. The MELD score is calculated using the following formula:\n\nMELD score = 10 * (0.957 ln (serum creatinine, mg/dl) + 0.378 ln (bilirubin, mg/dl) +1.12 ln (INR) + 0.643).",
                              "CLDQ was developed to evaluate the impact of chronic liver diseases (CLD) on quality of life. The CLDQ includes 29 items in the following domains: abdominal symptoms, fatigue, systemic symptoms, activity, emotional function and worry. The scores range from 1 to 7, whit higher values indicating better quality of life."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change of liver function through the Model for End Stage Liver Disease (MELD) score",
                              "Change in health-related quality of life using Chronic Liver Disease Questionnaire - (CLDQ)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "3 months, 6 months, 12 months after the UC-MSCs infusion",
                              "3 months, 6 months, 12 months after the UC-MSCs infusion"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05331872"
                        ]
                  },
                  {
                        "Rank": 234,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "left ventricular ejection fraction measured by magnetic resonance imaging"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Difference in left ventricular ejection fraction measured by magnetic resonance imaging at baseline and 12 months follow-up"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03902067"
                        ]
                  },
                  {
                        "Rank": 235,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Pump failure Killip classification",
                              "New York Heart Association(NYHA) classification",
                              "Occurrence of major adverse event"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "baseline, 1 week, 1 month, 6 month, 12 month,18 month",
                              "1 week, 1 month, 6 month, 12 month,18 month",
                              "3 day, 1 week, 1 month, 6 month, 12 month,18 month"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02666391"
                        ]
                  },
                  {
                        "Rank": 236,
                        "ResultsFirstSubmitDate": [
                              "December 1, 2021"
                        ],
                        "ResultsFirstSubmitQCDate": [
                              "February 18, 2022"
                        ],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Overall survival rate was defined as percentage of participants who survived. OS was defined as the time to death from the start of drug therapy.",
                              "Overall survival rate was defined as percentage of participants who survived. OS was defined as the time to death from the start of drug therapy.",
                              "OS rate was defined as percentage of participants who survived. OS was defined as the time to death from the start of drug therapy. Maximum severity of acute GVHD was assessed by using International Bone Marrow Transplant Registry (IBMTR) index. The severity index was defined as: Grade A (skin Stage 1: extent of rash <25%); Grade B (skin Stage 2: extent of rash 25 to 50% or liver Stage 1 to 2: total bilirubin 34 to 102 micromoles per liter [mcmol/L] or intestinal tract Stage 1 to 2: volume of diarrhea 550 to 1500 milliliters per day [mL/day]); Grade C (skin Stage 3: extent of rash > 50% or liver Stage 3: total bilirubin 103 to 255 mcmol/L or intestinal tract Stage 3: volume of diarrhea >1500 mL/day); Grade D (skin Stage 4: extent of rash bullae or liver Stage 4: total bilirubin >255 or intestinal tract Stage 4: volume of diarrhea severe pain and ileus).",
                              "OS rate was defined as percentage of participants who survived. OS was defined as the time to death from the start of drug therapy. The data was summarized for organ involvement: skin only, lower GI only, and multi-organ.",
                              "OR rate was defined as the percentage of participants who had achieved overall response. Overall response was defined as CR plus PR as per aGVHD response criteria. CR was defined as resolution of aGVHD in all involved organs. PR was defined as organ improvement of at least 1 stage without worsening of any other organ."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Overall Survival (OS) Rate at Day 100 Post Initiation of Therapy",
                              "OS Rate at Day 100 Post Initiation of Therapy, Stratified by Responder Status at Day 28",
                              "OS Rate at Day 100 Post Initiation of Therapy, Stratified by Baseline aGVHD Grade",
                              "OS Rate at Day 100 Post Initiation of Therapy, Stratified by Organ Involvement",
                              "OR Rate at Day 56 and 100 Post Initiation of Therapy"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Day 100",
                              "Day 100",
                              "Day 100",
                              "Day 100",
                              "Day 56 and Day 100"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment"
                        ],
                        "NCTId": [
                              "NCT02336230"
                        ]
                  },
                  {
                        "Rank": 237,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "one year after transplantation (patient will follow for any adverse event via one year after transplantation ( this measures will evaluate within follow up visits at 1th , 2th , 4th, 8th, 12th weeks and 6th and 12th month after transplantation",
                              "Evaluation the AMH serum level by blood sampling up to one year after transplantation (patient will follow for any adverse event via one year after transplantation ( this measures will evaluate within follow up visits at 1th , 2th , 4th, 8th, 12th weeks and 6th and 12th month after transplantation",
                              "Evaluation the number of antral follicle by sonography up to one year after transplantation ( this measures will evaluate within follow up visits at 1th , 2th , 4th, 8th, 12th weeks and 6th and 12th month after transplantation",
                              "Evaluation the antral follicle volume by sonography up to one year after transplantation ( this measures will evaluate within follow up visits at 1th , 2th , 4th, 8th, 12th weeks and 6th and 12th month after transplantation",
                              "Evaluation the menstruation recurrence rate up to one year after transplantation ( this measures will evaluate within follow up visits at 1th , 2th , 4th, 8th, 12th weeks and 6th and 12th month after transplantation",
                              "Evaluation the pregnancy rate up to one year after transplantation ( this measures will evaluate within follow up visits at 1th , 2th , 4th, 8th, 12th weeks and 6th and 12th month after transplantation"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Follicle Stimulating Hormone (FSH) serum level",
                              "Anti-Mullerian Hormone (AMH) serum level",
                              "Number of antral follicle",
                              "Antral follicle volume",
                              "Menstruation recurrence rate",
                              "Pregnancy rate"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Up to 12months",
                              "Up to 12months",
                              "Up to 12months",
                              "Up to 12months",
                              "Up to 12 months",
                              "Up to 12months"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Related Info"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://RoyanInstitute.org"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02603744"
                        ]
                  },
                  {
                        "Rank": 238,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05464381"
                        ]
                  },
                  {
                        "Rank": 239,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The time from randomization to death for any reason ( the last follow-up time for missing patients; end date of follow-up for patients who are live at the end of the study).",
                              "improvement of aGVHD staging in one or more organs without progression in other organs",
                              "Acute toxicity responses include impaired function of heart, kidney and liver"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Overall survival",
                              "Rate of partial remission",
                              "Infusion toxicity"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "At the end of Week 4 / 8 / 12 / 24 / 52.",
                              "4 weeks after treatment",
                              "From the beginning of to four hours after every infusion of UC-MSC"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04738981"
                        ]
                  },
                  {
                        "Rank": 240,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "EPIC001"
                        ],
                        "SecondaryIdDomain": [
                              "Other"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Other Identifier"
                        ],
                        "SecondaryOutcomeDescription": [
                              "CDAI score before and after intervention will be monitored over 12 months"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Crohn's disease activity Index (CDAI)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01659762"
                        ]
                  },
                  {
                        "Rank": 241,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Uterine and Ovary characteristics of B ultrasound\uff0c including Uterine/Ovarian size and Blood Flow",
                              "Modified Kupperman Score",
                              "Incidence of Adverse Events and Serious Adverse Events"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "48 weeks after treatment",
                              "48 weeks after treatment",
                              "48 weeks after treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01742533"
                        ]
                  },
                  {
                        "Rank": 242,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "e.g. fever, allergy, rash, infection",
                              "The length of survival time after first UC-MSC treatment for the patient during the follow-up period.",
                              "HCC deveopled in the patient during the follow-up period."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The incidence of adverse events",
                              "Disease-free survival time",
                              "Incidence of hepatocellular carcinoma (HCC) events"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "96 weeks",
                              "96 weeks",
                              "96 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03945487"
                        ]
                  },
                  {
                        "Rank": 243,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "FPDI was examined in the 24/2 visual field of the computerized perimetry records. The FPDI offers data explaining how many of the 100 flashing points and what percentage of the visual field could be correctly seen by the patient. For VF analysis, in order to avoid mistakes during the test, practice rounds were carried out three times before applications.",
                              "GCC is the thickness from the internal limiting membrane to the inner plexiform layer in the 3x3 mm of foveal area. The measurement done automatically by the OCTA device. GCC is the total thickness of the ganglion cells and retinal nerve fibers.",
                              "pVEP is a objective test that measures the electrical activity of the optical pathway in response to a light stimulus. The 120' patterns reveals responses from the all retinal quadrants. The measurements were taken according to the ISCEV standarts for both eyes. We used the 120'pattern VEP protocol, which combines p100 implicit time and amplitude, to create a numerical result."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Visual field sensitivity: Fundus perimetry deviation index (FPDI, %)",
                              "Ganglion cell complex thickness (GCC thickness, \u00b5m):",
                              "Pattern visual evoked potential (pVEP)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Change from baseline FPDI at 3 months",
                              "Change from baseline GCC thickness at 3 months",
                              "Change from baseline p100 latency and amolitude at 3 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04877067"
                        ]
                  },
                  {
                        "Rank": 244,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "ASIA Impairment Scale",
                              "Evoked potentials",
                              "Evoked potentials",
                              "Pain threshold perception",
                              "Urodynamic testing",
                              "Anorectal manometry test",
                              "Numerical scale (0 to 10)",
                              "Modified Ashworth scale",
                              "SCIM III scale",
                              "WHOQOL BREF questionnaire",
                              "Qualiveen questionnaire",
                              "Magnetic Resonance Imaging",
                              "Chimerism in cerebrospinal fluid",
                              "Antibodies anti-HLA in peripherical blood and in cerebrospinal fluid"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Extent and severity of a patient's spinal cord injury",
                              "Motor electrophysiology assessment",
                              "Somatosensory electrophysiology assessment",
                              "Electrical nerve stimulation on pain perception",
                              "Mictional dysfunction",
                              "Anal sphincter integrity",
                              "Neuropathic pain",
                              "Spasticity",
                              "Functionality",
                              "Quality of life (individual overall perception of quality of life, individual overall perception of their health, Physical health, Psychological, Social relationships, Environment)",
                              "Urinary disorder",
                              "Size injury",
                              "Presence of allogeneic cells",
                              "Immunology"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months",
                              "6 month",
                              "6 month",
                              "6 month",
                              "6 month",
                              "6 month",
                              "6 months",
                              "6 months",
                              "6 months",
                              "6 months",
                              "6 months",
                              "12 months",
                              "1 month",
                              "1 months"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Blood and Tissue Bank of Catalonia",
                              "Hospital de Neurorehabilitaci\u00f3 Institut Guttmann",
                              "Marat\u00f3 TV3"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://bancsang.net/en_index/",
                              "http://www.guttmann.com/en",
                              "http://www.ccma.cat/tv3/marato/en/"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03003364"
                        ]
                  },
                  {
                        "Rank": 245,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05279768"
                        ]
                  },
                  {
                        "Rank": 246,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Marker for efficacy of treatment",
                              "0-4 score, the higher the score is, the poor of the prognosis will be.",
                              "Number of participants with treatment-related adverse events",
                              "Markers of the heart function",
                              "Markers of infection",
                              "Marker of Immunology and inflammation",
                              "Marker of Immunology and inflammation",
                              "Markers of the heart function"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Rate of mortality within 28-days",
                              "Sequential organ failure assessment",
                              "Side effects in the UC-MSCs treatment group",
                              "Electrocardiogram, the changes of ST-T interval mostly",
                              "Concentration of C-reactive protein C-reactive protein, immunoglobulin",
                              "CD4+ and CD8+ T cells count",
                              "Concentration of the blood cytokine (IL-1\u03b2, IL-6, IL-8,IL-10,TNF-\u03b1)",
                              "Concentration of the myocardial enzymes"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "At baseline, Day 1, Week 1, Week 2, Week 4, Week 8",
                              "At baseline, Day 1, Week 1, Week 2, Week 4, Week 8",
                              "At baseline, Day 1, Week 1, Week 2, Week 4, Week 8",
                              "At baseline, Day 1, Week 1, Week 2, Week 4, Week 8",
                              "At baseline, Day 1, Week 1, Week 2, Week 4, Week 8",
                              "At baseline, Day 1, Week 1, Week 2, Week 4, Week 8",
                              "At baseline, Day 1, Week 1, Week 2, Week 4, Week 8",
                              "At baseline, Day 1, Week 1, Week 2, Week 4, Week 8"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04293692"
                        ]
                  },
                  {
                        "Rank": 247,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03389919"
                        ]
                  },
                  {
                        "Rank": 248,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Days of respirator treatment",
                              "Improvement of clinical symptoms including duration of fever and respiratory need",
                              "Mortality",
                              "Marker of Immunological function -CD4+ and CD8+ T cell count",
                              "C-reactive protein and leucocyte",
                              "Cytokine profile",
                              "Glomerular Filtration Rate",
                              "Duration of hospitalization"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "3 months",
                              "3 months",
                              "3 months",
                              "3 months",
                              "3 months",
                              "3 months",
                              "3 months",
                              "3 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04341610"
                        ]
                  },
                  {
                        "Rank": 249,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02270307"
                        ]
                  },
                  {
                        "Rank": 250,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The proportion of subjects who have a reduction of 90% or more from baseline in the psoriasis area-and-severity index score (PASI 90) at week 20",
                              "The proportion of subjects who have a reduction of 75% or more from baseline in the psoriasis area-and-severity index score (PASI 75) at week 12,16,36,52",
                              "The proportion of subjects who achieve a score of 0\uff08clear\uff09or 1\uff08almost clear\uff09on a 5-point Physician's global assessment\uff08PGA0/1) at week 12,16,36,52",
                              "Frequency of all Adverse Events (AEs) and Serious Adverse Events (SAEs) that occur during the whole trial including the observational period (AEs and SAEs include but not limited to headaches, allergies, fever and so on",
                              "The proportion of subjects who experience a psoriasis relapse at any time until week 52. Psoriasis relapse is defined as loss of > 50% of the initial PASI improvement measured at week 7"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Proportion of subjects who have 90% or more reduction in [Psoriasis area-and-severity index score (PASI)] (PASI90) at week 20",
                              "Proportion of subjects who have 75% or more reduction in [Psoriasis area-and-severity index score (PASI)] (PASI75) at week 12,16,36,52",
                              "Proportion of subjects who achieve a score of 0 or 1 on a 5-point Physician's global assessment\uff08PGA0/1) at week 12,16,36,52",
                              "Frequency of Adverse Events and Serious Adverse Events",
                              "Proportion of subjects who experience psoriasis relapse"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Week 20",
                              "Week 12,16,36,52",
                              "Week 12,16,36,52",
                              "Week 0 through week 52",
                              "Week 8 though week 52"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03424629"
                        ]
                  },
                  {
                        "Rank": 251,
                        "ResultsFirstSubmitDate": [
                              "September 27, 2016"
                        ],
                        "ResultsFirstSubmitQCDate": [
                              "March 28, 2019"
                        ],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2010-023285-46"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Sensitivity recovery was measured using the ASIA (American Spinal Injury Association) scale to measure the Surface sensitivity (LTS), pain sensitivity (PPS), and the degree of motor function in key muscles (MS). The sum of MS, LTS, and PPS configure total ASIA score. A minimum possible score is 0 points. A maximum possible score is 224 points for a patient with normal sensation.\n\nASIA score was obtained before surgery, and 3, 6, 9 and 12 months after surgery. Mean and standard deviation for the 12 patients were obtained at all the time points and statistically analyzed.",
                              "Changes in the level of chronic pain, measured by the pain section of the IANR-SCIFRS (Spinal cord injury functional rating scale (SCI-FRS) of the international association of neuroestoratology (IANR). The minimum posible score is 0, and the m\u00e1ximum posible score is 48, being a score of 48 a normal functioning across all categories, and 0 a severe degree of functional h\u00e1ndicap (significant impact of daily life).\n\nPain is classified as no pain; mild pain, ordinary pain killer, effective;severe pain, narcotics required; extreme pain, uncontrolled.",
                              "Changes in the neurophysiological parameters (SSEPs, somatosensory evoked potentials) measured as number of patients WITH SSEPs, each patient through underwent neurophysiological studies before treatment, as well as six and 12 months after surgery, paying attention mainly to the presence or abscence of somatosensory evoked potentials (SSEPs), the presence or absence of motor evoked potentials (MEPs) elicited by magnetic stimulation over the scalp, and to electromyographic (EMG) recording of motor unit potentials in infralesional muscles. Previous to cell therapy in any of the patients SSEPs were recorded.",
                              "Urodynamic studies in terms of voluntary micturition in flowmetry or in pressure/flow test, increase in bladder compliance. detrusor pressure (decrease on detrusor pressure is considered a clinical improvement). The neurogenic bladder is one of the biggest problems associated with SCI (spinal cord injury), with important personal and social implications.",
                              "Number of patients with a decrease in volume and hyperintensity of intramedullary lesions. In general, in the areas of SCI, variable degree of spinal cord atrophy and hiperintense images are observed. These images corresponds to cysts, gliosis and myelomalacia. After cell administration a reduction of supposed cyst and a decrease or disappearance of hyperintense lesions suggest a patient improvement."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Efficacy-Sensitivity Recovery Using ASIA Scale",
                              "Efficacy-Changes in the Level of Chronic Pain Based on the IANR-SCIFRS Scale (Pain Section)",
                              "Efficacy- Changes in the Neurophysiological Parameters Measured as the Number of Patients With SSEPs (Somatosensory Evoked Potentials)",
                              "Efficacy-Urodynamic Studies in Terms of m\u00e1ximum Cystometric Capacity",
                              "Efficacy-modification of Magnetic Resonance Imaging (MRI)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "sensitivity before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period)",
                              "Changes in the level of Chronic pain before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period)",
                              "Changes in the level neurophysiological parameters improvement (baseline visit) and 6, 12 months after surgery (follow-up period)",
                              "Urodynamic studies before surgery and 12 months after surgery (follow-up period)",
                              "changes in the spinal cord morphology on neuroimaging studies before surgery and 12 months after surgery (follow-up period)"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01909154"
                        ]
                  },
                  {
                        "Rank": 252,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "CORFO-11IEI-9766"
                        ],
                        "SecondaryIdDomain": [
                              "Government grants"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Other Identifier"
                        ],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "\u2022 Change in functional capacity measured in O2 consumption",
                              "\u2022 Occurrence of major adverse cardiac event",
                              "\u2022 Change in high sensitivity C-reactive protein (hs CRP)",
                              "\u2022 Reduction in level of B-type natriuretic peptide (BNP)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "0, 3, 6, 12 months",
                              "12 months",
                              "0, 3, 6, 12 months",
                              "0, 3, 6, 12 months"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Universidad de los Andes."
                        ],
                        "SeeAlsoLinkURL": [
                              "http://www.uandes.cl/"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01739777"
                        ]
                  },
                  {
                        "Rank": 253,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Safety",
                              "Improvement in myocardial perfusion and function measured by PET and MR",
                              "Exercise time",
                              "Clinical angina status"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months after treatment",
                              "6 months after treatment",
                              "6 months after treatment",
                              "6 months after treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT00260338"
                        ]
                  },
                  {
                        "Rank": 254,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Aberrant Behavior Checklist\uff0cABC",
                              "Adverse Event and Serious Adverse Event"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months after treatment",
                              "6 months after treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01343511"
                        ]
                  },
                  {
                        "Rank": 255,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Defined as the cumulative incidence of relapse after the day of transplantation.",
                              "chronic graft versus host disease will be diagnosed and graded by National Institute of Health Consensus (NIH Consensus).",
                              "Defined as cumulative incidence of viral, fungal and bacterial infections.",
                              "Defined as the cumulative incidence of lymphoproliferative disease after the day of transplantation."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Cumulative relapse incidence",
                              "cumulative incidence of chronic GVHD at one year",
                              "Cumulative Incidence of Infectious Complications",
                              "Cumulative Incidence of lymphoproliferative disease"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "180 days",
                              "180 days",
                              "180 days",
                              "180 days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05531266"
                        ]
                  },
                  {
                        "Rank": 256,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "clinical symptoms including fatigue (Fatigue Impact Score, FIS) and pruritus ( Visual Analog Scale ,VAS)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Histological changes in liver biopsies",
                              "Serum Bilirubin",
                              "Serum AST",
                              "Mayo risk score",
                              "Number of patients with Portal Hypertension after 12 weeks treatment",
                              "MELD score",
                              "Number of participants with improvement of clinical symptoms"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "baseline and 48 weeks",
                              "At base line and at week 4,8,12,24,36 and 48",
                              "At base line and at week 4,8,12,24,36 and 48",
                              "At base line and at week 4,8,12,24,36 and 48",
                              "At base line and at week 12,24,36 and 48",
                              "At base line and at week 4,8,12,24,36 and 48",
                              "At base line and at week 4,8,12,24,36 and 48"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01662973"
                        ]
                  },
                  {
                        "Rank": 257,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Number of participants with a change in disability as measured by the Autism Treatment Evaluation Checklist (ATEC)",
                              "Number of participants with a change in disability as measured by the Childhood Autism Rating Scale (CARS)",
                              "Change from baseline macrophage-derived chemokine (MDC)",
                              "Change from baseline thymus and activation-regulated chemokine (TARC)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "13 weeks, 25 weeks, 37 weeks, 49 weeks, 89 weeks",
                              "13 weeks, 25 weeks, 37 weeks, 49 weeks, 89 weeks",
                              "13 weeks, 25 weeks, 37 weeks, 49 weeks, 89 weeks",
                              "13 weeks, 25 weeks, 37 weeks, 49 weeks, 89 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02192749"
                        ]
                  },
                  {
                        "Rank": 258,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Number of days alive off mechanical ventilatory support calculated as the number of days, within the 60 days window, that patients were alive and free of mechanical ventilatory support.",
                              "Safety analyses will be assessed by adverse event rates calculated as the ratio of the total number of events over 30 days divided by total patient-time at risk for the specific event from randomization.",
                              "The number and percent of patients with resolution and/or improvement of ARDS at day 7",
                              "The number and percent of patients with resolution and/or improvement of ARDS at day 14",
                              "The number and percent of patients with resolution and/or improvement of ARDS at day 21",
                              "The number and percent of patients with resolution and/or improvement of ARDS at day 30",
                              "severity of ARDS according to Berlin Criteria at days 7 post-randomization Change from baseline of the severity of ARDS according to Berlin Criteria at days 7, 14, 21 and 30 post-randomization will be compared between treatment groups using a Cochran-Mantel-Haenszel test stratified by baseline severity.",
                              "severity of ARDS according to Berlin Criteria at days 14 post-randomization Change from baseline of the severity of ARDS according to Berlin Criteria at days 7, 14, 21 and 30 post-randomization will be compared between treatment groups using a Cochran-Mantel-Haenszel test stratified by baseline severity.",
                              "severity of ARDS according to Berlin Criteria at days 21 post-randomization Change from baseline of the severity of ARDS according to Berlin Criteria at days 7, 14, 21 and 30 post-randomization will be compared between treatment groups using a Cochran-Mantel-Haenszel test stratified by baseline severity.",
                              "severity of ARDS according to Berlin Criteria at days 30 post-randomization Change from baseline of the severity of ARDS according to Berlin Criteria at days 7, 14, 21 and 30 post-randomization will be compared between treatment groups using a Cochran-Mantel-Haenszel test stratified by baseline severity.",
                              "Hospital length of stay",
                              "number of readmission",
                              "Change from baseline in Clinical Improvement Scale at day 7. Clinical Improvement Scale full scale from 1 to 7, with higher score indicating more clinical improvement.",
                              "Change from baseline in Clinical Improvement Scale at day 14. Full scale from 1 to 7, with higher score indicating more clinical improvement.",
                              "Change from baseline in Clinical Improvement Scale at day 21. Clinical Improvement Scale full scale from 1 to 7, with higher score indicating more clinical improvement.",
                              "Change from baseline in Clinical Improvement Scale at day 30. Clinical Improvement Scale full scale from 1 to 7, with higher score indicating more clinical improvement.",
                              "Changes from baseline in plasma hs-CRP concentration at days 7",
                              "Changes from baseline in plasma hs-CRP concentration at days 14",
                              "Changes from baseline in plasma hs-CRP concentration at days 21",
                              "Changes from baseline in serum hs-CRP concentration at days 30",
                              "Changes from baseline in IL-6 inflammatory marker level at 7 days",
                              "Changes from baseline in IL-6 inflammatory marker level at 14 days",
                              "Changes from baseline in IL-6 inflammatory marker level at 21 days",
                              "Changes from baseline in IL-6 inflammatory marker level at 30 days",
                              "Changes from baseline in IL-6 inflammatory marker level at 7 days",
                              "Changes from baseline in IL-6 inflammatory marker level at 21 days",
                              "Changes from baseline in IL-6 inflammatory marker level at 14 days",
                              "Changes from baseline in IL-6 inflammatory marker level at 30 days",
                              "Changes from baseline in TNF-alpha inflammatory marker level at 7 days",
                              "Changes from baseline in TNF-alpha inflammatory marker level at 14 days",
                              "Changes from baseline in TNF-alpha inflammatory marker level at 21 days",
                              "Changes from baseline in TNF-alpha inflammatory marker level at 30 days",
                              "including the presence of emphysema, COPD, asthma, pulmonary fibrosis, other pulmonary disease, and the need for respiratory support will be reported by randomization",
                              "including the presence of emphysema, COPD, asthma, pulmonary fibrosis, other pulmonary disease, and the need for respiratory support will be reported by randomization"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Number of days alive off mechanical ventilatory support",
                              "Number of adverse events",
                              "Number of participants alive at day 7",
                              "Number of participants alive at day 14",
                              "Number of participants alive at day 60",
                              "Number of participants alive at day 90",
                              "Number of participants alive at 12 Months",
                              "Number of participants with resolution and/or improvement of ARDS",
                              "Number of participants with resolution and/or improvement of ARDS",
                              "Number of participants with resolution and/or improvement of ARDS",
                              "Number of participants with resolution and/or improvement of ARDS",
                              "Severity of ARDS",
                              "Severity of ARDS",
                              "Severity of ARDS",
                              "Severity of ARDS",
                              "Length of stay",
                              "Readmissions",
                              "Length of Stay in Intensive Care Unit",
                              "Clinical Improvement Scale",
                              "Clinical Improvement Scale",
                              "Clinical Improvement Scale",
                              "Clinical Improvement Scale",
                              "Change in plasma hs-CRP concentration",
                              "Change in plasma hs-CRP concentration",
                              "Change in plasma hs-CRP concentration",
                              "Change in serum hs-CRP concentration",
                              "Change in IL-6 inflammatory marker level",
                              "Change in IL-6 inflammatory marker level",
                              "Change in IL-6 inflammatory marker level",
                              "Change in IL-6 inflammatory marker level",
                              "Change in IL-8 inflammatory marker level",
                              "Change in IL-8 inflammatory marker level",
                              "Change in IL-8 inflammatory marker level",
                              "Change in IL-8 inflammatory marker level",
                              "Change in TNF-alpha inflammatory marker level",
                              "Change in TNF-alpha inflammatory marker level",
                              "Change in TNF-alpha inflammatory marker level",
                              "Change in TNF-alpha inflammatory marker level",
                              "Pulmonary symptoms",
                              "Pulmonary symptoms"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "60 days",
                              "30 days",
                              "7 days",
                              "14 days",
                              "60 days",
                              "90 days",
                              "12 Months",
                              "7 days",
                              "14 days",
                              "21 days",
                              "30 days",
                              "baseline and 7 days",
                              "baseline and 14 days",
                              "baseline and 21 days",
                              "baseline and 30 days",
                              "12 months",
                              "12 months",
                              "12 months",
                              "7 days",
                              "14 days",
                              "21 days",
                              "30 days",
                              "baseline and 7 days",
                              "baseline and 14 days",
                              "baseline and 21 days",
                              "baseline and 30 days",
                              "baseline and 7 days",
                              "baseline and 14 days",
                              "baseline and 21 days",
                              "baseline and 30 days",
                              "baseline and 7 days",
                              "baseline and 21 days",
                              "baseline and 14 days",
                              "baseline and 30 days",
                              "baseline and 7 days",
                              "baseline and 14 days",
                              "baseline and 21 days",
                              "baseline and 30 days",
                              "6 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04371393"
                        ]
                  },
                  {
                        "Rank": 259,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Reduced activities using Community Healthy Activities Model Program for Seniors questionnaire",
                              "slowing of mobility using 6-minute walk test",
                              "reduction of handgrip strength using dynamometer",
                              "exhaustion using multidimensional fatigue inventory questionnaire",
                              "the level of pain in the knee using Western Ontario and McMaster Universities Osteoarthritis Index",
                              "respiratory function using FEV1/FVC",
                              "Quality of Life using Short Form 36 items",
                              "information of patients' inflammation response to umbilical cord-derived mesenchymal stem/stromal cells administration",
                              "information of patients' immune response to umbilical cord-derived mesenchymal stem/stromal cells administration",
                              "Evaluation of immunoregulatory properties of umbilical cord-derived mesenchymal stem/stromal cells",
                              "Measurement of cellular senescence using qPCR will be conducted in CD3+ cell population to access the expression of cyclin-dependent kinase inhibitor 2A (CDKN2A) gene, a specific biomarker indicated the cellular senescence",
                              "metabolic profiles of CD3+ cells via Seahorse XF Cell Mito Stress Test Kit and Seahorse XF Cell Glycolysis Stress Test Kit (Agilent Technologies)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Reduced activities",
                              "Slowing of mobility",
                              "reduction of handgrip strength",
                              "exhaustion",
                              "the level of pain in the knee",
                              "respiratory function",
                              "Quality of Life",
                              "patients' inflammation",
                              "patients' immune",
                              "immunoregulatory properties of umbilical cord-derived mesenchymal stem/stromal cells",
                              "Cellular senescence",
                              "metabolic profiles of CD3+ cells"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "up to the 9-month period following treatment",
                              "up to the 9-month period following treatment",
                              "up to the 9-month period following treatment",
                              "up to the 9-month period following treatment",
                              "up to the 9-month period following treatment",
                              "up to the 9-month period following treatment",
                              "up to the 9-month period following treatment",
                              "up to the 9-month period following treatment",
                              "up to the 9-month period following treatment",
                              "up to the 9-month period following treatment",
                              "up to the 9-month period following treatment",
                              "up to the 9-month period following treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04919135"
                        ]
                  },
                  {
                        "Rank": 260,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "The levels of serum Total Bilirubin and Direct Bilirubin",
                              "The levels of serum Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Cholinesterase (CHE)",
                              "The level of alpha-fetoprotein (AFP)",
                              "The content of ascites",
                              "Survival rate and time",
                              "Body temperature, tetter and allergy",
                              "The levels of Prothrombin Activity (PA) and Prothrombin Time (PT)",
                              "The score for Model for End-Stage Liver Disease"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "2 years after treatment",
                              "2 years after treatment",
                              "2 years after treatment",
                              "2 years after treatment",
                              "2 years after treatment",
                              "Between 0 to 24 hours after UC-MSCs transfusion",
                              "2 years after treatment",
                              "2 years after treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01218464"
                        ]
                  },
                  {
                        "Rank": 261,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2008-007485-35"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Neutrophil gelatinase-associated lipocalin (NGAL)",
                              "N-acetyl-p- D glucosaminidase enzyme (NAG)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "At days 0,2,5,7,12,15,18 and 30.",
                              "At days 0,2,5,7,12,15,18 and 30."
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01275612"
                        ]
                  },
                  {
                        "Rank": 262,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03015623"
                        ]
                  },
                  {
                        "Rank": 263,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2016-000661-23"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "GFR will be measured by plasma clearance of unlabelled exogenous marker Iohexol and estimated by CKD-EPI and MDRD equations.",
                              "ACR will be measured on spot morning urine samples.",
                              "UAE will be measured on 24h urine samples using standardized methods.",
                              "Quality of life will be evaluated by the administration of SF36 questionnaire.",
                              "Quality of life will be evaluated by the administration of EQ-5D-5L questionnaire.",
                              "Blood and urine bio-chip-based multiplex assay",
                              "Biomarkers will include sTNFR1, sTNFR2, Il-6,TNF-alfa, IL-1beta, MCP-1 (CCL2), IL-8, FGF21.",
                              "Biomarkers will include Cystatin C, NGAL, Adiponectin, Leptin.",
                              "Biomarkers will include sTNFR1, sTNFR2, Il-6,TNF-alfa, IL-1beta, MCP-1 (CCL2), IL-8.",
                              "Cost-effectiveness of cell therapy will be evaluated by providing the patients with a healthcare resource diary."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Glomerular filtration rate (GFR)",
                              "Urinary Albumin/Creatinine Ratio (ACR)",
                              "Urinary albumin excretion (UAE).",
                              "Fasting blood glucose (target <126mg/dL)",
                              "HbA1c (target <75mmol/mol or <9%)",
                              "Total cholesterol (target <200 mg/dl)",
                              "LDL cholesterol (target <100 mg/dl)",
                              "Triglycerides (target <170 mg/dl)",
                              "Arterial blood pressure (the target value <130/80 mmHg)",
                              "Quality of life",
                              "Quality of life",
                              "Anti-HLA antibody development",
                              "Inflammation and fibrosis related soluble mediators",
                              "Serum/plasma concentrations (pg/ml) of biomarkers of inflammation.",
                              "Serum/plasma concentrations (ng/ml) of biomarkers of CKD progression.",
                              "Urine concentrations (pg/ml adjusted to urine creatinine concentration) of biomarkers of inflammation.",
                              "Proportion/total number of circulating T cells, B cells, NK cells, monocytes, dendritic cells",
                              "Cost-effectiveness of cell therapy"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Changes from baseline up to 18 months after cell or placebo infusion.",
                              "Changes from baseline at 6 months and then every six months to study completion,up to 18 months after cell or placebo infusion.",
                              "Changes from baseline at 6 months and then every six months to study completion,up to 18 months after cell or placebo infusion.",
                              "Proportion of study participants within target range (<126mg/dL) at baseline and at each time point (day 1, day 7, month 1,3,6,12,18 after cell or placebo infusion).",
                              "Proportion of study participants within target range (<75mmol/mol or <9%) at baseline and at each time point (day 1, day 7, month 1,3,6,12,18 after cell or placebo infusion).",
                              "Proportion of study participants within target range (<200 mg/dl) at baseline and at each time point (day 1, day 7, month 1,3,6,12,18 after cell or placebo infusion).",
                              "Proportion of study participants within target range (<100 mg/dl) at baseline and at each time point (day 1, day 7, month 1,3,6,12,18 after cell or placebo infusion).",
                              "Proportion of study participants within target range (<170 mg/dl) at baseline and at each time point (day 1, day 7, month 1,3,6,12,18 after cell or placebo infusion).",
                              "Proportion of study participants within target range (<130/80 mmHg)at baseline and at each time point (day 1, day 7, month 1,3,6,12,18 after cell or placebo infusion).",
                              "Changes from baseline to 1,3,6,12 and 18 months after cell or placebo infusion.",
                              "Changes from baseline to 1,3,6,12 and 18 months after cell or placebo infusion.",
                              "Changes from baseline to 3,12 and 18 months after cell or placebo infusion.",
                              "Changes from baseline to 7 days, 1,6,12 and 18 months after cell or placebo infusion.",
                              "Changes from baseline to 7 days, 1,6,12 and 18 months after cell or placebo infusion.",
                              "Changes from baseline to 7 days, 1,6,12 and 18 months after cell or placebo infusion.",
                              "Changes from baseline to 7 days, 1,6,12 and 18 months after cell or placebo infusion.",
                              "Changes from baseline to 7 days, 1,6,12 and 18 months after cell or placebo infusion.",
                              "Changes from baseline to 1,3,6,12 and 18 months after cell or placebo infusion."
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02585622"
                        ]
                  },
                  {
                        "Rank": 264,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2017-000391-28"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "SLEDAI measures activity by computing the score of 24 parameters. Range: 0 to 105.",
                              "Decrease of activity permits to decrease medication. Units are percent value of baseline.",
                              "Lymphocyte profiles, CD3, CD19, CD16+CD56,CD4/CD8, Tregs",
                              "Anti-DNA antibodies, complement"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in disease activity measured by change of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K)",
                              "Change in prednisone dose measured as percent of the baseline value",
                              "Cellular markers of inflammation and autoimmunity",
                              "Serum markers of inflammation and autoimmunity"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "0-52 wk",
                              "0-52 wk",
                              "0-52 wk",
                              "0-52 wk"
                        ],
                        "SeeAlsoLinkLabel": [
                              "SLE",
                              "Lupus"
                        ],
                        "SeeAlsoLinkURL": [
                              "https://ghr.nlm.nih.gov/condition/systemic-lupus-erythematosus",
                              "https://medlineplus.gov/lupus.html"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03673748"
                        ]
                  },
                  {
                        "Rank": 265,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The Child-Pugh grading standard is a grading standard commonly used in clinical practice to quantitatively evaluate the liver reserve function of patients with liver cirrhosis. Grading: 5~6 points for Grade A, 7~9 points for Grade B and 10~15 points for grade C;\n\nNote:\n\nFor Primary Biliary Cirrhosis (PBC) or Primary Sclerosing Cholangitis (PSC): total bilirubin (umol/L): 17~68 is 1 point, 68~170 is 1 point, and >170 is 1 point; The Child-Pugh grading standard has been widely recognized by clinicians, and provides a specific clinical reference for the selection of treatment options for patients with liver cirrhosis and has important clinical value.",
                              "Overall survival rate of participants in this study.",
                              "Indicators: Alanine transaminase (AST), Alanine transaminase (ALT)",
                              "MELD is a numerical scale, ranging from 6 (less ill) to 40 (gravely ill), used for liver transplant candidates age 12 and older. It gives each person a 'score' (number) based on how urgently he or she needs a liver transplant within the next three months.\n\nThe number is calculated by a formula using three routine lab test results:\n\nMELD score = 3.8\u00d7ln[bilirubin (mg/dl)] + 11.2\u00d7ln(INR) + 9.6\u00d7ln[Scr(mg/dl)] + 6.4\u00d7(Cause: Bile or alcoholic 0, other 1) Bilirubin (mg/dl) = Bilirubin (\u03bcmol/L)/17.1 Scr(mg/dl) = Scr(\u03bcmol/L)/88.4",
                              "KPS score is the Karnofsky (Karen, KPS, percentile method) functional status scoring standard. The higher the score, the better the health status, and the more the patient able to tolerate the side effects of treatment, hence a better curative effect. It is generally believed that a Karnofsky score above 80 is independent, which means the patient is able to take care of himself. Karnofsky score between 50 to 70 stands for a semi-independent status, that is, the patient is semi-self-care. A score of 50 means the patients require help from others. Those with a score greater than 80 are in better postoperative state and have a longer survival period.\n\nThe lower the score, the worse the health status. If the score is less than 60, many effective anti-tumor treatments cannot be implemented.",
                              "To test the blood coagulation index of Prothrombin time (PT);",
                              "To test the blood coagulation index of activated partial thromboplastin time (APTT);",
                              "To test the blood coagulation index of thrombin time (TT);",
                              "To test the blood coagulation index of fibrinogen (FIB);"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Child-Pugh score (effectiveness evaluation index)",
                              "Survival rate (effectiveness evaluation index)",
                              "Liver function (effectiveness evaluation index)",
                              "The Model for End-Stage Liver Disease (MELD) score (effectiveness evaluation index)",
                              "KPS score (effectiveness evaluation index)",
                              "Detection of Blood Coagulation Index of PT (effectiveness evaluation index)",
                              "Detection of Blood Coagulation Index of APTT (effectiveness evaluation index)",
                              "Detection of Blood Coagulation Index of TT (effectiveness evaluation index)",
                              "Detection of Blood Coagulation Index of FIB (effectiveness evaluation index)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "At baseline, 3, 7 and 21 days after the first administration, 21 days after the second administration (if any), and 1, 3, 6 and 12 months after the last administration.",
                              "12 months after the last administration.",
                              "Baseline, 3, 7, and 21 days after the first administration, 21 days after the second administration (if any), and 1, 3, 6, and 12 months after the last administration.",
                              "Baseline, 3, 7, and 21 days after the first administration, 21 days after the second administration (if any), and 1, 3, 6, and 12 months after the last administration.",
                              "Baseline, 3, 7, and 21 days after the first administration, 21 days after the second administration (if any), and 1, 3, 6, and 12 months after the last administration.",
                              "Baseline, 3, 7, and 21 days after the first administration, 21 days after the second administration (if any), and 1, 3, 6, and 12 months after the last administration.",
                              "Baseline, 3, 7, and 21 days after the first administration, 21 days after the second administration (if any), and 1, 3, 6, and 12 months after the last administration.",
                              "Baseline, 3, 7, and 21 days after the first administration, 21 days after the second administration (if any), and 1, 3, 6, and 12 months after the last administration.",
                              "Baseline, 3, 7, and 21 days after the first administration, 21 days after the second administration (if any), and 1, 3, 6, and 12 months after the last administration."
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05155657"
                        ]
                  },
                  {
                        "Rank": 266,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Being able to identify the iron-oxide labeled mesenchymal stromal cells on day 1",
                              "Being able to identify the iron-oxide labeled mesenchymal stromal cells on day 7",
                              "Being able to identify the iron-oxide labeled mesenchymal stromal cells after 2 weeks",
                              "Being able to identify the iron-oxide labeled mesenchymal stromal cells after 4 weeks",
                              "Being able to identify the iron-oxide labeled mesenchymal stromal cells after 8 weeks",
                              "Being able to identify the iron-oxide labeled mesenchymal stromal cells after 12 weeks",
                              "Being able to identify the iron-oxide labeled mesenchymal stromal cells after 26 weeks",
                              "Left ventricular ejection fraction, systolic and diastolic volumes after 12 weeks",
                              "Left ventricular ejection fraction, systolic and diastolic volumes after 26 weeks",
                              "Canadian Cardiovascular Society (CCS) class after 12 weeks",
                              "Canadian Cardiovascular Society (CCS) class after 26 weeks",
                              "Seattle Angina Questionnaire after 12 weeks",
                              "Seattle Angina Questionnaire after 26 weeks",
                              "Weekly number of angina attacks after 12 weeks",
                              "Weekly number of angina attacks after 26 weeks",
                              "Weekly nitroglycerin consumption after 12 weeks",
                              "Weekly nitroglycerin consumption after 26 weeks",
                              "Adverse events registration"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "MSC identification using MRI in-vivo on day 1",
                              "MSC identification using MRI in-vivo on day 7",
                              "MSC identification using MRI in-vivo after 2 weeks",
                              "MSC identification using MRI in-vivo after 4 weeks",
                              "MSC identification using MRI in-vivo after 8 weeks",
                              "MSC identification using MRI in-vivo after 12 weeks",
                              "MSC identification using MRI in-vivo after 26 weeks",
                              "Cardiac pump function changes",
                              "Cardiac pump function changes",
                              "CCS class",
                              "CCS class",
                              "Seattle Angina Questionnaire",
                              "Seattle Angina Questionnaire",
                              "Weekly number of angina attacks",
                              "Weekly number of angina attacks",
                              "Weekly nitroglycerin consumption",
                              "Weekly nitroglycerin consumption",
                              "Adverse events"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1 day",
                              "7 days",
                              "2 weeks",
                              "4 weeks",
                              "8 weeks",
                              "12 weeks",
                              "26 weeks",
                              "12 weeks",
                              "26 weeks",
                              "12 weeks",
                              "26 weeks",
                              "12 weeks",
                              "26 weeks",
                              "12 weeks",
                              "26 weeks",
                              "12 weeks",
                              "26 weeks",
                              "6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03651791"
                        ]
                  },
                  {
                        "Rank": 267,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Georges Respiratory Questionnaire has scores range from 0 to 100, with higher scores indicating more limitations",
                              "Changes of the lung fibrosis on chest CT at 6 months, and 12 months compared with baseline",
                              "arterial blood gas analysis (pH)",
                              "arterial blood gas analysis (PaO2)",
                              "arterial blood gas analysis (PaCO2)",
                              "arterial blood gas analysis (BE)",
                              "arterial blood gas analysis (HCO3-)",
                              "Respiratory functions (FEV1)",
                              "Respiratory functions (FEV1/FVC)",
                              "Respiratory functions (VC)",
                              "Respiratory functions (TLC)",
                              "Respiratory functions (RV)",
                              "Respiratory functions (DLCO)",
                              "Respiratory functions (DLNO/DLCO)",
                              "inflammatory response (CRP)",
                              "inflammatory response (Pro-BNP)",
                              "inflammatory response (Troponin-T)",
                              "cytokine analysis from patients' plasma",
                              "modified medical research council (mMRC)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Quality of Life using Georges Respiratory Questionnaire",
                              "Chest CT",
                              "arterial blood gas analysis (pH)",
                              "arterial blood gas analysis (PaO2)",
                              "arterial blood gas analysis (PaCO2)",
                              "arterial blood gas analysis (BE)",
                              "arterial blood gas analysis (HCO3-)",
                              "Respiratory functions (FEV1)",
                              "Respiratory functions (FEV1/FVC)",
                              "Respiratory functions (VC)",
                              "Respiratory functions (TLC)",
                              "Respiratory functions (RV)",
                              "Respiratory functions (DLCO)",
                              "Respiratory functions (DLNO/DLCO)",
                              "inflammatory response (CRP)",
                              "inflammatory response (Pro-BNP)",
                              "inflammatory response (Troponin-T)",
                              "cytokine analysis from patients' plasma",
                              "modified medical research council"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "up to the 12-month period following treatment",
                              "up to the 12-month period following treatment",
                              "up to the 12-month period following treatment",
                              "up to the 12-month period following treatment",
                              "up to the 12-month period following treatment",
                              "up to the 12-month period following treatment",
                              "up to the 12-month period following treatment",
                              "up to the 12-month period following treatment",
                              "up to the 12-month period following treatment",
                              "up to the 12-month period following treatment",
                              "up to the 12-month period following treatment",
                              "up to the 12-month period following treatment",
                              "up to the 12-month period following treatment",
                              "up to the 12-month period following treatment",
                              "up to the 12-month period following treatment",
                              "up to the 12-month period following treatment",
                              "up to the 12-month period following treatment",
                              "up to the 12-month period following treatment",
                              "up to the 12-month period following treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04433104"
                        ]
                  },
                  {
                        "Rank": 268,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01539902"
                        ]
                  },
                  {
                        "Rank": 269,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "weight gain, acne, facial rounding, dorsal hump formation, hirsutism, osteopenia and diabetes mellitus, et al",
                              "diffuse arthralgias, fatigue, generalized malaise, jaundice, abdominal pain, nausea, and loss of appetite"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Serum AST",
                              "Serum Tbil",
                              "Serum immunoglobulin G (IgG)",
                              "Serum \u03b3-globulin",
                              "MELD score",
                              "Number of participants with treatment side effects",
                              "Number of participants with improvement of clinical symptoms"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "At baseline and at week 12, 24, 36, 48, 72, 96",
                              "At baseline and at week 12, 24, 36, 48, 72, 96",
                              "At baseline and at week 12, 24, 36, 48, 72, 96",
                              "At baseline and at week 12, 24, 36, 48, 72, 96",
                              "At base line and at week 12, 24, 36, 48, 72, 96",
                              "At base line and at week 12, 24, 36, 48, 72, 96",
                              "At base line and at week 12, 24, 36, 48, 72, 96"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01661842"
                        ]
                  },
                  {
                        "Rank": 270,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Marker for efficacy of treatment",
                              "Evaluation of Pneumonia change",
                              "Marker of Immunology and inflammation",
                              "Degree of infection",
                              "Indirect response to lung function",
                              "Clearance time of COVID-19 in participant"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Rate of mortality within 28-days",
                              "Size of lesion area by chest imaging",
                              "CD4+ and CD8+ T cells count",
                              "Peripheral blood count recovery time",
                              "Duration of respiratory symptoms (fever, dry cough, difficulty breathing, etc.)",
                              "COVID-19 nucleic acid negative time"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "At baseline, Day 1, Day 2, Day 7, Week 2, Week 3, Week 4",
                              "At baseline, Day 1, Day 2, Day 7, Week 2, Week 3, Week 4",
                              "At baseline, Day 1, Day 2, Day 7, Week 2, Week 3, Week 4",
                              "At baseline, Day 1, Day 2, Day 7, Week 2, Week 3, Week 4",
                              "At baseline, Day 1, Day 2, Day 7, Week 2, Week 3, Week 4",
                              "At baseline, Day 1, Day 2, Day 7, Week 2, Week 3, Week 4"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04339660"
                        ]
                  },
                  {
                        "Rank": 271,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Rate of death until discharge or 40 weeks corrected gestational age, whichever comes first",
                              "Blood culture-proven sepsis\nPatent ductus arteriosus (treated medically or surgically)\nNecrotizing enterocolitis\nIsolated intestinal perforation\nRetinopathy of prematurity requiring treatment\nSevere intraventricular hemorrhage (\u2265 grade 3)\nCystic periventricular leukomalacia\nIncidence and Severity of BPD, Measured as mild, moderate, or severe",
                              "Time to extubation\nDuration of mechanical ventilation\nDuration of non-invasive positive pressure respiratory support\nDuration of supplemental oxygen",
                              "Targeted neonatal echocardiography to assess",
                              "Successful recruitment and administration of extracellular vesicles to 10 patients in 18 months",
                              "Proportion of potentially eligible patients that are successfully screened\nProportion of participants successfully screened who do not enroll (reason for failure to enroll will be recorded)",
                              "Median time from screening to enrollment\nMedian time from screening to extracellular vesicles",
                              "Proportion of patients that do not complete administration of extracellular vesicles\nProportion of patients enrolled that do not undergo scheduled follow-up",
                              "Assessment of cognitive, language, and motor development. Cognitive delay defined as mental developmental index (MDI) score of the Griffiths-II and Bayley Scales of Infant Development (2nd edition) < 85, cerebral palsy, or severe visual or hearing impairment.",
                              "Participant's overall health will be assessed through a questionnaire administered over the phone, once a year for 3 years"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Rate of death",
                              "Occurrence of Other Severe Complications of Prematurity",
                              "Need for Ventilatory Support",
                              "Changes in Hemodynamics",
                              "Feasibility: Administration",
                              "Feasibility: Recruitment Efficiency",
                              "Feasibility: Recruitment Timing",
                              "Feasibility: Participant Retainment",
                              "Griffiths-II and Bayley Scales of Infant Development (2nd edition)",
                              "Long-term Safety Follow-Up"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "From enrollment until discharge or 40 weeks corrected gestational age (whichever occurs first)",
                              "From enrollment until discharge or 40 weeks corrected gestational age (whichever occurs first)",
                              "From enrollment until discharge, 40 weeks corrected gestational age, or death (whichever occurs first)",
                              "Time Frame: At enrollment, 48 hours following intranasal administration of EVs, 28 days of life, and 36 weeks corrected gestational age",
                              "Day of life 1-10",
                              "Day of life 1-10",
                              "Day of life 1-10",
                              "From enrollment until follow-up at 18-36 months-of-age",
                              "18-36 months-of-age",
                              "3 years following follow-up visit"
                        ],
                        "SeeAlsoLinkLabel": [
                              "The Role of Extracellular Vesicles in the Developing Brain: Current Perspective and Promising Source of Biomarkers and Therapy for Perinatal Brain Injury",
                              "Brain Tissue-Derived Extracellular Vesicle Mediated Therapy in the Neonatal Ischemic Brain",
                              "The Role of Extracellular Vesicles in the Developing Brain: Current Perspective and Promising Source of Biomarkers and Therapy for Perinatal Brain Injury",
                              "Mesenchymal Stromal Cell-Derived Extracellular Vesicles Protect the Fetal Brain After Hypoxia-Ischemia",
                              "Mesenchymal stem cell-derived extracellular vesicles ameliorate inflammation-induced preterm brain injury"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8498217/",
                              "http://www.mdpi.com/1422-0067/23/2/620",
                              "http://pubmed.ncbi.nlm.nih.gov/34630028/",
                              "http://pubmed.ncbi.nlm.nih.gov/27160705/",
                              "http://pubmed.ncbi.nlm.nih.gov/27847282/"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05490173"
                        ]
                  },
                  {
                        "Rank": 272,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04445220"
                        ]
                  },
                  {
                        "Rank": 273,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Knee-joint specific function",
                              "Patient-reported activity",
                              "Health-related quality of life",
                              "To assess joint structure, inflammation, and cartilage status over time",
                              "Serum marker of cartilage metabolism",
                              "Serum pro-inflammatory marker",
                              "Urine marker of cartilage metabolism",
                              "Urine marker of cartilage metabolism",
                              "Urine marker of cartilage metabolism",
                              "Synovial fluid pro-inflammatory markers"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Knee Injury and Osteoarthritis Outcome Score (KOOS)",
                              "Marx Activity Scale (Patient-reported activity)",
                              "Short-Form 36 (Health-related quality of life)",
                              "Whole Organ MRI Score (WORMS), Gadolinium-enhanced MRI, T2 Mapping (To assess joint structure, inflammation, and cartilage status over time)",
                              "Cartilage oligomeric matrix protein (COMP)",
                              "Hyaluronic acid (HA)",
                              "C-terminal telopeptide of type II collagen (CTXII)",
                              "Types I and II collagen cleavage (C1,2C)",
                              "Type II collagen cleavage (C2C)",
                              "IL-6/TNF\u03b1/IL-15"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1 year",
                              "1 year",
                              "1 year",
                              "1 year",
                              "1 year",
                              "1 year",
                              "1 year",
                              "1 year",
                              "1 year",
                              "1 year"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02351011"
                        ]
                  },
                  {
                        "Rank": 274,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04456439"
                        ]
                  },
                  {
                        "Rank": 275,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Acute GVHD Staging per BMT MOP\n\nStage 1:\n\nSkin: Maculopapular Rash < 25% body surface area (BSA)\nGastrointestinal (GI): Diarrhea < 500 mL/day or persistent nausea\nLiver: Total bilirubin 2.1-3 mg/dL\n\nStage 2:\n\nSkin: Maculopapular Rash 25-50% BSA\nGastrointestinal (GI): Diarrhea > 500 mL/day\nLiver: Total bilirubin 3.1-6 mg/dL\n\nStage 3:\n\nSkin: Maculopapular Rash > 50% BSA\nGastrointestinal (GI): Diarrhea > 1000 mL/day\nLiver: Total bilirubin 6.1-15 mg/dL\n\nStage 4:\n\nSkin: Generalized erythroderma with bullae\nGastrointestinal (GI): Diarrhea > 1500 mL/day\nLiver: Total bilirubin >15 mg/dL",
                              "the number of participants that had acute GVHD incidence",
                              "To evaluate the total number of adverse events attributed to MSC and ECP therapy",
                              "number of participants with adverse events (above or equal to grade 3) attributed to MSC and ECP therapy",
                              "Average time to relapse. The Kaplan-Meier method will be used to estimate survivor function",
                              "the number of participants that had Chronic GVHD incidence",
                              "Average OS. The Kaplan-Meier method will be used to estimate survivor function",
                              "change in steroid dose from day 1 to day 28",
                              "Percentage of patients who are no longer taking systemic corticosteroids at day 28",
                              "Quality of life survey scores measured by change in FACT-BMT survey scores. The Functional Assessment of Cancer Therapy-General (FACT-G) subscales, total score on their 12-item BMT subscale including physical, social, emotional and functional well-being measured over time will be summarized by mean and standard deviation at each time point.\n\nThe QOL data will be further analyzed using repeated measures regression models, i.e., mixed-effects models 28-30 ,28-30 with an unstructured covariance matrix and a categorical effect of time to calculate between-group differences in improvement from baseline in these QOL outcomes",
                              "T cell subsets in responders vs. nonresponders as measured by percent Tregs",
                              "T cell subsets in responders vs. nonresponders as measured by cluster of differentiation (CD)4:CD8 ratio"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "aGVHD severity per Blood and Marrow Transplant Clinical Trials Network Manual of Operations (BMT MOP).",
                              "aGVHD incidence",
                              "Safety as measured by number of adverse events attributed to MSC and ECP therapy",
                              "Safety as measured by severity of adverse events attributed to MSC and ECP therapy",
                              "Number of participants with non-relapse mortality (NRM)",
                              "Number of participants with relapse-related mortality",
                              "Average time to relapse",
                              "Chronic GVHD incidence",
                              "Overall Survival (OS)",
                              "Steroid dose decrease",
                              "Steroid discontinuation rate",
                              "Change in FACT-BMT (Functional Assesment of Cancer Therapy-Bone Marrow Transplant) survey score",
                              "Percent regulatory T cells (% Tregs)",
                              "CD4:CD8 ratio"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "100 days post-intervention",
                              "100 days post-intervention",
                              "Day 30",
                              "Day 30",
                              "1 year",
                              "1 year",
                              "1 year",
                              "At 1 year from the start of treatment",
                              "1 year",
                              "Up to day 28",
                              "Up to day 28",
                              "1 year",
                              "Up to 1 year after treatment",
                              "Up to 1 year after treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05333029"
                        ]
                  },
                  {
                        "Rank": 276,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "T cell proliferation changes in patients undergoing renal transplant and infused with mesenchymal stem cells as compared to the control patients.",
                              "Changes in regulatory T cells in patients undergoing renal transplant and infused with mesenchymal stem cells as compared to the control patients.",
                              "Changes in memory T cells in patients undergoing renal transplant and infused with mesenchymal stem cells as compared to the control patients.",
                              "Changes in B cells in patients undergoing renal transplant and infused with mesenchymal stem cells as compared to the control patients.",
                              "Changes in cytokine profile in patients undergoing renal transplant and infused with mesenchymal stem cells as compared to the control patients."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "0day (one day before transpnatation), 30 days, 90days, 180 days, 1year, 2year post transplantation",
                              "0day (one day before transpnatation), 30 days, 90days, 180 days, 1year, 2year post transplantation",
                              "0day (one day before transpnatation), 30 days, 90days, 180 days, 1year, 2year post transplantation",
                              "0day (one day before transpnatation), 30 days, 90days, 180 days, 1year, 2year post transplantation",
                              "0day (one day before transpnatation), 30 days, 90days, 180 days, 1year, 2year post transplantation"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02409940"
                        ]
                  },
                  {
                        "Rank": 277,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "NCI-2014-01316",
                              "CASE1Z14",
                              "P30CA043703"
                        ],
                        "SecondaryIdDomain": [
                              "CTRP (Clinical Trial Reporting Program)",
                              "Case Comprehensive Cancer Center"
                        ],
                        "SecondaryIdLink": [
                              "https://reporter.nih.gov/quickSearch/P30CA043703"
                        ],
                        "SecondaryIdType": [
                              "Registry Identifier",
                              "Other Identifier",
                              "U.S. NIH Grant/Contract"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Descriptive statistics will be used.",
                              "The rate of neutrophil recovery and median time of recovery will be estimated using the methods of Kaplan and Meier.",
                              "The rate of platelet recovery and median time of recovery will be estimated using the methods of Kaplan and Meier.",
                              "The median time of neutrophil recovery will be estimated using the methods of Kaplan and Meier.",
                              "The median time of platelet recovery will be estimated using the methods of Kaplan and Meier."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Incidence of toxicities assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",
                              "Rate of neutrophil recovery",
                              "Rate of platelet recovery",
                              "Median time of neutrophil recovery",
                              "Median time of platelet recovery"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Up to 12 months",
                              "Up to 12 months",
                              "Up to 12 months",
                              "Up to 12 months",
                              "Up to 12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02181478"
                        ]
                  },
                  {
                        "Rank": 278,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The collection of functional outcomes score HHS at 6 weeks. The HHS is a measure of dysfunction so the higher the score, the better the outcome for the individual. The maximum score possible is 100. Results can be interpreted with the following: <70 as poor result; 70-80 as fair, 80-90 as good, and 90-100 as excellent results.",
                              "The collection of functional outcomes score HHS at 3 month after surgery. The HHS is a measure of dysfunction so the higher the score, the better the outcome for the individual. The maximum score possible is 100. Results can be interpreted with the following: <70 as poor result; 70-80 as fair, 80-90 as good, and 90-100 as excellent results",
                              "The collection of functional outcomes score HHS at 6 month after surgery. The HHS is a measure of dysfunction so the higher the score, the better the outcome for the individual. The maximum score possible is 100. Results can be interpreted with the following: <70 as poor result; 70-80 as fair, 80-90 as good, and 90-100 as excellent results.",
                              "The collection of functional outcomes score HHS at 12 month after surgery. The HHS is a measure of dysfunction so the higher the score, the better the outcome for the individual. The maximum score possible is 100. Results can be interpreted with the following: <70 as poor result; 70-80 as fair, 80-90 as good, and 90-100 as excellent results."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Harris Hip Score",
                              "Harris Hip Score",
                              "Harris Hip Score",
                              "Harris Hip Score"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 weeks after surgery",
                              "3 months after surgery",
                              "6 months after surgery",
                              "12 months after surgery"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04210440"
                        ]
                  },
                  {
                        "Rank": 279,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Relative Wound Area Regression of 40% or More at 6 Week"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 week"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02685722"
                        ]
                  },
                  {
                        "Rank": 280,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Change between baseline to follow up for the following panel of inflammatory markers: Interleukin-1 (IL-1), Interleukin-6 (IL-6), Tumor Necrosis Factor alpha (TNF\u03b1), and Vascular Endothelial Growth Factor (VEGF), & Stromal Cell Derived Factor (SDF-1a) levels from serum/plasma samples measured in pg/mL.",
                              "Change between baseline to follow up for the following inflammatory marker: Serum High sensitivity C-Reactive Protein (hsCRP) in mg/L.",
                              "Change in SCF levels from serum/plasma samples",
                              "Change in endothelial function will be reported as the change in Endothelial Progenitor Cell Colony Forming Unit (EPC-CFU) assessed via blood sample assay",
                              "FMD% will be assessed using brachial artery ultrasound"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in inflammatory markers",
                              "Change in hsCRP levels",
                              "Change in Stem Cell Factor (SCF) levels",
                              "Change in Endothelial Progenitor Cell-Colony Forming Units (EPC-CFUs)",
                              "Change in Flow Mediated Diameter Percentage (FMD%)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline to week 2, baseline to month 1, baseline to month 3, baseline to month 6",
                              "Baseline to week 2, baseline to month 1, baseline to month 3, baseline to month 6",
                              "Baseline to week 2, baseline to month 1, baseline to month 3, baseline to month 6",
                              "Baseline, 3 months",
                              "Baseline, 3 months"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Interdisciplinary Stem Cell Institute at the University of Miami Miller School website"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://isci.med.miami.edu"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03059355"
                        ]
                  },
                  {
                        "Rank": 281,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [
                              "Non-Probability Sample"
                        ],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Ability to prepare a dossier acceptable to the MHRA. Success will achieved if the dossier is deemed acceptable.",
                              "Successful manufacturing of products will be defined initially as the award of a Manufacturers Specials Licence to the CCTL to allow the manufacture of Bone Marrow-Mesenchymal Stromal Cells for compassionate use.",
                              "Successful manufacturing of products will be subsequently defined by production under MA(IMP) licence, allowing for future production under CTIMP and CTA.",
                              "Successful manufacturing of products, under MA(IMP) licence will be defined as the availability of Bone Marrow-Mesenchymal Stromal Cells to be used in the context of the COMET20 clinical trial."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Establishment of a robust process of production",
                              "Production of stability data to be used in the MHRA dossier for the COMET clinical trial.",
                              "Production of cell-based products to be administered to COVID-19 patients with severe pneumonitis.",
                              "Analysis of cells for understanding production, manufacture and related research."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Successfully opening the next phase of the trial in approx. 2 months",
                              "Successfully opening the next phase of the trial in approx. 2 months",
                              "Successfully opening the next phase of the trial in approx. 2 months",
                              "Successfully opening the next phase of the trial in approx. 2 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04397471"
                        ]
                  },
                  {
                        "Rank": 282,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "whether the patient survives",
                              "days of the patients in hospital",
                              "whether or not the 2019-nCoV antibody is positive",
                              "whether or not the 2019-nCoV nucleic acid test is positive",
                              "whether lung imaging examinations show the improvement of the pneumonia",
                              "counts of white blood cell in a litre of blood",
                              "counts of lymphocyte in a litre (L) of blood",
                              "procalcitonin in microgram(ug)/L",
                              "IL-2 in picogram(pg)/millilitre(mL)",
                              "IL-4 in pg/mL",
                              "IL-6 in pg/mL",
                              "IL-10 in pg/mL",
                              "TNF-\u03b1 in nanogram(ng)/L",
                              "\u03b3-IFN in a thousand unit (KU)/L",
                              "CRP in microgram\uff08\u03bcg\uff09/L",
                              "counts of CD4+ T-Lymphocytopenia in litre",
                              "counts of CD8+ T-Lymphocytopenia in a litre",
                              "counts of NK in a litre"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "28 day mortality",
                              "Hospital stay",
                              "2019-nCoV antibody test",
                              "2019-nCoV nucleic acid test",
                              "Improvement of lung imaging examinations",
                              "White blood cell count",
                              "Lymphocyte count",
                              "Procalcitonin",
                              "interleukin(IL)-2",
                              "IL-4",
                              "IL-6",
                              "IL-10",
                              "tumor necrosis factor(TNF)-\u03b1",
                              "\u03b3-interferon(IFN)",
                              "C-reactive protein(CRP)",
                              "CD4+ T-Lymphocytopenia",
                              "CD8+ T-Lymphocytopenia",
                              "natural killer cell(NK)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "on the day 28 after enrollment",
                              "up to 6 months",
                              "on the day 7,14,28 after enrollment",
                              "on the day 7,14,28 after enrollment",
                              "on the day 7,14,28 after enrollment",
                              "on the day 7,14,28 after enrollment",
                              "on the day 7,14,28 after enrollment",
                              "on the day 7,14,28 after enrollment",
                              "on the day 7,14,28 after enrollment",
                              "on the day 7,14,28 after enrollment",
                              "on the day 7,14,28 after enrollment",
                              "on the day 7,14,28 after enrollment",
                              "on the day 7,14,28 after enrollment",
                              "on the day 7,14,28 after enrollment",
                              "on the day 7,14,28 after enrollment",
                              "on the day 7,14,28 after enrollment",
                              "on the day 7,14,28 after enrollment",
                              "on the day 7,14,28 after enrollment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04269525"
                        ]
                  },
                  {
                        "Rank": 283,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Too evaluate histology of keloid",
                              "To see image inside the body"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Core Biopsy/Histopathology",
                              "Ultrasonography"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "3 month after injection",
                              "3 month after injection"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04326959"
                        ]
                  },
                  {
                        "Rank": 284,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "FFTF is defined as death, relapse or progression of the underlying disease, or addition or change to any further systemic immunosuppressive aGvHD therapy. Number of participants with FFTF will be reported.",
                              "Overall survival is defined as the time from randomization to the date of death due to any cause.",
                              "Number of participants with aGvHD response will be reported. aGvHD response will be categorized as OR (CR + PR), CR, PR, and NR. NR is defined as the absence of CR or PR.",
                              "aGvHD grades: Grade 0- no organ involvement (ie, Stage 0 skin, Stage 0 liver, and Stage 0 GI); Grade I-Stage 1 - 2 skin without liver/GI involvement; Grade II- Stage 3 skin and / or Stage 1 liver and / or Stage 1 GI; Grade III- Stage 2 - 3 liver and / or Stage 2 - 3 GI; Grade IV- Stage 4 skin and / or Stage 4 liver and/or Stage 4 GI.",
                              "Time to response is defined as the time from the date of the first treatment administration to the date of response.",
                              "Duration is calculated from time from the first OR (CR or PR) until the time point of no aGvHD response in comparison to baseline.",
                              "Best OR is defined as the achievement of an OR at any time point up to and including Day 28. Number of participants with best OR will be reported.",
                              "The cumulative dose of steroids given for SR-aGvHD per kg of body weight from baseline until Day 60 and until Visit Month 24 will be analyzed.",
                              "Number of participants with cGvHD will be reported.",
                              "Time to cGvHD is defined as the time between the last day of haematopoietic stem cell transplantation (HSCT) to the first episode of cGvHD.",
                              "Number of participants with GF will be reported.",
                              "Number of participants with relapse or progression in participants with underlying malignant disease will be reported.",
                              "Time to relapse or progression in participants with underlying malignant disease will be reported.",
                              "EFS is defined as the time from the date of randomization to the date of the event. An event is defined as GF, relapse or progression of the underlying disease, or death due to any cause.",
                              "NRM is defined as the time from the date of randomisation to the date of the event. An event is defined as death without previous relapse or progression of the underlying disease.",
                              "Severity will be graded based on Common Terminology Criteria for Adverse Events (CTCAE) v5.0: Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life-threatening consequences; urgent intervention indicated; Grade 4- Death related to the AE.",
                              "The Karnofsky performance score (KPS), which is reported on an ordinal scale from 0 to 100, provides a rough measure of the participant's well-being, including their ability to conduct activities of daily living and functional capacity. Higher score indicates normal, no complaints and no evidence of disease.",
                              "A Lansky score (recipient age greater than or equal to [>=] 1 years and less than [<] 16 years) will be recorded pre-treatment and measured serially at regular intervals after treatment. The score is a standard performance score that measures overall function of the child with a scale range from 0 to 100. Higher score indicates full activeness.",
                              "EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health \"TODAY\". Responses were used to generate a HSI. HSI ranges from 0 (dead) to 1.00 (full health).",
                              "EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine).",
                              "The FACT-BMT questionnaire was designed to measure the quality of life in subjects undergoing bone marrow (BM) transplantation. It consists of the following categories of assessment: physical well-being, social / family well-being, emotional well-being, functional well-being, and additional miscellaneous concerns that the subject may have concerning their healthcare, persons involved in their life, and other emotions and incapabilities. Score ranges from 0-164, with higher score indicating better quality of life."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Freedom from Treatment Failure (FFTF)",
                              "Overall Survival",
                              "Acute Graft-versus-host Disease (aGvHD) Response",
                              "Change from Baseline in aGvHD Grades",
                              "Time to Response",
                              "Duration of Response",
                              "Best Overall Response (OR)",
                              "Cumulative Dose of Steroids for SR-aGvHD per Kilogram (kg) of Body Weight",
                              "Number of Participants with Chronic Graft-versus-host Disease (cGvHD)",
                              "Time to Chronic Graft-versus-host Disease (cGvHD)",
                              "Number of Participants with Graft Failure (GF)",
                              "Number of Participants with Relapse or Progression in Participants with Underlying Malignant Disease",
                              "Time to Relapse or Progression in Participants with Underlying Malignant Disease",
                              "Event-free survival (EFS)",
                              "Non-relapse Mortality (NRM)",
                              "Number of Participants with Adverse Events (AEs) and Adverse Reactions (ARs)",
                              "Number of Participants with Adverse Events (AEs) and Adverse Reactions (ARs) by Severity",
                              "Change from Baseline in Performance score based on Karnofsky scale (recipient age >= 16 years)",
                              "Change from Baseline in Performance score based on Lansky Scale",
                              "Change from Baseline in EuroQol-5D-5L (EQ-5D-5L): Health Status Index (HSI)",
                              "Change from Baseline in EuroQol-5D-5L (EQ-5D-5L): Visual Analogue Scale (VAS)",
                              "Change from Baseline in Functional Assessment of Cancer Therapy-Bone Marrow Transplantation (FACT-BMT) Score"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Up to 6 months",
                              "Up to Month 24",
                              "Days 28, 60, 100 and 180",
                              "Baseline and Days 8, 15, 22, 28, 60, 100 and 180",
                              "Up to Month 24",
                              "Up to Month 24",
                              "Up to Day 28",
                              "Up to Day 60 and Month 24",
                              "Day 60 to Month 24",
                              "Day 60 to Month 24",
                              "Up to Month 24",
                              "Up to Month 24",
                              "Up to Month 24",
                              "Up to Month 24",
                              "Up to Month 24",
                              "Until Day 60 or until 30 days after last administration of trial treatment, whichever is later (Up to Month 24)",
                              "Until Day 60 or until 30 days after last administration of trial treatment, whichever is later (Up to Month 24)",
                              "Baseline, Days 8, 15, 22, 28, 60 and 100",
                              "Baseline, Days 8, 15, 22, 28, 60 and 100",
                              "Baseline, Days 28, 60, 100 and 180",
                              "Baseline, Days 28, 60, 100 and 180",
                              "Baseline, Days 28, 60, 100 and 180"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04629833"
                        ]
                  },
                  {
                        "Rank": 285,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "100 mm Visual Analog Scale. Range: 0 to 100 mm. Lower is better, higher is worse.",
                              "Tegner activity scale (Level 0 to Level 10). Higher is better, lower is worse.",
                              "modified Harris Hip Score (mHHS). Score 0 to 100. Higher is better, lower is worse.",
                              "Hip disability and osteoarthritis Outcome Score (HOS). Score 0 to 100. Higher is better, lower is worse.",
                              "Evaluation of joint morphology on hip X-rays, including standing antero-posterior, lateral, and false profile",
                              "Cartilage thickness on MRI",
                              "Cartilage volume on MRI",
                              "Cartilage morphology on MRI",
                              "Subchondral bone morphology (i.e. edema) on MRI",
                              "Evaluate periarticular tissues on MRI (i.e. visible synovitis)",
                              "Synovial fluid from attempted aspiration at the time of injection (and re-injection for the two injection cohort) will be analyzed for cells, cytokines, growth factors, and other similar biomarkers."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in Visual Analog Scale (VAS) for pain in the target hip following completion of treatment cycles",
                              "Change in Tegner activity scale in the target hip following completion of treatment cycles",
                              "Change in modified Harris Hip Score (mHHS) in the target hip following completion of treatment cycles",
                              "Change in Hip disability and osteoarthritis Outcome Score (HOS) in the target hip following completion of treatment cycles",
                              "Change in radiographic joint morphology",
                              "Change in cartilage thickness",
                              "Change in cartilage volume",
                              "Change in cartilage morphology",
                              "Change in subchondral bone morphology",
                              "Change periarticular soft-tissues",
                              "Change in synovial fluid biomarkers within the target hip"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, 6 weeks, 6 months, 12 months post-treatment cycle",
                              "Baseline, 6 weeks, 6 months, 12 months post-treatment cycle",
                              "Baseline, 6 weeks, 6 months, 12 months post-treatment cycle",
                              "Baseline, 6 weeks, 6 months, 12 months post-treatment cycle",
                              "Baseline, 6 months, and 12 months post-treatment cycle",
                              "Baseline, 6 months, and 12 months post-treatment cycle",
                              "Baseline, 6 months, and 12 months post-treatment cycle",
                              "Baseline, 6 months, and 12 months post-treatment cycle",
                              "Baseline, 6 months, and 12 months post-treatment cycle",
                              "Baseline, 6 months, and 12 months post-treatment cycle",
                              "Baseline at the time of AMSC injection, At time of second injection (1 month status post first injection) in 2-injection group"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Mayo Clinic Clinical Trials"
                        ],
                        "SeeAlsoLinkURL": [
                              "https://www.mayo.edu/research/clinical-trials"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03608579"
                        ]
                  },
                  {
                        "Rank": 286,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Changes in mmHg of Arterial partial pressure of oxygen / Fraction of inspiration O2 (PaO2/FiO2) in all participants",
                              "Changes in percentage of participants with reduction in bilateral ground-glass opacities",
                              "Changes in percentage of participants with reduction of pneumonia bilateral infiltration",
                              "Number of participants with a reduction in Lactate dehydrogenase (mg/dL)",
                              "Number of participants with a reduction in C-reactive protein (mg/dL)",
                              "Number of participants with a reduction in D-dimer (mg/dL)",
                              "Number of participants with a reduction in Ferritine (mg/dL)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Oxygen pressure in inspiration",
                              "ground-glass opacity",
                              "Pneumonia infiltration",
                              "Lactate dehydrogenase",
                              "C-reactive protein",
                              "D-dimer",
                              "Ferritine"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, and at days 2, 4 and 14 post-treatment",
                              "Baseline, and at day 14 post-treatment",
                              "Baseline, and at day 14 post-treatment",
                              "Baseline, and at days 4 and 14 post-treatment",
                              "Baseline, and at days 4 and 14 post-treatment",
                              "Baseline, and at days 4 and 14 post-treatment",
                              "Baseline, and at days 4 and 14 post-treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04456361"
                        ]
                  },
                  {
                        "Rank": 287,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "National Institutes of Health Stroke Scale (NIHSS) scores range from 0 to 42, with higher scores indicating more severe neurological deficit",
                              "Functional Independence Measure (FIM) is a widely accepted functional assessment measure used during inpatient rehabilitation with the possible total score ranging from 18 (lowest) to 126 (highest) level of independence",
                              "The modified Ashworth scale purpose is to grade muscle spasticity. The scale is from 0 (No increase in muscle tone) to 4 (affected part(s) rigid in flexion or extension)",
                              "Fine motor skills (FMI) scores range from 0 to 58",
                              "Short Form 36 items (SF-36) consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "National Institutes of Health Stroke Scale (NIHSS) score",
                              "Functional Independence Measure (FIM) score",
                              "Modified Ashworth Scale",
                              "Fine motor skills (FMI) score",
                              "Short Form 36 items (SF-36) score"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "up to the 12-month period following treatment",
                              "up to the 12-month period following treatment",
                              "up to the 12-month period following treatment",
                              "up to the 12-month period following treatment",
                              "up to the 12-month period following treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05292625"
                        ]
                  },
                  {
                        "Rank": 288,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The incidence of acute GVHD after HSCT.",
                              "The incidence of chronic GVHD after HSCT.",
                              "The implantation rate and implantation time."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "acute GVHD",
                              "chronic GVHD",
                              "Transplant-related mortality",
                              "Rates of relapse",
                              "The implantation"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "UP to 3 months after HSCT",
                              "UP to 2 years after HSCT",
                              "UP to 1 months after HSCT",
                              "UP to 2 years after HSCT",
                              "Up to 4 weeks after HSCT"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02247973"
                        ]
                  },
                  {
                        "Rank": 289,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04294290"
                        ]
                  },
                  {
                        "Rank": 290,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "assessed by WOMAC questionnaire",
                              "assessed by KOOS (Knee injury and Osteoarthritis Outcome Score questionnaire)",
                              "assessed by SAS questionnaire (The Short Arthritis Assessment Scale)",
                              "assessed by SF-36 questionnaire",
                              "Changes from baseline (Day 0) to months 1, 3, 6, 12 and 24 in use of painkillers",
                              "Changes from baseline (Day 0) to months 12 and 24 in femorotibial joint space of the index knee on X-ray",
                              "Changes from baseline (Day 0) to months 12 and 24 by MOAKS (MRI Osteoarthritis Knee score)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Disability (WOMAC)",
                              "Disability (KOOS)",
                              "Disability (SAS)",
                              "Change in Quality of life",
                              "painkillers consumption",
                              "Structural changes (X-Ray)",
                              "Structural changes (MRI)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Months 1, 3, 6, 12 and 24",
                              "Months 1, 3, 6, 12 and 24",
                              "Months 1, 3, 6, 12 and 24",
                              "Months 1, 3, 6, 12 and 24",
                              "Months 1, 3, 6, 12 and 24",
                              "Months 12 and 24",
                              "Months 12 and 24"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02838069"
                        ]
                  },
                  {
                        "Rank": 291,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Monitoring of time of hematopoietic recovery assessed by complete blood count",
                              "Monitoring of frequency (number of participants) and severity of neutropenic enterocolitis during the study period",
                              "Monitoring of frequency and severity of infectious complications during the study period. Frequency of infectious complications will be represented in number of infections verified by clinical, instrumental examination and/or laboratory methods.",
                              "Monitoring of frequency (number of participants) of transfusion needs during neutropenic period"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Time of hematopoietic recovery",
                              "Neutropenic enterocolitis",
                              "Infectious complications",
                              "Transfusion needs"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Follow up to completion (up to 3 months after treatment)",
                              "Follow up to completion (up to 3 months after treatment)",
                              "Follow up to completion (up to 3 months after treatment)",
                              "Follow up to completion (up to 3 weeks after treatment)"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02145923"
                        ]
                  },
                  {
                        "Rank": 292,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "the length of ventilation and hospital stay",
                              "the length of ventilation and hospital stay",
                              "the length of ventilation and hospital stay",
                              "the length of ventilation and hospital stay"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "the days of ventialtion and hospital stay",
                              "the days of ventialtion and hospital stay",
                              "the days of ventialtion and hospital stay",
                              "the days of ventialtion and hospital stay"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Day 3",
                              "Day 7",
                              "Day 14",
                              "Day 28"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04951882"
                        ]
                  },
                  {
                        "Rank": 293,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "adverse events include: allergic reaction, prothrombotic effects, opportunistic infections and malignancy"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "the rate of acute rejection",
                              "the rate of ischemic-type biliary lesions",
                              "safety: rate of (serious) adverse events in the study population"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "one year",
                              "one year",
                              "one year"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02706132"
                        ]
                  },
                  {
                        "Rank": 294,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "To assess in preliminary fashion the response of fistula healing induced by the GORE plug containing MSC i) Clinically by drainage assessment and ii) Radiographically by MRI, the gold standard test for assessment of healing."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "To assess in preliminary fashion the response of fistula healing induced by the GORE plug containing MSC"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "2-24 months"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Mayo Clinic Clinical Trials"
                        ],
                        "SeeAlsoLinkURL": [
                              "https://www.mayo.edu/research/clinical-trials"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01915927"
                        ]
                  },
                  {
                        "Rank": 295,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "12 and 52 weeks after final treatment",
                              "12 and 52 weeks from final treatment"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Number of subjects with a change in American Spinal Injury Association (ASIA) score from baseline",
                              "Number of subjects with a change in Frankel Scale score from baseline"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 weeks, 52 weeks",
                              "12 weeks, 52 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02237547"
                        ]
                  },
                  {
                        "Rank": 296,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Penile colour Doppler ultrasonography combined with prostaglandin-E1 injection",
                              "Safety and Tolerability assessed by Adverse Events"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1,3,6,9 and 12 months",
                              "1 month after intervention"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02579148"
                        ]
                  },
                  {
                        "Rank": 297,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The number of follicles developing was recorded by transvaginal ultrasound scan.",
                              "Serum E2 level was evaluated after surgery.",
                              "Serum FSH level was evaluated after surgery.",
                              "Serum AMH level was evelated after surgery.",
                              "The incidence of pregnancy following transfer of embryos produced from oocytes recovered from follicles developing was assessed by Serum Human Chorionic Gonadotropin (HCG) detection."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Number of Antral follicle development",
                              "Estradiol (E2) serum level",
                              "Follicle Stimulating Hormone (FSH) serum level",
                              "Anti-Mullerian Hormone (AMH) serum level",
                              "Pregnancy rate"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Once a week within 3 months after the surgery",
                              "Once a week within 3 months after the surgery",
                              "Once a week within 3 months after the surgery",
                              "Once a week within 3 months after the surgery",
                              "2 weeks after embryo implantation"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02644447"
                        ]
                  },
                  {
                        "Rank": 298,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [
                              "Non-Probability Sample"
                        ],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02829216"
                        ]
                  },
                  {
                        "Rank": 299,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05345418"
                        ]
                  },
                  {
                        "Rank": 300,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The subjects must fill in the questionnaire of IIEF-5 every visit to evaluate erectile function"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Improvement in IIEF-5 (International Index of Erectile Function)",
                              "Improvement in penile colour Doppler ultrasonography"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1,3,6,9 and 12 months",
                              "1,3,6,9 and 12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02745808"
                        ]
                  },
                  {
                        "Rank": 301,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Assessing the changes in total leukocyte upon MSCs administration, assessed prior to and 1st day after implantation, then once every 3 days post implantation",
                              "Assessing the changes in lymphocytes level upon MSCs administration, assessed prior to and 1st day after implantation, then once every 3 days post implantation",
                              "Assessing the changes in blood pH level upon MSCs administration, assessed prior to and 1st day after implantation, then once every 3 days post implantation",
                              "Assessing the changes in blood pH level upon MSCs administration, assessed prior to and 1st day after implantation, then once every 3 days post implantation",
                              "Assessing the changes in blood base excess level upon MSCs administration, assessed prior to and 1st day after implantation, then once every 3 days post implantation",
                              "Assessing the changes in blood oxygen partial pressure upon MSCs administration, assessed prior to and 1st day after implantation, then once every 3 days post implantation",
                              "Assessing the changes in blood level of HCO3 upon MSCs administration, assessed prior to and 1st day after implantation, then once every 3 days post implantation",
                              "Assessing the changes in blood level of O2 saturation upon MSCs administration, assessed prior to and 1st day after implantation, then once every 3 days post implantation",
                              "Assessing the changes in level of CRP, assessed prior to and 1st day after implantation, then once every 3 days post implantation",
                              "Assessing the changes in laboratory parameter, consist of SGOT/SGPT (AST/ALT) level, assessed prior to and 1st day after implantation, then once every 3 days post implantation",
                              "Assessing the changes in laboratory parameter, consist of ureum/creatinine level, assessed prior to and 1st day after implantation, then once every 3 days post implantation",
                              "Assessing the changes in laboratory parameter, consist of eGFR, assessed prior to and 1st day after implantation, then once every 3 days post implantation",
                              "Assessing the changes in level of sodium, assessed prior to and 1st day after implantation, then once every 3 days post implantation",
                              "Assessing the changes in level of potassium, assessed prior to and 1st day after implantation, then once every 3 days post implantation",
                              "Assessing the changes in level of chloride, assessed prior to and 1st day after implantation, then once every 3 days post implantation",
                              "Assessing the changes in procalcitonin level to assess the anti-inflammatory properties of MSCs, assessed prior to and 1st day after implantation, then once every 3 days post implantation",
                              "Assessing the changes in albumin level, assessed prior to and 1st day after implantation, then once every 3 days post implantation",
                              "Assessing the changes in total bilirubin level, assessed prior to and 1st day after implantation, then once every 3 days post implantation",
                              "Assessing the changes in D-Dimer to assess the anti-inflammatory properties of MSCs, assessed prior to and 1st day after implantation, then once every 3 days post implantation",
                              "Assessing the changes in fibrinogen to assess the anti-inflammatory properties of MSCs, assessed prior to and 1st day after implantation, then once every 3 days post implantation",
                              "Assessing the changes in troponin level to assess the anti-inflammatory properties of MSCs and their effect in cardiac remodelling, assessed prior to and 1st day after implantation, then once every 3 days post implantation",
                              "Assessing the changes in NT proBNP to assess the anti-inflammatory properties of MSCs and their effect in cardiac remodelling, assessed prior to and 1st day after implantation, then once every 3 days post implantation",
                              "Assessing the changes in leukemia inhibiting factor (LIF) to assess the anti-inflammatory properties of MSCs, assessed prior to implantation and on the 7th day post-implantation",
                              "Assessing the changes in level of IL-6 to assess the anti-inflammatory properties of MSCs, assessed prior to implantation and on the 7th day post-implantation",
                              "Assessing the changes in level of IL-10 to assess the anti-inflammatory properties of MSCs, assessed prior to implantation and on the 7th day post-implantation",
                              "Assessing the changes in vascular endothelial growth factor (VEGF) to assess the effect of growth factors in the MSCs, assessed prior to implantation and on the 7th day post-implantation",
                              "Assessing the changes in level of ferritin to assess the anti-inflammatory properties of MSCs, assessed prior to implantation and on the 7th day post-implantation",
                              "Assessing the changes in level of CXCR3 to assess the anti-inflammatory properties of MSCs, assessed prior to implantation and on the 7th day post-implantation",
                              "Assessing the changes in level of CD4 to assess the anti-inflammatory properties of MSCs, assessed prior to implantation and on the 7th day post-implantation",
                              "Assessing the changes in level of CD8 to assess the anti-inflammatory properties of MSCs, assessed prior to implantation and on the 7th day post-implantation",
                              "Assessing the changes in CD56 to assess the anti-inflammatory properties of MSCs, assessed prior to implantation and on the 7th day post-implantation",
                              "Assessing the changes in radiology examination (Chest X-Ray/CT Scan) for any increased in lung infiltration or ground glass opacity, assessed prior to implantation and once every 3 days post-implantation"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "General laboratory outcome from leukocyte level",
                              "General laboratory outcome from lymphocytes level",
                              "General laboratory outcome from blood pH",
                              "General laboratory outcome from blood level of CO2",
                              "General laboratory outcome from blood base excess level",
                              "General laboratory outcome from blood oxygen partial pressure",
                              "General laboratory outcome from blood level of HCO3",
                              "General laboratory outcome from blood level of O2 saturation",
                              "General laboratory outcome from level of CRP",
                              "General laboratory outcome from level of SGOT/SGPT (AST/ALT)",
                              "General laboratory outcome from the level of ureum/creatinine level",
                              "General laboratory outcome from the level of eGFR",
                              "General laboratory outcome from the level of sodium",
                              "General laboratory outcome from the level of potassium",
                              "General laboratory outcome from the level of chloride",
                              "Changes in procalcitonin level",
                              "General laboratory outcome from albumin level",
                              "General laboratory outcome from total bilirubin level",
                              "Changes in D-Dimer level",
                              "Changes in fibrinogen level",
                              "Cardiac changes from troponin level",
                              "Cardiac changes from NT proBNP level",
                              "Changes in Leukemia Inhibiting Factor",
                              "Changes in level of IL-6",
                              "Changes in level of IL-10",
                              "Changes in level of vascular endothelial growth factor (VEGF)",
                              "Changes in level of ferritin",
                              "Changes in level of CXCR3",
                              "Changes in level of CD4",
                              "Changes in level of CD8",
                              "Changes in level of CD56",
                              "Radiologic Improvement from Chest X-Ray/CT Scan"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "15 days",
                              "15 days",
                              "15 days",
                              "15 days",
                              "15 days",
                              "15 days",
                              "15 days",
                              "15 days",
                              "15 days",
                              "15 days",
                              "15 days",
                              "15 days",
                              "15 days",
                              "15 days",
                              "15 days",
                              "15 days",
                              "15 days",
                              "15 days",
                              "15 days",
                              "15 days",
                              "15 days",
                              "15 days",
                              "7 days",
                              "7 days",
                              "7 days",
                              "7 days",
                              "7 days",
                              "7 days",
                              "7 days",
                              "7 days",
                              "7 days",
                              "15 days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04457609"
                        ]
                  },
                  {
                        "Rank": 302,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "An improvement was judged by the outcome of the preoperative grade minus the postoperative grade in accordance with the Wrinkle Severity Rating Scale (WSRS).The severity was measured using the Wrinkle Severity Rating Scale (WSRS), where 0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Extreme, which is an ordinal scale.",
                              "An improvement was judged by the outcome of the preoperative grade minus the postoperative grade in accordance with the Global Aesthetic Improvement Scale (GAIS)."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Wrinkle Severity Rating Scale (WSRS) Evaluation",
                              "Global Aesthetic Improvement Scale (GAIS) Evaluation"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Change from baseline at week 2, 6 and 12.",
                              "Change from baseline at week 2, 6 and 12."
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02698813"
                        ]
                  },
                  {
                        "Rank": 303,
                        "ResultsFirstSubmitDate": [
                              "January 27, 2021"
                        ],
                        "ResultsFirstSubmitQCDate": [
                              "January 27, 2021"
                        ],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The secondary endpoint of this study is the number of adverse events occurring over a 12-month period post-treatment with hCT-MSC or AlloCB."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Number of Adverse Events"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment"
                        ],
                        "NCTId": [
                              "NCT03473301"
                        ]
                  },
                  {
                        "Rank": 304,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "a test to see improvement in LVEF(%), improvement in regional function, improvement in perfusion, reduction of infarct size.",
                              "a test to see improvement in LVEF (%), improvement in regional function, improvement in perfusion, reduction of infarct size.",
                              "Left ventricular volumes will be determined at end-diastole and end-systole by quantitative biplane assessment. Endocardial borders will be manually traced from apical four-chamber and two-chamber views. Left ventricular volumes will be used to calculate ejection fraction using the biplane modified Simpson's summation-of-disks method recommended by the American Society of Echocardiography.",
                              "Left ventricular volumes will be determined at end-diastole and end-systole by quantitative biplane assessment. Endocardial borders will be manually traced from apical four-chamber and two-chamber views. Left ventricular volumes will be used to calculate ejection fraction using the biplane modified Simpson's summation-of-disks method recommended by the American Society of Echocardiography.",
                              "to detects cardiac (heart) abnormalities by measuring the electrical activity generated by the heart as it contracts",
                              "to detects cardiac (heart) abnormalities by measuring the electrical activity generated by the heart as it contracts",
                              "to detects cardiac (heart) abnormalities by measuring the electrical activity generated by the heart as it contracts",
                              "hs-CRP, antioxidant, IL-6, IL-10, PA1, Fibrinogen",
                              "Haematology, Serum Chemistry, Cardiac Biomarker"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Cardiac MRI",
                              "Cardiac MRI",
                              "Echocardiography",
                              "Echocardiography",
                              "Electrocardiography (ECG)",
                              "Electrocardiography (ECG)",
                              "Electrocardiography (ECG)",
                              "Wellness Parameter",
                              "Laboratory Assessment"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months after stem cell",
                              "12 months after stem cell",
                              "6 months after stem cell",
                              "12 months after stem cell",
                              "3 months after stem cell",
                              "6 months after stem cell",
                              "12 months after stem cell",
                              "6 months after stem cell",
                              "12 months after stem cell"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04340609"
                        ]
                  },
                  {
                        "Rank": 305,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The ACR20 is a composite measure defined as both improvement of 20% in the number of tender and number of swollen joints, and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).",
                              "The ACR50 is a composite measure defined as both improvement of 50% in the number of tender and number of swollen joints, and a 50% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).",
                              "The ACR70 is a composite measure defined as both improvement of 70% in the number of tender and number of swollen joints, and a 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).",
                              "The DAS28-CRP is a composite measure of inflammation in Rheumatoid Arthritis and incorporates a tender and swollen joint count, CRP and Patient Global Assessment of Disease Activity expressed in a Gaussian distribution of variables ranging from 0 to 10. A DAS28-CRP score of <3.2 suggests a low level of disease activity, while a score of >5.1 suggests a high level of disease activity.",
                              "The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty when performing daily activities. Each question asks on a scale ranging from 0 to 3 if the categories can be performed without any difficulty (scale 0) up to cannot be done at all (scale 3).",
                              "The SDAI is the numerical sum of five outcome parameters: tender joint count and swollen joint count based on a 28-joint assessment, patient global health assessment and physician global health assessment (from 0=best to 10=worst), and C-reactive protein (CRP). SDAI total score= 0 to 86. SDAI <=3.3 indicates disease remission, >3.3 to 11 = low disease activity, >11 to 26 = moderate disease activity, and >26 = high disease activity.",
                              "Rheumatoid factor blood test result.",
                              "Anti-CCP blood test result."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Percentage of participants achieving ACR20 from Baseline at Week 12 and Week 24",
                              "Percentage of participants achieving ACR50 response from Baseline at Week 12 and Week 24",
                              "Percentage of participants achieving ACR70 response from Baseline at Week 12 and Week 24",
                              "Change from Baseline in the disease activity score 28-joint count using C reactive protein (DAS28-CRP) at Week 12 and Week 24",
                              "Change from Baseline in the health assessment questionnaire disability index (HAQ-DI) score at Week 12 and Week 24",
                              "Percentage of participants achieving remission by Simplified Disease Activity Index (SDAI) based criteria at Week 12 and Week 24",
                              "Change from Baseline of rheumatoid factor at Week 12 and Week 24",
                              "Change from Baseline of anti-cyclic citrullinated peptide (anti-CCP) at Week 12 and Week 24"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 weeks and 24 weeks after infusion",
                              "12 weeks and 24 weeks after infusion",
                              "12 weeks and 24 weeks after infusion",
                              "12 weeks and 24 weeks after infusion",
                              "12 weeks and 24 weeks after infusion",
                              "12 weeks and 24 weeks after infusion",
                              "12 weeks and 24 weeks after infusion",
                              "12 weeks and 24 weeks after infusion"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03828344"
                        ]
                  },
                  {
                        "Rank": 306,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Change from baseline to six months in the Combined Socialization Standard Score based on parent report. Scores range from 20 to 140. Higher scores indicate a higher functioning level",
                              "Change from baseline to six months of the Communication Score calculated from the parent/guardian questionnaire. The SRS-2 provides a continuous measure of social ability. Scores range from 40 to >= 90, with higher scores indicating greater social impairment.",
                              "Change from baseline to six months based on parent/guardian questionnaire. Scores range from 0-48. Higher scores indicate that behaviors in the subscale occur with higher frequency.",
                              "Change from baseline to six months based on parent report. Scores range from 0 to 100 and higher scores indicate a better Health-Related Quality of Life, or better functioning.",
                              "Change from baseline to six months based on parent report. Scores range from 0-100 and higher scores indicate better functioning.",
                              "Change from baseline to six months based on self report. Scores range from 0-100 and higher scores indicate a better Health-Related Quality of Life or better functioning."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The Vineland Adaptive Behavior Scale Interview, 3rd Edition, Comprehensive interview form",
                              "Social Responsiveness Scale, Second Edition (SRS-2)",
                              "Social Withdrawal Subscale of the Aberrant Behavior Checklist, Community Edition (ABC-C)",
                              "Pediatric Quality of Life Inventory General Core Scales",
                              "Pediatric Quality of Life Inventory Family Impact Measure",
                              "Pediatric Quality of Life Inventory General Core Scales - Adult Version"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline and 6 months",
                              "Baseline and 6 months",
                              "Baseline and 6 months",
                              "Baseline and 6 months",
                              "Baseline and 6 months",
                              "Baseline and 6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04484077"
                        ]
                  },
                  {
                        "Rank": 307,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "(\u00baC)",
                              "(cm)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Evaluation of vascularization though RMN",
                              "Rutherford-Becker scale",
                              "Wifi scale",
                              "Ankle arm index",
                              "Temperature",
                              "Twin perimeter",
                              "Neuropathic symptoms (altered sensitivity)",
                              "% amputations"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1 year",
                              "1 year",
                              "1 year",
                              "1 year",
                              "1 year",
                              "1 year",
                              "1 year",
                              "1 year"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04466007"
                        ]
                  },
                  {
                        "Rank": 308,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "To calculate the number of hemocyte and related protein (e.g. erythrocyte, lymphocyte, and hemoglobin) after mesenchymal stem cell treatment",
                              "After finish the mesenchymal stem cell treatment, observe the change in baseline outcome measures.\n\nPoints Class One-year survival Two-year survival 5-6 A 100% 85% 7-9 B 80% 60% 10-15 C 45% 35%"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Safety evaluation by detecting Blood routine",
                              "Validity evaluation by detection of the child-pugh of participants"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 month",
                              "12 month"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03826433"
                        ]
                  },
                  {
                        "Rank": 309,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The pain relief as measured by Visual Analogue Scale (VAS) 3 months after cell injection",
                              "Evaluation the patients' quality of life with Visual Analogue Score (VAS) 3months after cell transplantation.",
                              "Walking distance changes as measured by walking on treadmill 3 months after cell injection."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Pain",
                              "Quality of life",
                              "Walking distance"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "3months",
                              "3months",
                              "3months"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Related Info"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://RoyanInstitute.org"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02448849"
                        ]
                  },
                  {
                        "Rank": 310,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The levels of serum Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST),Cholinesterase (CHE) ,Total Bilirubin(TB),Direct Bilirubin(DB), Serum Albumin \uff08ALB\uff09",
                              "The level of alpha-fetoprotein (AFP)",
                              "The levels of Prothrombin Activity (PA) and Prothrombin Time (PT)",
                              "The improvement of clinical symptoms [including appetite, debilitation, abdominal distension, edema of lower limbs, et al",
                              "cluster of differentiation 4 (CD4+)T/ cluster of differentiation 8 (CD8+)T,T helper cell 1 (Th1)/ T helper cell 1(Th2),natural killer cell(NK),natural killer T(NK T),interleukin-1\u03b2(IL-1\u03b2),interleukin-4(IL-4),interleukin-6(IL-6),interleukin-8(IL-8),interleukin-12(IL-12),interleukin-15(IL-15),interleukin-17A(IL-17A),Tumor necrosis factor-alpha (TNF-\u03b1),Interferon-gamma (IFN-\u03b3)",
                              "The occurrence of complications [including body temperature, tetter and allergy]"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Liver function",
                              "Marker of liver cancer",
                              "The degree of hepatic necrosis",
                              "The improvement of symptoms",
                              "The score for Model for End-Stage Liver Disease",
                              "The improvement of immune function",
                              "complications",
                              "The incidence of hepatocellular carcinoma"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "72 weeks after treatment",
                              "72 weeks after treatment",
                              "2 years after treatment",
                              "72 weeks after treatment",
                              "72 weeks after treatment",
                              "72 weeks after treatment",
                              "Between 0 to 8 hours after MSC transfusion",
                              "72 weeks after treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01844063"
                        ]
                  },
                  {
                        "Rank": 311,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02940418"
                        ]
                  },
                  {
                        "Rank": 312,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "NCI-2015-00969",
                              "2014-0519"
                        ],
                        "SecondaryIdDomain": [
                              "CTRP (Clinical Trial Reporting Program)",
                              "M D Anderson Cancer Center"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Registry Identifier",
                              "Other Identifier"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Change from baseline left ventricular ejection fraction (LVEF) at 6 months after randomization, expressed as a percentage. The comparison will be between the two groups of patients.",
                              "As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between investigational and control groups. These intervals and the associate p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.",
                              "As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between investigational and control groups. These intervals and the associate p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.",
                              "As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between investigational and control groups. These intervals and the associate p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.",
                              "As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between investigational and control groups. These intervals and the associate p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.",
                              "As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between investigational and control groups. These intervals and the associate p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.",
                              "As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between investigational and control groups. These intervals and the associate p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.",
                              "As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between investigational and control groups. These intervals and the associate p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.",
                              "As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between investigational and control groups. These intervals and the associate p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.",
                              "As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between investigational and control groups. These intervals and the associate p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in improvement in left ventricular systolic function by 7 points",
                              "Development of acute heart failure decompensation",
                              "Emergency center visits for heart failure",
                              "Need for new pacemaker/automatic implantable cardioverter defibrillator",
                              "New onset arrhythmias",
                              "Sudden cardiac death",
                              "Acute pulmonary edema",
                              "Asymptomatic decrease in left ventricular ejection fraction (LVEF) of > 10%",
                              "Heart failure admission",
                              "Progression free survival"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline up to 6 months",
                              "Up to 6 months",
                              "Up to 6 months",
                              "Up to 6 months",
                              "Up to 6 months",
                              "Up to 6 months",
                              "Up to 6 months",
                              "Baseline to up to 6 months",
                              "Up to 6 months",
                              "Up to 12 months"
                        ],
                        "SeeAlsoLinkLabel": [
                              "MD Anderson Cancer Center Website"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://www.mdanderson.org"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02408432"
                        ]
                  },
                  {
                        "Rank": 313,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The secondary objective is to determine subacute and long-term safety of MSC treatment at 3 months. This will be measured by the occurence of treatment-related adverse events, such as infections or cerebral tumorigenicity on MRI. Follow-up assessment at 3 months is part of regular care for neonates with PAIS."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Incidence of adverse events related to intranasal MSC treatment (safety and tolerability) in the subacute/long-term setting"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "3 months postnatal age"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03356821"
                        ]
                  },
                  {
                        "Rank": 314,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Evaluation the increase of GFR 6 months after cell transplantation with scan isotope ."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "GFR"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6months"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Related Info"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://Royaninstitute.org"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02195323"
                        ]
                  },
                  {
                        "Rank": 315,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Number of participants with a change in disease activity index as measured by 28-DAS Score",
                              "Number of participants with a change in current disease activity as measured by EULAR Response Criteria",
                              "Change from baseline quality of life measure (based on Stanford HAQ)",
                              "Change from baseline C-reactive protein",
                              "Change from baseline erythrocyte sedimentation rate (ESR)",
                              "Change from baseline anti-citrulline antibody measure",
                              "Change from baseline rheumatoid factor (RF)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01985464"
                        ]
                  },
                  {
                        "Rank": 316,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The dose will be selected based on the assessment of dose-limiting toxicity and maximum tolerated dose.",
                              "The scale is as follows: 1. Death 2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 3. Hospitalized, on non-invasive ventilation or high flow oxygen devices 4. Hospitalized, requiring low flow supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care 7. Not hospitalized."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Selection of an appropriate dose of BX-U001 for the following Phase 2 study",
                              "All-cause mortality",
                              "Proportion of patients achieving clinical response by the improvement of at least 2 points on the 7-point ordinal scale.",
                              "Duration of ICU stay",
                              "Duration of hospital stay",
                              "Changes in blood cytokine levels"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Day 28",
                              "Day 28",
                              "Day 14",
                              "Day 28",
                              "Day 28",
                              "Day 28"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04452097"
                        ]
                  },
                  {
                        "Rank": 317,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "One of our inclusion criteria for enrollment of the cases was evidence of definite acquired abnormal imaging findings compatible with CP such as periventricular leukomalacia (PVL) , cystic encephalomalacia ,periventricular gliosis , porencephalic cyst , basal ganglia involvement and brain atrophy . Decrements in size or improvement of Brain imaging findings would be expected due to Stem Cell therapy and will be followed 12 months after injection .",
                              "One of our inclusion criteria for enrollment of the cases was evidence of definite acquired abnormal imaging findings compatible with CP such as periventricular leukomalacia (PVL) , cystic encephalomalacia ,periventricular gliosis , porencephalic cyst , basal ganglia involvement and brain atrophy . Decrements in size or improvement of Brain imaging findings would be expected due to Stem Cell therapy and will be followed 12 months after injection .",
                              "MRS allows noninvasive detection and measurement of normal and abnormal metabolites and biochemical changes in the brain . The frequency of different metabolites is measured in units called parts per million (PPM) and plotted on a graph as peaks of varying height . The metabolites normally detected in the brain, regardless of the adopted echo time, include Nacetyl aspartate (NAA),a neuronal marker, choline (Cho), a membrane marker, and creatine (Cr), an energy metabolism marker. Increase in NAA /Cr and NAA/Cho ratios expected as baseline and would be expected to have a change after Stem Cell therapy in favor of neuroglia cells load or number increase at the site of previous brain damage.",
                              "MRS allows noninvasive detection and measurement of normal and abnormal metabolites and biochemical changes in the brain . The frequency of different metabolites is measured in units called parts per million (PPM) and plotted on a graph as peaks of varying height . The metabolites normally detected in the brain, regardless of the adopted echo time, include Nacetyl aspartate (NAA),a neuronal marker, choline (Cho), a membrane marker, and creatine (Cr), an energy metabolism marker. Increase in NAA /Cr and NAA/Cho ratios expected as baseline and would be expected to have a change after Stem Cell therapy in favor of neuroglia cells load or number increase at the site of previous brain damage.",
                              "DTI is a modi\ufb01cation of the MRI technique that is sensitive to the Brownian motion of water molecules in biological tissues and is a new clinical method that can demonstrate the orientation and integrity of white matter \ufb01bers . Periventricular white matter injury is a major form of brain injury observed in CP . Signi\ufb01cant reduction in DTI \ufb01ber count on the periventricular or other regions of cerebral white matter injury involving corticospinal tract , corticobulbar tract and superior thalamic radiation expected as baseline . Increase in DTI \ufb01ber count would be expected due to Stem Cell therapy and will be followed 12 months after injection .",
                              "DTI is a modi\ufb01cation of the MRI technique that is sensitive to the Brownian motion of water molecules in biological tissues and is a new clinical method that can demonstrate the orientation and integrity of white matter \ufb01bers . Periventricular white matter injury is a major form of brain injury observed in CP . Signi\ufb01cant reduction in DTI \ufb01ber count on the periventricular or other regions of cerebral white matter injury involving corticospinal tract , corticobulbar tract and superior thalamic radiation expected as baseline . Increase in DTI \ufb01ber count would be expected due to Stem Cell therapy and will be followed 12 months after injection ."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change from baseline acquired Brain Magnetic Resonance Imaging (MRI) findings",
                              "Change from baseline acquired Brain Magnetic Resonance Imaging (MRI) findings",
                              "Change from baseline Brain Magnetic Resonance Spectroscopy (MRS)",
                              "Change from baseline Brain Magnetic Resonance Spectroscopy (MRS)",
                              "Change from baseline Diffuse Tensor Imaging (DTI) fiber count of periventricular white matter",
                              "Change from baseline Diffuse Tensor Imaging (DTI) fiber count of periventricular white matter"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline",
                              "\"month\" 12",
                              "Baseline",
                              "\"month\" 12",
                              "Baseline",
                              "\"month\" 12"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03795974"
                        ]
                  },
                  {
                        "Rank": 318,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "The levels of serum albumin",
                              "The levels of serum total bilirubin",
                              "The levels of serum prothrombin activity",
                              "the levels of serum cholinesterase",
                              "complications"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "48 weeks",
                              "48 weeks",
                              "48 weeks",
                              "48 weeks",
                              "48 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01220492"
                        ]
                  },
                  {
                        "Rank": 319,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "outcome measurement time frame would not exceed 1 year after birth"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Death or hydrocephalus required shunt operation"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "First discharge home, maximum time frame : 1 year"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02274428"
                        ]
                  },
                  {
                        "Rank": 320,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Hoehn and Yahr (H-Y) staging was used to determine the stage of PD based on clinical findings and functional disability. In H-Y staging is a rating scale measured in an ordinal level.",
                              "The MMSE was used to measure cognition. This test consists of 2 parts: language and performance. Its total score can range from 0 to 30, with a higher score indicating better function.",
                              "The HAMD 24 is used to assessed the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. There are 24 items in the HAMD 24.",
                              "The HAMA-14 is used to assessed the anxiety symptoms. Its total score can range from 0 to 56. Lower score represents a better outcome.",
                              "Adverse reaction including temperature changes,the change of blood pressure,allergy and so on."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Changes of in the Hoehn and Yahr staging",
                              "Changes of the Mini-Mental State Examination (MMSE)",
                              "Changes of the Hamilton depression scales 24 (HAMD 24)",
                              "Changes of the Hamilton Anxiety Scale 14 (HAMA-14)",
                              "Adverse reaction"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Post cell transplantation: 1, 3, 6, 12months",
                              "Post cell transplantation: 1, 3, 6, 12months",
                              "Post cell transplantation: 1, 3, 6, 12months",
                              "Post cell transplantation: 1, 3, 6, 12months",
                              "Post cell transplantation: 1, 3, 6, 12months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03550183"
                        ]
                  },
                  {
                        "Rank": 321,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "will be assessed by change in serum levels of Cr, Urea and GFR. Time Frame: 12 hr after injection,1,2 weeks then monthly until a year after 1st injection.",
                              "It will be assessed by change in serum levels of IL-2, 10. Time frame: 12 hour after injection then monthly until a year 1st injection.",
                              "It will be assessed by change in serum levels of Treg. Time frame: 12 hr after injection,1 week, 3, 6,12 months after 1st injection."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Renal function",
                              "Increase in anti inflammatory factors",
                              "Increase in Treg"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 hours",
                              "12 hours",
                              "12hours"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Related Info"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://royaninstitute.org"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02382874"
                        ]
                  },
                  {
                        "Rank": 322,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2010-024041-78"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "assessment of consolidation by determination of Hounsfield units in CT scan",
                              "assessment of bone callus characteristics by standard radiology",
                              "Clinical assessment by visual analogue scale for pain",
                              "EUROQoL-5D quality of life questionnaire"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "efficacy through CT scan",
                              "efficacy through xRay",
                              "efficacy by clinical assessment",
                              "efficacy by quality of life questionnaire"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "3 months",
                              "1, 3 and 6 months",
                              "1, 3 and 6 month",
                              "3, 6 and 12 month"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Blood and Tissue Banc of Catalonia",
                              "Hospital Cl\u00ednic de Barcelona",
                              "Hospital Clinic Foundation"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://bancsang.net",
                              "http://hospitalclinic.org",
                              "http://fundacioclinic.org"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02630836"
                        ]
                  },
                  {
                        "Rank": 323,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02881476"
                        ]
                  },
                  {
                        "Rank": 324,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Disease progression assessed in ALSFRS-R scale (Revised Amyotrophic Lateral Sclerosis Functional Rating Scale). Higher scores mean a better outcome.\n\nMinimum: 0 points Maximum: 48 points",
                              "Pulmonary function decline assessed in spirometry (forced vital capacity)",
                              "Muscle strength decline",
                              "Upper motor neuron function assessed in UMNS scale (Upper Motor Neuron Scale). Best outcome 16 points, worst outcomes: 0 points and 48 points Minimum: 0 points Maximum: 48 points",
                              "Cognitive function assessed in ECAS (The Edinburgh Cognitive and Behavioural ALS Screen). Higher scores mean a better outcome.\n\nMinimum: 0 points Maximum: 136 points",
                              "Quality of life changes, assessed by EQ-5D questionnaire - standardized instrument for measuring generic health status. Higher scores mean a better outcome.",
                              "The change of defined cytokines, chemokines, growth factors and pNFH level assessed in the samples of CSF",
                              "The change of defined cytokines, chemokines level assessed in the samples of blood serum",
                              "The change of creatinine and p75ECD level",
                              "Muscle function changes, assessed based on EMG examination (Electrophysiological examination of the muscle - MUNIX - motor unit number estimation)",
                              "The change of the brain visualization in MRI (T1, T2 and DTI)",
                              "The number of SAE/AE and (S)AESI - defined as in Outcome 1",
                              "The number of days from patients randomization to the end of the patients participation in the trial or to the one of the following:\n\nPAV (permanent assisted ventilation)\nTracheostomy\nDeath",
                              "Percentage of deaths in the entire study population."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Disease progression",
                              "Pulmonary function decline",
                              "Muscle strength decline",
                              "Upper motor neuron function",
                              "Cognitive function",
                              "Quality of life changes",
                              "The change of defined cytokines, chemokines, growth factors and pNFH (phosphorylated neurofilament heavy chain) level in CSF (Cerebrospinal fluid)",
                              "The change of defined cytokines, chemokines level in blood",
                              "The change of creatinine and p75ECD level in urine",
                              "Muscle function changes",
                              "The change of the brain visualization",
                              "SAE (Serious Adverse Event)/AE (Adverse Event) and (S)AESI",
                              "Survival period to disease progression",
                              "Mortality rate"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 18 month FU",
                              "screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU.",
                              "screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU",
                              "screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU",
                              "screening and 12 month FU",
                              "screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 18 month FU",
                              "run-in visit (-60 day), at baseline and at 1, 2 and 6 month FU (12 month FU optional)",
                              "screening visit, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU.",
                              "screening visit, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU.",
                              "baseline and at 1, 2, 6 and 12 month FU",
                              "run-in visit (-60 day), 6 and 12 month FU",
                              "18 month FU",
                              "18 month FU",
                              "18 month FU"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04651855"
                        ]
                  },
                  {
                        "Rank": 325,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Efficacy will be assessed by measuring:\n\nWOMAC (Western Ontario and McMaster Universities osteoarthritis index),\nShort Arthritis assessment Scale (SAS),\nrange of motion of the target knee joint,\nimaging through MRI evaluation, dGEMRIC and T1rho MRI.",
                              "Quality of life will be assessed by measuring:\n\npain-specific assessment\nglobal patient assessment (visual analog scale, Short-Form 8)\ndecrease in rescue paracetamol medication."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Functional status of the knee",
                              "Quality of life"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "during 365 days following injection",
                              "during 365 days following injection"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01585857"
                        ]
                  },
                  {
                        "Rank": 326,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Marker of vascular permeability (ex: Ang1 and 2), acute renal injury (ex: Urine TIMP2-IGFBP7, IL-18), muscle weakness (ex: micro RNA (miRNA) growth Differentiation Factor-15 and miR-181a)), mechanisms related to pathogen clearance (ex: cathelicidin, LL-37), and pro and anti-inflammatory cytokines (ex: IL-6, IL-8, IL-10, IL-1B and IL1-RA) related to potential MSC biological effects",
                              "All-cause mortality",
                              "Sequential Organ Failure Assessment (SOFA) Score",
                              "Duration of mechanical ventilation and/or vasopressor agents and/or dialysis/renal replacement therapy",
                              "Time in ICU",
                              "Time in Hospital",
                              "Functional Independence Measure (FIM)",
                              "SF-36 Score"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Biological endpoints as markers of vascular permeability",
                              "Mortality",
                              "Organ Failure Scores",
                              "Organ Support Measures",
                              "Length of ICU Stay (in days)",
                              "Length of Hospital Stay (in days)",
                              "Hospital Re-Admissions",
                              "Patient Reported Outcomes-FIM",
                              "Patient Reported Outcomes-SF 36"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "At baseline, 1, 2, 3 and 7 days post-randomization",
                              "Through to 12 months post-randomization",
                              "Through to 90 days post-randomization",
                              "Through to 90 days post-randomization",
                              "Number of elapsed days from admission until ICU discharge, up to one year",
                              "Number of elapsed days from admission until hospital discharge, up to one year",
                              "At 28 days, 3 and 12 months post-randomization",
                              "7 days and 6 months post-ICU discharge",
                              "7 days and 6 months post-ICU discharge"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03369275"
                        ]
                  },
                  {
                        "Rank": 327,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Improvements in sexual function based on the (IIEF)-5 questionnaire",
                              "Changes in mean scores of Sexual Encounter Profile (SEP) Question 2 and 3 will be evaluated and reported.",
                              "Changes in penile cavernosal artery peak systolic velocity in [cm/s] as determined by Penile colour Doppler ultrasonography combined with prostaglandin-E1 injection.",
                              "Monitor penis erection during sleep to assess erection function of the patients.",
                              "To assess the penile sensory pathway abnormalities of the patients with or without premature ejaculation.",
                              "Change of the maximum flow rate (Qmax) to assess the bladder function."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "IIEF-5 (International Index of Erectile Function)",
                              "Mean scores of the Sexual Encounter Profile (SEP) Question 2, 3",
                              "Penile cavernosal artery peak systolic velocity (PSV)",
                              "Nocturnal penile tumescence (NPT)",
                              "The change of results of Nerve electrophysiological examination",
                              "Maximum Flow Rate (Qmax)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1, 3, 6, 12 months",
                              "1, 3, 6, 12 months",
                              "1, 3, 6, 12 months",
                              "1, 3, 6, 12 months",
                              "1, 3, 6, 12 months",
                              "1, 3, 6, 12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02648386"
                        ]
                  },
                  {
                        "Rank": 328,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Patients will be evaluated for the efficacy of the intracavernous injection of Wharton Jelly derived Mesenchymal Stem Cells by Sexual Health Inventory for Men/International Index of Erectile Function/Erection Hardness Score (SHIM/IIEF/EHS) questionnaire."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by SHIM/IIEF/EHS questionnaire"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02945449"
                        ]
                  },
                  {
                        "Rank": 329,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Reduction of insulin requirement after transplantation",
                              "The changes in blood glucose level after transplantation"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Reduction of insulin requirement",
                              "The changes in blood glucose level"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "24 weeks after treatment",
                              "24 weeks after treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04441658"
                        ]
                  },
                  {
                        "Rank": 330,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03099239"
                        ]
                  },
                  {
                        "Rank": 331,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2019-000316-29"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Change in full blood count and differentials, INR, APTT, fibrinogen, Serum levels of ALT, AST, Creatine Kinase, Total bilirubin, Conjugated bilirubin, Alkaline phosphatase, Albumin, total protein, serum urea, serum levels of sodium, potassium, chloride, urea, creatinine and plasma Ammonia - from baseline to 52 weeks post treatment.",
                              "PedsQLTM Quality of Life Inventory questionnaires for parent and child will be completed at screening and week 52 visits. PedsQL - Parent Report for Infants, PedsQL - Parent Report for Toddlers (ages 2-4), PedsQL - Parent Report for Young Children (ages 5-7), PedsQL - Young Child Report (ages 5-7), PedsQL - Parent Report for Children (ages 8-12), PedsQL - Child Report (ages 8-12), PedsQL - Parent Report for Teenagers (ages 13-18), PedsQL - Teenager Report (ages 13-18) will be used. The items will be scored as per instructions on https://www.pedsql.org/score.html",
                              "As above",
                              "As above"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in blood marker levels including haematological, biochemical and coagulation baseline to 52 weeks post treatment.",
                              "Change in Quality of life measures from baseline to week 52",
                              "Patient survival with native liver at 52 weeks post treatment",
                              "Patient survival with transplanted or native liver at 24 and 52 weeks post treatment."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline to 52 weeks",
                              "Baseline and 52 weeks",
                              "Baseline to 52 weeks",
                              "Baseline to 24weeks and then 52 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05491135"
                        ]
                  },
                  {
                        "Rank": 332,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04385056"
                        ]
                  },
                  {
                        "Rank": 333,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "NCI-2016-01921",
                              "2015-0835"
                        ],
                        "SecondaryIdDomain": [
                              "CTRP (Clinical Trial Reporting Program)",
                              "M D Anderson Cancer Center"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Registry Identifier",
                              "Other Identifier"
                        ],
                        "SecondaryOutcomeDescription": [
                              "As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between each investigational group and the control group. If both investigation groups are significant at the p < .05 level, then the two investigational drugs can be compared using a gatekeeping procedure. These intervals and the associated p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.",
                              "As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between each investigational group and the control group. If both investigation groups are significant at the p < .05 level, then the two investigational drugs can be compared using a gatekeeping procedure. These intervals and the associated p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.",
                              "As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between each investigational group and the control group. If both investigation groups are significant at the p < .05 level, then the two investigational drugs can be compared using a gatekeeping procedure. These intervals and the associated p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.",
                              "As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between each investigational group and the control group. If both investigation groups are significant at the p < .05 level, then the two investigational drugs can be compared using a gatekeeping procedure. These intervals and the associated p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.",
                              "As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between each investigational group and the control group. If both investigation groups are significant at the p < .05 level, then the two investigational drugs can be compared using a gatekeeping procedure. These intervals and the associated p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.",
                              "As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between each investigational group and the control group. If both investigation groups are significant at the p < .05 level, then the two investigational drugs can be compared using a gatekeeping procedure. These intervals and the associated p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.",
                              "As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between each investigational group and the control group. If both investigation groups are significant at the p < .05 level, then the two investigational drugs can be compared using a gatekeeping procedure. These intervals and the associated p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in improvement of left ventricular (LV) systolic function as assessed by LVEF",
                              "LV end-systolic and end-diastolic volumes as determined by contrast-enhanced 2-dimensional(D)/3D echography",
                              "Cardiac death",
                              "Re-hospitalization after heart failure",
                              "Aborted death from an automatic implantable cardioverter defibrillator (AICD) firing",
                              "Nonfatal myocardial infarction",
                              "Revascularization"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline up to 6 months",
                              "Up to 6 months",
                              "Up to 6 months",
                              "Up to 6 months",
                              "Up to 6 months",
                              "Up to 6 months",
                              "Up to 6 months"
                        ],
                        "SeeAlsoLinkLabel": [
                              "MD Anderson Cancer Center"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://www.mdanderson.org"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02962661"
                        ]
                  },
                  {
                        "Rank": 334,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03751735"
                        ]
                  },
                  {
                        "Rank": 335,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "DIME 1001"
                        ],
                        "SecondaryIdDomain": [
                              "Ministry of Health, Viet Nam"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Other Identifier"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Reduction of insulin dose after transplantation",
                              "Assess the improvement in C-peptide level after transplantation",
                              "Assess the changes in blood insulin level after transplantation"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Insulin dose",
                              "C-peptide",
                              "Blood insulin level"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "during the course of 6 months",
                              "every month in the course of 6 months",
                              "every month in the course of 6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03484741"
                        ]
                  },
                  {
                        "Rank": 336,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Complete epithelization or epithelization more than 50% of the cells in the skin graft on the 10th day after autologous skin grafting are effective. The epithelialization less than 50% is not effective.",
                              "Dynamics of the phagocytic activity of neutrophils in the area of burn wounds, according to NBT-test.",
                              "Duration of treatment (days) to complete epithelialization of burn wounds;"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The dynamics of healing of skin flap",
                              "Dynamics of the phagocytic activity of neutrophils in the area of burn wounds, according to NBT-test.",
                              "Duration of treatment (days) to complete epithelialization of burn wounds;"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "up to 1 month",
                              "up to 1 month",
                              "up to 1 month"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Adipose tissue-derived mesenchymal cells support skin reepithelialization through secretion of KGF-1 and PDGF-BB: comparison with dermal fibroblasts.",
                              "4. Alexaki V.-I. et al. Adipose tissue-derived mesenchymal cells support skin reepithelialization through secretion of KGF-1 and PDGF-BB: comparison with dermal fibroblasts. Cell Transplantation. 2012;21(11):2441-2454."
                        ],
                        "SeeAlsoLinkURL": [
                              "https://www.ncbi.nlm.nih.gov/pubmed/22507764",
                              "https://www.ncbi.nlm.nih.gov/pubmed/22507764"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03113747"
                        ]
                  },
                  {
                        "Rank": 337,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Evaluation the change of (D/P Cr) in patients with UFF after cell therapy.",
                              "Evaluation the change of D/P in patients with UFF after cell therapy.",
                              "Evaluation the change of D/D glucose in patients with UFF after cell therapy.",
                              "Assessment of peritoneal membrane transport function by peritoneal equilibration test (PET)",
                              "Evaluation the change of Glomerular filtration rate (GFR) in patients with UFF after cell therapy."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Ratio of 4-hour dialysate/plasma creatinine (D/P Cr).",
                              "Ratio of 4-hour dialysate/plasma urea (D/P urea )",
                              "Ratio of dialysate glucose concentrations (D/D glucose )",
                              "peritoneal membrane transport function",
                              "Glomerular filtration rate (GFR):"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months",
                              "6 months",
                              "6 months",
                              "6 months",
                              "6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02801890"
                        ]
                  },
                  {
                        "Rank": 338,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2019-0497",
                              "SMPH/HUMAN ONCOLOGY/HUMAN ONCO",
                              "A533300",
                              "Protocol Version 7/24/2020"
                        ],
                        "SecondaryIdDomain": [
                              "Institutional Review Board",
                              "UW Madison",
                              "UW Madison",
                              "UW Madison"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Other Identifier",
                              "Other Identifier",
                              "Other Identifier",
                              "Other Identifier"
                        ],
                        "SecondaryOutcomeDescription": [
                              "The University of Michigan Xerostomia related quality of life scale (XeQOL) is a 15-item questionnaire about how a participants oral health affects their life. Each item is scored from 1-5 either 'not at all', 'a little', 'somewhat', 'quite a bit', or 'very much' for a total score of 15-75. Higher scores represent greater degree of symptoms.",
                              "The MD Anderson Dysphagia Inventory (MDADI) is a 20-item questionnaire about how a participants perceive their swallowing ability. Each item is scored from 'strongly agree', 'agree', 'no opinion', 'disagree', or 'strongly disagree'. One question provides a 'global score between 1-5 where 1 is extremely low functioning and 5 is high functioning. The remaining 19 questions measure a composite score from 20-100 where higher scores represent higher degree of function.",
                              "The Visual Analogue Scale (VAS) - xerostomia questionnaire is an 8-item questionnaire about how a participant perceives their dry mouth. Each item is visually scored on a sliding scale (100mm in length) between two extremes (Q1 and Q2 from 'not difficult at all' to 'very difficult', Q3 from 'A lot' to 'None', Q4-Q7 from 'Not Dry at All' to 'Very Dry', and Q8 from 'Not Thirsty at All' to 'Very Thirsty'. The participant places a line on the scale to mark their answer. Change between various time points can be determined based on measured distance along the scale for each answer.",
                              "Unstimulated saliva production will be measured at two time points by the passive drool method over a 5-minute time frame. Participants will allow saliva to pool in the mouth and, then, with head tilted forward, gently guide saliva into a saliva collection aid attached to a cryovial. Difference in weight of the cryovial empty and after the test will represent the amount of saliva produced.",
                              "Stimulated saliva production will be measured at two time points by having participants chew inert gum base to the pace of a metronome (70 beats per minute) while expectorating saliva (without swallowing) into the saliva collection aid for 5 minutes total. Difference in weight of the cryovial empty and after the test will represent the amount of saliva produced.",
                              "The size of salivary glands will be measured via ultrasound at baseline and up to 6 months on study."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in participant QoL: XeQOL",
                              "Change in participant QoL: MDADI",
                              "Change in participant QoL: VAS",
                              "Change in participant Salivary Function: Unstimulated",
                              "Change in participant Salivary Function: Stimulated",
                              "Change in participant Salivary Gland Size"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "baseline and up to 6 months",
                              "baseline and up to 6 months",
                              "baseline and up to 6 months",
                              "baseline and up to 6 months",
                              "baseline and up to 6 months",
                              "baseline and up to 6 months"
                        ],
                        "SeeAlsoLinkLabel": [
                              "University of Wisconsin Carbone Cancer Center"
                        ],
                        "SeeAlsoLinkURL": [
                              "https://cancer.wisc.edu/"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04007081"
                        ]
                  },
                  {
                        "Rank": 339,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The Glasgow coma scale (GCS) is based on a 15-point scale for estimating and categorizing the consciousness. The test measures the motor response (1 to 6), verbal response (1 to 5) and eye opening response (1 to 4). The score is determined by the sum of the score in each of the 3 categories, with a maximum score of 15 and a minimum score of 3. A lower number indicating a more severe injury and a poorer prognosis.",
                              "The Glasgow outcome score (GOS) applies to patients with brain damage allowing the objective assessment of their recovery. This allows a prediction of the long-term course of rehabilitation to return to work and everyday life. Scale consists of five grades from 1 to 5. 1 denotes death. 2 denotes persistent vegetative state.3 denotes severe disability. 4 denotes moderate disability and 5 denotes low disability."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Mortality rate",
                              "Change in Glasgow coma scale (GCS) score",
                              "Change in Glasgow outcome scale (GOS) score",
                              "MRI (T1, T2, Flair, DWI) scanning"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "1 month",
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04074408"
                        ]
                  },
                  {
                        "Rank": 340,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [
                              "Probability Sample"
                        ],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03562715"
                        ]
                  },
                  {
                        "Rank": 341,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "13HH0228"
                        ],
                        "SecondaryIdDomain": [
                              "Imperial College"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Other Identifier"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Number of contrast enhancing lesions identified over months 1, 3 and 6 will be compared between treatment groups.",
                              "The number of contrast enhancing lesions counted over months 7, 9 and 12 (cross-over re-treatment) compared between treatment periods (placebo vs. active treatment) for each patient.",
                              "The number of new or enlarging T2, or enhancing or re-enhancing lesions.",
                              "number of relapses in MSC treatment group vs. placebo group in the first 6 months and after cross-over re-treatment in the two groups",
                              "time to sustained progression of disability and proportion of progression-free patients.",
                              "The proportion of disease-free patients (i.e. patients without relapses) and progression of MRI activity in the two groups.",
                              "the changes in the Multiple Sclerosis Functional Composite (MSFC) score in MSC treatment group compared to the placebo group.",
                              "changes in immune cell frequencies and serum cytokines after MSCs",
                              "The effect of mesenchymal stem cells on delayed type hypersensitivity (Type 4 hypersensitivity reaction) as measured by the Mantoux test"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "contrast enhancing lesions identified over months 1, 3 and 6 will be compared between treatment groups.",
                              "Comparison of contrast enhancing lesions between treatment periods",
                              "Combined unique MRI activity",
                              "Relapses",
                              "Progression of disability",
                              "Disease free patients",
                              "MSFC score",
                              "peripheral immune responses",
                              "Type 4 hypersensitivity reaction"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Months 1, 3 and 6",
                              "Months 1-12",
                              "Months 1-12",
                              "20 months",
                              "36 months",
                              "36 months",
                              "36 months",
                              "48 weeks",
                              "48 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01606215"
                        ]
                  },
                  {
                        "Rank": 342,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [
                              "20710046"
                        ],
                        "RetractionSource": [
                              "de la Fuente R, Bernad A, Garcia-Castro J, Martin MC, Cigudosa JC. Cancer Res. 2010 Aug 15;70(16):6682"
                        ],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01686139"
                        ]
                  },
                  {
                        "Rank": 343,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Through periapical radiographs evaluate the maintenance of the bio ceramic cement in contact with the implant",
                              "By means of pulse oximeter evaluate the increase of the activity"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Stability of bio ceramic cements used in the obturation of the access cavity",
                              "Evaluate blood circulation within the root canal"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 to 12 months",
                              "6 to 24 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04545307"
                        ]
                  },
                  {
                        "Rank": 344,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "CDAI is defined as Clinical Disease Activity Index",
                              "The Short Inflammatory Bowel Disease Questionnaire (SIBDQ) is a health-related quality of life (HRQoL) tool measuring physical, social, and emotional status. It includes 10-item form of questions. Each question is scored on a Likert scale from 1 (worst) to 7 (best), scores from each item are summed to produce a total score, increased more than 3 scores were considered remission.",
                              "A 10 to 20 centimeter (cm) biopsy sample of inflamed mucosal tissue was taken from the worst affected area and scored using the Riley Index. The Riley Index is a histologic scoring system for the assessment of the activity and severity of ulcerative colitis, ranging from 0 to 24. It consists of 6 histologic features (acute inflammatory cell infiltrate, crypt abscesses, mucin depletion, surface epithelial integrity, chronic inflammatory cell infiltrate, and crypt architectural irregularities), all scored on a 4-point scale (higher scores indicate more severe disease).",
                              "A number of soluble mediators are detected, including proinflammatory cytokines (TNF, IFN-\u03b3, IL-6.) and anti-inflammatory cytokines (IL-10, IL-4.).",
                              "An AE was any untoward medical occurrence in a participant"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change from Baseline in clinical response (CDAI points)",
                              "To evaluate the quality of life index, Short Inflammatory Bowel Disease Questionnaire (SIBDQ)",
                              "Histologic Evaluation of Ulcerative Colitis",
                              "Immune response in ulcerative colitis.",
                              "Incidence of Treatment Adverse."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, 8 weeks",
                              "Baseline, 8 weeks",
                              "Baseline, 8 weeks",
                              "Baseline, 1, 4, 8 weeks",
                              "Baseline, 1, 4, 8 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03609905"
                        ]
                  },
                  {
                        "Rank": 345,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "To evaluate the safety and efficacy of human umbilical cord -derived mesenchymal stem cells for BPD.",
                              "To evaluate the safety of human umbilical cord -derived mesenchymal stem cells for BPD.",
                              "To evaluate the safety of human umbilical cord -derived mesenchymal stem cells for BPD. Blood pressure is measured by electronic sphygmomanometer .",
                              "To evaluate the safety of human umbilical cord -derived mesenchymal stem cells for BPD.",
                              "To evaluate the safety of human umbilical cord -derived mesenchymal stem cells for BPD.",
                              "To evaluate the safety of human umbilical cord -derived mesenchymal stem cells for BPD.",
                              "To evaluate the safety and efficacy of human umbilical cord -derived mesenchymal stem cells for BPD."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Changes of high-resolution chest CT in participants",
                              "Changes of temperature in participants",
                              "Changes of blood pressure in participants",
                              "Changes of heart rate in participants",
                              "Changes of respiratory rate in participants",
                              "Changes of oxygen saturation in participants",
                              "Growth velocity (Z-score) in participants"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "within 2 years after administration",
                              "3 days after administration",
                              "3 days after administration",
                              "3 days after administration",
                              "3 days after administration",
                              "3 days after administration",
                              "within 2 years after administration"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03558334"
                        ]
                  },
                  {
                        "Rank": 346,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "To evaluate the safety of human umbilical cord -derived mesenchymal stem cells for moderate and severe bronchopulmonary dysplasia. Blood pressure is measured by electronic sphygmomanometer .",
                              "To evaluate the safety of human umbilical cord -derived mesenchymal stem cells for moderate and severe bronchopulmonary dysplasia."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Changes of blood pressure in participants",
                              "Changes of heart rate in participants"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "24 hours after administration",
                              "24 hours after administration"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03601416"
                        ]
                  },
                  {
                        "Rank": 347,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The secondary end point was efficacy, which was assessed in terms of the absolute change in the global LV ejection fraction (LVEF) from baseline to 12 months post-treatment, as measured by cardiac magnetic resonance imaging (CMRI). Furthermore, CMRI assessments measured scar mass and viable myocardial mass in the left ventricle, scar size, cardiac volumes, global function, regional function, and 6-min walk tests in all patients from baseline to 12 months post-treatment."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The secondary end point was efficacy in absolute change of the global LV ejection fraction (LVEF) from baseline to 12 months by MRI"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02368587"
                        ]
                  },
                  {
                        "Rank": 348,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "REC Reference: 07/Q0108/104"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Visual function (acuity and colour)",
                              "Visual evoked potential latency",
                              "Optic nerve Magnetisation Transfer Ratio",
                              "Retinal nerve fibre layer thickness (by optical coherence tomography)",
                              "Brain lesion Magnetisation Transfer Ratio",
                              "MRI brain T1 hypointensity load",
                              "Multiple Sclerosis Functional Composite Score",
                              "Expanded Kurtzke Disability Status Score"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 and 52 weeks post treatment",
                              "12 and 52 weeks post treatment",
                              "12 and 52 weeks post treatment",
                              "12 and 52 weeks post treatment",
                              "12 and 52 weeks post treatment",
                              "12 and 52 weeks post treatment",
                              "12 and 52 weeks post treatment",
                              "12 and 52 weeks post treatment"
                        ],
                        "SeeAlsoLinkLabel": [
                              "University of Cambridge Dept. of Clinical Neurosciences",
                              "UCL Institute of Neurology",
                              "Study protocol and baseline characteristics of the cohort"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://www-neurosciences.medschl.cam.ac.uk",
                              "http://www.ion.ucl.ac.uk",
                              "http://www.trialsjournal.com/content/12/1/62/abstract"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT00395200"
                        ]
                  },
                  {
                        "Rank": 349,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "To gather preliminary information of the efficacy of the experimental treatment in terms of combined MRI activity and clinical efficacy (incidence of relapses and disability progression)."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "48 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01730547"
                        ]
                  },
                  {
                        "Rank": 350,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Number of participants with a change in cartilage thickness of knee OA using MRI",
                              "Number of participants with a change in joint function from baseline WOMAC assessment",
                              "Number of participants with a change in arthritis pain scores on the visual analogue scale",
                              "Number of participants with a change in SF-36"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "radiographic evidence",
                              "WOMAC assessment",
                              "VAS",
                              "SF-36"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1 Year",
                              "1 Year",
                              "1 Year",
                              "1 Year"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03028428"
                        ]
                  },
                  {
                        "Rank": 351,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Frequency of all adverse events (AEs) including any serious AEs (SAEs) at or prior to Week 52.",
                              "Change in SLE disease activity between Baseline and Week 24 measured by change in SLEDAI score and change in prednisone dose.",
                              "Changes between Baseline and Week 24 in patient-reported quality of life",
                              "Changes between Baseline and Week 24 in patient-reported measures of fatigue.",
                              "Changes between Baseline and Week 24 in patient-reported measures of pain.",
                              "Changes between Baseline and Week 24 in patient-reported measures of depression.",
                              "Changes between Baseline and Week 24 in cellular markers of inflammation and autoimmunity. Mechanistically, the study will test the hypothesis that MSC infusions in patients with active SLE will increase Treg numbers via enhancing TGF-beta activity while decreasing T and B cell effector subsets.",
                              "Changes between Baseline and Week 24 in serum markers of inflammation and autoimmunity. Mechanistically, the study will test the hypothesis that MSC infusions in patients with active SLE will increase Treg numbers via enhancing TGF-beta activity while decreasing T and B cell effector subsets."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Frequency of All Adverse Events",
                              "Change in Disease Activity",
                              "Change in Patient Reported Outcomes - Life",
                              "Change in Patient Reported Outcomes - Fatigue",
                              "Change in Patient Reported Outcomes - Pain",
                              "Change in Patient Reported Outcomes - Depression",
                              "Change in Disease Biomarkers - Cellular",
                              "Change in Disease Biomarkers - Serum"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline to Week 52",
                              "Baseline to Week 24",
                              "Baseline to Week 24",
                              "Baseline to Week 24",
                              "Baseline to Week 24",
                              "Baseline to Week 24",
                              "Baseline to Week 24",
                              "Baseline to Week 24"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03171194"
                        ]
                  },
                  {
                        "Rank": 352,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "MRI plain scan of brain.",
                              "Using Inventory of Non-Ataxia Symptoms (INAS) score to determine the presence and severity of non-ataxia signs.",
                              "Patients is observed by professionals, compare the changes of each observation point and baseline. Baseline is the data acquire from patients before stem cells treatment."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Image examinations",
                              "Inventory of Non-Ataxia Symptoms (INAS) score",
                              "Cerebrospinal fluid (csf) routine"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03378414"
                        ]
                  },
                  {
                        "Rank": 353,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "To evaluate walking ability",
                              "To evaluate ability of daily activities after spinal cord injury",
                              "To evaluate walking ability",
                              "0-4 score, to evaluate spasticity",
                              "To evaluate the degree of pain"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Walking Index of Spinal Cord Injury (WISCI)",
                              "Spinal Cord Independence Measure (SCIM)",
                              "Kunming Locomotion Scale (KLS)",
                              "Modified Ashworth Scale (MAS)",
                              "Visual Analogous Scale (VAS)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Change from Baseline at 12 months after treatment",
                              "Change from Baseline at 12 months after treatment",
                              "Change from Baseline at 12 months after treatment",
                              "Change from Baseline at 12 months after treatment",
                              "Change from Baseline at 12 months after treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04213131"
                        ]
                  },
                  {
                        "Rank": 354,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Changes of the lung fibrosis on chest CT at 6 months compared with baseline"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The lung fibrosis"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "at 6 months post treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04062136"
                        ]
                  },
                  {
                        "Rank": 355,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "After first treatment\nAfter final treatment",
                              "After first treatment\nAfter final treatment",
                              "After first treatment\nAfter last treatment"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Number of patients with a change in pulmonary function from baseline as measured by Forced Expiratory Volume (FEV1) following American Thoracic Society (ATS) guidelines",
                              "Number of patients with a change in pulmonary function from baseline as measured by Forced Vital Capacity (FVC) following American Thoracic Society (ATS) guidelines",
                              "Number of patients with a change in quality of life from baseline as measured by the University of Pittsburgh Medical Center (UPMC) Asthma Questionnaire"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "a) 1 week, 2 weeks, 3 weeks, 4 weeks b) 1 month",
                              "a) 1 week, 2 weeks, 3 weeks, 4 weeks b) 1 monrh",
                              "a) 1 week, 2 weeks, 3 weeks, 4 weeks b) 1 month"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02192736"
                        ]
                  },
                  {
                        "Rank": 356,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04357600"
                        ]
                  },
                  {
                        "Rank": 357,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Number of participants with a change in joint function from baseline WOMAC assessment at 12 months",
                              "Number of participants with a change in radiogrpahic evidence of knee OA from baseline Kellegren-Lawrence grading system at 12 months"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02003131"
                        ]
                  },
                  {
                        "Rank": 358,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "HHSN268201000010C"
                        ],
                        "SecondaryIdDomain": [
                              "NATIONAL HEART, LUNG, AND BLOOD INSTITUTE"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Other Grant/Funding Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Cell surface expression profile will be obtained using Flow Cytometry. Additional characterization includes cell differentiation profile."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Characterization profile of MSC during and after expansion will be assessed"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Examine the cell surface marker profile of MSC using standard flow cytometry"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01463475"
                        ]
                  },
                  {
                        "Rank": 359,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Assessed by Unified Parkinson's Disease Rating Scale (UPDRS).",
                              "Assessed by UPDRS",
                              "Assessed by UPDRS",
                              "Assessed by UPDRS"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Effect assessment",
                              "Effect assessment",
                              "Effect assessment",
                              "Effect assessment"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1 month after transplantation",
                              "3 months after transplantation",
                              "6 months after transplantation",
                              "12 months after transplantation"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01446614"
                        ]
                  },
                  {
                        "Rank": 360,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "somatosensory and motor evoked potentials",
                              "Assessed by the Frankel scale.",
                              "Assessed by ASIA score",
                              "somatosensory and motor evoked potentials",
                              "Assessed by the Frankel scale.",
                              "Assessed by ASIA score",
                              "somatosensory and motor evoked potentials",
                              "Assessed by the Frankel scale.",
                              "Assessed by ASIA score",
                              "somatosensory and motor evoked potentials",
                              "Assessed by the Frankel scale.",
                              "Assessed by ASIA score"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Electromyogram and Electroneurophysiologic test",
                              "Muscle strength assessment",
                              "Motor and sensory assessment",
                              "Electromyogram and Electroneurophysiologic test",
                              "Muscle strength assessment",
                              "Motor and sensory assessment",
                              "Electromyogram and Electroneurophysiologic test",
                              "Muscle strength assessment",
                              "Motor and sensory assessment",
                              "Electromyogram and Electroneurophysiologic test",
                              "Muscle strength assessment",
                              "Motor and sensory assessment"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1 month after transplantation",
                              "1 month after transplantation",
                              "1 month after transplantation",
                              "3 months after transplantation",
                              "3 months after transplantation",
                              "3 months after transplantation",
                              "6 months after transplantation",
                              "6 months after transplantation",
                              "6 months after transplantation",
                              "12 months after transplantation",
                              "12 months after transplantation",
                              "12 months after transplantation"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01446640"
                        ]
                  },
                  {
                        "Rank": 361,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The secondary end point was efficacy, which was assessed in terms of the change in low attenuation plaque volume LAPV by Coronary computed tomography angiography (coronary CTA) from baseline to 12 months.",
                              "The level of high-sensitivity C-reactive protein (hsCRP) from baseline to 12 months."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The secondary end point was measuring low attenuation plaque volume LAPV",
                              "The secondary end point was efficacy 2"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "up to 10 months",
                              "up to 10 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04551456"
                        ]
                  },
                  {
                        "Rank": 362,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Hematologic response",
                              "Relapse",
                              "Clonal evolution to PNH, myelodysplasia or acute leukemia",
                              "Survival"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "up to 1 year",
                              "up to 1 year",
                              "up to 1 year",
                              "up to 1 year"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01305694"
                        ]
                  },
                  {
                        "Rank": 363,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The NYHA classification is used to grade the severity of functional limitations in a patient with heart failure with Class I=no limitations to Class IV=unable to carry on any physical activity without discomfort.",
                              "MACE are defined as death, recurrent MI, stroke, target vessel revascularization.",
                              "Change of serum level of NT pro-BNP from baseline visit to subsequent visits will be summarized by descriptive statistics.",
                              "The FEV1 will be tested by Spirometry and recorded.",
                              "Change of regional left ventricular wall motion score in total score from baseline visit to subsequent visits will be displayed by descriptive statistics",
                              "Change of LVESV in mL from baseline visit to subsequent visits will be displayed by descriptive statistics",
                              "Change of LVEDV in mL from baseline visit to subsequent visits will be displayed by descriptive statistics",
                              "Change of LV fractional shortening in % from baseline visit to subsequent visits will be displayed by descriptive statistics",
                              "Change of LVEF in % from baseline visit to subsequent visits will be displayed by descriptive statistics",
                              "Change of LVEF in % from baseline visit to subsequent visits will be summarized by descriptive statistics",
                              "Change of regional left ventricular wall motion score in total score from baseline visit to subsequent visits will be summarized by descriptive statistics",
                              "Change of LVESV in mL from baseline visit to subsequent visits will be summarized by descriptive statistics",
                              "Change of LVEDV in mL from baseline visit to subsequent visits will be summarized by descriptive statistics",
                              "Change of scar volume in % from baseline visit to subsequent visits will be summarized by descriptive statistics",
                              "Change of myocardial fibrosis quantification in % from baseline visit to subsequent visits will be summarized by descriptive statistics"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "New York Heart Association (NYHA) Classification",
                              "Incidence of major adverse cardiovascular events (MACE)",
                              "Serum level of amino-terminal pro-brain natriuretic peptide (NT pro-BNP)",
                              "Pulmonary function test",
                              "Echocardiogram",
                              "Echocardiogram",
                              "Echocardiogram",
                              "Echocardiogram",
                              "Echocardiogram",
                              "Cardiac MRI (cMRI) for baseline and efficacy evaluation",
                              "Cardiac MRI (cMRI) for baseline and efficacy evaluation",
                              "Cardiac MRI (cMRI) for baseline and efficacy evaluation",
                              "Cardiac MRI (cMRI) for baseline and efficacy evaluation",
                              "Cardiac MRI (cMRI) for baseline and efficacy evaluation",
                              "Cardiac MRI (cMRI) for baseline and efficacy evaluation"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 weeks",
                              "from screen visit to 12-month follow-up period",
                              "52 weeks",
                              "52 weeks",
                              "52 weeks",
                              "52 weeks",
                              "52 weeks",
                              "52 weeks",
                              "52 weeks",
                              "52 weeks",
                              "52 weeks",
                              "52 weeks",
                              "52 weeks",
                              "52 weeks",
                              "52 weeks"
                        ],
                        "SeeAlsoLinkLabel": [
                              "First-in-human pilot trial of combined intracoronary and intravenous mesenchymal stem cell therapy in acute myocardial infarction"
                        ],
                        "SeeAlsoLinkURL": [
                              "https://www.frontiersin.org/articles/10.3389/fcvm.2022.961920/full"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04056819"
                        ]
                  },
                  {
                        "Rank": 364,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Measured using self-reported 10 mm VAS",
                              "Measured using the PROMIS-CAT-Physical Function assessment with questions to evaluate self-reported physical function on a scale of 5 to 1, with higher scores indicating better outcomes.",
                              "Measured using the International Hip Outcome Tool (IHOT12). 12-item self-reported questionnaire assessing function of hip on a scale of 0 to 10, with higher outcomes indicating worse outcomes"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in pain",
                              "Change in physical function",
                              "Change in hip function"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, 1-2 weeks, 6 weeks, 12 weeks, 24 weeks, 52 weeks, 18 months, and 24 months post-treatment",
                              "Baseline, 1-2 weeks, 6 weeks, 12 weeks, 24 weeks, 52 weeks, 18 months, and 24 months post-treatment",
                              "Baseline, 1-2 weeks, 6 weeks, 12 weeks, 24 weeks, 52 weeks, 18 months, and 24 months post-treatment"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Mayo Clinic Clinical Trials"
                        ],
                        "SeeAlsoLinkURL": [
                              "https://www.mayo.edu/research/clinical-trials"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05553132"
                        ]
                  },
                  {
                        "Rank": 365,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Compare annual relapse rate before and one year after MSC infusion",
                              "Compared lesion load before and one year after MSC infusion",
                              "Compared RNFL before and one year after MSC infusion",
                              "Compare cognition questionnaire scale before and one year after MSC infusion",
                              "Compare anti-aquaporin4-ab before and one year after MSC infusion.",
                              "Compare immune cell subpopulation before and one year after MSC infusion.",
                              "Compare cytokine kinetics before and one year after MSC infusion.",
                              "Compare cerebral volume before and one year after MSC infusion"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Annual relapse rate",
                              "Lesion load",
                              "Retinal nerve fiber layer (RNFL)",
                              "Cognition",
                              "Immunological assessments",
                              "Immunological assessments",
                              "Immunological assessments",
                              "cerebral volume"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1 year after infusion",
                              "1 year after infusion",
                              "1 year after infusion",
                              "1 year after infusion",
                              "1 year after infusion",
                              "1 year after infusion",
                              "1 year after infusion",
                              "1 year after infusion"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02249676"
                        ]
                  },
                  {
                        "Rank": 366,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02285673"
                        ]
                  },
                  {
                        "Rank": 367,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Change in Amyotrophic Lateral Sclerosis (ALS) Functional Rating Scale (ALS-FRS) slopes from the pre-transplantation period to the post-transplantation period between the treatment and placebo groups through 24 weeks post-transplantation.",
                              "Change in SVC slopes from the pre-transplantation period to the post-transplantation period between the treatment and placebo groups through 24 weeks post-transplantation"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "At all study visits: Visit 1 through visit 10",
                              "Visits 1,2,3,5,6,7,8,9,10"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02017912"
                        ]
                  },
                  {
                        "Rank": 368,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Quantities over time of MSC will be fit to an exponential decay curve using a residual pseudo-likelihood procedure and cell half-life (\u03bb) will be estimated. Binomial confidence intervals at the 95% confidence level and p-values will be calculated for the presence or absence of MHC expression and SDF-1activation. The correlation between capillary density (CD31 counts) with tissue perfusion (ICA) for each time point will be estimated by Spearman's rank coefficient. The gene and protein expression profiles and histological findings will be used to test the hypotheses that MSCs have limited survival post-injection.",
                              "Continuous confidence intervals at the 95% level will be constructed to explore differences among the time-tiered administration of MSC for (1) the CD34+CD133+ pro-angiogenic hematopoietic cells recruitment of HIF-1\u03b1/SDF-1/CXCR4 to ischemic muscle, (2) the quantify of capillary density in muscle fibers using hematoxylin phloxin saffron and CD31 counts, (3) VEGF-A,C,D, hepatocyte growth factor, angiopoietin-1 to characterize angiogenic cytokine expression, (4) percent coverage, fiber diameter and cross-sectional area to examine changes in morphology. The gene and protein expression profiles and histological findings will be used to test the hypotheses that MSCs act to recruit CD34+CD133+ proangiogenic hematopoietic cells."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Gene and protein arrays, IHC staining, and multiparametric flow cytometry will measure the time period of retention of allogeneic MSCs in harvested human skeletal muscle tissue post-MSC implantation.",
                              "Recruitment of proangiogenic hematopoietic cells into sites of ischemia will be measured and reported as assessed by the role of MSCs injected in human skeletal muscle at the time of amputation."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Primary follow up in a 6 month period",
                              "Primary follow up in a 6 month period"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02685098"
                        ]
                  },
                  {
                        "Rank": 369,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Cumulative Incidence of Graft-versus Host Disease",
                              "Incidence of Systemic Infections",
                              "Mean Time to Engraftment",
                              "Transplant-Related Mortality",
                              "Rates of Relapse"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "up to 2 years after HSCT",
                              "up to 2 years after HSCT",
                              "Baseline to engraftment, assessed minimally 28 days post transplant",
                              "up to 1 months after HSCT",
                              "up to 2 years after HSCT"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04247945"
                        ]
                  },
                  {
                        "Rank": 370,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04961658"
                        ]
                  },
                  {
                        "Rank": 371,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "R01DK118529-01A1"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [
                              "https://reporter.nih.gov/quickSearch/R01DK118529-01A1"
                        ],
                        "SecondaryIdType": [
                              "U.S. NIH Grant/Contract"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Change in beta cell function",
                              "Change in beta cell function",
                              "Change in beta cell function",
                              "Change in beta cell function"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "6 Month Change in C-Peptide area under the curve after a 2-hour MMTT",
                              "6 Month peak C-peptide after a 2-hour MMTT",
                              "1 year peak C-peptide after a 2-hour MMTT",
                              "Change in 24-hour insulin dose per kilogram between baseline and 1 year measurements"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months (plus or minus 14 days) after infusion",
                              "6 months (plus or minus 14 days) after infusion",
                              "1 year (plus or minus 30 days) after infusion",
                              "1 year (plus or minus 30 days) after infusion"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04061746"
                        ]
                  },
                  {
                        "Rank": 372,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Death prior to discharge from initial hospitalization",
                              "1 year (12 - 16 postnatal months) Bayley Scales of Infant and Toddler Development, Third Edition (Bayley III) assessments in cognitive, language and motor development. Moderate to Severe CP will be assigned with cognitive score ,70, motor score ,70 and with Gross Motor Function Classification System >=2."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Survival",
                              "Neurodevelopmental Assessments"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Up to 6 months",
                              "Up to 16 postnatal months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03635450"
                        ]
                  },
                  {
                        "Rank": 373,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "the CD38 expression on CD8 T cells",
                              "Number of Participants with Adverse Events as a Measure of Safety and Tolerability",
                              "plasma RNA copies/mL",
                              "the ratio of CD4 and CD8 T cells",
                              "the HLA-DR expression on CD8 T cells",
                              "Quality of live",
                              "the occurring rate of tumor",
                              "occurring rate of opportunistic infections"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "At Baseline and at week 4, 12, 24, 36,48,60,72,84,96",
                              "at baseline and up to week 96",
                              "At Entry and at Weeks 24, 48, 72, 96",
                              "At Baseline and at week 4, 12, 24, 36,48,60,72,84,96",
                              "At Baseline and at week 4, 12, 24, 36,48,60,72,84,96",
                              "At Baseline and at week 4, 12, 24, 36,48,60,72,84,96",
                              "At Baseline and at week 24, 48, 72, 96",
                              "At Baseline and at week 24, 48, 72, 96"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01213186"
                        ]
                  },
                  {
                        "Rank": 374,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Improvement in sensitivity and motor strength will be measured through change in American Spinal Injury Association (ASIA) score from baseline",
                              "Functional Independence will be measured by FIM scoring",
                              "Shall be done using Frankel scale"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Sensory and motor strength",
                              "Functional Independence",
                              "Muscle strength assessment"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1 year",
                              "1 year",
                              "1 year"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02482194"
                        ]
                  },
                  {
                        "Rank": 375,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Changes in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) between the experimental and placebo group.",
                              "Frequency of renal and non-renal organ system flares at or before Weeks 12, 24, and 52, defined by the BILAG criteria.",
                              "\u2022 Change in SLICC-DI from Baseline to Week 52 to assess for accumulation of new damage (SLE-related or treatment-related)",
                              "Changes in HR-QOL (measured by SF36 v2) from Baseline to Weeks 12, 24, and 52",
                              "Changes in fatigue (measured by PROMIS Fatigue Short Form (SF)) from Baseline to Weeks 12, 24, and 52",
                              "Changes in pain (measured by PROMIS Pain SF) from Baseline to Weeks 12, 24, and 52",
                              "Changes in depression (measured by PROMIS Depression SF) from Baseline to Weeks 12, 24, and 52",
                              "Changes in patient-reported lupus-specific disease status (measured by the LupusPro and LIT) from Baseline to Weeks 12, 24, and 52",
                              "Steroid-sparing effect (measured by discontinuation of corticosteroids and time to discontinuation among those taking corticosteroids)",
                              "Cumulative systemic steroid dose (PO, IV, IM) at Week 52",
                              "Changes in the presence of serum and urine biomarkers of SLE activity: SLE-related cytopenias, low serum complement levels, anti-dsDNA levels or urine protein measures from Baseline to Weeks 12, 24, and 52."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in SLEDAI score between groups",
                              "Renal and non-renal organ system flares",
                              "Changes in SLICC-DI",
                              "Changes in HR-QOL",
                              "Changes in Fatigue",
                              "Changes in Pain",
                              "Changes in Depression",
                              "Changes in patient-reported lupus-specific disease status",
                              "Steroid-sparing effect",
                              "Cumulative systemic steroid dose",
                              "Changes in the presence of serum and urine biomarkers of SLE activity:"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline to Weeks 12, 24, and 52",
                              "At or before Weeks 12, 24, and 52",
                              "Baseline to Week 52",
                              "Baseline to Week 52",
                              "Baseline to Week 52",
                              "Baseline to Week 52",
                              "Baseline to Week 52",
                              "Baseline to Week 52",
                              "Baseline to Week 52",
                              "Week 52",
                              "Baseline to Week 52"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02633163"
                        ]
                  },
                  {
                        "Rank": 376,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Net change of Glasgow Coma Scale (Score Range: 3~15; the higher score the better outcome) from baseline visit to subsequent visits will be summarized by descriptive statistics",
                              "Net change of NIHSS (Score Range: 0~42; the higher score the worsen outcome) from baseline visit to subsequent visits will be summarized by descriptive statistics",
                              "The transition (improved, stable, and worsened) from baseline visit to subsequent visits will be summarized by descriptive statistics",
                              "Net change of FMT from baseline visit to subsequent visits will be summarized by descriptive statistics.",
                              "Net change of BI from baseline visit to subsequent visits will be summarized by descriptive statistics",
                              "Net change of infarcted area in the brain will be summarized by descriptive statistics.",
                              "Net change of mean transit time (MTT) presented in second and the ratio of MTT between the affected and unaffected hemispheres will be summarized by descriptive statistics",
                              "Net change of cerebral blood flow (CBF)(presented in ml/100g/min) and the ratio of CBF between the affected and the unaffected hemisphere will be summarized by descriptive statistics.",
                              "Net change of cerebral blood volume (CBV)(present in mL/100g) and the ratio of CBV between the affected and the unaffected hemisphere will be summarized by descriptive statistics."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Changes of Glasgow Coma Scale (GCS; Score range: Max.15, Min. 3) from Baseline Visit (Visit 1) to subsequent scheduled visits",
                              "Changes in National Institute of Health Stroke Scale (NIHSS; Score Range: 0~42; the higher score the worsen outcome) from Baseline Visit (Visit 1) to subsequent scheduled visits",
                              "Changes in mRS from Baseline Visit (Visit 1) to subsequent scheduled visits.",
                              "Changes in FMT from Baseline Visit (Visit 1) to subsequent schedules visits",
                              "Changes in BI from Baseline Visit (Visit 1) to subsequent schedules visits",
                              "Change and ratios of MRI image from baseline to subsequent scheduled visits",
                              "Change and ratios of SPECT perfusion image from baseline to subsequent scheduled visits",
                              "Change and ratios of SPECT perfusion image from baseline to subsequent scheduled visits",
                              "Change and ratios of SPECT perfusion image from baseline to subsequent scheduled visits"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "From \"baseline visit, prior to the investigational product administration\" to \"24 weeks\"",
                              "From \"baseline visit, prior to the investigational product administration\" to \"24 weeks\"",
                              "From \"baseline visit, prior to the investigational product administration\" to \"24 weeks\"",
                              "From \"baseline visit, prior to the investigational product administration\" to \"24 weeks\"",
                              "From \"baseline visit, prior to the investigational product administration\" to \"24 weeks\"",
                              "From \"baseline visit, prior to the investigational product administration\" to \"24 weeks\"",
                              "From \"baseline visit, prior to the investigational product administration\" to \"24 weeks\"",
                              "From \"baseline visit, prior to the investigational product administration\" to \"24 weeks\"",
                              "From \"baseline visit, prior to the investigational product administration\" to \"24 weeks\""
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04434768"
                        ]
                  },
                  {
                        "Rank": 377,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Partial response: with a decrease at least of one degree of GVHD",
                              "VGPR: decrease to the stage I of GVHD",
                              "Stable disease: when there is a stability of the disease (by Clinical evaluation)",
                              "Number of infection (by Clinical and laboratory evaluation)",
                              "Type of infection (by Clinical and laboratory evaluation)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "It will be evaluated the patients response who received MSC infusion or conventional therapy in the 28th day of the study.",
                              "It will be evaluated the patients response who received MSC infusion or conventional therapy in the 28th day of the study.",
                              "It will be evaluated the patients response who received MSC infusion or conventional therapy in the 28th day of the study.",
                              "First 100 days after transplant",
                              "First 100 days after transplant"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02770430"
                        ]
                  },
                  {
                        "Rank": 378,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [
                              "Non-Probability Sample"
                        ],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Full Name of Outcome: HOS--Hip Outcome Score, which consists of two subscores: Hip Outcome Score-Activity of Daily Living (HOS-ADL), Hip Outcome Score-Sports Sub-scale (HOS-SSS)\n\nPurpose: Validated Hip Patient Reported Outcome Measurements (PROMs) to assess the patient's functional outcomes post-surgery.\n\nScale of HOS--ADL:\n\nMin: 0 Max: 68\n\nConverted to a percentage, by dividing patient's score by 68.\n\nNo standardized scoring categories (i.e. excellent, good, fair, poor).\n\nHigher score indicates better hip functionally.\n\nScale of HOS--SSS:\n\nMin: 0 Max: 36\n\nConverted to a percentage, by dividing patient's score by 36.\n\nNo standardized scoring categories (i.e. excellent, good, fair, poor).\n\nHigher score indicates better hip functionally.",
                              "Full Name of Outcome: Non-Arthritic Hip Score (NAHS)\n\nPurpose: Validated Hip Patient Reported Outcome Measurements (PROMs) to assess the patient's functional outcomes post-surgery:\n\nScale of NAHS:\n\nMin: 0 Max: 100\n\nNo standardized scoring categories (i.e. excellent, good, fair, poor).\n\nHigher score indicates better hip functionally.\n\nNo subscores or subscales.",
                              "Full Name of Outcome: Lower Extremity Functional Scale (LEFS)\n\nPurpose: Validated Hip Patient Reported Outcome Measurements (PROMs) to assess the patient's functional outcomes post-surgery.\n\nScale of LEFS:\n\nMin: 0 Max: 80\n\nConverted to a percentage, by dividing patient's score by 80.\n\nNo standardized scoring categories (i.e. excellent, good, fair, poor).\n\nHigher score indicates better hip functionally.\n\nNo subscores or subscales",
                              "Full Name of Outcome: modified Harris Hip Score (mHHS)\n\nPurpose: Validated Hip Patient Reported Outcome Measurements (PROMs) to assess the patient's functional outcomes post-surgery.\n\nScale of mHHS:\n\nMin: 0 Max: 100\n\nScoring of mHHS:\n\nExcellent: 90--100 Good: 80--89 Fair: 70--79 Poor: <70\n\nHigher score indicates better hip functionally.\n\nNo subscores or subscales.",
                              "RAND-36 Measure of Health-Related Quality of Life (RAND 36 or SF 36):\n\nThe most widely used health-related quality-of-life survey instrument\n\nConsists of 36 questions that assess eight components of health: physical functioning, role limitation due to physical health problems, role limitations due to emotional problems, social functioning, emotional well-being, energy/fatigue, pain, and general health perceptions, with a simple mean of these responses ranging from 0 to 100, with 100 representing the best possible quality-of-life score.",
                              "At routine follow-up visits patients will be asked to rate hip pain using the VAS (Visual Analog Scale) Score\n\nMin: 0--no pain Max: 10--worst pain experienced in their life\n\nIncrements of 1.\n\nCategories:\n\n1--3: mild pain 4--6: moderate pain 7--10: severe pain",
                              "Three Yes/No Questions:\n\nAre you satisfied with the treatment you received?\nAre you satisfied with the treatment regimen that you were given?\nIf given the choice in the future, would you choose the same treatment?"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change HOS Surveys from preoperative to various postoperative timepoints",
                              "Change NAHS Surveys from preoperative to various postoperative timepoints",
                              "Change LEFS Surveys from preoperative to various postoperative timepoints",
                              "Change mHHS Surveys from preoperative to various postoperative timepoints",
                              "Change RAND-36 Surveys from preoperative to various postoperative timepoints",
                              "Degree of Improvement on Hip VAS Pain Score",
                              "Patient Satisfaction Questionnaires"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline (pre-operative), 3 months, 6 months, 12 months, and annually thereafter",
                              "Baseline (pre-operative), 3 months, 6 months, 12 months, and annually thereafter",
                              "Baseline (pre-operative), 3 months, 6 months, 12 months, and annually thereafter",
                              "Baseline (pre-operative), 3 months, 6 months, 12 months, and annually thereafter",
                              "Baseline (pre-operative), 3 months, 6 months, 12 months, and annually thereafter",
                              "Baseline (pre-operative), 3 months, 6 months, 12 months, and annually thereafter",
                              "12 months and annually thereafter"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03909139"
                        ]
                  },
                  {
                        "Rank": 379,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Number of participants with a change in disability as measured by Expanded Disability Status Scale (EDSS)",
                              "Number of participants with a change in neurological impairment as measured by Scripps Neurological Rating Scale",
                              "Number of participants with a change in cognitive function as measured by the \u2022 Paced Auditory Serial Addition Test (PASAT)",
                              "Number of participants with a change in upper extremity function as measured by the Nine Hole Peg Test",
                              "Number of participants with a change in mobility and leg function as measured by the 25 foot walking test",
                              "Number of participants with a change in quality of life as measured by the Short form 36 (SF-36) quality of life questionnaire",
                              "Number of participants experiencing pulmonary edema as measured by 12-lead electrocardiogram (ECG)",
                              "Number of participants with a change in brain or spinal cord lesions as measured by gadolinium-enhanced magnetic resonance imaging (MRI)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months",
                              "1 month, 3 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02034188"
                        ]
                  },
                  {
                        "Rank": 380,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04432545"
                        ]
                  },
                  {
                        "Rank": 381,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "We will evaluate mRNA gene expression for mature fat and fat related transcription factors.",
                              "Velocity of pulse travelling throughout the Body in m/s",
                              "Augmentation Index calculated of ratio of reflected waveform from the end arterioles",
                              "Body mass index measured using Bio metric Impedance Scale",
                              "Percent of Body Fat measured using Bio metric Impedance Scale",
                              "Ratio of Hip to Waist",
                              "hemoglobin percent",
                              "ratio of LDL over HDL"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Gene Expression of Subcutaneous Adipose cell",
                              "Arterial Stiffness: Pulse Wave Velocity",
                              "Arterial Stiffness: Pulse Wave Analysis",
                              "Body Composition: BMI",
                              "Body Composition: Body Fat Percent",
                              "Hip to Waist Ratio",
                              "Biochemistry: HbA1c",
                              "Biochemistry: LDL over HDl Ratio"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "24 Weeks",
                              "24 Weeks",
                              "24 Weeks",
                              "24 Weeks",
                              "24 Weeks",
                              "24 Weeks",
                              "24 Weeks",
                              "24 Weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04126603"
                        ]
                  },
                  {
                        "Rank": 382,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Proportion of enrolled patients alive on Day 21",
                              "Proportion of enrolled patients alive and free of respiratory failure on Day 21",
                              "Improvement of COVID 19 pneumonia confirmed by chest radiographs or computed tomography on Day 21 or on the day of discharge compared with baseline",
                              "Improvement of clinical symptoms including duration of fever in degrees C and respiratory failure on Day 21 or on the day of discharge compared with baseline",
                              "Duration of ventilator usage or oxygen therapy on Day 21 or on the day of discharge compared with baseline",
                              "Levels of tumor necrosis factor-alpha (TNF-\u03b1) in pg/ml, interleukin-6 (IL-6) in pg/ml and interleukin-10 (IL-10) in pg/ml, and C-reactive protein (hsCRP) in mg/dl on Day 21 or on the day of discharge compared to baseline",
                              "Troponin I level as assessed via serum blood samples on Day 21 or on the day of discharge compared with baseline",
                              "ICU admission rate on Day 21 or on the day of discharge with historical data",
                              "Percentage of subjects recorded in each severity rating based on Clinical classification of the COVID-19 (NCOSS scores from 1 to 8\uff1bhigher scores mean a worse outcome) on Day 14 compared with historical data",
                              "Percentage of subjects recorded in each severity rating based on Clinical classification of the COVID-19 (NCOSS scores from 1 to 8\uff1bhigher scores mean a worse outcome) on Day 21 compared with historical data",
                              "Average time (days) for which the patients are alive and free of respiratory failure during the treatment period",
                              "Proportion of patients who need ICU care on Day 21 based on the clinical indicative of admission to ICU",
                              "Proportion of patients who has been discharged form hospital on Day 21",
                              "Number of Participants with infusion-related and allergic reactions during the treatment period",
                              "Secondary infection, treatment emergent adverse event (TEAE), serious adverse event (SAE), and suspected and unexpected serious adverse reaction (SUSAR) incidences over the study period. The toxicities will be assessed by CTCAE V5.0 during the whole study period (380 days)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Secondary Efficacy Endpoints",
                              "Secondary Efficacy Endpoints",
                              "Secondary Efficacy Endpoints",
                              "Secondary Efficacy Endpoints",
                              "Secondary Efficacy Endpoints",
                              "Secondary Efficacy Endpoints",
                              "Secondary Efficacy Endpoints",
                              "Secondary Efficacy Endpoints",
                              "Secondary Efficacy Endpoints",
                              "Secondary Efficacy Endpoints",
                              "Secondary Efficacy Endpoints",
                              "Secondary Efficacy Endpoints",
                              "Secondary Efficacy Endpoints",
                              "Secondary Safety Endpoints",
                              "Secondary Safety Endpoints"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "21 days of the treatment period",
                              "21 days of the treatment period",
                              "21 days of the treatment period",
                              "21 days of the treatment period",
                              "21 days of the treatment period",
                              "21 days of the treatment period",
                              "21 days of the treatment period",
                              "21 days of the treatment period",
                              "14 days of the treatment period",
                              "21 days of the treatment period",
                              "through study completion, an average of 1 year",
                              "21 days of the treatment period",
                              "21 days of the treatment period",
                              "21 days of the treatment period",
                              "through study completion, an average of 1 year"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05501418"
                        ]
                  },
                  {
                        "Rank": 383,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The proportion of the improvement of PASI(Psoriasis Area and Severity Index) from baseline",
                              "The improvement in PASI score from baseline after treatment",
                              "The proportion of patients who achieve at least 50% improvement in PASI score from baseline.",
                              "The proportion of patients who achieve at least 75% improvement in PASI score from baseline.",
                              "Pruritus Scores on the Visual Analogue Scale",
                              "the Body Surface Area",
                              "the Dermatology Life Quality Index"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Improvement rate of PASI(Psoriasis Area and Severity Index)",
                              "PASI(Psoriasis Area and Severity Index)",
                              "PASI-50",
                              "PASI-75",
                              "Pruritus Scores on the Visual Analogue Scale",
                              "BSA",
                              "DLQI\uff08Dermatology Life Quality Index\uff09"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 weeks (plus or minus 3 days) after treatment",
                              "12 weeks (plus or minus 3 days) after treatment",
                              "12 weeks (plus or minus 3 days) after treatment",
                              "12 weeks (plus or minus 3 days) after treatment",
                              "12 weeks (plus or minus 3 days) after treatment",
                              "12 weeks (plus or minus 3 days) after treatment",
                              "12 weeks (plus or minus 3 days) after treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03265613"
                        ]
                  },
                  {
                        "Rank": 384,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Interleukin levels change from Baseline to 24 hours after each MSC infusion",
                              "Angiopoietin levels change from Baseline to 24 hours after each MSC infusion",
                              "Number of deaths at day 28"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Biomarkers of systemic inflammatory response",
                              "Biomarkers of endothelial function",
                              "ICU mortality"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Change from Baseline to 24 hours after each MSC infusion",
                              "Change from Baseline to 24 hours after each MSC infusion",
                              "Day 28"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04865107"
                        ]
                  },
                  {
                        "Rank": 385,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "CFB for EDSS of follow up visits (Visit 6-10)",
                              "CFB for brain MRI parameters of follow-up visits (Visit 6 -10)",
                              "Quality of life: CFB for MSQoL-54 questionnaire score of follow-up visits (Visit 6 -10)",
                              "CFB of T25FW scores of follow-up visits (Visit 6-10)",
                              "CFB of 9-HPT scores of follow-up visits (Visit 6-10)",
                              "CFB of PASAT scores of follow-up visits (Visit 6-10)",
                              "CFB of SDMT scores of follow-up visits (Visit 6-10)",
                              "CFB of RNFL thickness, measured by OCT of follow-up visits (Visit 6-10)",
                              "CFB of MSFC of follow-up visits (Visit 6-10)",
                              "Time to onset of CDW confirmed by EDSS at least 6 months",
                              "ARR (Annualized relapse rate), where relapse is defined as new or worsening neurological symptoms lasting for >24 hours",
                              "CFB of follow-up visits (Visit 6 -10) for EDSS",
                              "CFB of follow up visits (Visit 6-10) for brain MRI parameters",
                              "Quality of life: CFB of follow up visits (Visit 6-10) for MSQoL-54 questionnaire score",
                              "CFB of follow up visits (Visit 6-10) for T25FW scores",
                              "CFB of follow up visits (Visit 6-10) for 9-HPT scores",
                              "CFB of follow up visits (Visit 6-10) for PASAT scores",
                              "CFB of follow up visits (Visit 6-10) for SDMT scores",
                              "CFB of follow up visits (Visit 6-10) for RNFL thickness, measured by OCT",
                              "CFB of follow up visits (Visit 6-10) for MSFC",
                              "SAE, SUSAR, and AE incidences over the study period",
                              "CFB of laboratory data to subsequent visits",
                              "CFB of physical examination to subsequent visits",
                              "CFB of vital signs to subsequent visits",
                              "CFB of AFP, CEA, CA199, SCC, IgA, anti-EBV, \u03b2-HCG, CA125, CA153, and PSA to Visit 6 (Phase I) or Visit 10 (Phase IIa)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Efficacy endpoint for phase I portion",
                              "Efficacy endpoint for phase I portion",
                              "Efficacy endpoint for phase I portion",
                              "Efficacy endpoint for phase I portion",
                              "Efficacy endpoint for phase I portion",
                              "Efficacy endpoint for phase I portion",
                              "Efficacy endpoint for phase I portion",
                              "Efficacy endpoint for phase I portion",
                              "Efficacy endpoint for phase I portion",
                              "Efficacy endpoints for phase IIa portion",
                              "Efficacy endpoints for phase IIa portion",
                              "Efficacy endpoints for phase IIa portion",
                              "Efficacy endpoints for phase IIa portion",
                              "Efficacy endpoints for phase IIa portion",
                              "Efficacy endpoints for phase IIa portion",
                              "Efficacy endpoints for phase IIa portion",
                              "Efficacy endpoints for phase IIa portion",
                              "Efficacy endpoints for phase IIa portion",
                              "Efficacy endpoints for phase IIa portion",
                              "Efficacy endpoints for phase IIa portion",
                              "The safety endpoints are listed below for both phase I and IIa portions",
                              "The safety endpoints are listed below for both phase I and IIa portions",
                              "The safety endpoints are listed below for both phase I and IIa portions",
                              "The safety endpoints are listed below for both phase I and IIa portions",
                              "The safety endpoints are listed below for both phase I and IIa portions"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "from visit 2 to 12-month follow-up period",
                              "from visit 2 to 12-month follow-up period",
                              "from visit 2 to 12-month follow-up period",
                              "from visit 2 to 12-month follow-up period",
                              "from visit 2 to 12-month follow-up period",
                              "from visit 2 to 12-month follow-up period",
                              "from visit 2 to 12-month follow-up period",
                              "from visit 2 to 12-month follow-up period",
                              "from visit 2 to 12-month follow-up period",
                              "from visit 2 to 6-month follow-up period",
                              "from visit 2 to 12-month follow-up period",
                              "from visit 2 to 12-month follow-up period",
                              "from visit 2 to 12-month follow-up period",
                              "from visit 2 to 12-month follow-up period",
                              "from visit 2 to 12-month follow-up period",
                              "from visit 2 to 12-month follow-up period",
                              "from visit 2 to 12-month follow-up period",
                              "from visit 2 to 12-month follow-up period",
                              "from visit 2 to 12-month follow-up period",
                              "from visit 2 to 12-month follow-up period",
                              "from visit 2 to 12-month follow-up period",
                              "from visit 2 to 12-month follow-up period",
                              "from visit 2 to 12-month follow-up period",
                              "from visit 2 to 12-month follow-up period",
                              "from visit 2 to 12-month follow-up period"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05532943"
                        ]
                  },
                  {
                        "Rank": 386,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The improvement in PASI score from baseline after treatment",
                              "Relapse can be defined only for patients who achieve PASI50\uff0cand occurs when the improvement in the PASI score falls below 50% from the baseline PASI score.",
                              "The proportion of patients who achieve at least 50% improvement in PASI score from baseline",
                              "The proportion of patients who achieve at least 75% improvement in PASI score from baseline",
                              "Pruritus was assessed using the Visual Analogue Scales; The Scale scores ranged from 0-10. The higer the scores were, the more itching the patient suffered.",
                              "the Body Surface Area",
                              "the Dermatology Life Quality Index"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "PASI(Psoriasis Area and Severity Index)",
                              "Relapse rate in treatment period / follow-up period",
                              "PASI-50",
                              "PASI-75",
                              "Pruritus Scores on the Visual Analogue Scale",
                              "BSA",
                              "DLQI\uff08Dermatology Life Quality Index\uff09"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 weeks (plus or minus 3 days) after treatment",
                              "During the treatment period of 12 weeks / follow-up period of 12 weeks after treatment period",
                              "12 weeks (plus or minus 3 days) after treatment",
                              "12 weeks (plus or minus 3 days) after treatment",
                              "12 weeks (plus or minus 3 days) after treatment",
                              "12 weeks (plus or minus 3 days) after treatment",
                              "12 weeks (plus or minus 3 days) after treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03392311"
                        ]
                  },
                  {
                        "Rank": 387,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Changes in ASIA score with respect to baseline value as detailed at https://asia-spinalinjury.org/international-standards-neurological-classification-sci-isncsci-worksheet/",
                              "Changes in motor evoked potentials score with respect to baseline value. Higher scores mean a better outcome",
                              "Changes in somatosensory evoked potentials score with respect to baseline value. Higher scores mean a better outcome",
                              "Changes in electrical pain threshold perception score with respect to baseline. Lower scores mean a better outcome",
                              "Will be assessed using a dynamometer. Changes in the score with respect to baseline values. Higher scores mean a better outcome",
                              "Changes in the walk test WISCIII score with respect to baseline value. The score ranges from 0 (most severe impairment) to 20 (least severe impairment)",
                              "Changes in the numerical scale for neuropathic pain score with respect to baseline value. Score ranges from 0 (no pain) to 10 (unbearable pain)",
                              "Changes in the modified Ashworth scale score with respect to baseline value. It is a 5 point numerical scale that graded spasticity from 0 to 4, with 0 being no resistance and 4 being a limb rigid in flexion or extension, and includes a 1+ value.",
                              "Changes in the SCIM III scale score with respect to baseline value. Score ranges from 0 to 20 with higher scores meaning better outcome.",
                              "Changes in the WHOQOL-BREF score with respect to baseline value. It contains contains 26 questions each punctuated from 1 to 5 and assesses the individual's overall perception of quality of life (1 to 5), overall perception of their health (1 to 5) and 4 domains of physical health, psychological, social relationships, environment (0-100 each domain). higher scores denote higher quality of life.",
                              "Changes in the PGWBI score with respect to baseline value. Score ranges from 0 to 132, with higher scores meaning a better outcome.",
                              "Changes in the HADS score with respect to baseline value. This is a 14-item self-administered questionnaire containing 2 subscales (one for anxiety and one for depression), with a score range of each subscale from 0-21. Higher score indicates higher anxiety and depression.",
                              "Changes in the CIQ-IG score with respect to baseline value. Score ranges from 0 to 25, with higher scores meaning a better outcome.",
                              "Presence or absence of antiHLA antibodies in the CSF after two WJ-MSC infusions",
                              "Short tandem repeat (STR) analysis to detect permanence of donor cellularity (WJ-MsC) in the CSF"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "American Spinal Injury Association (ASIA) impairment scale",
                              "Motor evoked potentials",
                              "Somatosensory evoked potentials",
                              "Electrical pain threshold perception",
                              "Handgrip Strength",
                              "Walking index for spinal cord injury (WISCI II)",
                              "Numerical scale for neuropathic pain assessment",
                              "Modified Ashworth scale for spasticity",
                              "Spinal Cord Independence Measure III (SCIM III)",
                              "World Health Organization Quality of life questionnaire (WHOQOL-BREF)",
                              "Psychological general well-being index (PGWBI)",
                              "Hospital Anxiety and Depression Scale (HADS)",
                              "Community Integration Questionaire (CIQ-IG)",
                              "AntiHLA antibodies in cerebrospinal fluid (CSF)",
                              "Detection of donor cells in CSF"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "At 1, 3, 4, 6 and 12 month follow-up",
                              "At 6 and 12 month follow-up",
                              "At 6 and 12 month follow-up",
                              "At 6 and 12 month follow-up",
                              "At 6 and 12 month follow-up",
                              "At 6 and 12 month follow-up",
                              "At 6 and 12 month follow-up",
                              "At 6 and 12 month follow-up",
                              "At 6 and 12 month follow-up",
                              "At 6 and 12 month follow-up",
                              "At 12 month follow-up",
                              "At 12 month follow-up",
                              "At 12 month follow-up",
                              "At 7 days and at 1 month follow-up after each infusion",
                              "At 7 days after each infusion"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Blood and tissue bank of Catalonia, cell producer and sponsor of the trial",
                              "Hospital specialized in spinal cord injury",
                              "Hospital specialized in spinal cord injury"
                        ],
                        "SeeAlsoLinkURL": [
                              "https://www.bancsang.net",
                              "https://www.guttmann.com/",
                              "https://xxicoruna.sergas.gal/Paxinas/web.aspx?tipo=paxtxt&idContido=595&idLista=4"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05054803"
                        ]
                  },
                  {
                        "Rank": 388,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2019-002446-21"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Evaluation of quality of life using Short Form-12 Health Survey questionnaire (SF12) [score range from 0 (the worst health status for that dimension) to 100 (the best health status)]",
                              "Rate of products not conforming to the validation criteria in each arm of experimental treatment.",
                              "Rate of adverse events and other pharmacovigilance parameters in the three treatment arms."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Perceived general well-being.",
                              "Feasibility assessment of a multicentre strategy production of both cell types with several Cell Production Units",
                              "Evaluation of presence of adverse events related with investigational medical product (IMP)."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6, 12 and 24 months",
                              "24 months",
                              "24 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05086939"
                        ]
                  },
                  {
                        "Rank": 389,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "liver functions\uff1aAlbumin (ALB), Alanine aminotransferase (ALT), Aspartate Aminotransferase (AST), Prealbumin(PA), total bilirubin (TB), and direct bilirubin (DB) kidney function\uff1aBlood urea nitrogen (BUN), Urea (UA), and Crea (Cr)",
                              "Total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglycerides (TG), very low density lipoprotein cholesterol (VLDL-C), and Non-HDL-C; blood sugar;",
                              "IL-1\u03b2, IL-4, IL-6, IL-8, IL-10, IL-12(p40), IL-15, IL-17A, TNF\u03b1, TNF\u03b2, IFN-\u03b3, RANTES, TGF\u03b2, lymphotactin, and C-reactive protein level (CRP)",
                              "Serum levels of Hepatitis B and C",
                              "The classification for uncomfortable reaction is: 0, no discomfort; 1, slightly unwell, does not affect daily life; 2, moderate discomfort, affects daily life and work; 3, moderately unwell, significantly affects life, and bed rest; 4, severely unwell, life-threatening.\n\nA serious adverse event is defined as fatal, life threatening, permanently disabling, and tumors, particularly hepatocellular carcinoma.",
                              "abdominal distension, appetite, debilitation, and edema of lower limbs."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Serum markers regarding liver and kidney function",
                              "Serum markers regarding lipid and sugar profile",
                              "Serum markers regarding cytokine profile",
                              "Serum levels of Hepatitis B and C",
                              "tolerance and the adverse events",
                              "Changes of any clinical symptoms"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "0, 3, 6, 9 and 12 months",
                              "0, 3, 6, 9 and 12 months",
                              "0, 3, 6, 9 and 12 months",
                              "0, 3, 6, 9 and 12 months",
                              "3-year follow up",
                              "3-year follow up"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01573923"
                        ]
                  },
                  {
                        "Rank": 390,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Pain measured by VAS scale after first week of treatment",
                              "Synovitis measured by effusion grading scale (zero to 3+) after first week of treatment",
                              "Change in VAS score after 52 weeks",
                              "Change in Womac subscale related to function (C) after 52 weeks",
                              "According to OMERACT-OARSI Criteria Index Response after 52 weeks"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Incidence of injection-related pain according to VAS scale (0-100mm)",
                              "Incidence of injection-related sinovitis according to effusion grading scale of knee joint",
                              "Pain reduction",
                              "Disability reduction",
                              "Percentage of responders"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1 week",
                              "1 week",
                              "52 weeks",
                              "52 weeks",
                              "52 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05060107"
                        ]
                  },
                  {
                        "Rank": 391,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT00749164"
                        ]
                  },
                  {
                        "Rank": 392,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Quality of life estimated by validated questionnaire: the Short Form (36) Health Survey (SF-36).",
                              "Changes in volume and density of bone tissue at the site of manipulation and newly formed bone micro-architecture assessed by cone beam CT (morphometrical analysis using Hounsfield unit measurements)",
                              "Biopsy of bone tissue at the site of sinus lift will be performed as a part of dental implant installation. Bone sample will be evaluated histologically: absolute value of the newly formed bone will be calculated using histomorphometrical analysis."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Quality of life monitoring",
                              "Changes in bone tissue volume",
                              "Correlation of morphometrical analysis using cone beam CT scan with absolute value of the newly formed bone"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "up to 24 weeks after treatment",
                              "up to 24 weeks after treatment",
                              "24 weeks after treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02209311"
                        ]
                  },
                  {
                        "Rank": 393,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Neutrophil engraftment (ANC>500/ul) in subjects as demonstrated by number of subjects with engraftment <=21 days."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Engraftment"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "2 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01624701"
                        ]
                  },
                  {
                        "Rank": 394,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Adverse events (AEs) will be listed individually by patient and dose group (dose and schedule). The number of patients experiencing each AE will be summarised by the CTCAE grade. The number and percentage of patients with adverse events in different categories (eg, causally related, CTCAE grade \u22653 etc) will be summarised by dose group, and events in each category will be further summarised.",
                              "Tumour response data will be summarised using the following response categories: Complete Response (CR), Partial Response (PR), Stable Disease (SD), Progressive Disease (PD) and Non-Evaluable (NE).\n\nWaterfall plots (bar charts) indicating the percentage change from baseline in sum of the diameters of target lesions (TLs) may be produced depending on how much data is obtained in patients with measurable disease at baseline. These may be individual patient plots of changes in tumour size over time or dose level plots with the best percentage change per patient displayed.",
                              "Progression Free Survival (PFS) is defined as the time from randomization to time of progression (as per RECIST v1.1 criteria) or time of death from any cause. PFS will be analysed using KM plots and will be presented along with median PFS.",
                              "Overall Survival (OS) is defined as the time from randomization to time of death from any cause. OS will be analysed using KM plots and will be presented along with median OS."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Frequency of adverse events (Phase 1 & 2)",
                              "Best Overall response (Phase 1&2)",
                              "Progression free survival (Phase 1 & 2)",
                              "Overall survival (Phase 2)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Up to 12 weeks post 1st MSCTRAIL infusion",
                              "Until end of follow up period (Phase 1: 1 year post last treatment, Phase 2: 2 years post last treatment)",
                              "End of follow up period (Phase 1: 1 year post last treatment, Phase 2: 2 years post last treatment)",
                              "End of follow up period (2 years post last treatment)"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03298763"
                        ]
                  },
                  {
                        "Rank": 395,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Scar outcome assessment",
                              "Incidence of contracture release or revision surgeries",
                              "Incidence of increased temperature sensitivity",
                              "Incidence of paresthesias, pain, dulling of sensation assessed",
                              "Incidence and severity of infections at grafting sites",
                              "Incidence of all adverse events",
                              "Percentage area of re-grafting as determined"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Up to Month 36 after the last grafting day",
                              "Up to Month 36 after the last grafting day",
                              "Up to Month 36 after the last grafting day",
                              "Up to Month 36 after the last grafting day",
                              "Up to Month 6 after the last grafting day",
                              "Up to Month 36 after the last grafting day",
                              "Up to Month 6 after the last grafting day"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Related Info"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://link.springer.com/article/10.1007%2Fs11427-007-0069-2"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02672280"
                        ]
                  },
                  {
                        "Rank": 396,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "IRB201903442",
                              "OCR33722"
                        ],
                        "SecondaryIdDomain": [
                              "UF IRB",
                              "UF OnCore"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Other Identifier",
                              "Other Identifier"
                        ],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04723303"
                        ]
                  },
                  {
                        "Rank": 397,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Serious adverse event frequency and severity"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1 year"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01143168"
                        ]
                  },
                  {
                        "Rank": 398,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Assessment of cosmetic outcome based on clinical photos before (baseline), one, four and twelve months after the procedure when compared to baseline, evaluated by 5 independent plastic surgeons blinded to the intervention using a scale of 1-5 to determine the difference in appearance over time."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in cosmetic facial appearance over time after facial filling"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, one, four and twelve months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03258164"
                        ]
                  },
                  {
                        "Rank": 399,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "To evaluate biomarkers (such as cell-secreted neurothrophic factors, inflammatory factors, and cytokines in pg/ml) in the cerebrospinal fluid (CSF) as well as in serum samples throughout the study to evaluate their relationship to treatment with NurOwn\u00ae (MSC-NTF cells)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Biomarkers"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Through selected post-treatment time points up to 20 weeks post transplant"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03280056"
                        ]
                  },
                  {
                        "Rank": 400,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Number of participants with complete clinical healing post-injection of 75 million allogeneic bone marrow derived MSC's for the treatment of perianal fistula(s) in the setting of Crohn's disease.\n\nComplete Healing is defined as:\n\nRadiographic Healing: MRI with an absence of a fluid collection >2 cm in 3 of 3 dimensions, lack of edema, inflammation or sign of active inflammatory response. A remnant scar of a fistula tract may remain\n\nClinical Healing: 100% cessation of drainage on both clinical exam with deep palpation and per patient report and epithelization of the external fistula opening"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Complete clinical healing"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Month 6, Month 12"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04519671"
                        ]
                  },
                  {
                        "Rank": 401,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The improvement in PASI score from baseline after treatment",
                              "The proportion of patients who achieve at least 50% improvement in PASI score from baseline",
                              "The proportion of patients who achieve at least 75% improvement in PASI score from baseline",
                              "Pruritus was assessed using the Visual Analogue Scales; The Scale scores ranged from 0-10. The higer the scores were, the more itching the patient suffered",
                              "the Body Surface Area",
                              "the Dermatology Life Quality Index"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "PASI(Psoriasis Area and Severity Index)",
                              "PASI-50",
                              "PASI-75",
                              "Pruritus Scores on the Visual Analogue Scale",
                              "BSA",
                              "DLQI(Dermatology Life Quality Index)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 weeks (plus or minus 3 days) after treatment",
                              "12 weeks (plus or minus 3 days) after treatment",
                              "12 weeks (plus or minus 3 days) after treatment",
                              "12 weeks (plus or minus 3 days) after treatment",
                              "12 weeks (plus or minus 3 days) after treatment",
                              "12 weeks (plus or minus 3 days) after treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04275024"
                        ]
                  },
                  {
                        "Rank": 402,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Duration (in minutes) of the surgery",
                              "Including the number of participants with:\n\npost-surgery infections\ntemporal or permanent damage of nerve as a result of pressure or hematoma\nwith venose thrombosis, pulmonary embolism or heart stroke",
                              "Comparison of the overall costs and results of both groups"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Surgical time",
                              "Complication rate",
                              "Cost-effective comparative analysis"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "During surgery",
                              "Two years follow up from baseline (surgery)",
                              "Two years follow up from baseline (surgery)"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03905824"
                        ]
                  },
                  {
                        "Rank": 403,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Median WOMAC scores at 3, 6 and 12 months (total; pain; stiffness; function)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Number of patients whose clinical effusion scores improve at 3, 6 and 12 months",
                              "Number of patients whose semi-quantitative MRI cartilage scores improve at 6 and 12 months",
                              "Median KOOS scores at 3, 6 and 12 months (pain; other symptoms; function in daily living; function in sport; knee-related QoL; average score)",
                              "Western Ontario and McMaster Universities Arthritis Index (WOMAC)",
                              "Visual Analogue Scale (VAS)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "3, 6 and 12 months",
                              "up to 12 months",
                              "3, 6 and 12 months",
                              "3, 6 and 12 months",
                              "3, 6 and 12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02696876"
                        ]
                  },
                  {
                        "Rank": 404,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Improvement in mortality status.",
                              "Improvement in clinical function as assessed by Ventilator Free Days (VFD).",
                              "Improvement in clinical function as assessed by change in Oxygenation Index (OI).",
                              "Improvement in clinical function as assessed by change in Lung Injury Score (LIS), 0-16 points, severity increasing with higher points.",
                              "Improvement in clinical function as assessed by change in positive end-expiratory pressure (PEEP).",
                              "Improvement in clinical function as assessed by change in Lung Static Compliance",
                              "Improvement in clinical function as assessed by change in acute physiology and chronic health evaluation score (APACHE II), higher scores correspond to more severe disease and a higher risk of death."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Changes in mortality status",
                              "Ventilator Free Days (VFD)",
                              "Change in Oxygenation Index (OI)",
                              "Change in Lung Injury Score (LIS)",
                              "Change in positive end-expiratory pressure (PEEP)",
                              "Change in Lung Static Compliance",
                              "Change in acute physiology and chronic health evaluation score (APACHE II)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "15 months from the day of administration.",
                              "28 days from the day of administration",
                              "7 days or discharge from ICU after the day of administration",
                              "7 days or discharge from ICU after the day of administration",
                              "7 days or discharge from ICU after the day of administration",
                              "7 days or discharge from ICU after the day of administration",
                              "7 days from the day of administration"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04347967"
                        ]
                  },
                  {
                        "Rank": 405,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Clinical remission is defined as the closure of all treated external openings that were draining at baseline despite gentle finger compression.",
                              "Clinical response is defined as closure of at least 50% of all treated external openings that were draining at baseline despite gentle finger compression.",
                              "PDAI is a scoring system for assessing the severity of perianal lesions associated with Crohn's disease.It consists of the following five items :(a) perianal secretions;(b) Pain and movement;(c) Sexual life;(d) Perianal manifestations;(e) Sclerosing.Each item is rated on a five-point scale from asymptomatic (0) to severe (4), with an overall score of 0 to 20.The higher the score, the more severe the disease.",
                              "IBDQ questionnaire score is used to investigate the quality of life of patients. There are 32 questions in total, and each question has 1 to 7 answers of different degrees, with 1 representing the most severe degree and 7 representing the least severe degree",
                              "VAS scale was used to evaluate the pain. 0 points indicated no pain, less than 3 points indicated mild pain, 4-6 points indicated pain affecting sleep but tolerable, 7-10 points indicated pain and discomfort, affecting appetite and sleep. The higher number, the pain was more obvious.",
                              "Wexner incontinence score"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Percentage of Participants who Achieve Clinical Remission",
                              "Percentage of Participants who Achieve Clinical Response",
                              "Percentage of Participants who decrease in PDAI",
                              "Percentage of Participants who decrease in IBDQ",
                              "Percentage of Participants who decrease in VAS scale",
                              "Percentage of Participants who decrease in Wexner incontinence score"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Up to Week 24",
                              "Up to Week 24",
                              "0\u30014\u30018\u300116\u300124 weeks",
                              "0\u30014\u30018\u300116\u300124 weeks",
                              "0\u30014\u30018\u300116\u300124 weeks",
                              "0\u30014weeks"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Thoreson R, Cullen JJ. Pathophysiology of inflammatory bowel disease: an overview. Surg Clin North Am. 2007 Jun;87(3):575-85. Review."
                        ],
                        "SeeAlsoLinkURL": [
                              "https://pubmed.ncbi.nlm.nih.gov/17560413/"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04939337"
                        ]
                  },
                  {
                        "Rank": 406,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "1510579216"
                        ],
                        "SecondaryIdDomain": [
                              "IU IRB"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Other Identifier"
                        ],
                        "SecondaryOutcomeDescription": [
                              "This trial will also test the hypothesis that MSCs, in a dose dependent fashion (1 x106 MSC/kg. vs. 3.0 x 106 MSC/kg. ), promote the frequency and immune suppressor function of Treg cells as measured by 18-fluorodeoxyglucose positron emission tomography/computed tomography compared to baseline."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Changes in circulating inflammatory cell phenotypes as measured by 18-FDG PET/CT"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02846883"
                        ]
                  },
                  {
                        "Rank": 407,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "COMP, MMP-13, IL-6",
                              "COMP, MMP-13, IL-6",
                              "COMP, MMP-13, IL-6",
                              "MRI T2 mapping is used for cartilage evaluation"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Laboratory Asessment",
                              "Laboratory Asessment",
                              "Laboratory Asessment",
                              "Magnetic Resonance Imaging (MRI) T2 mapping"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "2 weeks after injection",
                              "1 month after injection",
                              "3 months after injection",
                              "6 month after injection"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04314661"
                        ]
                  },
                  {
                        "Rank": 408,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01993368"
                        ]
                  },
                  {
                        "Rank": 409,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "myocardial infarction",
                              "pulmonary embolism",
                              "ischemic stroke",
                              "deep venous thrombosis",
                              "other arterial or venous thrombosis",
                              "Infection requiring IV antibiotics"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "90 days after stroke onset",
                              "90 days after stroke onset",
                              "90 days after stroke onset",
                              "90 days after stroke onset",
                              "90 days after stroke onset",
                              "90 days after stroke onset"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT00908856"
                        ]
                  }
            ]
      }
}